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SUMMARY
This thesis concerns the development, validation and use of enzyme- 
linked immunosorbent assays (ELISA) to determine homidium concentrations 
in sera of treated cattle.
Previously published work with particular emphasis on control and 
specifically, chemotherapy of animal trypanosomiases are reviewed in Chapter 
One. This includes the development and use of trypanocidal drugs detailing 
previous analytical techniques used in the determination of drug levels in 
plasma/serum of treated cattle.
Chapter 2 describes the general materials and methods used in the 
experiments reported in the later Chapters of this thesis.
Chapter 3 describes the development of two highly sensitive homidium 
ELISA methods (detection limit 0.1 ng m l1); Assay 1 an indirect competition 
assay and the Assay 2 a direct competition assay. Validation of the assays was 
carried out on serum samples obtained from treated Friesian calves. Using 
Assay 2, the serum homidium concentrations obtained following treatment of 
calves showed less variations between individual animals when compared to 
Assay 1. It was thereafter adopted for use in all subsequent experiments.
Following the development and validation of the ELISA method, 
several experiments were carried out in cattle using homidium bromide at 1 
mg k g 1 b.w. to establish baseline data on serum homidium concentrations and 
pharmacokinetics in cattle. Serum homidium concentrations and 
pharmacokinetics were determined following i.v. treatment of Friesian calves. 
No drug was detectable after approximately 17 days of treatment in four out of 
five and in 21 days in the remaining calf showing rapid elimination of the 
drug.
Following the establishment of homidium pharmacokinetics in the 
Friesian cattle in work carried out in Scotland, the studies were extended to 
Boran (Bos indicus) cattle, a breed of cattle which is commonly kept in the
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trypanosomiasis endemic areas, in Kenya. Following i.m. treatment with 
homidium bromide at 1 mg k g 1, serum homidium concentrations were 
determined. The results showed a wide variation in serum homidium 
concentrations between individual Boran cattle when compared to the 
Friesian. However, both groups showed similar the serum homidium 
concentration-versus-time profiles.
The results of investigations into homidium as a chemotherapeutic drug 
are reported in Chapter 5. Two groups of five animals were inoculated with 
two different populations of T. congolense; one drug-sensitive (IL 1180) and 
the other drug-resistant (IL 3330). The animals were treated with homidium 
bromide at 1 mg k g 1 seven days following detection of trypanosomes. No 
trypanosomes were detected in the cattle infected with the drug-sensitive 
trypanosome population within 24 hours in four and 48 hours in of five cattle 
following treatment. The animals remained aparasitaemic up to the end of the 
observation period of 90 days post-treatment. Whist trypanosomes did not 
disappear from the circulation following treatment of cattle infected with drug- 
resistant trypanosome population, low serum homidium concentrations of 
between 0.1 and 0.3 ng m l1 remained in the circulation for over 10 weeks 
following treatment. Both groups showed an increase in the rate of drug 
elimination within the first week of treatment which reverted back to normal 
following disappearance of trypanosomes from circulation of cattle treated 
with drug-sensitive trypanosome population. This accelerated rate of drug 
elimination was maintained in the presence of drug-resistant trypanosomes 
until no drug was detectable within 10 days of treatment.
Investigations into homidium as a chemoprophylactic drug under 
controlled conditions are reported in Chapter 6. Following monthly 
trypanosome challenge of homidium-treated cattle using the same T. 
congolense populations mentioned above, trypanosomes were detected in 
blood of the five cattle challenged with the drug-sensitive trypanosome
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population after 120,134, 137, 143 and 144 days following treatment. 
Homidium concentrations of between 0.1 and 0.3 ng m l1 were detectable for 
over 10 weeks in circulation in four out of five cattle challenged with drug- 
sensitive trypanosome population. However, trypanosomes were detected in 
the circulation of all the five cattle challenged with the drug-resistant 
trypanosome population eight to nine days following the first challenge at 30 
days post-treatment. Serum homidium concentrations were undetectable 
within 13 days of challenge.
Reported in Chapter 7 is a field study on homidium prophylaxis carried 
out on Galana Ranch, Kenya, an area of endemic trypanosomiasis, to 
determine serum homidium concentrations in cattle under prophylactic cover 
exposed to natural trypanosome challenge and to investigate possible 
indications of drug resistance. Over 90% of exposed animals were protected 
for a period of 14 weeks following treatment. The results also demonstrated 
that serum homidium concentrations could be determined successfully in 
ranch cattle where large numbers of animals were involved. There was 
evidence of drug resistance.
Homidium pharmacokinetics in Boran cattle using both ELISA and 
radiometric methods are compared in Chapter 8. Extensive extravascular 
distribution of the drug was demonstrated using both methods. However, 
following i.v. injection, no drug was detectable within 17 days of treatment 
using the ELISA method whilst concentrations of approximately 4 ng m l1 
were detectable up to 4 weeks using the radiometric method. This suggested 
presence of metabolites. For periods after 24 hours following i.m. treatment, 
concentrations were ten-fold higher using the radiometric method when 
compared with those obtained by use of the ELISA method.
In a comparative study reported in Chapter 9 between 6-14C homidium 
and 6-14C isometamidium, extensive extravascular distribution of both drugs 
was demonstrated following i.v. treatment of Boran cattle. Following i.m.
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treatment, the rate of release of homidium from the injection site depot was 
faster than that observed following treatment of cattle with isometamidium
1
hence differences in prophylactic periods.
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PART ONE
THE AFRICAN TRYPANOSOMIASES 
Overview
The African trypanosomiases constitute a group of closely related 
diseases that affect man and livestock whose causative organism is the 
haemoprotozoan parasite, the trypanosome. The disease is known as 'nagana' 
in cattle, 'surra’ in camels and ’sleeping sickness' in humans.
The severe epidemics of human trypanosomiases experienced by many 
African countries in the early decades of the 20th century led to the 
development and use of trypanocidal drugs to control the epidemics with little 
attention given to the animal trypanosomiases (Jordan, 1994). The increase in 
the human population following these control measures led to a demand for 
increased outputs from domestic livestock, thereby shifting the attention to 
animal trypanosomiasis. As in the case of human trypanosomiasis, control of 
the disease in livestock was mainly by use of drugs. However, up to the 
present day, the strong influence of the disease in precluding the keeping of 
susceptible breeds of cattle and other livestock is still apparent in many areas. 
Trypanocidal drugs have, however, permitted cattle and tsetse to co-exist and 
the heavily infested fly belts are slowly being exploited for cattle rearing by 
use of integrated tsetse and trypanosomiasis control measures in which tsetse 
populations are reduced by use of traps and targets and infected animals are 
treated with the available trypanocidal drugs.
In sub-Saharan Africa, domestic livestock have varied and important 
roles within the rural communities in which they are kept, and the benefits 
derived from livestock are both direct and indirect. Domestic animals provide 
meat, milk, transport, animal traction, manure, hides, skins, fuel and wool. 
Furthermore, milk and live animals are not only sold to obtain extra income 
for households as a direct benefit, but also to provide protein for improved
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nutritional status to the population as an indirect benefit. Wealth in many 
communities is measured by the number of animals one possesses. Thus, the 
social security provided by domestic livestock to most of the rural 
communities who consider livestock as their major investment is also 
important.
Trypanosomiasis has severely limited animal production in many 
countries of sub-Saharan Africa, covering approximately 10 million square 
kilometres in 38 countries (WHO/FAO/OIE, 1963). An increase in the human 
population of approximately 50% between 1965 and 1992 in sub-Saharan 
Africa (Winrock Report, 1992) emphasises the need to increase animal 
production in order to be able to provide enough protein for this ever 
increasing population. However, the risk of trypanosomiasis precludes farmers 
from keeping cattle and small ruminants in many areas, and accounts for much 
of Africa's low livestock productivity. Current figures approximate the 
continent's production of animal protein per hectare at one seventieth that 
produced by Europe (ILRAD Report, 1990). Since many of the areas inhabited 
by the tsetse flies are potentially the most agriculturally productive in Africa, 
the impact of trypanosomiasis is even greater than these figures suggest. At the 
present time, 30% of Africa's cattle population, estimated at 174 million, as 
well as comparable numbers of small ruminants (ILRAD Report, 1990) are at 
risk from the disease. According to the KETRI Strategic Plan, 1990-2000 
(1991), 30 million of the 174 million cattle are found in 7 million square 
kilometres of savannah and light woodland. FAO estimates that if the 7 
million square kilometres were cleared of the disease, the cattle population 
would be raised by a further 120 million head.
Kenya will be used to illustrate how natural resources in many areas of 
Africa remain under-exploited due to trypanosomiasis. One of the many 
problems facing Kenya now and in the future is the generation of employment 
and an adequate food supply for its population. The mainstay of the Kenyan
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economy is agriculture which contributes 60% of Kenya's total exports and 
accounts for 80% of the wage and non-wage employment in the country. 
Furthermore, it is estimated that by the year 2000, Kenya will need 540,000 
tonnes of beef (three times the 1990 consumption) for its population taking 
into account the population increase. It is further estimated that the country 
will only be able to produce 420,000 tonnes of beef per year using the present 
production technologies. Reclamation of the arid and semi-arid areas, over 
60% of which are tsetse infested, appears to be the only option open to the 
government to significantly increase beef production (KETRI Strategic Plan, 
1990-2000).
Kenya's livestock population has been estimated at 20 million head of 
cattle, 30 million sheep and goats and 800,000 camels out of which three- 
quarters are in the arid and semi-arid areas. It is estimated that about 25% of 
the Kenya landmass cannot support livestock because of trypanosomiasis. 
Losses of up to 30% have been experienced where cattle have been kept in 
these areas despite the disease. Camels which are economically important in 
the arid and semi-arid areas have an estimated mortality rate o f up to 70% due 
to the disease (KETRI Strategic Plan, 1990-2000).
Both indigenous cattle and exotic milk and beef cattle are kept on a 
commercial basis while sheep, goats and camels are kept on a subsistence 
level by the small scale farmer. The majority of beef cattle, sheep, goats and 
camels are found in the arid and semi-arid areas of Kenya, areas of extremely 
fragile ecosystems. Furthermore, most of Kenya's farmers are small scale 
farmers, living on land holdings of less than two hectares and carrying out 
mixed farming using mostly family labour. With fewer resources to support 
livestock production, cost-effective and sustained methods of disease control 
must be targeted to actively involve the local communities. The economic 
planning for Kenya has recognised the important role played by both crops 
and livestock in the economy and this has led to the introduction of
3
programmes such as zero-grazing dairy farming through the National Dairy 
Development Project (NDDP) for the small scale farmer. An assessment of the 
impact of tsetse and trypanosomiasis under the zero-grazing programme 
involving the small scale farmer in both the high and low trypanosomiasis risk 
areas of the coastal region of Kenya has been described by Maloo (1993).
From the aforegoing, it is evident that tsetse and trypanosomiasis are of great 
economic importance to Kenya where many areas have remained under­
exploited due to the presence of the disease.
It has been demonstrated that wildlife act as reservoirs for both human 
and animal-infective trypanosomes (Guedegbe et al., 1992) but because 
wildlife in the parks are the most important foreign exchange earner in most 
African countries, conservation strategies have to take this into account, 
because of the conflict that has emerged between man, livestock and wildlife 
due to pressure on the land by the expanding rural population.
Because of the other, more important communicable diseases in Africa, 
control programmes for human trypanosomiasis have not received due 
attention. WHO (Kuzoe, 1993) estimates suggest that some 50 million people 
are at risk of acquiring the disease which is endemic in 36 countries of sub- 
Saharan Africa. This estimate, may, however, be much lower since tsetse 
habitats have been affected over the years due to human activity. Surveillance 
breakdown was the major cause of the outbreaks of the disease in Uganda and 
Sudan in the 1980s. As has already been mentioned, agricultural activities in 
most of the countries affected by tsetse and trypanosomiasis are carried out by 
the small scale farmer, who is dependent mainly on family labour. The 
presence of the human disease will therefore affect agricultural production and 
reduce family incomes through lack of farm labour.
The impact o f trypanosomiasis on livestock is difficult to assess 
directly, but it has been estimated that over 25 million doses of trypanocidal 
drugs are used annually for treatment (Holmes and Torr, 1988). The number of
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of trypanocidal drugs currendy on the market for the treatment of animal 
trypanosomiasis is limited. Apart from melarsenoxide cysteamine for 
treatment of the disease in camels and horses, no new drugs have been 
introduced for a long time and the situation is likely to remain so for some 
time to come due to the expenses involved in producing new drugs, and the 
inability of the African farmers to pay high prices for veterinary drugs. Lack 
of control in the use of trypanocidal drugs has led to problems such as 
underdosing and the resultant development of drug resistance. Ideally, 
application of trypanocidal drugs should be under the control of qualified 
veterinary authorities, but in most of sub-Saharan Africa this is not the case 
and livestock owners apply the drugs themselves often resulting in 
inappropriate drug usage. Strategic use of trypanocidal drugs under the 
supervision of qualified personnel could assist in increasing animal 
productivity, while minimising the problem of drug resistance. The recently 
developed enzyme-linked immunosorbent assay (ELISA) for the detection and 
monitoring of isometamidium in cattle blood plus the work reported in this 
thesis on an ELISA for homidium will enhance our understanding of the 
pharmacokinetics and pharmacodynamics of trypanocides in the field. The 
assays will also be useful in identifying suspected cases of drug resistance in 
the field.
To be able to work out appropriate control strategies, data is needed not 
only on the species of tsetse, fly populations and infection rates in both the 
flies and livestock but also on the type of vegetation and the prevailing 
climatic conditions. The use of meteorological and remotely-sensed satellite 
data has been used in the prediction of fly movements and when the disease 
incidence is likely to be high (Rogers and Williams, 1993; Rogers et al.,
1994). Rogers et al. (1994) used a combination of ground-based and remotely- 
sensed data to describe the distribution of five species of tsetse in Togo. Their 
work highlighted the importance of spatial and temporal variations in risk as
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important determinants of the impact of trypanosomiasis on humans, domestic 
animals and agricultural activities. Similar analyses in other affected countries 
could be used to predict occurrence and abundance of flies in order to plan 
tsetse control campaigns and appropriate drug treatment regimens.
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PART TWO
THE AFRICAN TRYPANOSOMIASES 
THE PARASITE
Trypanosomes are members of the Order Kinetoplastida, Family 
Trypanosomatidae and Genus Trypanosoma. They are divided into two 
groups, depending on their site of development in the insect vector and mode 
of disease transmission. The salivarian group, to which most of the parasites 
of veterinary importance belong, complete their development in the salivary 
glands and the proboscis of tsetse flies (Genus: Glossina). The stercoraria 
group, of which T. cruzi is the most important member, develop in the 
alimentary canal of the vector.
In the invertebrate host
When tsetse feed on an infected animal, trypanosomes are taken in with 
the blood meal. They develop in various organs of the fly. The life cycle 
stages for T. brucei, T. congolense and T. vivax may be identified partly by 
the shape of the trypanosome and partly by the relative positions of the 
nucleus, kinetoplast and point of origin of the flagellum. The various stages 
include the trypomastigotes, epimastigotes and metatrypanosomes. Only the 
metatrypanosomes (metacyclics or the bloodstream forms) are infective to 
susceptible mammals on which the infected fly feeds.
In the vertebrate host
Once infected, the trypanosomes multiply initially under the skin at the 
site o f inoculation. This happens at the same time as the development of a 
swelling (chancre) at the site of the tsetse bite (Akol and Murray, 1982). The 
trypanosomes assume a flattened spindle shape known as the trypomastigote 
which has an undulating membrane bordered by a flagellum running along the
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length of the body. The flagellum arises at one end of the body, the posterior 
end, near to a deeply staining body, the kinetoplast. After running along the 
length of the undulating membrane, it may continue as a free flagellum past 
the end of the body as in T. vivax or there may be no free flagellum as in T. 
congolense. Some bloodstream forms of T. brucei have a free flagellum whilst 
others do not.
THE VECTOR
The genus Glossina to which the tsetse fly belongs is divided into three 
distinct groups (subgenera) whose importance is determined by their 
distribution and feeding preferences (Mulligan, 1970). These are:
The fusca or forest group
Out of the twelve species contained in this group only three are of 
economic importance because of their role in the transmission of pathogenic 
trypanosomes to livestock. These are G. brevipalpis, G. longipennis and G. 
fuscipleuris.
The palpalis or riverine group
The important species in the palpalis or riverine group are G. palpalis 
and G.fuscipes; both are vectors of human and animal trypanosomiasis.
The morsitans or savannah group
The most important species in this group is G. morsitans which occurs 
in East, West and Central Africa, and is the major vector for the transmission 
o f pathogenic trypanosomes to humans. It is found mainly in the savannah 
woodlands. The other species of significance in this group are G. longipalpis, 
G. pallidipes and G. austeni.
DISEASE TRANSMISSION
The main mode of disease transmission is by inoculation through an 
infective insect bite. The exception is T. cruzi in which infection is either by 
skin contamination or oral ingestion by the host. Trypanosoma cruzi is the 
causative organism of Chagas' disease, occurring mainly in Central and South 
America. Since this parasite is not the subject of the present study, it will not 
be discussed further.
The female tsetse fly mates only once in its lifetime and once infected 
remains infected for life. Besides the tsetse fly, several species of biting flies 
also appear to play an important role in parasite transmission. They are 
believed to be particularly important in the transmission of Trypanosoma 
evansi, the causative organism of camel trypanosomiasis, and T. vivax.
THE DISEASE IN CATTLE
In sub-Saharan Africa, mixed trypanosome infections are commonly 
observed in cattle in the field (Stephen, 1970; Mwangi, 1993), and in cattle the 
disease is caused mainly by T. congolense and T. vivax transmitted cyclically 
through the tsetse fly.
Pathology and pathogenesis
The pathology and pathogenesis of African trypanosomiasis in 
domestic livestock is dominated by the trypanosome's ability to undergo 
antigenic variation. Murray and Morrison (1980) recognised three broad areas 
when considering the pathology and pathogenesis of animal trypanosomiasis. 
These included the early events following the tsetse fly bite and the 
subsequent changes in the lymphoid system, anaemia and specific organ and 
tissue damage.
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Development of chancre
Generally, in 4 to 10 days following the bite from an infective 
Glossina, a hard, painful nodule usually develops at the site of the bite and 
there is often heat and swelling of the surrounding tissues. This lesion is 
referred to as the 'trypanosomal chancre' and it is here that the metacyclic 
trypanosomes develop into long thin forms which multiply rapidly and 
ultimately invade the bloodstream and tissues via the lymph vessels and nodes. 
It has been shown that development of the chancre and the enlargement of the 
draining lymph nodes occur simultaneously (Akol and Murray, 1982). One to 
three weeks after the infective bite (commonly 10 days) there is often a sharp 
attack of fever in response to the invasion of the peripheral blood by the 
trypanosomes.
Pre-patent period
The period between the infective tsetse bite and the demonstration of 
trypanosomes in peripheral blood (pre-patent period) in the vertebrate host 
varies. According to Stephen (1986), 'factors governing the length of the pre­
patent period in the vertebrate host are undoubtedly complex. They probably 
relate to a number of elements in the host such as innate resistance, antibody 
levels, nutritional state, age, sex, intercurrent infections, hormonal levels and 
others; to the life history of the trypanosome such as residence in an abnormal 
host, exposure to therapeutic drugs or plasma immunoglobulins, frequency of 
cyclical or mechanical passage, age of metatrypanosomes (metacyclics) and 
others; to the characteristics of the fly vector such as ability o f mouth parts to 
probe deeply and extensively, suitability of the saliva to support cyclical 
development, density of metacyclics per unit volume of saliva, sex and age of 
the fly and the presence of mixed infections' For one to two weeks following 
a tsetse fly bite, parasitaemias are often low and it can be difficult to find 
trypanosomes using the wet smear technique commonly employed in the field.
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The sensitivity of the diagnostic method used is, therefore, important in the 
detection of early infections.
Clinical signs
Trypanosome infections in man and domestic animals have been 
associated with peaks of fever. These fever peaks usually coincide more or 
less with the appearance of trypanosomes in the bloodstream. These pyrexial 
reactions are often severe with temperatures reaching 105°F (40.5°C) in cattle, 
sheep and goats. With less virulent populations of trypanosomes, the pyrexial 
peaks and parasitaemia levels may gradually lessen until hardly noticeable. 
Other clinical signs include the development of anaemia, swelling of the 
lymph nodes and general wasting.
Pathophysiology
Following establishment of a trypanosome infection, several changes 
occur in the host. These include anaemia, low packed cell volume, decreased 
serum albumin, decreased total serum globulin levels, changes in endocrine 
function (Mutayoba et al., 1995) and gross anatomy.
Katunguka-Rwakishaya et al. (1995), studied the influence of energy 
intake on the pathophysiology of T. congolense in sheep. Their studies 
involved the measurement of intensity of parasitaemia, degree of anaemia, live 
body weight gains and biochemical changes in two groups of sheep, one on 
high protein diet and the other on a low protein diet. Their findings 
demonstrated that infected animals with a low energy intake had a longer 
mean pre-patent period (between 12 and 26 days) than the animals with a high 
energy intake (between 12 and 16 days). However, following the 
establishment of infection, low energy intake animals developed more severe 
anaemia and greater growth retardation compared to the animals with a high 
energy intake. The anaemia observed was due to destruction of red blood cells
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and haemodilution. Both infected groups exhibited significant reductions in 
serum total lipids, phospholipids, plasma cholesterol and albumin. These 
changes were more severe in the low energy intake animals.
Most tissues and organs are damaged during the course of infection 
although some are more severely affected than others. One organ which 
undergoes persistent damage is the heart. Initially, lesions occur beneath the 
epicardium and the endorcardium and in advanced cases the entire 
myocardium may be involved (Murray and Morrison, 1980). This leads to 
distortion and degeneration of myocardial fibres. The pericardium eventually 
fills with fluid, probably due to increased vascular permeability. Based on the 
clinical and pathological findings, death in trypanosome-infected cattle is 
usually due to congestive heart failure caused by a combination of anaemia, 
micro-circulatory disturbances and myocardial damage.
The effects of trypanosome infections on reproduction have been 
studied in sheep, goats and cattle (Bealby et al., 1993; Okuna et al., 1993; 
Mutayoba et al., 1995). Most of these reproductive disorders have been 
reviewed in detail by Sekoni (1994). These include degeneration of the 
hypothalamus, pituitary glands and gonads with consequent disruptions in the 
secretions and plasma concentrations of the hormones necessary for the 
normal reproductive processes in both sexes. Reproductive disorders in male 
animals include delayed puberty, loss of libido and severe degenerative 
changes of genitalia manifested by production of very poor semen. In female 
animals, the disease causes severe genital lesions plus abnormal oestrus 
cycles. In addition, trypanosome infections induce abnormal pregnancy, 
abortion, premature birth, low birth weight and stillbirths. Early treatment with 
trypanocides has shown that some of these disorders may be prevented 
(Bealby et al., 1993; Okuna et al., 1993) with a corresponding increase in 
reproduction.
Changes have also been observed in carbohydrate and lipid
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metabolism. Elevated levels of pyruvate have been reported in blood and urine 
of infected rabbits (Ashman and Seed (1973) cited by Tizard, 1985) draining 
the host's carbohydrate stores. The muscle wasting observed in chronically 
infected animals could be an attempt by the host through protein catabolism of 
muscle tissue to improve the poor energy state brought about by the excretion 
of large amounts of energy-rich compounds such as pyruvate. Both the 
pathophysiological and immunological changes observed during trypanosome 
infection are important in the pathogenesis of animal trypanosomiasis.
Clausen et al. (1993) in their studies on the pathology and pathogenesis 
of the disease in different breeds of cattle observed that in susceptible cattle 
the disease is associated with a marked reduction in food intake, swelling of 
subcutaneous glands and development of a rough hair coat which has a spiked 
appearance. As the disease progresses the mucous membranes become pale 
and the animals become weak and unable to walk. The animals also become 
thin and emaciated with evident muscular wasting and weight loss.
The role of other diseases
Ticks and helminths have been reported to influence the course of 
trypanosomiasis in cattle. Dwinger et al. (1994) in their studies on the effects 
of trypanosome and helminth infections on health and production parameters 
of N'Dama cattle in The Gambia found that there was an increased 
susceptibility to trypanosomiasis in animals infected with helminths.
Host nutritional status
Studies have been carried out on the effects of nutrition on the degree 
of anaemia in infected N'Dama cattle (Agyemang et al., 1990) in which the 
PCV, as a measure of anaemia, was monitored. Two nutritional groups were 
compared; both grazing on natural unimproved pastures but one group given 
supplements. Whereas both groups became naturally infected with
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T. congolense while grazing, the group which received supplements recovered 
more rapidly from the anaemia produced by trypanosome infections. This 
indicates that the lack of adequate nutrition which occurs under field 
conditions constitutes a stressful condition that could weaken the degree of 
trypanotolerance of animals. In studies involving two groups of sheep infected 
with T. congolense, one on a high and the other on a low protein diet, 
Katunguka-Rwakishaya et al. (1993) showed that both groups developed 
similar degrees of anaemia. However, the mean corpuscular volumes and 
appearance of normoblasts in the circulation was greater in animals on a high 
protein diet. Gain in live weight in animals on the high protein diet was similar 
to the uninfected controls whereas those on low protein diet gained 
significantly less weight. They also found that all infected animals in the two 
groups recovered from anaemia following treatment with isometamidium 
chloride but the recovery rate was faster in the animals on the high protein 
diet. This showed that high protein intake enhances the rate of recovery 
following chemotherapy.
SOCIO-ECONOMIC IMPACT OF TSETSE AND
TRYPANOSOMIASIS
There are direct and indirect consequences of tsetse and 
trypanosomiasis. One study carried out in Busia, Western Kenya, (Kamara and 
Echessah, 1994) demonstrated some of the commonly observed consequences. 
The direct consequences included decreased growth rate and increased 
mortality of cattle and other livestock. These adversely affected agricultural 
production due to a reduction in the number of draft animals and manure for 
use as fertiliser thereby affecting the crop yield; reduced incomes due to 
decreases in milk, live animals and other farm products for sale and fewer 
animals to pay dowry leading to fewer wives per husband and a reduction in 
family labour.
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Finally, because of trypanosomiasis, livestock improvement was 
inhibited because local communities prefer not to cross-breed the local Zebus 
for fear that the animals may die of the disease. However, crossbreeds have 
performed well in other parts of sub-Saharan Africa where they have been 
introduced and their reproductive performance evaluated (Itty et al., 1995a, 
b).
Traditionally, tsetse-infested areas have been avoided and this leads to bush 
encroachment, and often further expansion of tsetse habitats. Several social 
activities such as fetching water from streams, visiting relatives, weeding or 
just relaxing outside one's house are also affected for fear of contracting the 
disease.
From the aforegoing, it is evident that trypanosomiasis is of great 
economic significance due to its impact on animal productivity and human 
activity in the tsetse infested countries o f sub-Saharan Africa. Besides 
affecting humans in terms of reduced activity, the economic losses due to the 
disease in susceptible animals are high.
DIAGNOSTIC TECHNIQUES
Treatment of infections in the field depends on clinical diagnosis or the 
demonstration of parasites in the peripheral blood. However, the success of 
diagnosis depends on the sensitivity of the diagnostic technique used, 
especially in cases of chronic disease when parasites cannot often be detected 
by parasitological techniques (Ogwu et al., 1985).
Once animals are infected, intervention with drugs leads to recovery if 
the parasites are drug sensitive. However, the success o f treatment also 
depends on when the drug is administered to infected animals; greater success 
in treatment is achieved when the animals are treated early in infection 
(Murray and Dexter, 1988). Several techniques have been used in diagnosis 
including clinical, parasitological, immunological and biochemical.
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Clinical diagnosis
The occurrence of clinical signs may indicate cattle are suffering from 
trypanosomiasis but they are not associated exclusively with the disease. Thus, 
acute forms of trypanosomiasis may be confused with diseases such as 
babesiosis and rinderpest. Chronic trypanosomiasis may be difficult to 
distinguish clinically from malnutrition and/or severe intestinal helminthiasis. 
A presumptive diagnosis must, therefore, be confirmed by demonstration of 
trypanosomes in infected animals.
Parasitological techniques
These techniques depend on the demonstration of trypanosomes in the 
peripheral blood of infected animals.
Wet films
A wet blood smear consists of a small drop of fresh blood obtained 
from an ear or tail vein placed on a slide, covered with a coverslip and 
examined for trypanosomes. The parasites are detected by their movement or 
by the disturbance they cause among the blood cells. Examination of wet films 
provides a quick and easy means of diagnosis in the laboratory.
Thick films
A drop of blood is placed on a clean microscope slide and a thick film 
prepared by using the comer of another slide to produce a rounded smear of 1- 
2 cm in diameter. The slide is then rapidly air dried, placed in distilled water 
for five minutes to dehaemoglobinise prior to staining in 10% Giemsa and 
examination under the microscope (MacLennan, 1957). This technique is the 
most commonly used method for routine diagnosis of bovine trypanosomiasis 
in the field. Thick films are usually used in conjunction with thin films in 
which species identification can be made more confidently.
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Thin films
A drop of blood is placed at one end of a clean grease-free microscope 
slide and a thin film prepared by spreading the drop along the length of the 
slide with a straight edge of another slide or rectangular coverslip, quickly air- 
dried and fixed for three minutes in methanol. The film is then stained in 10% 
Giemsa for 30 minutes followed by examination for parasites under oil 
immersion.
Buffy coat dark ground illumination
An EDTA-coated capillary tube is filled with blood and centrifuged in a 
microhematocrit centrifuge for 10 minutes. The capillary is then cut with a 
diamond pencil one mm below the buffy coat to include the uppermost layer 
of red cells and two mm above to include plasma. The usual practice in the 
field, however, is that the capillary tube is cut once two mm away from the 
buffy-coat junction. The contents of the tube are then gently expressed onto a 
clean slide, mixed and covered with a 22 x 22 mm coverslip and examined 
under the microscope. To provide phase contrast, a combination of Phaco 2 
NPL 25/0.50 objective, a Zemicke 402 condenser and a periplan NF xlO 
eyepieces may be used (Murray et al., 1977).
Mouse sub-inoculation
Blood from an infected animal in 0.2 ml phosphate-buffered-saline- 
glucose, pH 8.0, is inoculated intraperitoneally into individual mice. Wet film 
preparations of tail blood from these mice are then examined three times a 
week for at least the following 30 days for the detection of trypanosomes.
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Immunological techniques
(a) Antigen enzyme linked immunosorbent assays (ELISA)
Scientists at the International Livestock Research Institute (ILRI; 
formerly International Laboratory for Research on Animal Diseases, ILRAD) 
have developed assays which can be used to detect circulating antigens of T. 
congolense and T. vivax (ILRAD Report, 1990; Masake and Nantulya, 1991). 
These are referred to as antigen-trapping ELISAs. In these assays, 
trypanosome species-specific monoclonal antibodies are used to capture the 
circulating trypanosome antigens in the serum of infected animals. The same 
antibody labelled with horseradish peroxidase is then introduced and binds to 
the free antigen epitopes of the immobilised antigen. The chromogen changes 
colour due to the activity of the peroxidase in the presence of substrate and is 
used to detect the labelled antibody. This is a sandwich ELISA.
(b) Antibody ELISA
In this technique, the circulating antibodies in the infected animals are 
detected rather than the antigen. The limitation of this technique is that it will 
not differentiate between current and past infections because antibodies may 
persist for long periods following treatment (Luckins et al., 1979).
A recent study was carried out to compare several diagnostic 
techniques using serum samples collected over a period of three years (1989- 
1991) from cattle maintained under conditions of varying trypanosomiasis 
risk in different parts of Kenya (Mwangi, 1993). The results showed that 
antigen ELISA detected a high proportion of infections and demonstrated the 
existence of a high proportion of mixed infections in comparison to the 
parasitological techniques. In high tsetse challenge areas, antigens were 
detected in over 50% of the animals compared to 20% in the low tsetse 
challenge areas. Following treatment o f infected animals and their withdrawal
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from the trypanosomiasis risk area, parasites were no longer demonstrated but 
both antigens and antibodies persisted for up to 7 months. The antigen-ELISA 
is therefore a useful diagnostic method in the detection of early infections. 
Even so, Nantulya (1989) showed that early in the infection, the test can give 
negative results due to absence or low levels of antigens in blood. He 
suggested that, in some situations, a combination of techniques such as the 
antigen-ELISA with parasitological techniques such as the microhematocrit 
centrifugation may be necessary. The results suggest that in epidemiological 
studies, a combination of techniques is necessary for complete assessment of 
the infection rates.
Biochemical techniques
DNA probes
DNA probes have been developed that will detect the trypanosome 
genes rather than the products of trypanosome genes which are the basis of 
antigen-ELISA diagnostic procedures. The DNA probe technique is highly 
specific and sensitive but its reliance on radioisotope labelling is a major 
drawback. The production of probes using alternative labelling will make the 
technique much safer to use in the field.
TSETSE AND TRYPANOSOMIASIS CONTROL 
Overview
Methods employed in the control of the disease have been many and 
varied. These include methods directed at the vector and those directed at 
controlling the parasite that causes the disease. For vector control, several 
methods have been employed, some of which are now no longer in use such as 
game eradication. Others, however, have undergone tremendous 
improvements such as tsetse traps. The most popular and widespread method 
o f parasite control remains the use of chemotherapy.
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Parasite Control 
Introduction
Control of animal trypanosomiasis by targeting the parasites has relied 
on three methods: (a) use of chemotherapeutic and chemoprophylactic agents
(b) rearing of trypanotolerant breeds of cattle and (c) vaccination against 
trypanosomiasis. Each of these methods will be considered separately.
Chemotherapy
Besides the expenses involved, vector control methods alone have, 
almost without exception, not been effective on a long-term basis in dealing 
with trypanosomiasis and there continues to be extensive use o f trypanocidal 
drugs for treatment and/or prophylaxis. Even in areas where traps and targets 
are in force, trypanocidal drugs are still needed to deal with infections due to 
the residual tsetse populations. Chemotherapy, therefore, constitutes an 
important method of controlling the disease in man and livestock in most 
African countries.
Treatment of animals in the field has relied on demonstration of 
parasites in the peripheral blood. As already mentioned, detection of parasites 
early during an infection will depend on the sensitivity of the diagnostic 
method used. Treatment of cattle following trypanosome infection leads to 
cure if the trypanosomes are drug sensitive. A brief look at the interaction 
between drugs, trypanosomes and cattle in the field is important in 
understanding drug performance under different field situations.
Natural trypanosomiasis incidence and chemotherapy
Whiteside (1962) in his work on the interactions between drugs, 
trypanosomes and cattle under field conditions observed that in a given area, 
the frequency of infective tsetse bites is proportional to the fly density and this 
affects the degree of protection afforded by drugs.
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This observation has been confirmed by studies carried out in the 
coastal region of Kenya by Dolan et al. (1990, 1992) and Maloo (1993). It was 
demonstrated that a low number of treatments per annum afforded good 
protection when the fly density was low (Mwambu, 1971; Dolan et al., 1990; 
Maloo, 1993). However, when trypanosome challenge was high more frequent 
treatments were required. It appears, therefore, that the successful use of drugs 
is dependant on the density of infected flies, the rate of transmission to 
susceptible animals and the drug sensitivity of the trypanosomes being 
transmitted; the higher the incidence of infections and/or the less the 
sensitivity of trypanosomes being transmitted to the drugs, the shorter the 
prophylactic period.
Immune response, drugs and natural trypanosomiasis incidence
Whiteside (1962), in studies carried out at the Kenyan coast using Zebu 
cattle maintained on diminazene treatment, observed that there was a 
connection between drugs and immune response; animals receiving regular 
treatment and exposed to natural tsetse challenge slowly developed immunity. 
This was demonstrated by a reduction in the number of infections from five to 
just over one in a year following diminazene treatment of infected animals 
exposed to natural tsetse challenge.
Following infection of animals with trypanosomes, there is an 
activation of the immune system. Associated with this activation, some 
animals such as the mice suffer from severe immunosuppression (Tizard, 
1985). Whilst immunosuppression during trypanosome infections in cattle is 
much less marked, it is significant in the laboratory animals. Holmes et al. 
(1979) in their studies on the immunological clearance of 75Se-labelled T. 
brucei in mice demonstrated that between 97 and 99% of the radioactivity was 
protein bound in the parasite and spontaneous elution in vitro was 10% in 4 
hours. The vast majority of labelled trypanosomes remained in the circulation
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of normal mice but in immune mice, they rapidly disappeared from the blood.
In their review on the immune dependence of chemotherapy, Doenhoff 
et al. (1991) noted that immunosuppression reduces the efficacy of 
chemotherapy of several parasitic diseases including trypanosomiasis, 
schistosomiasis and malaria.
Osman et al. (1992) studied the effects of immunosuppression on the 
development of drug resistance by trypanosomes in mice infected with various 
clones of T. evansi. Their results demonstrated the rapid development of high 
levels of resistance to melarsenoxide cysteamine, diminazene and 
isometamidium in the clones following frequent passage in immunosuppressed 
mice given sub-curative drug treatments. However, drug resistance did not 
develop when frequent passage was undertaken in normal immunocompetent 
mice infected with the same clones of T. evansi. Their results suggested that 
impairment of the host immune system may lead to rapid development of 
resistance. An intact immune response is therefore, necessary for effective 
chemotherapy.
Drug resistance
Failure of trypanosomes to disappear completely from the blood 
following the administration of therapeutic doses of drugs could be attributed 
to many factors, one of which is drug resistance. Resistance has been reported 
to all the trypanocides currently in use, including the recently introduced 
melarsenoxide (Osman et al. 1992; Pospichal et al., 1994). Resistance can be 
either innate or acquired. Wemsdorfer (1994) in his review on resistance in 
Plasmodium falciparum, noted that natural populations of this parasite are 
composed of different populations of parasites with varying degrees of drug 
sensitivity. Sensitive populations include all organisms which will be 
eliminated by the minimum effective concentration. There is, however, a small 
proportion of parasites that is able to survive the minimum concentration. This
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small group in the natural population which has not been exposed to the drug 
can be said to posses innate resistance. Innate resistance in T. vivax to 
homidium has been reported (Unsworth, 1954b). If a parasite population is 
exposed to the minimum effective drug concentrations, the sensitive 
population will be eliminated leaving a population that can withstand the these 
concentrations. This results in the selection of a new population that is less 
sensitive than the population prior to exposure. Further selection will take 
place upon renewed drug pressure, resulting in enhanced resistance (acquired).
When parasites are exposed to drug concentrations below the minimum 
effective concentration or to the minimum concentration but for a shorter 
period than is required to kill them, drug failure will occur.
Both innate and acquired resistance have been reported involving the 
different trypanocidal compounds ( reviewed by Kinabo, 1993; Peregrine and 
Mamman,1993). Jones-Davies (1967,1968) in his work on tsetse fly- 
transmitted trypanosomes of cattle in Northern Nigeria found strains o f T. 
vivax isolated from three different localities that were resistant to diminazene 
at 3.5 mg kg-1 b.w.; two of the isolates were sensitive to 7.0 mg kg-1 b.w. This 
was despite the fact that diminazene had been in use for a very short time (2 
years) since the withdrawal of homidium. Mwambu and Mayende (1971) have 
also reported the occurrence of diminazene-resistant strains of T. vivax in an 
area o f Eastern Uganda; the trypanosomes were resistant to 3.5 mg kg-1 b.w. 
and 7.0 mg kg-1 b.w. but sensitive to homidium at 1.0 mg kg-1 b.w. At the time 
of isolation of these trypanosomes, quinapyramine was widely used in this 
area, suggesting that these populations of trypanosomes may generally be 
resistant to quinapyramine and cross-resistant to diminazene. Both diminazene 
and quinapyramine are derivatives of Surfen C.
Bauer (1962) failed to induce resistance to diminazene in T. congolense 
in cattle by administering sub-curative doses of diminazene. In contrast, 
Whiteside (1963) produced two diminazene-resistant variants of
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T. congolense. Cross-resistance tests indicated that the trypanosomes 
remained susceptible to the recommended curative doses of other 
trypanocides. Gray and Roberts (1971), investigating the stability of 
diminazene resistance in a T. vivax strain showed that diminazene resistance 
can be maintained by cyclical transmission to antelope for a long period of 
time; the T. vivax strain retained resistance to diminazene aceturate at a dose 
rate of 7.0 mg kg*1 b.w. and quinapyramine sulphate at 5.0 mg kg-1 b.w. for 
periods o f 7 months in tsetse flies and antelope, and for a total period o f 29 
months in tsetse flies and cattle. More recent studies on diminazene resistance 
have demonstrated an 80-fold increase in diminazene resistance by the sub­
curative treatment of immunosuppressed mice infected with a cloned 
population of T. evansi over a 9-week period (Osman et al., 1992)
Occurrence of trypanosomes resistant to isometamidium has been 
reported in several studies (Pinder and Authie, 1984; Schonefeld et al., 1987; 
Peregrine et al., 1991). Using mice, Pinder and Authie (1984) isolated stocks 
of T. congolense from Burkina Faso which expressed a high level of resistance 
to both isometamidium and diminazene. Peregrine et al. (1991) derived 9 
clones from one of the T. congolense stocks reported by Pinder and Authie 
(1984) and characterised them in mice for their sensitivity to both diminazene 
and isometamidium. The results showed that all clones expressed high levels 
of resistance to isometamidium chloride and to diminazene aceturate with a 
50% curative dose value in mice ranging from 1.5 to 5.1 mg kg-1 b.w. for 
isometamidium and 5.1 to 21.0 mg kg-1 b.w. for diminazene. When the clone 
expressing the highest level of resistance to isometamidium in mice was tsetse 
transmitted to Boran cattle, the resulting infections were shown to be resistant 
to 2.0 mg kg-1 b.w. isometamidium chloride and 14 mg kg-1 b.w. diminazene 
aceturate given by the intramuscular route.
Fairclough (1963b) compared metamidium, isometamidium, 
diminazene and homidium under field conditions in an area o f medium to high
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tsetse challenge in Nigeria, and concluded that signs of drug resistance only 
appeared in the homidium group. Periods between infections in the 
diminazene and isometamidium groups lengthened as the tsetse fly numbers 
decreased. In contrast, the time between infections in the homidium-treated 
groups continued to shorten with decreased fly numbers; an indication of the 
development of drug resistance.
In the experiments of Jones-Davies and Folkers (1966), T. congolense 
strains resistant to 1 mg kg-1 b.w. homidium bromide were isolated from cattle 
in Nigeria and inoculated into groups of cattle. In one group, treatment with 
homidium at various dose rates ranging from 0.10 to 1.0 mg kg-1 was carried 
out 24 hours after inoculation with parasites; in the other group treatment was 
carried out at various dose rates ranging from 1.0 to 2.0 mg kg-1 on the seventh 
day of parasitaemia. Results showed that trypanosomes in all cattle established 
and multiplied producing disease symptoms suggesting the presence of 
homidium resistant trypanosomes. The strain of T. congolense used appeared 
to be resistant to homidium bromide at 2.0 mg kg*1 b.w. Scott and Pegram 
(1974) have reported the presence of T. congolense strains that are resistant to 
homidium in Ethiopia.
Development o f  drug resistance by trypanosomes
In the laboratory, resistance in trypanosomes has been induced through 
exposure to sub-curative doses whilst in the field, underdosing could be a 
contributing factor to the development of drug resistance. There are several 
ways in which underdosing can occur in the field. These include (1) 
inappropriate drug use in which drugs are administered by unqualified 
personnel often in the absence of proper diagnosis (2) treating animals on the 
basis of average rather than individual weights resulting in animals being 
underdosed and (3) keeping cattle on prophylactic treatment in a high tsetse 
challenge area for long periods of time. Prophylactic regimens give good
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protection throughout the year when the incidence of infections is low but this 
period is reduced in the presence of high tsetse challenge when incidence of 
infections is high (Dolan et., 1990,1992; Stevenson et al., 1995). It has been 
proposed that low concentrations of prophylactic agents remain in the 
circulation for long periods of time and if these are sub-curative, trypanosomes 
are exposed to these agents, which could lead to the development of 
resistance. The period of exposure of trypanosomes to drug levels below the 
minimum effective concentration with chemoprophylactic agents would be 
longer than with the curative drugs such as diminazene. This may be the 
reason why reports of resistance to prophylactic agents are more than those 
due to therapeutic drugs (Whiteside, 1962; Mamman et al., 1995).
Mass drug administration has been identified as a probable cause of 
drug resistance because it exerts a high selection pressure especially if sub- 
therapeutic doses are used (Wemsdorfer, 1994). Thus, the mass treatments 
with homidium which followed its introduction into the field, could have 
contributed to the rapid development of resistance to this drug in Northern 
Nigeria (Jones-Davies and Folkers, 1966).
Cross- resistance
Trypanosome populations resistant to one trypanocidal drug compound 
have been found to be resistant to other active trypanocidal drug compounds 
(Whiteside, 1962). The earliest report of cross-resistance was of 
quinapyramine-resistant trypanosomes showing resistance to 
phenanthridinium compounds. Later, a diminazene-resistant population of T. 
congolense was produced using quinapyramine in the laboratory (Whiteside,
1962).
Finally, development of multiple-drug resistance involving T. vivax in 
cattle in Kenya and Somalia, and T. congolense in Somalia, Burkina Faso and 
Ethiopia has been reported (Rottcher and Schillinger, 1985; Schonefeld et al.,
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1987; Ainanshe et al., 1992; Clausen et al., 1992; Codjia et al., 1993). It is 
possible that cross-resistance could have contributed to the multi-drug 
resistance observed.
Cross-resistance and chemical structure
Many of the currently available trypanocidal compounds share at least 
one moiety. It is therefore possible for trypanosomes resistant to one drug to 
be cross-resistant to the other related compound. Examples are homidium and 
isometamidium which share the homidium moiety; diminazene and 
isometamidium which share part of diminazene molecule; and diminazene and 
quinapyramine both of which are derivatives of Surfen C. From the 
aforegoing, it is possible for trypanosomes resistant to quinapyramine to be 
cross-resistant to diminazene and isometamidium due to structural similarities. 
The only two trypanocides which do not possess structural similarities are 
homidium and diminazene and these have been shown not to produce cross- 
resistant trypanosomes to each other. These were described as a 'sanative' pair 
by Whiteside (1962).
Control o f  drug resistance in the field
As mentioned above, the only drugs which do not produce trypanosome 
populations cross-resistant to each other are diminazene and homidium. Thus, 
Whiteside (1962) suggested the use of homidium in the field until signs of 
drug resistance appear, after which the drug should be withdrawn to be 
replaced by diminazene for one year followed by re-introduction of 
homidium. Use of diminazene alone in the field as a cure for infected animals 
is expensive because of the number of doses required to treat each animal per 
year since it does not provide long periods of protection (Mwambu, 1971).
The usual practice in the field has therefore been the use of block treatment 
with diminazene followed by another block treatment with a
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chemoprophylactic agent such as homidium or isometamidium. Any animal 
developing breakthrough trypanosome infections during the prophylactic 
cover would be treated with diminazene. This has made it possible to keep 
cattle economically in tsetse infested areas.
Trypanotolerant breeds of cattle
Although the wild animals of Africa harbour trypanosomes, they are 
generally resistant to the effects of trypanosome infections. They have become 
resistant (or tolerant) to the effects of trypanosome infections due to constant 
exposure to infection over many generations. In domestic livestock, the 
susceptibility to trypanosome infection varies in different breeds. Resistant 
(trypanotolerant) breeds of cattle include the N'Dama and the Muturu in which 
the disease is usually transient and terminates in recovery. In susceptible 
breeds such as the West African Zebu, the disease is acute or chronic and 
usually terminates in death if there is no intervention with drugs. Results of 
several studies involving trypanosome-infected cattle breeds such as the 
N'Dama, Baoule, Orma and Galana Boran and the Masai Zebu have shown 
superior performance of trypanotolerant cattle in terms of control of anaemia 
(measured by the packed cell volume) during infection compared to the 
susceptible breeds (Ismail, 1988; Kora et al., 1992; Clausen et al., 1993; 
Mwangi, 1993; Andrianarivo et al., 1995). The introduction of trypanotolerant 
breeds of cattle into areas and communities devoid of cattle has been reported 
(Itty et al., 1995a, b) and their productivity evaluated (Dwinger et al., 1994).
Although usually tolerant to trypanosomiasis, trypanotolerant breeds 
can succumb to trypanosomiasis when exposed to high challenge in a new 
area, or when under stress caused by factors such as malnutrition or inter­
current infection.
Using the N'Dama, Trail et al. (1994) matched animal health and 
performance data in a two-year period of exposure of the cattle to natural
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tsetse challenge in a high natural tsetse challenge situation in Zaire. Four 
parameters which were regarded as possible indicators o f trypanotolerance, 
namely, species of the trypanosomes detected, length of time parasitaemic, 
intensity of parasitaemia and anaemic condition as estimated by the packed 
cell volume values were measured. The relative effects of changes in these 
parameters on trypanocidal drug requirements and growth were determined. It 
was found that all four criteria had approximately equal effects on the 
trypanocidal drug requirements and on the daily live weight gain. From this 
study it was concluded that absence of information on any of these criteria 
would significantly affect the accuracy of the estimate of an animal's overall 
trypanotolerant phenotype in a particular situation in which it is being 
assessed.
Programmes involving the introduction of trypanotolerant breeds of 
cattle in areas devoid of cattle due to high prevalence of infections have been 
reported. The introduction of the N'Dama in an area devoid of cattle in Zaire 
(Itty et al., 1995a) was reported to be successful in that rearing cattle in this 
area was found to be cost-effective and cattle are now established as part of 
the farming system. In Togo, however, the introduction of N'Dama was not as 
successful as that of Zaire (Itty et al., 1995b) as the scheme was found not to 
be profitable to the communities due to high inputs. It appears then that a 
thorough evaluation of health and performance and the costs incurred in 
introducing trypanotolerant breeds in new areas is necessary for projects 
involving these breeds to be successful.
Trypanotolerance has also been reported in sheep and goats (Osaer et 
al., 1994). Two cloned strains of T. congolense, o f West African and East 
Africa origin, were used to infect female Djallonke sheep and West African 
Dwarf goats. Parasitaemia, PCV, body weight and clinical parameters were 
followed in these animals for three months in an effort to evaluate their 
trypanotolerant nature. The results showed that the West African strain was
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more pathogenic than the East African strain. Despite these observations, both 
the Djallonke sheep and the West African Dwarf goats showed a high degree 
of trypanotolerance, as reflected in the lack of mortality and an increase in 
body weight during 12 weeks of observation.
In conclusion, although well controlled studies have been carried out on 
productivity and general performance of trypanotolerant breeds compared with 
non-trypanotolerant breeds, both in traditional and ranch management 
systems, and when exposed to different levels of risk to trypanosomiasis, it 
will take some time before these breeds are established and integrated in 
animal production systems in areas beyond West Africa.
Vaccination
Immunisation as a method of trypanosomiasis control is not foreseeable in the 
near future due to the substantial antigenic variation that is exhibited by 
trypanosome populations. When an animal becomes infected, the 
trypanosomes composing a parasitaemia peak population are usually a mixture 
of antigenic types in various proportions (Meirvenne et al., 1975). Whereas the 
major types are eliminated by the host's defence system, the minor variants 
appear to keep the infection going. The range of variable antigen types (VATs) 
that a single trypanosome can produce is known as the VAT repertoire; the 
precise number that can be produced is not known. However, Capbem et al. 
(1977) have reported at least 101 VATS produced from a clone of T. 
equiperdum . This has limited progress in the development of a vaccine for 
trypanosomiasis.
Despite the above limitation in the search for a vaccine against 
trypanosomiasis, recent advances have been made in this area. In a recent 
study (Powell, 1993) rabbits were immunised with specially prepared sub- 
cellular fractions of a cloned T. b. brucei stock. In in vitro studies the sera from 
these immunised rabbits killed different parasites of T. brucei which were
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grown in continuous culture of salivary gland cells from G.m. morsitans. In 
another study, Grootenhuis and Olubayo (1993) isolated serum proteins from 
wild African buffalo which had trypanocidal activity against all species of 
trypanosomes. Olaho et al. (1995) have reported successful trials using 
flagellar pocket antigens from T.b. rhodesience in the vaccination of cattle 
against T. congolense and T. vivax. Their results showed that cattle were 
partially protected against natural tsetse challenge.
Destruction of wildlife reservoirs
Recent studies carried out in the Pendjari National Park, Benin, have 
confirmed that in this area, wild animals are reservoirs of most trypanosome 
species pathogenic to livestock and humans. Among them, Adenota kob and 
Panthera leo are carriers of T.b. gambiense that causes human 
trypanosomiasis (Guedegbe et al., 1992). Depending on the fly feeding 
preferences, selective destruction of game animals which act as reservoirs is 
the only method apart from total clearing of vegetation which would 
completely free the land from trypanosomiasis, by interfering with the fly's 
food supply. However, the success of this method of control would depend on 
the accuracy of the data generated from blood meal analyses. Although this 
control measure would lead to selective elimination of the reservoirs, it would 
be unacceptable for environmental reasons relating to wildlife conservation.
Vector Control 
Clearing of vegetation
Clearing of vegetation is the oldest and the most effective method of 
eliminating Glossina spp. since it destroys their habitat. The clearing of 
vegetation can either be total or partial (Ford et al., 1970). Total clearing 
involves destruction of all trees and shrubs; they are cut down and, if  possible, 
destroyed by uprooting or burning. Partial clearing involves selective,
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descriminate clearing in which certain types of vegetation are targeted. This 
method has been successful in areas where the tsetse habitat is well defined; 
for example, in the control of human sleeping sickness associated with G .f 
fuscipes in Western Kenya (Maina, 1977). With the current emphasis on the 
need to conserve the environment in order to prevent desertification such 
methods have no place in today's tsetse control programmes.
Hand-catching
Although the avoidance of the fly belt was probably the traditional 
method of preventing losses from tsetse transmitted trypanosomiasis, the hand 
catching method, although no longer in use, is one of the oldest methods of 
insect control, having been tried for the first time in 1913 (Glasgow and Potts, 
1970). Its main advantage is that it is absolutely specific for the insect under 
attack. One can also obtain an exact record of the number of insects destroyed. 
The disadvantage of the technique is that it requires a large labour force, 
especially if substantial areas are to be tackled. There are also problems of re­
infestation, unless one is working in an isolated area. However, this is one of 
the methods that is environmentally acceptable, and therefore remains suitable 
for tsetse. The technique has, however, been superseded by more modem 
technologies.
Insecticides
The first insecticide to be introduced for tsetse control was 
dichlorodiphenyltrichloroethane (DDT) (Burnett, 1970). Because of its 
stability and volatility, it was used mainly for ground spraying. When out o f 
direct sunlight, the deposits remain lethal to tsetse for up to one year (Baldry,
1963). Dieldrin, which has similar properties of stability and volatility as 
DDT, soon replaced DDT after trials revealed that lethal deposits persisted 
better than DDT following spraying of vegetation (Glover et al., 1958).
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Endosulphan, when used for residual treatment was found to be less persistent 
than DDT and dieldrin, and had high intrinsic toxicity and better solubility in 
spray solvents (Jordan, 1986). These properties made it suitable for use as a 
spray when dispersed as an aerosol of fine droplets from an aircraft, as 
demonstrated in Tanzania (Hocking et al., 1966). Synthetic pyrethroids such as 
deltamethrin have also been employed for impregnating traps and screens for 
tsetse control (Luguru et al., 1993).
Ground spraying
This involves the application of a residual insecticide to shrubs and 
bushes, where it remains lethal for the maximum pupal period of 60 days; the 
time for flies to emerge from the pupae below the ground. By the nature of the 
mode of application it is effective in areas that are inaccessible to insecticide 
from aerial spraying. Recent studies (Shereni and Pope, 1993) on the effects of 
residual deposits of deltamethrin applied by the ground spraying technique 
against tsetse populations in North-West Zimbabwe have shown that the flies 
(mainly G.m. morsitans and G. pallidipes) were eliminated within 4 months of 
treatment.
Aerial spraying
This method involves application of an aerosol o f insecticide by low 
flying aircraft or helicopter, targeting mainly the adult flies. Very low doses 
are applied, killing the insects on contact. As a result, the environment has to 
have sufficient residual insecticide, either continuously or at intervals for the 
duration of the maximum pupal period, to prevent the survivors from 
larvipositing. However, aerial spraying affects not only the target species but 
also the non-target species and would be environmentally unacceptable as a 
control measure when compared to the improved and less expensive trap and 
target technologies.
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Traps, targets and screens
Targets and screens were introduced after field observations on the 
response of tsetse flies to visual stimuli. Furthermore, several trap designs 
have been produced since the three-dimensional, box-shaped Harris trap of 
1930 and the "animal" traps of Morris and Morris (1949). Large numbers of 
the Harris traps were used in an attempt to eliminate G. pallidipes from 
Zululand, and marked reductions in fly populations were achieved (Harris, 
1938, reviewed by Jordan, 1986). Problems associated with traps have been 
difficulties in siting them so as to give consistent and comparable catches that 
will provide an effective method of investigating the absolute number o f tsetse 
flies that are present.
The development of the biconical trap (Challier and Laveissiere, 1973) 
generally solved this problem since it could be used in areas covering various 
ecological zones in many African countries (reviewed by Challier, 1982). 
When used for tsetse control, the biconical traps are impregnated with a 
persistent insecticide; this modification followed observations that more flies 
visited and alighted on the traps than entered them (Hargrove, 1972; Vale and 
Hargrove, 1979).
Impregnated traps have been used successfully on the border of Cote 
d'Ivoire with Burkina Faso; an area infested with G.p. gambiensis and G. 
tachinoides, where a 98% reduction in the fly populations was achieved and 
maintained for 4 months (Reviewed by Jordan, 1986). Monoconical traps 
(which are in effect targets since the attracted insects are not retained) 
impregnated with deltamethrin have been used in the Republic of Congo 
where they were found to be more effective than the biconical trap in 
controlling G .f quanzensis (Lancien, 1981; reviewed by Jordan, 1985). Simple 
screens o f blue material (120 x 90 cm) impregnated with deltamethrin have 
been used along the borders of Cote d'Ivoire and Burkina Faso, as in the above
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experiment with traps (reviewed by Jordan, 1985). Finally, results of work 
done in Zimbabwe (Hargrove, 1972; Vale, 1974; Vale and Hargrove, 1979) 
have indicated that even with the best current traps, the trapping efficiency is 
about 50% compared with an incomplete ring of electrified nets (around the 
trap to be evaluated) which capture 95% of tsetse that collide with them. Using 
this method of evaluating trap efficiency, the efficiency of the Morris and 
Morris trap was only 10%. Other studies have shown that even in the presence 
of odour, the biconical trap is relatively inefficient for G.m. morsitans; found 
mainly in the savannah woodlands. An effective trap that would be efficient 
for most tsetse species is yet to be designed (Hargrove, 1980; Vale, 1982).
Several odours have been identified for use in conjunction with traps, 
targets and screens. These include l-octen-3-ol, p-cresol, acetone and 3-n- 
propylphenol (reviewed by Holmes and Torr, 1988).
Traps, targets and screens offer several advantages as compared to hand 
catching, ground and aerial spraying because they require less labour, and 
work can be carried out throughout the year. The disadvantages of the 
technologies are associated with maintenance of the traps and targets since 
they are prone to thefts, bush fires and degradation (dependant on the 
prevailing climatic conditions). Incorporation of a UV absorber into the 
insecticide formulation has been found to extend the effective life of the target 
and the insecticide (Opiyo et al., 1993).
Also to be mentioned is the 'pour-on' technique. This is a relatively new 
technique for tsetse control and involves the application of insecticide in an 
oily emulsion to the back of animals, thereby killing any flies which come in 
contact with the animal. This is in effect a moving target. The technique is not 
only effective on tsetse, but is also effective for control of ticks. Successful use 
of synthetic pyrethroids such as deltamethrin (Muguwa et al., 1993), 
cypermethrin (Byamungu and Mramba, 1993; Kamau et al., 1993) and 
alphamethrin (Kitwika and Malele, 1993) in pour-on formulations have been
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reported. These studies showed significant declines in tsetse catches.
However, Muguwa et al. (1993) concluded that the pour-on application cannot 
be sustained by peasant farmers for economic reasons. The technique, 
therefore, still requires extensive field evaluation in terms of its sustainability 
in community-based programmes.
As in the use of traps, targets and screens, with or without insecticide 
for tsetse control, the use of pour-ons renders the environment favourable to 
the fly when discontinued. The flies may, therefore, re-establish themselves. 
Thus, for the insecticide operations to succeed on a long-term basis, re­
infestation by Glossina has to be prevented by barriers of some sort.
Note should be made of the fact that toxic hazards to man and other 
animals were not often considered in the past when choosing insecticides for 
tsetse control. This is not the case now due to increased awareness about the 
impact of insecticides on the environment. For instance, insecticide residues, 
and specifically DDT, have been shown to have adverse effects on some non­
target species; e.g., eggshell thinning in fish eagles in Zimbabwe (Matthiessen, 
1983). The use of insecticides on traps ensures that only the target species is 
affected.
Parasites and predators of Glossina
This is an area that has not been fully exploited despite the discovery of 
some bacteria and fungi that are pathogenic to Glossina spp. (Nash, 1970). 
Under natural conditions, predators and parasites play an important role in 
controlling tsetse populations. However, this is unlikely to find a place in 
practical control programmes due to the recent improvements in trapping 
techniques.
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Biological control 
Use of chemosterilants
The use o f chemosterilants is one of the biological methods of 
trypanosomiasis control, besides the sterile insect technique. Suggestions have 
been made that it would be more efficient and probably more environmentally 
acceptable to interfere with the reproduction of the flies rather than kill them 
by the use of insecticides (Bursell, 1977; Hargrove, 1977). Use of 
chemosterilants would assist in increasing the effectiveness of'traps' for the 
control o f populations of G.m. morsitans and G. pallidipes. The method would 
involve the capture, sterilisation, and release of the flies. The sterilized 
females and males would then return to the local tsetse population where they 
would interfere with the mating of unsterilised populations.
A field trial employing this method has been carried out to determine 
the efficacy of pyriproxyfen, a juvenile hormone mimic, in combination with 
odour-baited biconical traps on suppression of G. pallidipes in Kiboko, 
Machakos District, Kenya (Mango et al., 1993). Results of the study indicated 
that with time there was a suppression of the fly population in the 
experimental area as assessed by the use of biconical traps plus attractants and 
the electrical mobile screen. The findings also indicated that the G. pallidipes 
population consisted mainly of old flies as assessed by the mean wing fray 
ratio of both males and females, ovarian ageing of the females and the 
pteridine fluorescent ratio in heads and wings. There was, therefore, a 
reduction in catches of young flies showing that the reproduction cycle had 
been interfered with, resulting in reduced fly challenge and low incidence of 
infections in cattle.
Sterile male technique
In this method, large numbers of male tsetse are sterilized by irradiation 
and released in an infested area. The numbers of such males must be high
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enough to overflood the natural population of wild males (Jordan, 1985).
Thus, in actual practice, the sterile males are released when the population of 
the wild males has been reduced considerably by other existing tsetse- control 
methods. For the successful use of this method (1) information is needed on 
tsetse population dynamics and behaviour in a given area, (2) suppression of 
the tsetse population has to be initially carried out using an alternative method 
of control, such as traps or targets, and (3) an efficient system for rearing 
tsetse is required since thousands or hundreds of thousands of sterile males 
may be required per month, depending on the area o f control (Glasgow, 1970). 
This method has been successfully used in Burkina Faso where G.p. 
gambiensis occupying an area of 100 km2 along a stream was eradicated 
within 16-24 months (reviewed by Holmes and Torr, 1988). In Tanzania, an 
average of 81% control of G.m. morsitans was achieved over an area of 195 
km within 15 months using the same method. Provided that re-infestation is 
prevented by barriers of some sort, eradication is possible in a linear habitat 
using the sterile insect technique, so long as it is combined with impregnated 
traps and targets that are either baited or unbaited to initially reduce fly 
populations.
Community level participation in tsetse control programmes
In most tsetse-infested countries of sub-Saharan Africa, tsetse and 
trypanosomiasis control has been dependant on central governments, with 
little or no participation from local communities. Recently, efforts have been 
made to involve local communities in tsetse and trypanosomiasis control 
activities (Mate, 1993; Swallow and Mulatu, 1993; Swallow et al., 1993; 
Kamara and Echessah, 1994; Itty et al., 1995a, b). In Ethiopia, Swallow et al. 
(1993) organised a survey in an effort to find how to stop thefts of targets 
following the socio-political disturbances of 1990. Results of this survey are 
being used to modify the programme towards greater community
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participation. Kamara and Echessah (1994) in their studies on the assessment 
of socio-economic factors affecting implementation of community-based 
tsetse control in Busia, Kenya, using baited targets, found that there were 
several factors which determined the willingness of communities and 
individuals to participate. These included ownership and use o f livestock, 
beliefs and attitudes concerning trypanosomiasis, and the length of contact 
with the disease and control programmes. According to the findings o f this 
study, important issues to be considered in community-based programmes 
were community organisational capacity, incentives needed to initiate and 
sustain programmes, and the intra-community distribution of programme 
benefits.
Community participation in projects involving assessment of the 
productivity and socio-economic benefits of trypanotolerant cattle have also 
been reported, in Zaire (Itty et al., 1995a) and Togo (Itty et al., 1995b). In the 
case o f Togo (Itty et al. 1995b) the study examined the economics o f village 
production of trypanotolerant cattle recently introduced in an area previously 
devoid of cattle. Social-level economics and private level financial analyses 
were performed using a herd model. Results showed that cattle production was 
profitable to cattle owners but returns were especially vulnerable to alterations 
in costs of inputs; for example, cattle purchase and veterinary care. In this 
study, foreign financed subsidies did not enhance the farmer's participation in 
the development process and distorted the incentive structure. In Zaire (Itty et 
al., 1995a), the study revealed that cattle production was profitable and that a 
cattle lease scheme provided substantially higher returns than when the 
farmers had to purchase all their livestock.
Due to the dynamic nature o f the tsetse populations, Rogers and 
Williams (1993) noted that there has been a shift in emphasis from tsetse 
eradication to tsetse control. The future role of central governments will 
remain crucial, however, in determining the areas in which different control
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options are practised, in facilitating control by local communities and in 
protecting control areas from re-invasion by flies from other areas.
In summary, most vector control methods are expensive and tend to 
interfere with already fragile ecosystems since most tsetse species occur in 
arid and semi-arid areas of the African continent. Furthermore, there are 
always problems of re-infestation unless barriers are put in place to prevent 
immigration of flies. In this regard, regional co-operation is essential in order 
to achieve any long lasting sustainable impact.
TRYPANOCIDAL DRUGS 
Classification of animal trypanocides
Table 1.1 summarises the characteristics of the drugs used for the 
treatment and prophylaxis of animal trypanosomiasis. Their chemistry is given 
in Appendix A.
Outline of the history of the chemotherapy of animal 
trypanosomiasis
Potassium antimony tartrate (tartar emetic)
Chemotherapy of animal trypanosomiasis dates as far back as the turn 
of the century when in 1908, Plimmer and Thompson showed potassium 
antimony tartrate (tartar emetic) could cure infections due to T. brucei and T. 
evansi in laboratory rodents. The drug was given by intravenous injection 
since it caused tissue reactions when administered intramuscularly. In cattle, 
dose rates of 1.0 - 1.5 mg kg-1 body weight in a 5% w/v solution were found to 
be effective against T. congolense and T. vivax infections but not T. brucei 
infections (Bevan, 1928; Curson, 1928). The drug remained in use for nearly 
40 years.
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Suramin
Suramin came into general use in 1920 after it had been developed in 
Germany during the first world war. It was found to be active against T. 
equiperdum in horses and T. evansi infections in camels (Knowles, 1925). 
Because of its slow rate of excretion, Findlay in 1930 pointed out that it could 
confer protection for two months. Suramin has remained the drug of choice 
for the treatment of T. evansi in camels.
Suramin has been demonstrated to undergo complex formation with 
other active trypanocidal drugs. Several of these complexes have been 
prepared and their trypanocidal activity determined. These include the 
pentamidine-suramin complex (Guimaraes and Lourie, 1951); the toxicity of 
pentamidine in this complex was reduced without affecting its prophylactic 
activity. Other suramin complexes have been reported by Desowitz (1957) 
and Williamson (1957) involving pyrithidium, dimidium, homidium, 
quinapyramine and diminazene, but their use was limited due to reactions at 
the injection site. However, some of them did confer longer periods of 
protection to cattle than the individual constituents.
Trypaflavine
The phenanthridinium drugs in use today owe their origin to Ehrlich's 
work on dyestuffs based on the acridine nucleus. This led to the development 
of trypanosan, acridinium yellow, trypaflavine (acriflavine) and the 
styrylquinolines. Trypaflavine was found to be a highly active anti-bacterial 
agent whereas some of the styrylquinolines were found to possess powerful 
antiseptic properties (Browning et al. (1922) cited by Williamson, 1970).
Phenidium chloride
Further improvements in drug development led to the synthesis of 
phenidium chloride, a phenanthridine which was found to have a marked
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effect on T. congolense infections in cattle (Browning et al., 1938) unlike the 
styrylquinolines which acted only on T. brucei. Other disadvantages with the 
styrylquinolines were that they acted slowly on trypanosomes, were 
systemically toxic and produced serious reactions at the injection site. 
However, they were retained for longer periods in the body than the drugs that 
were available at that time. The activity of phenidium chloride against T. 
congolense infections in cattle was confirmed in trials in Africa. However, it 
had low solubility and a narrow therapeutic index (Williamson, 1970).
Dimidium bromide
More research into drug development revealed an active and water 
soluble derivative of phenidium with two amino groups in the phenanthridine 
portion of the molecule. This compound, dimidium bromide, the next 
phenanthridine to be introduced after phenidium, was readily soluble and was 
shown to be active against T. congolense in cattle in the field by Carmichael 
and Bell (1944) when given subcutaneously at 1 mg kg*1 b.w. The drug was 
used extensively in East and Central Africa until drug resistance occurred by 
1952 as a result of mass treatments. The use of doses higher than 1 mg kg-1 to 
overcome resistance led to severe toxicity (Randall and Beveridge, 1946; 
Evans, 1948).
Surfen C
In 1937 Jensch reported the synthesis of a series o f new compounds: 4- 
aminoquinoline derivatives. In one of these compounds, two 4-aminoquinoline 
moieties were linked together through amino substitution in the 6 -position to 
melamine to produce Surfen C. Surfen C was the first metal-free anti­
trypanosomal drug and was found to be active against T. congolense infections 
in the field. When evaluated under field trials, however, the drug showed 
variable and unacceptable toxic effects (Le Roux, 1938; Van Rensberg, 1938).
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Quinapyramine
Quinapyramine was synthesised following Jensch's (1937) work, by 
restructuring the Surfen C molecule. The compound was introduced in the 
field in 1950, being the first prophylactic drug for use in cattle against T. 
congolense and T. vivax. Quinapyramine is used either in the form of a soluble 
dimethosulphate salt for treatment of infections with most trypanosomes that 
are pathogenic to livestock (Curd and Davey 1949, 1950; Davey, 1950), or as 
a mixture of dimethosulphate and the chloride to form "Quinapyramine 
Prosalt", which is used as a prophylactic agent. Although cases of resistance to 
quinapyramine in T. evansi and T. congolense have been reported (Gill, 1971; 
Ndoutamia et al., 1993), it is still widely used in the field against T. evansi in 
camels.
Homidium bromide/chloride
In 1952, Watkins and Woolfe reported the development of homidium 
(given the trivial name 'ethidium bromide') by changing the nature and 
position of substituents on the phenanthridine nucleus of dimidium. In the 
synthesis of homidium the quartemizing group -CH3 in dimidium was 
replaced by -C2 H5 . Homidium was found to be effective against T. 
congolense and T. vivax in cattle at 1 mg kg’1 b.w. The efficacy of this drug, 
plus quinapyramine, led to mass treatments of cattle which became infected in 
the field through contact with tsetse flies (Wilson, 1960).
Diminazene aceturate
Diminazene aceturate is a derivative of Surfen C and consists o f two 
amidinophenyl moieties linked by a triazene bridge. It was first introduced in 
1955. Bauer (1955a,b) and Fussganger (1955) reported trials with this drug in 
the field. It has also been used in the control of homidium-resistant cattle 
infections in both East and West Africa (Whiteside, 1962). A dose of 3.5 mg
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kg-1 b.w. was claimed to cure T. congolense and T. vivax infections in cattle, 
but a higher dose was recommended as necessary to eliminate T. brucei 
infections. The drug did not appear to be effective against T. simiae but it had 
a considerably wider therapeutic index than the other trypanocidal drugs that 
were available at that time; Fairclough (1963 a) reported the safe use at a 
dosage of 21 mg kg-1 b.w. when given subcutaneously. Diminazene was 
therefore used in place of quinapyramine or homidium in the field following 
the withdrawal of the latter drugs from field use in Northern Nigeria in 1963 
and 1965, because of the development of drug resistance (MacLennan, 1968).
Pyrithidium bromide
The synthesis of pyrithidium bromide was reported in 1956 (Watkins 
and Woolfe, 1956). The molecule was produced by combining a portion of the 
quinapyramine molecule with the phenanthridine-resembling phenidium. It 
was shown to have marked therapeutic and prophylactic activity (Finelle and 
Lacotte, 1965). Whiteside in 1960 found that 0.2-0.4 mg kg-1 b.w. would cure 
T. congolense infections in cattle. Furthermore, Finelle and Lacotte (1965) 
were able to protect cattle for 4-6 months in an area of high tsetse challenge, 
and donkeys for even longer. However, the drug produced severe local 
reactions when given subcutaneously at doses over 25 mg kg-1 b.w. (Stephen, 
1963). In addition, intramuscular injections of 5 mg kg-1 b.w. were considered 
to be responsible for deaths (Leach and El Karib, 1960).
Isometamidium chloride
Wragg et al. (1958) reported the synthesis o f metamidium from a 
coupling reaction that involved m-amidinobenzenediazonium chloride and 
homidium chloride. A mixture of two isomers was produced; one red and the 
other purple. The red was more soluble and active than the purple, both 
therapeutically and prophylactically, against a strain o f T. congolense in mice,
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and accounted for 55% of the total mixture. The more active form was later 
isolated (Berg, 1960, 1963) and marketed as isometamidium. It was 
recommended that this drug should be given intramuscularly at a dose rate of 
0.5 mg kg-] b.w. for drug-sensitive infections, 1.0 mg kg-1 b.w. for drug- 
resistant infections, and 2 .0  mg kg-1 b.w. for prophylaxis.
Melarsenoxide cysteamine
Melarsenoxide cysteamine was discovered in 1985 and is 
recommended for use against T. evansi infections in camels. Otsyula et al. 
(1992) have reported results of a study carried out in an area in the Eastern 
Province of Kenya to evaluate the efficacy of a range of doses o f the drug in 
camels. The doses investigated were 0.2, 0.4, 0.6 and 1.2 mg kg-1 b.w. 
administered by the subcutaneous route as a single treatment. The trial 
demonstrated therapeutic activity of the drug against natural T. evansi 
populations in camels in Kenya at all the dose rates used. Symptoms of 
systemic reactions to the drug included frequent urination, drooling saliva and 
muscular tremors amongst others. Swellings were produced at the site of 
injection with doses equal, to or more than, 0.4 mg kg-1; more severe swellings 
being observed at higher doses. Swellings disappeared within 72 hours in all 
animals except those treated at 1.2 mg kg-1. In a study by Zhang et el. (1992) it 
was demonstrated that all of 14 unrelated T. evansi clones used were sensitive 
to the drug in vivo, the curative doses in mice ranging from 0.25 - 4 mg k g 1. 
Resistance to the drug has however, been reported in T. evansi clones and in T. 
brucei brucei populations in laboratory studies using immunosuppressed mice 
(Osman et al., 1992; Pospichal et al., 1994).
ECONOMICS OF DRUG USE
Until recently (see Section 1.9), the economics of trypanosomiasis and 
tsetse control were governed more by possible benefits to agriculture than by
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the cost of control schemes (Jahnke (1974) reviewed by Holmes and Scott, 
1982). As observed by Holmes and Scott (1982), logistical and financial 
problems are a major constraint on the effective application of chemotherapy 
in the field. These include the vast areas involved, most of which are 
inaccessible due to lack of all-weather roads, purchase and maintenance of 
vehicles and inaccessibility to facilities such as diagnostic laboratories.
The cost of drugs and the infrastructure required for their distribution 
and use is considerable and often beyond the means of the small scale farmers. 
When the drugs have been afforded by the farmers, preparation and 
administration has been carried out by themselves with little or no knowledge 
as to their preparation and administration, often leading to underdosing of 
animals.
Holmes and Scott (1982) pointed out that foreign aid and government 
support has been essential to date but may be reduced in future and hence the 
recent introduction of community participation in control programmes on a 
cost-sharing basis is considered essential to ensure their future.
In the study by Jahnke (1974, reviewed by Holmes and Scott, 1982), it 
was shown that in land with high potential and high incidence of 
trypanosomiasis, tsetse control constitutes the method of choice. However, on 
land with low cattle populations and a low incidence of trypanosomiasis, it is 
preferable to protect cattle with drugs instead of controlling tsetse.
In work carried out on Mkwaja ranch, Tanzania involving 20,000 cattle 
(Holmes and Torr, 1988), an analysis was made of matching animal health, 
animal productivity and trypanocidal drug treatment for a period of 10 years 
(1973-1982). The animals on the ranch could not survive without the use of 
trypanocidal drugs. The number of treatments administered to each animal was 
on average 4.6 isometamidium and 0.7 diminazene per year. A high level o f 
productivity was achieved under this drug regime demonstrating that in an 
area of Africa where cattle, if left untreated, rapidly succumb to
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trypanosomiasis, the strategic use of the trypanocidal drug isometamidium, 
under a high standard of management can permit cattle to survive and be 
productive.
Ideally, the application of trypanocidal drugs, like other veterinary 
drugs should be controlled by qualified personnel. When this is so as observed 
by Holmes and Torr (1988), trypanocidal drugs can be used effectively and 
economically in the field. However, in most areas of sub-Saharan Africa, 
application of trypanocidal drugs lies in the hands of the cattle owner who 
purchases the drugs over the counter and there is lack of strict control. The 
mushrooming of shops dispensing veterinary drugs in many of these areas, e.g. 
Kajiado town, Kajiado District, Kenya, is a testimony to the demand for such 
drugs (Mdachi, personal communication).
Usually, cattle in the field are treated following clinical signs or 
detection of parasites in the peripheral blood. However, most traditional cattle 
owners do not have access to weighing and diagnostic facilities. Weights are 
therefore, estimated and doses calculated based on these estimated weights. 
Economic pressure tends to encourage underdosing. Administration of drugs 
without proper diagnosis, mostly relying on clinical signs which may not 
necessarily be due to trypanosomiasis may result in inappropriate drug use.
The efficacy of isometamidium prophylaxis in the field has been 
reported in several studies in addition to the Tanzanian study referred to above 
(Dolan et al., 1990, 1991; Maloo, 1993; Eisler et al., 1994; Stevenson et al, 
1995). Studies by Dolan et al. (1990, 1992) using homidium bromide and 
isometamidium chloride and Maloo (1993) using isometamidium chloride 
showed that prophylactic treatments were more effective in the low tsetse 
challenge areas or areas of low trypanosomiasis risk where the drug has shown 
prophylactic cover of over four months, with an increase in cattle productivity, 
than in the high trypanosomiasis risk areas. Reduced periods of protection 
following isometamidium chemoprophylactic cover were shown to occur in
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the high trypanosomiasis risk areas (Maloo, 1993; Dolan et al. 1992). The 
isometamidium prophylactic cover afforded in high risk areas ranged between 
2 and 45 days (Maloo, 1993) and averaged 28.4 days (Dolan et al. 1992). 
Trypanosomiasis was found to be responsible for limiting wide scale adoption 
o f dairy farming by the small scale farmer in the high trypanosomiasis risk 
areas of the Kenya Coast. Studies reported by Maloo (1993) and Dolan (1992) 
also showed that isometamidium did not protect cattle against outbreaks of 
haemorrhagic T. vivax infections. Maloo (1993) observed that with the small 
number of dairy herds at the Kenya coast scattered over large areas, large scale 
tsetse campaigns may not be economical. He suggested a short term solution 
which would be dependant on early detection of the disease followed by 
curative therapy using diminazene. Diminazene was found to cure all 
parasitaemias from breakthrough trypanosome infections. No deaths were 
reported in the control herd not given prophylactic treatment but maintained 
on diminazene curative therapy (Dolan et al, 1992).
The use of homidium both as a chemotherapeutic and chemoprophylactic 
agent is discussed in more detail below.
Homidium
Original use
Homidium has been used primarily as a curative drug in cattle at a dose 
rate of 1 mg kg-1 b.w. following field studies carried out in Kenya, Tanzania 
and Nigeria to investigate its curative effects against T. congolense and T. 
vivax (Wilde and Robson, 1953; Wilson and Fairclough, 1953; Unsworth, 
1954a, b). The manufacturers recommended that the drug be given by 
intramuscular injection due to local reaction at the injection site following 
subcutaneous administration.
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Homidium as a chemotherapeutic drug
Following the introduction of homidium, the numbers of cattle treated 
with the drug in Northern Nigeria rose from 45,000 in 1951-2 to 641,000 in 
1957-8 (Williamson, 1970). The following five years saw a decline in the 
numbers of treated cattle to 25,000 in 1962-63, and this was taken to be an 
indication of the effectiveness of homidium in the control of animal 
trypanosomiasis (MacGregor (1965) cited by Williamson, 1970). In Tanzania, 
the cattle population which stood at 6.5 million in 1946 increased to 8 million 
in 1954 following treatments with homidium (Ford, 1965).
In an area in Uganda where quinapyramine had been used extensively, 
an investigation into a block treatment regimen with homidium at 1 mg kg-1 
b.w. was carried out involving 11,200 head of cattle in 200 herds (Mwambu 
(1967) cited by Williamson, 1970). Infections in these cattle were no longer 
responding to quinapyramine therapeutic treatment. Results obtained 
following homidium treatment showed no clinical cases or deaths due to 
trypanosomiasis and that there was great improvement in the feeding and milk 
yield o f animals two to three months after homidium treatment.
Current use
Although originally recommended for use as a chemotherapeutic drug, 
homidium has been used extensively as a chemoprophylactic drug (Mwambu, 
1971; Dolan et al., 1990, 1992; Stevenson et al., 1995). Due to its strong 
intercalation with DNA, it has also been used extensively as a biochemical 
probe (Newton, 1976).
As a chemoprophylactic agent
Although homidium was introduced and recommended as a therapeutic 
drug, reports have appeared showing that it possesses prophylactic properties 
as well (Mwambu, 1971; Dolan et al. 1990; Stevenson et al., 1995). The drug
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treatment regimen used in the field of administering therapeutic treatment to 
only clinically sick or positively diagnosed animals was found to exclude 
healthy carriers (Mwambu, 1971) and encouraged transmission of the disease 
to susceptible animals. The results obtained from the use of a block treatment 
regimen with homidium at 1 mg kg-1 b.w. showed a marked reduction in 
disease incidence which was maintained for three months and a reduction in 
calf mortality. Mwambu (1971) concluded that four regular treatments in a 
year would sufficiently control the disease in cattle in the Uganda situation. 
Use of diminazene curative therapy in the same area required six treatments 
per year per animal making it more expensive than the block treatment 
regimen using homidium.
In a 12-month study on homidium prophylaxis on Galana Ranch, Coast 
Province of Kenya (Dolan et al., 1990), homidium was demonstrated to confer 
protection against infection for more than four months during a period of low 
disease incidence. During a similar study in the same area involving homidium 
and isometamidium a year later, animals in both the isometamidium and the 
homidium herds required 8 prophylactic treatments each during the 12 months 
at a dose rate of 1 mg kg-1 b.w. The mean period of protection for homidium 
was 25.4 days (range 19-35) while that afforded by isometamidium was 28.4 
days (range 14-53) with a reported disease incidence in control cattle (not 
given the prophylactic treatment) three-fold higher than that obtained in 1990 
(Dolan et al., 1990). The period of protection obtained following treatment of 
cattle with homidium at 1 mg kg-1 b.w. in the same area in 1990 (Dolan et al., 
1990) was over four months. They observed that the period of protection in 
individual cattle treated with homidium was less variable than that observed in 
cattle treated with isometamidium. Similar findings of variability (2 - 45 days) 
in isometamidium prophylaxis have been reported by Maloo (1993).
During the first six months of a 12-month study, Dolan et al. (1992) 
showed that 12 out of 90 animals in the herd on isometamidium treatment had
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lost weight while no weight loss was recorded in the homidium herd despite 
poor grazing. It was established that animals on isometamidium prophylactic 
treatment which required three diminazene treatments (7 mg k g 1 b.w.) 
following the development of breakthrough trypanosome infections, lost 27 kg 
compared with a gain of 5 kg in those which required no diminazene 
treatment. Weight gains were recorded in all animals on homidium treatment, 
the highest gain being in animals that required fewer diminazene treatments to 
treat breakthrough trypanosome infections. With improvement in grazing all 
animals gained weight despite a more intense trypanosome challenge. The 
homidium group showed the highest weight gain, followed by the control herd 
which was maintained on diminazene curative therapy and the lowest in the 
isometamidium herd. No deaths occurred in either the homidium or the control 
herds in the 12-month period whereas mortality was 67% in the cattle on 
isometamidium prophylactic treatment in which diminazene was used to treat 
breakthrough trypanosome infections. These deaths were attributed to liver 
toxicity as a result of frequent sometamidium/diminazene alternate treatments.
A recent study on homidium prophylaxis was carried out at Nguruman, 
Kenya (Stevenson et al., 1995) covering the period between Febuary 1990 to 
February 1991. A high incidence of infection was observed between weeks 2 
and 23 of the study period (March to July). Eleven homidium group treatments 
were required during the year. A total of 38 new infections of which 60% 
were T. congolense were detected in a group of 30 animals during the 
experimental period. During the same period, 15 infections did not respond to 
homidium bromide treatment and were considered to be drug resistant. 
Thirteen animals required diminazene treatment because of persisting 
infections, low PC Vs or poor clinical condition.
Treatment of parasitaemic animals in the control group with 
diminazene at a dose rate of 7 mg k g 1 b.w. on individual basis failed to 
produce effective control. Twenty five percent of animals in this group either
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died or were removed from the trial due to their extremely weak condition. It 
was observed that homidium bromide at 1 mg k g 1 b.w. was more sensitive 
against T. vivax than against T. congolense.
Because of the high incidence of infection and the appearance of drug 
resistant populations of T. congolense, the use of homidium as a 
chemoprophylactic was rather complicated. However, when compared to 
maintenance of a similar group of cattle on isometamidium prophylaxis under 
similar conditions, the use of homidium was approximately four times less 
expensive.
MECHANISM(S) OF DRUG ACTION
The anti-trypanosomal activity observed with diminazene, homidium 
and isometamidium is attributed to the primary mode of action of blocking 
nucleic acid synthesis through binding to kinetoplast DNA. With the 
phenanthridinium compounds, the binding is by intercalation between base 
pairs (Newton, 1976). With diminazene, however, the binding does not occur 
by intercalation but via specific interaction with sites rich in adenine-thymine 
(A-T) base pairs (Newton, 1972). Thus, diminazene has been shown to 
selectively fragment kinetoplast DNA (MacAdam and Williamson; 1972).
TOXICITY
While diminazene's toxicity in cattle has not been documented, toxicity 
to this drug in dogs and camels has been reported (Losos and Crockett, 1969; 
Homeida et al., 1981). Doses of 30-35 mg k g 1 b.w. in dogs cause spastic 
paralysis, involuntary movements, vomiting, and death in two or three days.
Most phenanthridinium compounds have been reported to be toxic 
(Randall and Beveridge, 1946; Unsworth, 1954a; Fairclough, 1958; Dolan et 
al., 1992). The toxic effects include local tissue reactions at the site of 
injection, involving swelling and oedema, and are more pronounced in animals
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given doses that are higher than the recommended therapeutic dose. The 
results of studies reported by Dolan et al. (1992) have shown that liver toxicity 
occurs in animals given frequent isometamidium prophylactic treatments 
alternating with diminazene therapy for animals which develop breakthrough 
infections during the prophylactic cover and particularly so in the presence of 
poor grazing in the field.
EVALUATION OF THE EFFICACY OF THE DRUGS UNDER 
FIELD CONDITIONS
A thorough understanding of the pharmacokinetics and 
pharmacodynamics of current trypanocidal drugs is required to be able to 
understand their interaction with the host in the course of treatment. This 
understanding would be useful in designing treatment regimens that could be 
more appropriate for each of the drugs. Availability of sensitive analytical 
techniques have made it possible for studies to be carried out on diminazene 
and isometamidium. However, a sensitive method is yet to be developed for 
homidium which would allow a similar evaluation of the drug to be made 
under field conditions. These field evaluation studies are needed to be able to 
understand the following:
(a) how animals can be maintained in medium to high tsetse challenge areas 
following drug administration without the development of drug resistance.
(b) the contribution of the injection drug depot and the secondary tissue depots 
to circulating drug concentrations and how these could be exploited in terms 
of maintaining the minimum effective concentrations for longer periods 
through slow release formulations.
(c) the nature and extent of resistance in the field. This would be done
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through determination of drug concentrations in treated cattle in the field and 
isolating trypanosomes that persist at various drug concentrations for further 
characterisation.
TISSUE DRUG RESIDUES AND METABOLITES
The subject of drug residues and metabolites is discussed within the 
sections that discuss the various methodologies used to determine the drug 
levels in tissues and biological fluids. Although extensive use has been made 
of these drugs, more work still needs to be done in the area of residues and 
metabolites and the role they play, if any, in the prophylaxis of animal 
trypanosomiasis. Furthermore, apart from diminazene, it is still unclear 
whether homidium or isometamidium remain in the same unchanged form or 
exist as active metabolites in the body.
REVIEW OF THE CURRENT ANALYTICAL METHODS 
Ultraviolet/Visible Spectrophotometry
According to Clarke's isolation and identification of drugs (1969), 
homidium has two absorption wavelength maxima in dilute acid; one at 242 
nm and the other at 283 nm (E l% ,lcm  = 785). Similarly, diminazene has 
absorption wavelength maxima in dilute acid at 257 nm (E l% ,lcm  = 305) and 
in dilute alkali at 247 nm (broad peak, E l% ,lcm  = 239). Although these 
absorption wavelength maxima have not been used, the information was the 
basis of the work carried out by Phillips et al. (1967) who described two 
methods for the quantification of isometamidium in plasma, tissues, urine and 
faeces. In the first method, isometamidium was extracted with ether from a 
basic solution containing the drug. Briefly, homogenates of tissue (10%w/v) 
and faeces (2.5%w/v) were prepared in water. Urine and plasma were also 
diluted in water. To 4 ml of each of the various preparations were added 2 g 
sodium chloride, 25 ml ether and 1 ml of 30%w/v sodium hydroxide. The
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mixtures were then centrifuged and the two phases separated. The drug was 
extracted from 20 ml of the ether into 4 ml 0.1 M acetate buffer, pH 4.7, 
shaken for 10 minutes, and the absorbance of the buffer determined at 378 nm; 
the absorption wavelength maximum for isometamidium. An absorbance of 1 
unit was obtained with a solution containing 21.2 pg in 0.1M acetate buffer, 
pH 4.7, and this was used to calculate isometamidium concentrations in the 
various materials analysed. Recoveries from aqueous solutions containing 
isometamidium were 80.0±1.6%. Recoveries from rat liver, spleen, kidney, 
heart, small intestine and plasma that had been spiked with isometamidium 
were 100-103%. Finally, recovery from brain and faecal homogenates and 
urine spiked with the drug was 80-86%. Limits of detection for the various 
tissues and body fluids were as follows: plasma, 0.7 pg m l1; tissue, 3.3 pg g 1; 
faeces, 13 pg g 1; urine, 13 pg m l1 per 24 hour collection.
The second method of Phillips et al. (1967) was an improvement to Method 1, 
mainly to solve the problem of frothing which had been observed when the 
samples were shaken. In this method, isopropanol, ether and sodium 
hydroxide were added to the homogenates, while the rest of the procedure 
remained as in Method 1. The sensitivity was very much improved with this 
method. The limits of detection were as follows: blood, 1.3 pg m l1; kidney,
1.3 pg g 1; and liver, 2.5 pg g-1.
This second method has been used by several workers interested in 
carrying out studies on isometamidium residues in cattle after treatment 
(Eghianruwa and Uduebholo, 1979; Braide and Eghianruwa, 1980; Shetty, 
1986).
Lastly, Raether et al. (1972) described a colorimetric procedure for 
diminazene in which diminazene was split into 4-amidinophenyldiazonium 
chloride and 4-aminobenzamidine. After converting the 4-aminobenzamidine 
to a diazonium salt, both components were coupled to an azo dye (reaction 
according to Bratton and Marshall [1939]). The optical density of the colour
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produced by the reaction was determined at 545 nm. Since this reaction was 
light sensitive, light was avoided. The limit of detection of the assay was 0.5 p 
g m l1 serum.
Fluorescence microscopy
Homidium and isometamidium are highly fluorescent in UV light. This 
property has therefore been used to demonstrate the distribution of the drugs 
in various organs and tissues of animals after treatment with the drugs (Hill 
and MacFadzean, 1963; Phillips et al., 1967).
Hill and McFadzean (1963) in their work on isometamidium used 
fluorescence microscopy to study the role of drug depots in mice and rats in 
prophylaxis against T. congolense. The technique involved fixation of tissues 
for 1 hour in formol saline, followed by cutting of 10 pm frozen sections 
which were examined immediately. The organs examined were liver, spleen, 
kidney, gut, lung, skin, muscle, bone-marrow and the brain. In initial work, 
serum taken from a mouse at 1, 3 and 6 hours after sub-cutaneous (s.c.) 
injection of 0.16 mg (cation) g 1 b.w. fluoresced when spotted on paper. No 
red or orange fluorescence was observed in the organs from untreated animals. 
However, orange fluorescence was detected in the liver, kidneys, and at the 
injection site, of the animals given s.c. or intravenous (i.v.) injection of 0.0006 
mg (cation) g 1 b.w. Cellular level distribution could not be determined under 
these conditions. This technique, however, was found to be more sensitive and 
simpler than the other available methods.
Phillips et al. (1967), using fluorescence microscopy, also examined 
organs of animals treated with isometamidium. Their results showed that all 
the tissues contained isometamidium.
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Paper chromatography
Phillips et al. (1967) used the paper chromatographic technique to look 
at faecal extracts for the presence of metabolites of isometamidium. Sodium 
hydroxide and sodium chloride were added to aqueous solutions of 
isometamidium, homidium and to faecal extracts. These mixtures were then 
extracted with ether. The extracts were then evaporated, the residues 
dissolved in acetone, spotted on Whatman No. 3 paper, and dried. The dried 
spots were then developed using ascending chromatography with the 
following systems:
Dimethylformamide: water 1:1 (v/v)
Triethylamine:water:dimethylformamide 1:5:14 (v/v/v)
Acetic acid:water:dimethylformamide 1:5:14 (v/v/v)
The dried chromatograms were then viewed under UV light for orange- 
pink fluorescent spots. These were not seen with the faecal extracts from 
untreated animals. However, small pink zones were seen at the origin of the 
chromatograms of spots of faecal extracts of treated rats showing the presence 
of isometamidium. The technique is only suitable for qualitative work because 
of the difficulties in quantifying the spots.
Thin Layer Chromatography (TLC)
This technique, though simple and fast, is mainly for qualitative and 
sometimes semi-quantitative work. The materials usually used for the 
stationary phase are silica and alumina which are coated on a sheet of glass as 
a support. After spotting the plate with samples and reference standards, the 
plates are developed in an equilibrated tank containing an appropriate solvent 
system. Various compounds migrate differently depending on their size and 
polarity. Detection is achieved by viewing under UV light for fluorescent 
substances; the spots can be quantified using a scanning densitometer. TLC is 
a technique usually employed for general screening of samples, followed by
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more sensitive techniques. Moffat (1986) has described several solvent 
systems which have been established for general screening of basic 
nitrogenous drugs, which include diminazene, homidium and isometamidium. 
TLC was used by Kellner et al. (1985) to determine the presence of 
metabolites in urine from diminazene-treated cattle. Their findings were that 
the metabolite pattern in the urine of the first day after treatment was different 
in two animals. In one calf, three radioactive peaks were detected; the largest 
of the peaks, which accounted for 74% of the total radioactivity, was the 
original compound diminazene. The next smaller peak (Rf = 0.53) was 
identified as p-aminobenzamidine and accounted for 2 2 % of the radioactivity. 
The third peak (Rf = 0.63) was identified as p-aminobenzamine and accounted 
for only 4%. Interestingly, these two latter peaks were undetected in the 
second calf, showing only the presence of diminazene.
Mass Spectrometry
Diminazene has an established mass spectrum with principal peaks at 
m/z 30, 43, 72, 102, 73, 42, 118 and 99 (Moffat, 1986). There is no established 
analytical method that has made use of this technique on its own, except one in 
which gas liquid chromatography has been coupled to a mass 
spectrophotometer.
Gas Liquid Chromatography- Mass Spectrometry (GLC-MS)
All the trypanocidal drugs currently in use are polar compounds. 
Determination of such polar compounds by gas liquid chromatography is 
impossible since the technique requires that compounds must be non-polar, 
volatile and thermally stable. The procedure for diminazene required the 
conversion of the drug to a non-polar compund before extraction and clean-up, 
and determination by GLC-MS.
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Infra-red (IR) Spectrometry
Using a potassium bromide disk, the principal peaks of the trypanocidal 
compounds shown below have been established at the following 
wavenumbers:
Homidium - 1628, 1492, 1260, 1312, 836, 1077 
Diminazene - 1610, 1635, 1588, 1171, 1267, 1198
The IR spectra of these drugs have not been exploited in terms of 
developing procedures for detection and quantification of the drugs in 
biological materials. At the moment the technique is only suitable for pure 
drug compounds or for determination of the active ingredient in formulations.
Radiometric
Gilbert and Newton (1982) studied the pharmacokinetics of homidium 
in T. congolense-mfected and non-infected rabbits and calves; 14C-labelled 
homidium bromide was administered at dose rates of 1 or 10 mg kg-1 b.w. to 
the rabbits and at 1 mg kg-1 b.w. to calves. In non-infected rabbits homidium 
concentrations reached a maximum of 180 ng mb1 in blood, and 50 ng m b1 
tissue fluid, within one hour following drug administration. After this there 
was a rapid fall to less than 10 ng mb1 in blood at 96 hours. In non-infected 
calves the levels in blood after one hour were 120-170 ng mb1. Concentrations 
then fell rapidly within the first 24 hours and then slowly to 15 ng mb1 within 
the next 8 days. It was also observed that 80-90% of the total dose given was 
excreted within 96 hours; one-third in urine and two-thirds in faeces. Between 
63 and 79% of the drug was found bound to trypanosomes separated from ear 
vein blood obtained one hour following intramuscular drug administration to 
calves.
Nine days after drug administration to rabbits, it was estimated that 
only 2 - 3% of the total dose given was present in tissues; the highest levels of
0.44 and 0.42 pg g-1 wet tissue were in liver and kidneys, respectively. In
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normal calves, ten days following treatment, these levels were 1.54 and 1.02 
pg g-1 wet tissue and in infected calves they were 1.47 and 0.48 jLXg g*1 wet 
tissue, respectively.
Using both thin-layer and gel chromatography, all radioactivity in 
serum from non-infected and infected rabbits and calves treated with 14C 
homidium was found to chromatograph in the same position as homidium. Gel 
chromatography of urine and bile, however, showed two components eluting 
before homidium, representing up to 46% of the total radioactivity eluted. One 
o f the components carried about 38% of the total radioactivity. Neither o f the 
components was the monoacetyl or the diacetyl conjugates of homidium. Acid 
extraction of urine indicated that all activity in the extract was due to the 
presence of homidium when chromatographed. This indicated that the two 
components mentioned above were not recovered in the acid extract.
Results from the above studies indicate that homidium is excreted very 
rapidly. It is therefore difficult to relate these results to field observations on 
the prophylactic activity of homidium; of 8 to 17 weeks (Dolan et al., 1990).
In 1983, Gilbert used radiolabelled diminazene aceturate to study its 
pharmacokinetics in rabbits. After intramuscular administration of bis-phenyl- 
U-14C-labelled diminazene aceturate at a dose rate of 3.5 mg kg-1 b.w., 
radioactivity was determined in blood, tissue fluid, urine, faeces and tissues. 
One hour after treatment, the drug level obtained in blood was 1.1 pg mb1 and 
that o f tissue fluid was 0.2 pg mb1. The level o f the drug in the blood 7 days 
later was 25 ng mb1. Sixty-five percent of the dose given was excreted within 
7 days, 44% through urine.
Kellner et al. (1985) administered radiolabelled diminazene aceturate 
(bis-phenyl-U-14C) to two calves at a dose rate of 3.5 mg kg-1 b.w. by 
intramuscular injection. Radioactivity was determined in blood, plasma, urine, 
faeces and edible tissues. The maximum drug levels, obtained 15 minutes after 
drug administration, were 4.6 and 4.7 pg mb1 blood. The values for the two
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individual animals were 0.62 and 0.36 pg ml-1 after 7 and 20 days, 
respectively. The disappearance of the drug from plasma was bi-phasic. The 
total amount of drug excreted through urine and faeces within the first 7 days 
after drug administration was 47.1% and 7.6%, respectively of the total dose 
administered. These values were 72.2% and 10.3%, respectively, after 20 
days.
High Performance Liquid Chromatography (HPLC)
The term chromatography embraces a family of closely related 
methods. Three of these methods, namely paper chromatography, thin layer 
chromatography and gas chromatography, have already been discussed. The 
other method is high performance liquid chromatography (HPLC). The 
distinguishing feature of this method is that two mutually immiscible phases 
are brought into contact; one phase is stationary and the other mobile. The 
sample mixture is introduced into the mobile phase and undergoes a series of 
interactions between the stationary and the mobile phases as it is carried 
through the system by the mobile phase. Differences between the physical and 
chemical properties of the components of the sample govern the rate of 
migration of the individual components.
Various compounds differing in both physical and chemical properties 
can be analysed by HPLC, so long as they are soluble in a solvent of some 
sort, aqueous or non-aqueous. In the normal HPLC, the stationary phase 
employed is polar (possessing amino or cyano functional groups) with a non­
polar mobile phase. In the reverse-phase HPLC the stationary phase is non­
polar and the mobile phase polar. It is the reverse of normal HPLC, and hence 
its name. Reverse phase chromatography utilises a hydrophobic bonded phase 
packing usually possessing octadecylsilane (C18; ODS) or octylsilane (C8; RP- 
8) functional groups, and a polar mobile phase. In this type of separation, the 
polar compounds prefer the polar mobile phase and elute first. Retention is
62
usually longer for non-polar compounds since they prefer the hydrophobic 
stationary phase. The simplicity and reproducibility of reversed phase 
chromatography on bonded phases make this method particularly attractive in 
clinical chemistry. Because the water content of the mobile phase can range 
from 100% to very low percentages, or none at all, a broad spectrum of 
biomolecules can be chromatographed; lipophilic, ionic, small or large. 
Bonded phases tend to be unstable in the presence of strong acids and bases. 
Strong acidic and basic systems cannot be handled by ordinary liquid 
chromatographic techniques involving bonded phases. However, by forming 
an ion-pair (association of two ions of opposite electrical charge) with a 
suitable counterion, ionic or ionisable compounds can be converted to 
eletrically neutral compounds which can then be chromatographed. A large 
organic counterion added to the mobile phase forms a reversible ion-pair 
complex with the ionised sample; this complex behaves as an electrically 
neutral and non-polar (lipoliphic) compound. The extent to which the ionised 
sample and counterion form an ion-pair complex affects the degree to which 
the retention is increased. This in turn depends on the pH of the solvent.
In the procedure of Fauda (1977), diminazene was first converted to 4- 
aminobenzamidine which was then extracted and analysed by ion-pair reverse- 
phase liquid chromatography; 3,4-dimethoxybenzamidine was used as an 
internal standard. The analytical column used was a C8 column; the effluent 
was monitored at 310 nm. The mobile phase consisted of methanol, water and 
glacial acetic acid in the ratio 7:3:0.05 to which was added 8 mg 1-pentane 
sulphonic acid as a counter ion in every 100 ml of solution. The flow-rate was 
1.2 ml per minute with a pressure of 1850 pounds per square inch (psi). With 
this procedure, diminazene levels as low as 0.1 pg mb1 were detected.
The introduction of solid-phase extraction (SPE) columns has 
revolutionised HPLC techniques in terms of sample clean-up before analysis. 
A number of such methods have been described for the trypanocidal drugs
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diminazene (Aliu and Odegaard, 1983; Murilla and Kratzer, 1989), and 
homidium, isometamidium and quinapyramine (Perschke and Vollner, 1985), 
resulting in much improved limits of detection.
Aliu and Odegaard (1983) used paired-ion extraction and HPLC to 
determine diminazene concentrations in plasma. The SPE columns for sample 
clean-up were C j8. The analytical column was a cyano-propyl column; the 
effluent was monitored at 254 nm. The mobile phase was 
acetonitrile:methanol in the ratio 50:50, plus 2% v/v triethylamine, at a flow- 
rate of 0.8 ml min-1. The internal standard was imidocarb [(3,3'-di(2- 
imidazolin-2 -yl) carbanilide)], and the counter-ion was 1-heptane-sulphonic 
acid. Linearity was established with diminazene over the range 0.05-5.0 jag 
m l1. Recovery from plasma, without any concentration step, was 92.0±7.8% 
with a limit of quantification of 50 ng mb1.
Murilla and Kratzer (1989) described a reversed-phase HPLC 
procedure for diminazene in which the sample clean-up was done using silica- 
gel SPE columns. The analytical column used was a reversed-phase C 18 
column, and the mobile phase consisted of methanol:water:acetic acid in the 
ratio 20:80:0.03 pumped at 1.5 ml min-1. The column effluent was monitored 
at 370 nm and the limit of detection was 25 ng mb1 serum or plasma, and 
100 ng g-1 tissue.
In the method of Perschke and Vollner (1985), concentrations of 
homidium, isometamidium and quinapyramine were determined after sample 
clean-up on disposable silica-gel columns. Isometamidium was cleaved and 
determined as homidium. The analytical column was C 18 and the mobile phase 
(pumped at a flow-rate of 2 ml min-1) was acetonitrile:water:perchloric acid in 
the ratio 40:60:0.03 (v/v/v) for homidium and 20:80:0.03 (v/v/v) for 
quinapyramine. Both homidium and the cleaved isometamidium were detected 
using a UV detector at a wavelength of 292 nm, whereas quinapyramine was 
determined using a fluorescence detector with an excitation wavelength of 296
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nm and an emission wavelength of 405 nm. The detection limits achieved by 
this procedure were 50 ng of homidium, 100 ng of isometamidium and 30 ng 
of quinapyramine per ml serum when 1 ml serum was processed; and 5 ng of 
homidium, 20 ng of isometamidium and 3 ng of quinapyramine per ml when 
up to 10 ml of serum was processed. Finally, the different procedures were 
developed using spiked samples and were not validated with samples from 
treated animals.
Kinabo and Bogan (1988a) established a solid-phase extraction and ion- 
pair reversed-phase HPLC technique with fluorescence detection for 
isometamidium in bovine serum and tissues. The procedure utilises enzyme 
hydrolysis to release the drug bound to protein before the clean up and 
analysis. However, the long extraction procedure reduces the sensitivity of the 
method, making it unsuitable for routine analysis. Thus, the method has only 
been used to detect and monitor isometamidium concentrations in serum 
during the first 24 hours after drug administration. It has also been used to 
investigate the absorption and distribution patterns of isometamidium in 
tissues of cattle (Kinabo and Bogan, 1988b). Finally, the method has also 
facilitated an examination of isometamidium's pharmacokinetics in lactating 
goats (Kinabo and McKellar, 1990) and in pigs (Kinabo and McKellar, 1991). 
The procedure is, however, not sensitive enough to detect and monitor the 
drug levels for periods longer than 24 hours in serum of treated cattle.
Biological assays 
In vivo
In vivo drug assays for the different trypanocidal drugs currently in use 
have been reported. These include methods of Hill and McFadzean (1963), 
Cunningham et al. (1964), Hill (1965) and Goodwin and Tierney (1977).
In the procedure of Hill and McFadzean (1963), groups of mice were 
given a sub-cutaneous injection of isometamidium. Heart blood was then taken
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at various times post-treatment and sera prepared. The sera were then injected
i.v. into other mice immediately after they had been inoculated i.p. with 
T. conglonse. In all experiments, there were untreated infected controls and 
infected controls given normal mouse serum. Some infected mice were given 
known doses of isometamidium in aqueous solution. The level of parasitaemia 
of all mice was monitored several times per week for 4 weeks after 
inoculation, and the pre-patent period compared to the controls. Mice which 
remained negative at the end of the 4 weeks were considered to be fully 
protected. The results indicated that there was a slight elongation of the 
parasitaemia pre-patent period by serum taken 3, 24, 48 hours and 7 days after 
the s.c. injection of 0.04 mg (cation) g-1 b.w. In order to be able to detect 
maximum activity, 0.16 mg g-1 b.w. was used, which was the largest dose that 
would not cause toxicity. Prolongation of the onset o f parasitaemia to various 
degrees was observed with sera taken after 1, 3 hours and 7 days following 
treatment from mice which the elevated dose. One mouse was protected 
completely by the serum taken 1 hour after drug administration, but serum 
taken 14 days later had no effect at all. These responses were compared to the 
effect of the standard aqueous solutions of isometamidium. The comparison 
indicated that the bio-assay of serum from mice given 0.16 mg isometamidium 
(cation) g-1 b.w. showed it contained approximately 0.0004 mg mb1, 1 or 3 
hours after treatment, and approximately 0.0002 mg mb1, 24 hours later. 
Lastly, the serum fluoresced up to 6 hours after treatment, but no fluorescence 
could be seen 24 hours later.
The bio-assay for diminazene described by Cunningham et al. (1964) 
was different from that of Hill and McFadzean (1963) for isometamidium. In 
this method, estimates of drug levels in cow serum after treatment were made 
by comparing the infectivity of trypanosomes after in vitro exposure to serum 
from a cow before, and at intervals after treatment, with the infectivity of 
trypanosomes after in vzYro-exposure to serum containing known
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concentrations of diminazene.
In the method of Hill (1965), three drugs were investigated in mice; 
namely, homidium, isometamidium and pyrithidium The protocol followed 
was similar to that of Hill and McFadzean (1963) except that higher dose rates 
were used. The results indicated that none of the mice inoculated with serum 
taken 24 hours after treatment with homidium at 7.5 mg kg-1 b.w. were cured. 
The donor mice, however, were cured with homidium bromide doses as low as 
0.75 mg kg-1 b.w. The CD50  in mice of the T. congolense used was 0.2 mg 
kg-1 b.w.
Finally, Goodwin and Tierney (1977) used a biological assay to 
determine the trypanocidal activity of body fluids from rabbits treated with 
homidium bromide at 10 mg kg-1 b.w., suramin at 100 mg kg-1 b.w., 
diminazene aceturate at 15 mg kg-1 b.w., and isometamidium chloride at 
10 mg kg-1 b.w. In this bioassay the serum, or tissue fluid collected from tissue 
cages implanted s.c. in treated rabbits, was serially diluted in a 96-well 
microtest plate and incubated at 35°C in the presence of 50,000 trypanosomes 
o f T. brucei in basic medium. The highest dilution in which trypanosomes 
could still be seen moving was taken as the end point and was recorded after 
24 and 48 hours incubation, or longer in some experiments. Controls, to which 
normal rabbit serum and tissue fluid were added, were used on all the plates, 
together with serial dilutions of the appropriate trypanocidal drug in basic 
medium containing Medium 199 with Earle's Salts, 25mM HEPES buffer, L- 
glutamine, glucose, sodium penicillin G, and streptomycin. For homidium 
bromide, the approximate dilutions of drug in microtest plates required to kill 
100% of the trypanosomes were 1:1.5x10^ after a 24-hour and 1:5.0x10^ after 
a 48-hour incubation at 35°C. Exposure for 48 hours to body fluids from 
rabbits treated with phenanthridinium derivatives did not show much increase 
over the 24-hour figure. Lastly, results for diminazene indicated that after i.m. 
injection, significant trypanocidal activity appeared in tissue fluid before it
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reached the plasma.
In  v itr o
When tsetse ingest blood from infected animals, trypanosomes are 
taken in with the bloodmeal and immediately lose their infectivity to 
mammals. These trypanosomes develop into different forms in various organs 
of the fly. The mammalian infective forms are the metatrypanosomes 
(metacyclics). Non-infective procyclic trypanosomes have been grown in 
culture since 1903, but in vitro assays to assess drug sensitivities of 
trypanosomes using this stage of the life cycle have been unsuccessful as 
results do not correlate with those obtained from animal experiments 
(Hawking, 1963; Elrayah and Kaminsky, 1991). Elrayah and Kaminsky (1991) 
examined the effect of diminazene and isometamidium on cultured procyclic 
forms of drug-susceptible and drug-resistant T. congolense and demonstrated 
that it was not possible to distinguish between drug-resistant and drug- 
susceptible stocks or clones using growth inhibition or death of the 
trypanosomes.
Efforts directed towards improvement of the techniques for in vitro 
propagation of mammalian infective, bloodstream form, trypanosomes have 
been successful for T. brucei ( Cunningham and Honigberg, 1977; Hirumi et 
al., 1977), T. congolense (Gray et al., 1981; Hirumi and Hirumi, 1984) and 
T. vivax (Brun and Moloo, 1982). These culture systems have thereafter been 
developed and used successfully in screening for drug sensitivity in 
T. congolense and T. brucei trypanosome species. Gray et al. (1993) used in 
vitro-derived metacyclic trypanosomes to determine the drug sensitivity of 7 
populations of T. congolense collected from cattle and tsetse flies. In this 
assay, the metacyclic trypanosomes were incubated for 48 hours at 35°C with 
concentrations of homidium bromide, homidium chloride, isometamidium 
chloride and diminazene aceturate ranging from 0.5 ng to 50 jig m l1. The
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trypanosomes were then tested for their ability to survive on a bovine aortic 
endothelial monolayer over a period of 5 days in the absence of drugs. With 
the stocks of T. congolense used, the results obtained correlated well with field 
observations; that is, the stocks which showed resistance in the field to the 
drugs showed resistance in vitro.
Radioimmunoassays
Kinabo and Bogan (1988c) have described a radioimmunoassay 
technique for isometamidium which has not found much application in studies 
on isometamidium. This is probably because it has been superseded by easier 
and safer enzyme-linked immunosorbent assays. In the development of the 
radioimmunoassay procedure, sheep were immunised using an 
isometamidium-glutaraldehyde-human serum albumin conjugate. The 
antiserum obtained after 18 weeks of immunisation was used in the 
radioimmunoassay procedure. About 50% of the radioligand was bound at a 
final dilution of 1:500 in the absence of unlabelled isometamidium. The limit 
of detection of the assay was 38.3 ng mb1. When serum samples from calves 
treated with isometamidium chloride at 0.5 mg kg-1 b.w. were tested, the 
highest concentration measured was 69.3 ng ml*1, attained 30 minutes 
following treatment. Thereafter, within 4 hours, it declined rapidly to below 
the detection limit.
A SUMMARY OF THE LIMITATIONS OF THE CURRENT 
METHODS FOR MONITORING OF TRYPANOCIDAL DRUGS 
IN TREATED ANIMALS
In summary, colorimetric methods lack both sensitivity and specificity. 
For example, certain samples such as plasma and urine may naturally give 
colour reactions that will interfere with the compound of interest.
Although fluorescence methodologies are by nature more sensitive than the
69
colorimetric methods, any substances in the solution that quench the emitted 
light will interfere with the sensitivity of the method. Thus, using HPLC with a 
fluorescence detection method, Kinabo and Bogan (1988a) were unable to 
detect isometamidium in serum of treated cattle for more than 24 hours after 
drug administration. The fluorescence method on its own has been useful in 
examining the distribution of drugs, especially phenanthridines, in tissues.
Paper and thin-layer chromatography are not sensitive enough to 
determine sub-microgramme levels of the drug, especially in serum or plasma 
following administration of low doses. Thin-layer chromatography is useful as 
a screening method since it is cheap, simple, well adapted to routine use and 
multiple samples can be run on one plate. However, the disadvantage with this 
technique is that it is difficult to quantify and therefore not suitable as an 
analytical method.
Gas liquid chromatographic methods are sensitive but require that 
samples must be volatile and thermally stable. All the trypanocidal drugs are 
polar compounds and therefore require derivatisation to non-polar compounds 
before they can be chromatographed. This is time consuming as it requires 
long and tedious procedures of derivatisation, extraction and clean-up before 
analysis. Furthermore, only one sample can be analysed at a time, making it 
unsuitable for routine analysis.
Radiometric methods, although sensitive, lack specificity because they 
determine the total radioactive components, some of which could be 
metabolites.
Use of in vitro methods for drug-sensitivity tests has been successful, 
but the time taken in adapting trypanosomes to culture could be as long as 
three months, making the time taken to get any results too long. Extrapolation 
of data to different animal species is also often difficult.
As a result of the aforementioned problems and limitations of the 
analytical methods available for the anti-trypanosomal compounds, it was
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necessary to develop methods with better sensitivity and specificity for the 
detection and monitoring of the drugs in animals following treatment. Lack of 
a sensitive and specific analytical method for evaluating levels of homidium in 
serum of treated cattle, and, until recently, isometamidium, in the field has 
been one of the factors limiting our knowledge on the relationship between the 
drugs' therapeutic and prophylactic activity and their pharmacokinetic 
properties.
Of the three drugs currently recommended for use in cattle (that is, 
diminazene, homidium and isometamidium), diminazene, which is purely a 
curative drug, can be investigated adequately at the present time with the 
available HPLC analytical methods since the drug can be monitored up to 28 
days after administration of the recommended doses. Similarly, 
isometamidium, a widely used chemoprophylactic drug can be investigated 
adequately with the use of the recently established ELISA method (Eisler et 
al., 1993). However, homidium which was originally introduced as a 
chemotherapeutic drug and has been demonstrated to possess prophylactic 
properties cannot be investigated due to lack of sensitive analytical methods.
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PART THREE
INTRODUCTION TO THE PRESENT STUDY
Sensitivities of most drug assays that involve sample extraction and 
clean-up are usually lowered (1) because drug is lost through the many steps 
involved, and (2 ) co-extracted proteinous material interferes with the detection 
of the drug of interest. Thus, direct methods not involving extractions, one of 
which is the enzyme-linked immunosorbent assay, are now the method of 
choice in many clinical analyses.
Enzyme-linked immunosorbent assays
Many drugs are administered at low dose rates e.g. mg k g 1 b.w. and it 
might be expected that concentrations in the blood will be low, frequently at 
nanogram levels, and therefore, difficult to detect. Therefore, suitable tests for 
the determination of low drug concentrations in biological fluids would have 
to be of high sensitivity and specificity. They should also be:
- devoid of extraction steps
- easy to perform
- suitable for analysis of a wide range of samples
- permit analysis large numbers of samples
- relatively cheap
Radioimmunoassays (RIA) utilising radiolabelled antigen and later, 
enzyme-linked immunoassays (ELISA) utilising enzyme-labelled antigen 
fulfilled many of these criteria and have made a significant contribution in the 
area of drug analysis.
Since drugs are small molecular weight molecules (haptens) not 
capable of inducing the formation of antibodies, they are usually coupled to a 
carrier protein to form an antigen. The most common carriers are serum 
albumin of various animal species, keyhole limpet haemocyanin, and
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thyroglobulin.
The determination of a substance in a biological fluid consists of two 
steps: reaction and detection. Both RIA and ELISA are binding assays and 
involve antigen and antibody reactions. In most immunoassay reactions, the 
reagents are permitted to react for long enough for equilibrium to be reached.
At equilibrium: Ag + Ab <=> AgAb
The distribution of antigen between bound and free phases is directly 
related to the amount of antigen present. This provides a means of quantifying 
the antigen. Therefore, the principle of all binding assays is: 'Given a fixed 
amount of antibody, the ratio of bound to free antigen at equilibrium will be 
quantitatively related to the total amount of antigen present'.
Based on the above principle, methods have been developed for the 
determination of various substances in biological fluids. RIA was first 
introduced by Yalow and Berson (1960). Later, Engvall and Perlmann 
(1971,1972) introduced the idea of using enzymes conjugated with antibody or 
with antigen to detect and measure antigens and antibodies respectively. 
Rubenstein et al. (1972) described an ELISA method for morphine in which as 
little as lxlO '9 M morphine could be detected. Elliot et al. (1995) have 
described a method that is a modification of the conventional ELISA in which 
extremely low concentrations of (5-agonist residues have been determined in 
bovine eye and hair samples. This is a simple qualitative screening test 
suitable for use on farms or in slaughterhouses in residue control programmes.
In the field of trypanosomiasis, Kinabo and Bogan (1988c) developed a 
radioimmunoassay method for the determination of isometamidium in serum 
of treated cattle which had a limit of detection of 38 ng mb1. This method had 
several disadvantages which included (a) lack of sensitivity (b) use of 
radiolabelled drug which is expensive and required special equipment and
73
special handling facilities (c) application was limited to laboratory use and (d) 
physical separation of the labelled from the unlabelled drug before the 
determination of radioactivity.
The use of enzymes as labels which are relatively cheap and require no 
special facilities and physical separation of samples is rapidly replacing 
radioisotopes. Using enzyme immunoassays, very low drug concentrations can 
be determined in biological fluids as will be demonstrated later.
Use of enzyme immunoassays in the study of parasitic diseases had 
previously been limited mainly to disease diagnosis. The technique is 
however, the method of choice in many clinical analyses in which detection of 
low levels of drugs is required. All drug ELISA methods are competition 
assays. Competition may be direct or indirect. In a direct competition assay, 
the solid phase is coated with antibody followed by addition of test serum 
diluted in a solution containing enzyme-labelled antigen. The free drug in 
solution (from the test sera) competes directly with the enzyme-labelled 
antigen for the antibody. Detection is by spectrophotometric method after 
addition of enzyme substrate and chromogen. The higher the concentration of 
free drug in test sera, the less the enzyme-labelled antigen will bind and the 
less the intensity of colour.
In an indirect competition ELISA, the solid phase is coated with 
antigen. The test serum, diluted in antibody solution is added and incubated 
for some time (any specific antibody attaches to the antigen). Washing 
removes unreacted components as well as any antibody attached to free 
antigen (from the test sera). A conjugate of enzyme-labelled antiglobulin is 
then added and incubated. This is followed by the addition of substrate and 
chromogen as in the direct method described above.
In the ELISA of Eisler et al. (1993) for isometamidium, anti- 
isometamidium antibody was produced in sheep after immunisation with an 
isometamidium-bovine serum albumin conjugate. High antibody titres were
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obtained using this procedure. The antibody was purified using the ammonium 
sulphate precipitation method. Thereafter, it was biotinylated. For the assay, 
isometamidium-ovalbumin conjugate was adsorbed onto the wells of 96-well 
microtitre plates. The purified, biotinylated, antibody was then added, 
followed by streptavidin-horseradish peroxidase enzyme conjugate 
(streptavidin has a high affinity for biotin). After addition of substrate and 
chromogen, the optical density of the resulting colour change was determined 
in an ELISA reader. In order to analyse serum samples from treated animals 
for the drug, the serum was mixed with the biotinylated antibody in a micronic 
tube before addition to the wells on a microtitre plate. The ELISA is, 
therefore, an indirect competition ELISA for isometamidium in which 
isometamidium is detected via the biotin-streptavidin bridge. The method has 
been used to study the pharmacokinetics and the pharmacodynamics of 
isometamidium in catde in the field (Eisler et al., 1994).
Investigations into the circulating concentrations of homidium in serum 
of treated animals in the field have not been carried out for reasons already 
mentioned, such as the lack of sensitive analytical techniques. The purpose of 
this study, therefore, was to develop a sufficiently sensitive enzyme-linked 
immunosorbent assay that would be used to determine the levels of homidium 
in serum of treated animals in the field, and to relate these levels to the 
curative and prophylactic activity of homidium observed in the field.
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T H E  STUDY OBJECTIVES
In view of the lack of a sensitive and specific method for the detection 
anid monitoring of homidium in serum of treated animals, the objectives of this 
work were to:
1. Develop an enzyme-linked immunosorbent assay that is sufficiently specific 
an d sensitive for the assay of homidium in plasma, urine, tissues and tissue 
flmid.
2. Validate the method using serum samples from homidium-treated cattle.
3. Use the validated method to:
(a) collect baseline data in laboratory studies on:
(i) serum concentrations in normal cattle treated with homidium at the 
recommended therapeutic dose of 1 mg kg-1.
(ii) serum homidium concentrations following treatment of cattle infected with 
Trypanosoma congolense populations with varying sensitivities to homidium.
(iii) the relationship between the serum homidium concentrations and the 
prophylactic period following monthly trypanosome challenge of homidium- 
treated cattle with T. congolense populations of varying sensitivities to the 
recommended therapeutic dose of homidium.
(b) carry out a pharmacodynamic study of homidium in the field.
(c) compare values obtained for homidium levels in serum of treated animals
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with those obtained by use of a radiometric method.
(d) carry out a metabolite study in serum and, if possible, determine the role of 
metabolites in chemotherapy and prophylaxis of animal trypanosomiasis. This 
would be possible with the use of a combination of techniques, for example, 
the radiometric and ELISA techniques.
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CHAPTER TWO
GENERAL MATERIALS AND METHODS
Homidium bromide
Homidium bromide was obtained from two different sources (Cameo 
Animal Health, Cambridge, U.K; Laprovet, Toure, France) was used. Details 
including the batch numbers is provided in the relevant Chapters. A 2.5%w/v 
solution of the drug was prepared in sterile water freshly and administered at a 
dose rate of 1 mg kg-1 b.w. It was given as a single bolus by either intravenous 
(i.v.) or deep intramuscular (i.m.) injection into the muscles of the neck using 
IV2" x 18 gauge needle.
Animals 
Boran cattle
The animals used in the experiments in Kenya were Boran (.Bos 
indicus) weaner male castrates aged between six and nine months and 
weighing between 120 and 180 kg purchased from areas of Kenya free from 
endemic trypanosomiasis. These animals had already been vaccinated by the 
farmers against babesiosis and anthrax at the time of purchase.
On arrival at the Kenya Trypanosomiasis Research Institute (KETRI) 
laboratories, the steers were ear-tagged. They were also sprayed twice at an 
interval of three days with a solution containing 12.5%w/v amitraz ( Triatix®, 
Coopers (K) Ltd.) against ticks within the first week of their arrival after 
which they were housed in a fly-proof bam. Blood smears were prepared on 
clean microscopic slides, stained with Giemsa and examined microscopically 
for theileriosis, babesiosis and anaplasmosis. Faecal samples were examined 
for nematode infection. The animals were orally given a dmg formulation 
containing 3.0% oxyclozanide BP and 1.5% levamisole hydrochloride BP 
(Nilzan® Plus with Cobalt, Cooper Kenya Ltd.) at the dose rate of 0.5ml per 
kg body weight (b.w.) recommended by the manufacturer against worms. Two 
weeks later the animals faecal samples were re-examined to ascertain that they 
were worm-free. The animals were maintained on hay, protein diet supplement
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(Ranch cubes, Unga Ltd., Kenya) at 250 g per animal per day plus mineral 
supplements. During the experiments the animals were weighed once a week.
Friesian cattle
Healthy Friesian cattle aged approximately six months, purchased from 
two different farms in the UK, were used in the studies in Scotland. On arrival 
at the Veterinary Hospital, University of Glasgow, the animals were housed in 
a closed bam, ear-tagged and maintained on hay plus concentrate supplements, 
and had free access to water. The experiments were initiated after the animals 
were acclimatised to the laboratory conditions.
Sheep
Scottish Blackface aged six months, obtained from a commercial farm 
were used in the production of hyperimmune serum. They were fed on hay 
plus concentrate supplements and had free access to water.
Preparation of antisera
Preparation of homidium-keyhole limpet hemocyanin (homidium-KLH) 
conjugate
This conjugate was prepared through a diazotisation procedure. To 50 
mg homidium bromide dissolved in 1 ml 0.5M hydrochloric acid on ice, was 
added 1 ml of ice-cold 0.127M sodium nitrite. The mixture was stirred on ice 
for 10 minutes in the absence of light. Four hundred microlitres of this mixture 
equivalent to 10 mg homidium was added to 96 mg KLH dissolved in 2 ml 
0.1M sodium bicarbonate, pH 8.3. The mixture was stored at +4°C until 
required.
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Immunisation of sheep and collection of hyperimmune sera
Three sheep were immunised with homidium-KLH conjugate to raise 
antibodies against homidium using the method described by Whitelaw et al. 
(1991). Three dilutions of the conjugate containing 2 mg, 1 mg and 500 |ig 
KLH per ml were prepared. Four doses were given to each sheep by 
subcutaneous injection.
The primary immunisation consisted of 2 mg KLH in 3 ml of water-in­
oil emulsion containing conjugate and Freund's Complete Adjuvant (FCA) 
mixed in the ratio 1:2 v:v conjugate:FCA. Each sheep received 1.5 ml of this 
emulsion in each hind leg. Four weeks later each sheep received a booster 
immunisation containing 1 mg KLH also in 3 ml of an emulsion containing 
conjugate plus Incomplete Freund's Adjuvant (IFA) mixed in the ratio 1:2 
conjugate:IFA. Ten ml blood was collected 10 days after this second booster 
immunisation, serum separated and the protein concentration determined by 
measuring the OD at 280 nm in a UV/Visible spectrophotometer (Pye Unicam, 
SP 800; OD of 1.0 = 0.75 mg protein per ml).
Second and third booster immunisations given also at 4 weekly 
intervals consisted of 500pg KLH in 3 ml of an emulsifiable suspension 
prepared as described above in Incomplete Freund's Adjuvant. Similarly, ten 
ml samples of blood were collected after each of these booster immunisations, 
serum separated and protein concentration determined. The sheep were bled 
out under terminal anaesthesia ten days after the third booster immunisation. 
Serum was prepared, aliquoted and stored at -20°C.
Purification of anti-homidium IgG
In a 250 ml glass beaker, one volume anti-serum was added to two 
volumes of 0.06M acetate buffer, pH 4.0, to give a seram-buffer solution of 
pH 4.8. On a high speed magnetic stirrer, 3.20 ml caprylic acid was added 
dropwise for every 100 ml serum to the acetate-serum mixture. Serum albumin
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was precipitated leaving the globulins in solution. The mixture was stirred for 
30 minutes after which it was then aliquoted into 25 ml universal bottles and 
centrifuged at 3000 rpm for 10 minutes. The supernatant was separated and the 
pH adjusted to 5.7 with 1M sodium hydroxide solution. The salt content of the 
supernatant was lowered by a 24 hour dialysis against 0.015M acetate buffer, 
pH 5.7.
After this overnight dialysis, the antibody containing solution was 
centrifuged since it appeared cloudy after the dialysis. The optical density was 
measured at 280 nm and the protein concentration calculated (OD of 1.0 s  
0.75 mg mb1 protein solution at 280 nm measured in 1 cm cuvette). The 
remaining contaminants, if any, were removed by batch adsorption of the 
globulin-containing solution using the Whatman DE-52 medium. The DE 52 
medium (50 g for every 2 ml supernatant) was equilibrated by stirring in 0.1M 
acetate buffer, pH 5.7.
The particles were allowed to settle (approximately 10 minutes) and the 
buffer decanted. This was repeated three times but using 0.015M acetate 
buffer instead of the 0.1M. This medium was left overnight in 500 ml of the 
0.015M buffer at +4°C. After this equilibration, two different protocols were 
followed in further purification of the antibody.
(a) One fraction was loaded onto a column packed with pre-equilibrated DE 
52. The globulins were desorbed using a gradient elution with different molar 
concentrations of sodium chloride starting at 0.1M and ending with 2M 
solutions. During the gradient elution, five millilitre fractions of the column 
effluent were collected during the elution and their optical densities (ODs) 
determined. Fractions representing each of the various peaks were pooled 
separately. The various pooled solutions were concentrated using an 
immersible-CX low binding filter unit, 10 000 (Millipore (U.K.) Ltd., 
Edinburgh, Scotland). The protein concentration was determined as above
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from the ODs. The volume of the solutions was adjusted such that each 
solution contained 2 mg protein /ml. The solutions were stored at -20°C.
Finally, the antibody activity of the two peaks collected separately in 
the effluent of the DE-52 column were titrated by ELISA using doubling 
dilutions (See section on assay optimisation).
(b) In the second DE-52 protocol the DE 52 medium in 0.015M acetate buffer, 
pH 5 .7 was filtered through an All Glass Filter Holder, 47 mm (Millipore 
(U.K) Ltd., Edinburgh, Scotland) with a funnel capacity of 300 ml. This was 
done under gentle suction taking care not to let the gel compress. The suction 
was removed as soon as the buffer was at the level of the gel. To the wet DE 
52 in a glass beaker was added the caprylic acid purified antibody (2g DE 52 
per 1 ml of antibody solution). This was stirred with a glass rod and left on the 
bench for 2 hours (with occasional stirring). The slurry was aliquoted, in 25 
ml universal bottles and centrifuged at 3000 rpm for 40 minutes. The 
supernatant was separated, the OD measured and the protein concentration 
calculated. The solution was then dialysed against PBS overnight, the OD 
determined and the protein calculated. After the overnight dialysis, the 
solution was concentrated using the immersible-CX low binding filter unit,
10,000 (Millipore (U.K.) Ltd) and the protein adjusted to 2 mg m l1 and tested 
for antibody activity using titrations. This purified antibody solution was, 
thereafter, biotinylated. The determination of protein after every step in the 
purification was necessary so that the recovery could be monitored.
Sample collection 
Pre-treatment sera
Fifty millilitres of blood were collected aseptically from each animal by 
jugular venipuncture before the homidium treatment. The time at which the 
pre-treatment sera was collected and the number of animals used is described 
in the appropriate Chapters. The blood samples were incubated for 4 hours at
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37°C, overnight at +4°C and centrifuged at 1500 g for 20 minutes and the sera 
separated. These pre-treatment samples served as negative control sera from 
which a pool was prepared, aliquoted and stored at -20°C until required.
Blood samples of cattle for parasitological examination
Ear-vein blood samples were collected in heparinised capillary tubes 
daily during the first four weeks following infection and thereafter three times 
a week to the end of the observation period specified under the various 
Chapters.
Blood samples for biochemical and drug analysis
Ten millilitre blood samples were collected from each animal as 
described above immediately before treatment and at pre-determined intervals 
following homidium treatment. The interval at which samples were collected 
is described in the appropriate Chapters. These samples were used to 
determine total serum protein, serum albumin levels and serum homidium 
concentrations.
Enzyme-linked immunosorbent assay (ELISA) reagents 
Purification of homidium-horseradish peroxidase (homidium-HRP) 
conjugate
A 30 cm dialysis tubing (size 2, inflated diameter 14.3 mm, BDH, 
Poole, England) was placed in a beaker of water and boiled for 15 minutes. 
One end of the tube was tightly clipped and using a glass dropper, the 
conjugate solution was added to the tubing. After removal of air from the 
tubing, another clip was used to close the other end. The tubing plus contents 
were then placed in a beaker containing 2  litres of the sodium chloride 
solution and dialysed for 5 hours with constant stirring. The dialysis solution 
was replaced with that which had been freshly prepared and the dialysis
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continued for a further 16 hours. After the dialysis, one end of the tubing was 
cut, purified conjugate removed and placed in a glass bijou. A volume of 
500pl of the double strength charcoal was added and vortex mixed. The 
contents were further mixed on an end-over-end mixer for 15 minutes after 
which they were transferred to mini-centrifugation tubes (Eppendorf) and 
centrifuged at 12,000 g for 10 minutes. The supernatant was removed, 
aliquoted into 500pl fractions, mixed with an equal volume of glycerol and 
stored at -20° C.
ELISA substrate and chromogen solution
A 42 mM stock solution of 3,3',5,5'-Tetramethylbenzidine (TMB) 
(Sigma Chemical Ltd., Poole, England) was prepared by dissolving 100 mg of 
TMB in 10 ml of dimethyl sulphoxide (DMSO). This solution was stored at 
+4°C until required. A 3%v/v solution of hydrogen peroxide was also prepared 
in water. One ml of the TMB in DMSO solution was slowly added to 100 ml 
0.1M sodium acetate/citrate buffer pH 6.0 followed by 145.8 pi of the diluted 
hydrogen peroxide to give a final concentration of 1.3mM per litre. This 
TMB/H2 O2  solution was prepared just prior to use. It was also allowed to 
warm up to 37°C just before addition to the plate.
Buffers
Unless where otherwise specified, all chemicals used in reagent 
preparation were supplied by Sigma Chemical Co. Ltd., Poole. England. Water 
was de-ionised and distilled.
Acetic acid, 5% (v/v)
This solution was prepared by adding 50 ml glacial acetic acid (BDH, 
Poole, England) to water and adjusting the volume to 1 litre.
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Acetate buffer, 0.015M, pH  5.7
Solution A was made by dissolving 4.88g of anhydrous sodium acetate 
in 4 litres of distilled water and solution B by adding 0.85 ml of glacial acetic 
acid to water and adjusting the volume to 1 litre. A volume of 380 ml of 
solution B was added to solution A and the pH adjusted with acetic acid.
Acetate buffer, 0.06M, pH  4.0
Solution A was made by dissolving 2.46g sodium acetate in water and 
adjusting the volume to 500 ml. Solution B was made by adding 1.72 ml 
glacial acetic acid to water in a 500 ml volumetric flask and adjusting to 
volume. Solution A was mixed with solution B and the pH adjusted 
accordingly using acetic acid.
Acetate buffer, 0.1M, pH  5.7
Solution A was made by dissolving 8.203g of sodium acetate in water 
and adjusting the volume to 1 litre. Solution B was prepared by adding 5.73 ml 
glacial acetic acid to water in a 1 litre volumetric flask and making up to 
volume. A volume of 95 ml of solution B was mixed with solution A and the 
pH adjusted accordingly using acetic acid.
Acetate/citrate buffer, 0.1M, pH  6.0
A solution of 0.1M sodium acetate was prepared by dissolving 8.203g 
in water and adjusting the volume to 1 litre. The pH of this solution was 
adjusted to 6.0 by the addition of small amounts o f 0.1M citric acid.
Hydrochloric acid, 0.5M
This solution was prepared by adding 15.5 ml of concentrated 
hydrochloric acid (BDH, Poole, England) to water and adjusting the volume to 
1 litre.
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Sodium nitrite, 0.1M
This solution was prepared by dissolving 6.95 g sodium nitrite in water 
and the volume adjusted to 1 litre.
Sodium bicarbonate buffer, 0.1M, p H  8.5
This buffer was prepared by dissolving 8.4g sodium bicarbonate in 1 
litre o f water.
Sodium carbonate/bicarbonate buffer, 0.1M, p H  9.2
Solution A was made by dissolving 8.4g sodium bicarbonate in water 
and making to 1 litre. Solution B was prepared by dissolving 2.65g sodium 
carbonate in water and adjusting the volume to 250 ml. The pH of 900 ml of A 
was adjusted using B. The volume was adjusted to 1 litre with water.
Phosphate buffer, 0.1M, pH  7.4
Solution A was made by dissolving 57.52g di-sodium hydrogen 
phosphate in 2025 ml of water. Solution B was made by dissolving 31.21 g 
sodium dihydrogen phosphate in 1 litre of water. A volume of 420 ml of 
solution B was added to solution A and the pH adjusted by adding small 
quantities of B. The final volume was made up to 5 litres.
Phosphate buffered saline (PBS)
Phosphate buffered saline was prepared by dissolving 16g sodium 
chloride, 2.96g di-sodium hydrogen phosphate and 0.86g potassium di­
hydrogen phosphate in water and adjusting the volume to 1 litre.
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EDTA saline glucose (ESG; pH  8.0)
A solution of ESG containing 8mM EDTA, 2.7mM potassium di­
hydrogen phosphate, 0.14M sodium chloride and 1 ImM glucose was prepared 
in water and the pH adjusted to 8.0.
Phosphate buffered saline plus glucose, p H  7.4 (PSG)
A solution of PSG was prepared by adding 1.5 g glucose to every 100 
ml PBS.
Phosphate buffered saline plus Tween 20 (PBST)
Phosphate buffered saline plus Tween 20 was made by adding 500pl of 
Tween 20 (BDH, Poole, England) to every litre of the buffer solution.
Washing buffer
A 5-fold dilution was made from PBS after which 1 ml Tween 20 was 
added for every 2 litres of solution.
Activated charcoal
This reagent was prepared by weighing out 2.5g activated charcoal 
(BDH, Poole, England) and 0.25g dextran adding 1 litre o f distilled w ater, 
mixing and storing at +4°C until required.
Trypanosomes
Two populations of Trypanosoma congolense with differing sensitivity 
to homidium were used, one sensitive and the other resistant to the 
recommended therapeutic dose of homidium of 1 mg kg*1 b.w. Stabilates of 
these trypanosome populations had been maintained in microcapillary tubes in 
liquid nitrogen in the Kenya Trypanosomiasis Research Institute (KETRI) 
trypanosome bank. One population was T. congolense ILRAD 1180 first
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described by Nantulya et al. (1984) and reported to be sensitive to diminazene 
and isometamidium at CD50 values of 2.3 mg k g 1 b.w., and 0.018 mg k g 1 b.w 
respectively in mice (Peregrine et al., 1991). The other population was T. 
congolense EL 3330 which was isolated from the Ghibe area of Ethiopia 
(Codjia et al., 1993) and has been reported to be multi-resistant to therapeutic 
doses of the three most commonly prescribed trypanocides. Gray et al., 1993 
found the population to be resistant to diminazene (>30 mg k g 1 b.w.), 
homidium (> 2 0  mg k g 1 b.w) and isometamidium (> 2 0  mg k g 1 b.w) in vitro. 
The procedures followed in the preparation of the inoculum and the size of 
inoculum given are described in detail in the relevant chapters.
To prepare the inoculum for infection of cattle, trypanosome stabilates 
were inoculated intraperitoneally into irradiated mice. At the first peak of 
parasitaemia, the mice were bled out by cardiac puncture under chloroform 
anaesthesia, using EDTA as an anticoagulant. The trypanosome density in the 
pooled blood from the infected mice was determined with a haemocytometer 
and subsequently the blood was diluted in ESG to give a density of lxlO6 
trypanosomes per millilitre. The stabilates were passaged twice in mice before 
inoculation into cattle.
Detection of anti-trypanosome antibodies
The indirect fluorescent antibody test (IFAT) of Katende et al. (1987) 
was used for the detection of anti-trypanosome antibodies in serum of treated 
and untreated cattle. A group of 10 male Swiss white mice were infected 
intraperitoneally with T. congolense EL 1180. The inoculum given from the 
stabilate was 1 x 106 trypanosomes per mouse. The mice were bled out into 
EDTA-containing tubes at the first peak parasitaemia and the blood 
centrifuged at 12000g for 15 minutes at +4°C. The trypanosome-rich buffy 
coat was then re-suspended in phosphate-buffered saline plus glucose (PSG), 
pH 8.0, separated on DE 52 and washed three times with cold PSG.
Thereafter, the trypanosomes were re-suspended in cold physiological saline 
to give a concentration of 1 x 106 trypanosomes per ml, then fixed in a 
mixture of 80% acetone and 0.25% saline in the ratio 1:2 trypanosome 
suspension:fixative. After overnight fixation at -20°C, the trypanosomes were 
centrifuged at 450g for 15 minutes at +4°C, washed 3 times with physiological 
saline, then re-suspended in PBS containing 0.2% bovine serum albumin with 
no azide to yield a final concentration of 1 x 105 trypanosomes per millilitre. 
The fixed trypanosomes were stored at -20°C in aliquots of 0.5 ml.
Elimination of non-specific fluorescence commonly associated with 
this assay was carried out by prior absorption of the test sera with normal 
bovine lymphocyte lysate. This lysate was prepared according to the method 
described by Goddeeris et al. (1982). In brief, a splenectomised, four-month 
old calf was maintained under tick and tsetse-free conditions. Blood smears 
were examined for parasites (after Giemsa staining) weekly for a period of 
four weeks inorder to exclude any possibility of latent infections. All 
accessible lymph nodes were removed at the time of slaughter and sliced in 
cold PBS, pH 7.2 in the presence of anticoagulant (EDTA).
Cells were separated from tissue debris by passing through a sieve. The 
cells were then washed three times with PBS-EDTA by centrifugation at 200 g 
for 20 minutes at +4°C. The washed cells were re-suspended in PBS without 
EDTA to give a final concentration of 5 x 107 cells per ml. The solution 
containing the cells was sonicated in 100  ml aliquots on ice at one minute 
intervals using the 3/8 probe (Virsonic 16 850, Virtis Company, Gardiner, 
NY). The sonicated material was centrifuged at 400 g for 30 minutes at +4°C 
and the supernatant containing 5 mg protein per ml stored at -70°C in four ml 
aliquots.
Sheep anti-bovine immunoglobulins were prepared following the 
procedure described by McGuire (1979) cited by Katende et al., 1987). In 
brief, ten ml sheep anti-bovine IgG containing 10 mg m l1 total protein were
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dialysed against 100 ml of 0.05M carbonate/bicarbonate buffer, pH 9.5, 
containing 1 mg fluorescein isothiocyanate (FITC) and 0.025% sodium azide 
while continuously stirring, at 4°C for 24 hours. Un-conjugated FITC was 
removed by gel filtration through sephadex G-50 (Pharmacia Fine Chemicals, 
Sweden) while the optimally conjugated protein was separated from the over­
conjugated and under-conjugated protein on a diethylaminoethyl (DEAE) 
cellulose 52 column.
The fixed trypanosomes were thawed out at room temperature and the 
antigens were distributed onto the wells of the Teflon-coated multitest slides 
(Cooper Wellcome, Erembodegem, Belgium) using a 200 pi Eppendorf 
pipette. The antigens were dispensed and the trypanosome suspension 
immediately sucked leaving a thin layer of trypanosomes on each well. The 
slides were dried at 37°C for 10 minutes. A 1/20 dilution of test sera was 
made in the lymphocyte lysate (1 0  pi of test sera plus 190 pi lysate) and 
incubated at room temperature for 30 minutes. Twenty-five pi of the diluted 
test sera was then added onto the slides bearing the antigens. On each slide 
negative and positive controls were included diluted in a similar manner to the 
test sera.
After the addition of the test sera to the antigen, the slides were 
incubated at room temperature in a moist chamber for 30 minutes. The slides 
were washed twice with PBS for 30 minutes at 15 minute intervals.
Ten microlitres of sheep anti-bovine immunoglobulin conjugate, in 
which was incorporated Evan's blue as a counter stain, were applied onto each 
well. The slides were incubated for 30 minutes at room temperature in a moist 
chamber, washed with PBS as before and mounted in 50% glycerol in PBS, 
pH 8.0. The slides were thereafter viewed under a Leitz Ortholux 11 
microscope equipped with epi-ploem illumination (100W mercury lamp), UV 
filter block, 6.3 x eyepieces and a Phaco FL 40/1.3 oil objective.
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Bright yellowish green flourescence from the fixed the trypanosome 
antigens indicated the presence of anti-trypanosome antibodies in the test sera
Blood parameters 
Parasitological examination
After the determination of the PCV, the buffy coat was examined for 
trypanosomes. Trypanosomes were detected by the darkground/buffy coat 
method of Murray et al. (1977). The intensities of parasitaemia were graded 
using the scoring system shown below (Table 3, Magnification = x 400).
Table 2.1: Parasitaemia estimation
No. of trypanosomes 
per field
Estimated parasitaemia 
tryps/ml
1 - 3 per film 102 - 103
4 - 1 0  per film 103-104
1 per field 5 x 103 -5x104
2 -1 0  per field 5 x 104-5x105
> 1 0  per field >5 x 105
> 1 0 0  per field > 6  x 1C)6
Haematological examination
Packed cell volume (PCV)
The collection of blood samples was as described in Section 2.3.1.2.
The blood filled-capillary tubes were centrifuged in a haematocrit centrifuge at
12 ,0 0 0  g for 10 minutes after which they were read with a microhaematocrit 
reader (Hawksley micro-haematocrit reader, Hawksley, England).
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Blood biochemistry 
Total serum protein
Total serum protein was determined using the Coomassie® Plus Protein 
Assay Reagent (Pierce, Rockford, DL U.S.A.)* The Micro Assay Procedure was 
followed for determining protein concentrations in the range of 1-25 pg m l1. 
This assay is based on the absorbance shift from 465 to 595 nm which occurs 
when Coomassie® Blue G-250 (Pierce, Rockford, IL U.S.A.) binds to proteins 
in an acidic medium, with the resulting colour change from reddish brown to 
blue. The blue-coloured complex formed is stable up to 90 minutes.
A protein concentration series of 1, 5,10, 15 and 25 pg ml-1 was 
prepared by diluting a stock of bovine serum albumin (BSA) (Sigma Chemical 
Co. Ltd., Poole, England) in normal saline (0.9% w/v sodium chloride). To 1 
ml of each of the diluted standard solutions in a test tube was added 1 ml of 
the protein assay reagent, mixed and the absorbance determined against water 
at 595 nm. A blank was prepared by adding one ml of the protein reagent to 1 
ml of the normal saline in a test tube. The absorbances of all samples were 
measured against this reagent blank. All the determinations were carried out in 
duplicate. A standard curve was plotted from the mean absorbances of the 
above standards. Test serum samples were treated in exactly the same way as 
the standards. Using the standard curve, the protein concentration of each of 
the unknown protein samples was then determined. The dilutions made for 
each of the test serum samples are described in the relevant chapters.
Total serum albumin
For the determination of total serum albumin, a quantitative, 
colorimetric method of determination (Procedure No. 631, Sigma Diagnostics) 
was used. In this method, albumin binds to bromocresol green to produce a 
green-coloured complex with an absorbance maximum at 628 nm; the
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magnitude of which was directly proportional to the albumin concentration in 
the sample.
A series of test tubes for reagent blank, standard and test samples were 
prepared. Into each of these test tubes was placed 1.0 ml Albumin Reagent 
(bromocresol green). At timed intervals, 10 pi o f deionised water was added to 
the reagent blank test tube, 10 pi of the standard to the standard test tube and 
10 pi of the test serum sample to the test sample test tube respectively. The 
absorbances of the above solutions were read at 628 nm exactly 30 seconds 
after the addition of bromocresol green. Since the coloured complex was 
extremely unstable, the absorbances were therefore read within 30 seconds 
after either the standards or the test samples were added. In order to ensure 
reproducibility and consistency in the readings all absorbances of the blanks, 
standards and test samples were determined at exactly 30 seconds after the 
addition of the albumin reagent.
Calculation of the albumin concentrations was as follows:
Sample albumin concentration (g/100 ml) = 
absorbance of the test sample
_____________________________ x concentration of albumin standard
absorbance of the albumin standard
Serum globulin levels
The total serum globulin levels were determined as the difference 
between the total serum protein and the total serum albumin levels.
Statistical evaluation
The serum homidium concentrations, total serum protein levels, serum 
albumin levels, total globulin levels, PCV and body weights are presented as 
means ±standard deviation (±sd). The PCV, the live weight, total serum 
proteins, serum albumin and globulin data was analysed on the basis o f change
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from their respective pre-infection values. Comparison of pharmacokinetic 
parameters between assays and between various treatment groups were 
subjected to the student's t test to test for significance at both 95 and 99% 
confidence limits.
Handling of drug ELISA data
An automated data handling system was used for the enzyme-linked 
immunosorbent assays (ELISA) in which the microtitre plate reader was 
interfaced with a computer, such that there was direct input of data from the 
reader to the computer. Using the appropriate software (Eiaquik, Lotus 123 
Release 4 for windows) similar to that used by Eisler et al.(1993) the standard 
deviation and coefficient of variation of sample replicates, and the intra- and 
inter-assay, and the intra- and inter-sample, coefficients of variation (CVs) 
were calculated.
Typical immunoassay data usually gives a linear dose-response curve. 
However, as reagents age, the assay tends to lose sensitivity. To normalise this 
effect, B/B0 as a response parameter was plotted against dose. Because the 
curve still remains curve linear, an accurate fit was obtained by plotting B/B0 
against logarithm of the dose transforming the curve into an S shape. Further 
transformation of the curve to a linear shape was obtained by plotting the logit 
of the response versus the logarithim of the dose (Chan and Perlstein, 1987; 
Eisler et al., 1993).
B/Bo
logit = lo g --------------
1 - B/BO
All graphs were fitted using the SlideWrite Plus computer package. The 
lines which appear in the drug profiles following i.v. treatment are predicted 
concentrations obtained using the compartmental modelling using
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PCNONLIN. Those which appear in the drug profiles following i.m. treatment 
are predicted concentrations obtained using log curve-fit.
Pharmacokinetic analysis
Pharmacokinetic evaluation of the serum concentration versus time 
profiles was carried out using PCNONLIN computer software (Statistical 
Consultants, I.nc., 1992 SCI Software, Carl M Metzler and Daniel L. Weiner). 
Both compartmental and non-compartmental data analyses were carried out on 
the intravenous data. Non-compartmental model was selected arbitrarily for 
the intramuscular data. For the compartmental analyses, the number of 
exponents best describing each data set was confirmed using Akaike's 
Information Criteria (Yamaoka et al. 1978). Non-linear regression was used to 
fit the model to the experimental data. The formulae shown below for the 
various pharmacokinetic parameters used in the data analysis were as 
described by Baggot (1977), Gibaldi and Perrier (1982):
• The elimination half-life, tV6 , in hours =  0.693/p where p is the 
elimination rate constant
• The plasma concentration at time 0, CpO, in ng m l1 = sum of 0 
time intercepts of the coefficients A and B (Fig. 2.1).
• The volume of the central compartment, Vc, in 1 k g 1 =  Dose/CpO
• The area under the curve, AUC, in ng.h m l1 and the area under the 
moments curve, AUMC, in ng.h2 m l1 were estimated by the
trapezoidal rule from the serum concentration versus time plots (Figs. 2.2 
and 2.3).
• The apparent volume of distribution, Vdarea, in 1 k g 1= Dose/AUC.p
• Body clearance, Clb, in ml h 1 k g 1 =  Dose/AUC 
•The elimination rate constant, kel, in hours =  Clb/Vc 
•The Mean Residence Time, MRT, in hours =  AUMC/AUC
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The rate constants k u k21, k13 and k31 were determined using tri-exponential 
equations as described by Gibaldi and Perrier (1982).
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Fig. 2.1
CT>
Time
Shows how the intercepts A and B are derived from the plasma/serum drug 
concentration versus time plot (After Clark and Smith, 1986). The 
plasma/serum decline can be divided into two phases, 1 and 2. The first phase 
(1) includes the distribution of the drug from the central compartment 
(plasma/serum) and rapidly distributed tissues into a second compartment. 
After a certain time period expressed here as X, equilibrium will be attained 
between the two compartments when they behave essentially as one: the graph 
then moves into log/linear phase (2) (line (b)). This log/linear phase represents 
elimination from the central compartment in equilibrium now with the second 
compartment. The slope of line (b) is used to determine a rate constant ((3). In 
the figure shown Cq = CpO = A + B
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Fig. 2.2
The area (A) is described as the area under the curve or AUC
00
AUC0_ CO Cp dt.
Time t
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Fig. 2.3
A comparison of plots of the concentration versus time (hollow squares) used 
in the calculation of AUC and of the product concentration x time versus time 
(filled diamonds) used in the calculation of AUMC (after Hladky, 1990)
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CHAPTER THREE
DEVELOPMENT AND VALIDATION OF AN ENZYME- 
LINKED IMMUNOSORBENT ASSAY (ELISA) FOR
HOMIDIUM
INTRODUCTION
This chapter describes the development o f two enzyme-linked 
immunosorbent assays for the determination of homidium in the serum of 
treated cattle. One is an indirect and the other a direct competition assay.
Homidium, a phenanthradine compound has been used in the treatment 
of animal trypanosomiasis since its introduction in 1952 (Watkins and Woolfe, 
1952). Although widely used, many aspects of its efficacy in the field have not 
been possible due to lack of sensitive and specific methods for detecting and 
monitoring the serum drug levels. Goodwin and Tierney (1977) used a 
biological assay to determine the trypanocidal activity of body fluids from 
rabbits treated with homidium bromide; very high doses were administered so 
that activity could be detected in the body fluids for as long as was practically 
possible. Serum dilutions of 1:1.5x10^ and 1:5.0xl0^ were able to kill 
Typanosoma brucei in vitro when collected 24 and 48 hours, respectively, 
after treatment. Gilbert and Newton (1982) studying the pharmacokinetics of 
homidium bromide in T. congolense-infected and non-infected rabbits, and 
non- infected cattle using 14C labelled homidium showed that the drug was 
eliminated rapidly following i.m. injection. Although sensitive, these 
radiometric and biological procedures (Goodwin and Tierney (1977; Gilbert 
and Newton, 1982) lacked specificity since all the radioactive and biologically 
active components in solution were measured. Finally, a high performance 
liquid chromatographic (HPLC) procedure for quantification of the drug was 
described by Perschke and Vollner (1985) which used a solid-phase extraction 
methodology and a C18-reversed-phase analytical column with UV detection 
at 292 nm. This procedure, using spiked serum, had recoveries of over 99% 
and detection limits of 50 ng m l1 when 1 ml was processed, and 5 ng mb1 
when 10 ml serum was processed. The high volumes of plasma or serum 
required to achieve the lower detection limit were impractical for use in field
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samples. Furthermore, the procedure was not validated with serum samples 
from treated animals.
In the treatment of infected animals, low doses of homidium were 
recommended by the manufacturers (i.e. 1 mg kg-^due to the fact that these 
doses were found to be effective against trypanosome infections and that high 
doses of phenathridinium compounds were shown to be toxic to cattle 
(Unsworth, 1954 a, b). Therefore, due to the low doses administered, the 
circulating levels in blood would be expected to be equally low.
Determination of these low levels by chemical means is laborious and often 
with low sensitivity due to the extensive extraction and purification steps that 
are required.
For reasons discussed in Chapter 1 (Section Three), the development of 
an ELISA for the detection of homidium was judged to be a realistic and 
desirable objective.
The aim of the present study was to develop an ELISA for homidium 
which can be used on field samples to detect and monitor homidium 
concentrations in serum from treated cattle. Such a method has been lacking 
since the present methods, other than HPLC, measure activity rather than the 
drug of interest. Ideally, an assay should have a level of sensitivity that will 
allow it to detect and monitor homidium levels for the duration of the 
prophylactic period observed in the field (Dolan et al., 1990; 1992).
In this Chapter the development and validation of two ELISA methods 
for homidium detection are reported, one utilising homidium-ovalbumin 
conjugate (Assay 1) in which homidium was detected via a biotin-streptavidin- 
horseradish peroxidase system similar, in principle, to that described by Eisler 
et al. (1993) and the other utilising homidium-horseradish peroxidase 
conjugate (Assay 2).
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STUDY OBJECTIVES
(a) To develop a sensitive ELISA method for the determination of homidium
using spiked serum homidium standard solutions.
(b) Validate the method by determination of homidium concentrations in
serum obtained from Friesian cattle following intramuscular (i.m.) 
treatment with homidium bromide at a dose rate of 1 mg kg-1 body 
weight (b.w.).
MATERIALS AND METHODS 
Friesian cattle
Five healthy male Friesian cattle aged approximately six months, and 
weighing between 150 and 165 kg purchased from a commercial farm were 
used in the studies in Scotland. Their management before and during the 
experiments was as described in Chapter 2. The experiments were initiated 
after the animals were acclimatised to the laboratory conditions.
Two weeks after being housed, the cattle were treated with homidium.
Sheep
Scottish Blackface aged six months, obtained from a commercial farm 
were used in the production of hyperimmune serum. They were fed on hay 
plus concentrate supplements and had free access to water.
Drug treatment
Homidium bromide (Ethidium®, Cameo, U.K; Lot B4B3) was used at 
a dose rate of 1 mg kg-1. A 2.5%w/v solution was prepared in sterile water 
immediately prior to treatment and given by deep intramuscular (i.m) injection 
into the neck muscles.
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Sample collection
Pre-treatment sera
One week prior to treatment, 50 ml blood samples were collected by 
veni-puncture into plain vacutainers from the jugular of each of the five 
Friesian cattle and sera prepared as previously described (Chapter 2). A pool 
was made out of the individual serum samples, aliquoted also as previously 
described (Chapter 2) and stored at -20°C until required.
Serum samples fo r  drug analysis
Ten ml blood samples were collected from the cattle immediately prior 
to treatment, and at the following intervals after treatment: one, eight hours, 
twice daily during week 1, once a day during week 2 , thrice a week during 
week 3, twice a week during week 4 and once a week from week 5 to the end 
of the observation period of 90 days. Serum prepared and stored as described 
in Chapter 2 until required.
Normal bovine serum
Normal bovine sera were obtained from 20 Friesian cattle in Glasgow 
with no history of exposure to trypanosomiasis or trypanocidal drugs.
Assay 1: utilising homidium-ovalbumin conjugate
Preparation o f  homidium-ovalbumin conjugate
This conjugate was prepared using a diazotisation process. One ml o f a 
1 in 4 dilution of concentrated hydrochloric acid in water and 1 ml o f a 0.1 M 
solution of sodium nitrite were added to 50 mg homidium bromide in a glass 
bijou and stirred on ice for 10 min. Ten microliters of the resulting mixture 
was added to 5 ml of a solution containing 4 mg chicken egg albumin (CEA) 
per ml 0.1M phosphate buffer, pH 7.4, (ratio 1:80 w/w homidium:CEA).
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The homidium-CEA mixture was mixed on an end-over-end mixer for 
2 hours in the dark at +4°C followed by an overnight dialysis against 5% 
acetic acid also in the dark. After the overnight dialysis, the dialysis solution 
was changed twice more at intervals of one hour. The dialysed homidium- 
ovalbumin conjugate was aliquoted in 500pl fractions, mixed with an equal 
volume of glycerol and stored at -20°C.
Biotinylation o f anti-homidium IgG
The procedure followed for biotinylation of the purified anti-homidium 
IgG was as described by Eisler et al. (1993). In brief, the antiserum was 
dialysed against 0.1M bicarbonate buffer, pH 8 .2-8.6 for 16 hours. The protein 
content was adjusted to 1 mg m l1 with the bicarbonate buffer. The solution 
was aliquoted in 1 ml portions into glass bijou. A solution of N- 
hydroxysuccinamide ester (NHS-Biotin) was prepared in dimethyl sulphoxide 
(DMSO) to give a concentration of 1 mg m l1. A volume of 120 pi of NHS- 
Biotin in DMSO was immediately added to every 1 ml of the 1 mg m l1 protein 
solution and left to stand at room temperature for 4 hours.
The biotinylated IgG was dialysed against PBS, pH 7.0-7.4 for 16 
hours at +4°C. The buffer solution was replaced by that which had been 
freshly prepared and the dialysis continued for a further 15 minutes. The 
resulting purified and biotinylated antibody in a universal bottle was 
concentrated to the original volume using the immersible-CX low-binding 
filter unit, 10 000 (Millipore (U.K.) Ltd., Edinburgh, Scotland), with constant 
stirring. The protein concentration was determined and the volume of the 
solution adjusted with PBS to 2 mg m l1, aliquoted into 500pl fractions and 
stored at -20°C.
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The assay
All the optimal dilutions used were obtained by chequerboard titration 
of the conjugate and the biotinylated anti-homidium IgG (See Section below 
on optimisation of assay reagents). Homidium-ovalbumin was used to coat the 
96 well microtitre plates (Immulon 4, Dynatech, U.K.) by adding 100(0,1 per 
well at the optimal dilution of 1/3200 in carbonate/bicarbonate buffer, pH 9.2 
followed by an overnight incubation at +4°C. The plates were washed five 
times using washing buffer (prepared as described in Chapter 2). This was 
followed by addition of lOOpl per well of a dilution of 1/7000 biotinylated 
anti-homidium IgG in PBST.
Test serum samples from treated animals were diluted ten-fold in 
1/7000 biotinylated anti-homidium IgG in PBST before addition to wells of 
the plate (lOOpl per plate). This was carried out by adding 25pl of the test 
serum to 225|il of a dilution of 1/7000 biotinylated anti-homidium IgG in 
PBST in micronic tubes (Micronic Systems, Muratech Scientific, Aylesbury), 
mixing, and adding on to the plate. The volume of 250pl was adequate for 
duplicate wells.
Test serum samples containing high homidium concentrations were pre­
diluted in pooled negative control sera followed by the ten-fold dilution in 
1/7000 biotinylated anti-homidium IgG in PBST. Following addition of the 
antibody, the plates were incubated for one hour at 37°C in a shaker incubator 
(Verishaker, Dynatech, U.K.). The plates were then washed as before and 100 
pi of 1/3000 streptavidin-peroxidase added, incubated for 45 minutes and 
washed five times as described above. This was followed by lOOpl of the 
TMB/H2 O2  (chromogen/substrate solution prepared as described in Chapter 
2) and incubated for 10 minutes with shaking at 37°C. A redox reaction in 
which hydrogen peroxide was reduced to oxygen and water, TMB was 
oxidised to produce a blue coloured complex. The reaction was stopped with 
lOOpl 2M sulphuric acid after the 10 minutes of incubation, producing a
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yellow coloured complex. Optical densities of the yellow coloured complex 
were determined at 450 nm using an ELISA plate reader (Multiskan Plus Mk 
II, Labsystems Oy, Helsinki, Finland).
In every assay, duplicate determinations with coefficients of variation 
(CVs) above 12% were rejected and the samples re-tested. Homidium-
spiked standards for assay calibration were included in duplicate in every 
assay on routine basis. The quality control standards were included twice in 
different locations on the plate to monitor both intra- and inter-assay 
variations. A diagrammatic representation of Assay 1 is shown in Fig 3.1.
Optimisation o f  assay reagents
After the preparation of the conjugate and antibody solutions, the 
optimal reagent dilutions were determined by chequerboard titration using 
doubling dilution of the antibody and conjugate reagents. End-points of the 
titrations were considered to be those dilutions which resulted in ODs for 
negative samples of around 1.0, and in 50% displacement resulting from the 
smallest concentration of homidium.
Whole plate CVs
Whole plate coefficient of variation values (CVs) were determined 
following the establishment of the optimal reagent dilutions. This was carried 
out by preparing a ten-fold dilution of the pooled negative control sera in a 
dilution of 1/7000 biotinylated IgG in PBST and adding lOOpl per well of the 
96-well microtitre plate. This was carried out as part of assay optimisation to 
assess the possible variations due to the solid phase.
Spiked homidium standard solutions
Commercial normal bovine serum (NBS) and pooled negative control 
sera prepared from pre-treatment sera as described in Chapter 2 was spiked
106
Fig. 3.1
A diagrammatic representation of Assay 1
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3.1 Assay 1: Indirect competition ELISA for hom idium
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with a range of homidium concentrations. Starting with a top concentration of 
250 ng m l1 a series of 3-fold dilutions were made in the pool and stored at -20 
°C. Only the set of standards in use was stored at +4°C for one week. Eight of 
the standard solutions which gave the true shape of the sigmoidal standard 
curve were included in each microtitre plate daily during sample testing.
The results obtained were used to construct a calibration curve from 
which the homidium concentrations in the test serum samples were calculated. 
With the assistance of appropriate statistical software, precision profiles (plot 
of homidium concentrations of standard solutions against CVs) were 
determined for every assay calibration curve, indicating the range of 
concentrations over which the results of the test sample would be acceptable 
and beyond which the results would be unacceptable depending on the CVs 
obtained.
Quality control (Q.C) standards
A serum pool was made consisting of an aliquot from each of the serum 
samples collected from all the Friesian cattle 2 days following homidium 
treatment. The pooled sample was diluted either in pre-treatment sera or in 
commercially available normal bovine serum (NBS, Gibco, Paisley, U.K.).
The dilutions were made such that they represented both the highest and also 
the sensitive parts of the calibration curve. Also included as part of the quality 
control standards was a zero dose serum sample. The three quality control 
standards were included twice in different locations of the microtitre plate 
daily during sample analysis (giving a total of 12 replicates in each plate). This 
was carried out as part of as assessment of assay performance.
Intra-assay variation
The intra-assay CVs were determined on the QC standards tested daily 
in duplicate (n = 10) at the same time as the test sera as described above. The
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mean ODs were determined for the duplicate samples in each assay and 
concentrations calculated with the aid of the calibration curve. The mean 
variance of the duplicate QC standards were also calculated.
Inter-assay variation
The inter-assay CVs were determined from the mean concentrations of 
duplicate determinations o f the QC standards.
Assay detection limit
This was determined by assaying zero dose sera in duplicate (n = 20). 
The Mean ODs, B/B0 (B0 = OD obtained from the calibration curve at zero 
dose; B = ODs of individual animal sera) values and the standard deviation 
(SD) among negative animals were determined. A concentration 
corresponding to the B/Bq value of Mean minus 3SD read from the calibration 
curve was taken as the least detectable dose.
Parallelism
A pooled serum sample collected on Day 2 following treatment of the 
Friesian cattle was diluted serially at 1/4, 1/8, 1/16 and 1/32 in the pooled 
negative control sera. Similarly, the same Day 2 pooled serum sample was 
diluted in commercially available normal bovine serum (NBS, Gibco, Paisley, 
Scotland). Homidium concentrations in the diluted sera were determined using 
Assay 1. The final concentrations were calculated by multiplying by the 
appropriate dilutions and the results plotted against the dilution of the sample. 
A parallel response was inferred from a horizontal line.
Cross-reactivity
Cross-reactivity o f the Assay 1 reagents was investigated with other 
trypanocides commonly used in cattle; namely, diminazene aceturate (Berenil 
®, Hoechst, Germany) and isometamidium chloride (Samorin®, May and
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Baker). This was carried out by assaying a range of diminazene and 
isometamidium-spiked control sera along with the homidium-spiked serum. 
Cross-reactivity was expressed as the dose of diminazene or isometamidium 
required to reduce by 50% the maximum optical density obtained in the 
absence of the drug (concentration at 50% B/B0).
mass of competitor at 50% displacement
Cross-reactivity = --------------------------------------------------  x 100
mass of homidium at 50% displacement
where competitor = diminazene or isometamidium 
Assay validation
Serum samples from animals treated with homidium were tested in a 
competition assay in which the free drug in the serum competed with the 
homidium in the homidium-ovalbumin conjugate for the biotinylated antibody. 
On every plate were included a set of homidium standard solutions prepared 
as already described for assay calibration. These were also diluted in antibody 
solution using the micronic tubes before addition onto the plate, similar to the 
test serum samples.
Assay 2: utilising homidium-horseradish peroxidase (homidium-HRP) 
conjugate
Preparation o f homidium-horseradish peroxidase (homidium-HRP) conjugate 
Homidium was conjugated to horseradish peroxidase (Boeringer 
Mannheim, GmbH, Germany) in the presence of l-ethyl-3-(3- 
dimethylaminopropyl) carbodiimide (Boeringer Mannheim GmbH, Germany). 
Ten milligrammes of horseradish peroxidase were weighed, dissolved in 1 ml 
water in a glass bijou and vortex mixed. This solution was placed at +4°C 
until required.
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To ten milligrammes of homidium bromide in a glass bijou, were added 
250|l i 1 pyridine and 250pl water and vortex mixed. Similarly, 10 mg of 1- 
ethyl-3-(3-dimethlaminopropyl) carbodiimide in a glass bijou was dissolved in 
250 pi and vortex mixed. With constant stirring, the carbodiimide solution was 
added in 50 pi aliquots to the homidium solution. Over a period of 15 minutes, 
the homidium-carbodiimide was added to the peroxidase solution in 2 0 0  pi 
amounts also with constant stirring. The homidium-carbodiimide-peroxidase 
mixture was incubated at 37°C for 20 hours after which it was purified by 
dialysis against 0.9%w/v sodium chloride following procedures described in 
Chapter 2.
The assay
All the optimal dilutions used were obtained by chequerboard titration 
of the conjugate and the sheep anti-homidium serum (See Section on 
optimisation of assay reagents, Assay 1). The microtitre plates (Immulon 4, 
Dynatech, U.K.) were coated with anti-homidium antiserum at an optimal 
dilution of 1/20,000 in carbonate/bicarbonate buffer, pH 9.2, and incubated 
overnight at +4°C. The plates and the contents were frozen in situ and stored 
at -20°C. When required, the plates were thawed at room temperature and 
washed as in assay 1. Homidium-HRP conjugate diluted 1/20000 in PBST was 
then added (lOOpl per well). The plates were incubated overnight at +4°C, 
washed, developed and the ODs determined as described above.
Test serum samples from treated animals were diluted ten-fold in 
1/20000 homidium-HRP in PBST before addition to wells of the plate. This 
was carried out by adding 25pl of the test serum to 225pl of a dilution of 
1/20000 homidium-HRP in PBST in micronic tubes, mixing and adding on to 
the plate. The volume of 250p,l was adequate for duplicate wells. Test serum 
samples containing high homidium concentrations were pre-diluted in pooled 
negative control sera followed by the ten-fold dilution in 1 /2 0 0 0 0  homidium-
l i i
Fig. 3.2
A diagrammatic representation of Assay 2
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HRP in PBST. Assays were calibrated using homidium-spiked sera as in 
Assay 1. A diagrammatic representation of this assay is shown in Fig 3.2.
Whole plate CVs
These were determined in a similar manner as in Assay 1 but with the 
plates coated with sheep anti-homidium serum and the 1/10  dilution of the 
negative control serum made in 1/20000 dilution of homidium-HRP in PBST 
under Assay 2 conditions.
Intra-assay variation
This was estimated using the mean of the variances of duplicate wells 
of the QC standards analysed in replicate (n = 15).
Intra-assay variation
This was estimated using the mean absorbances of duplicate 
determinations of the QC standards analysed in replicate (n = 15).
The protocols followed for the assay optimisation, preparation of the spiked 
homidium standard solutions, the QC standards, the assay detection limit, 
parallelism, cross-reactivity and assay validation were as described under 
Assay 1, but using Assay 2 reagents and assay conditions.
Data evaluation
The procedures and the software used for evaluation of the results were 
as already described in the General Materials and Methods (Chapter 2). The 4- 
parameter logistic method was used in the data reduction (Eisler et al., 1993). 
Serum homidium concentrations of the test sera were calculated, and the intra- 
and inter-sample variances determined.
RESULTS 
Assay 1
Reagent titrations
Following the immunisation, collection and purification of the sheep 
anti-homidium sera, high antibody titres were obtained. The high titres 
allowed small volumes of reagents to be used. The optimal dilutions obtained 
following the chequerboard titration were 1/3200 for homidium-ovalbumin 
conjugate and 1/7000 for the biotinylated anti-homidium IgG. The number of 
samples analysed per plate was 34 (excluding the eight homidium-spiked 
standards and the six QC standards). Analysis of 34 samples at a biotinylated 
anti-homidium IgG dilution of 1/7000 showed that one ml of the undiluted 
biotinylated antibody and approximately two ml of the homidium-ovalbumin 
conjugate would be adequate for the analysis of approximately 2 0 ,0 0 0  
samples.
Calibration curves
A typical calibration curve for Assay 1 is shown in Fig. 3.3. Using the 
four-parameter logistic method for curve fitting, the results obtained from the 
response of the QC standards diluted in either pooled negative control sera or 
the commercially available NBS was expected.
Parallelism
Parallelism was demonstrated following determination of homidium 
concentrations in the pooled Day 2 serum sample diluted in either pooled 
negative control serum or in commercially available NBS.
Intra- and inter-sample variation
The results obtained for the intra- and inter-assay (intra- and inter­
sample) variance (calculated as described by Eisler et al., [1993]) are shown in
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Fig. 3.3
A typical dose response curve obtained from the mean (±SD) B/B0 
values of the spiked serum homidium standards analysed in replicate 
(n = 15) using either Assay 1 or Assay 2.
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Table 3.1. The low variance obtained following sample pre-dilutions resulted 
in the overall low intra- and inter-assay CVs. Using the QC standards, the 
intra- and inter-assay variations were also shown to be low (Table 3.2).
Cross-reactivity
Cross-reactivity of the anti-homidium reagents with diminazene was 
negligible. The result showed cross-reactivity of 0.002%. There was however, 
significant cross-reactivity with isometamidium in which a value of 86.7% 
was obtained.
Assay detection limit
Using the mean and the SD of the B/B0 of the negative sera (zero dose 
samples; n = 2 0 ), the serum homidium concentration, read from the standard 
curve corresponding to the mean minus 3SD was 0.1 ng ml-1. This was taken 
as the least detectable dose or the assay limit of detection.
Determination o f homidium in serum o f treated cattle
The mean (±SD) serum homidium concentration versus time plot 
following determination of homidium in serum samples from treated cattle 
using Assay 1 is shown in Fig. 3.4. The mean drug concentration one hour 
following i.m. treatment was 69.78±7.92 ng m l1 (range 50.6 - 88.1). This 
declined exponentially to 12.63±1.57 ng m l1 (range 9.85 - 18.22) in 24 hours, 
0.31±0.02 ng m l1 (range 0.25 - 0.36) in 60 days and 0.16±0.02 ng m l1 (range 
0.15 - 0.20) in 90 days (limit of detection: 0.1 ng ml-1). The results showed 
extremely low concentrations in serum over long periods of time. The first 
sample was collected one hour following treatment, therefore no peak 
concentrations were observed. A wide variation in serum concentrations 
between individual animals was observed using this assay. Inconsistency in 
the reproducibility of homidium concentrations was reflected in the wide
116
Table 3.1
Intra-sampie (intra-assay and inter-sample (inter-assay) variance expressed as 
coefficients of variation, CVW and CVb, including the mean response o f r 
replicates, CVX, calculated for homidium-free sera from normal Friesian calves 
tested in duplicate at 1/10 dilution using homidium Assays 1 and 2.
Assay 1 (n = 20) Assay 2 (n = 20)
cvw 4.0% 6.9%
CVb 6.4% 11.5%
CVX r = 4 5.1% 9.0%
r = 2 6 .0 % 10.7%
r=  1 7.5% 13.4%
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Table 3.2
Intra-sample (intra-assay and inter-sample (inter-assay) variance, expressed as 
coefficients of variation (%), CVW and CVb calculated from the concentrations 
obtained for the quality control standards (QC 1 and QC2) tested in duplicate at 
a dilution of 1/10 using homidium Assays 1 and 2.
QC1
Assay 1 
n =  10
QC2 QC1
Assay 2 
n = 15
QC2
CVW 7.6 4.4 10.0 5.3
CVb 14.4 14.5 18.4 12.2
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Assay 1: Mean (+SD, n = 5) serum homidium concentrations in normal 
cattle treated with homidium at a dose rate of 1 mg kg-1
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scatter of data points along a line obtained by a log curve fit of the mean ± SD 
serum homidium concentration versus time plot (Fig. 3.4)
Assay 2
Reagent titrations
On the basis of the procedure described for the immunisation of sheep, 
high anti-homidium titres were obtained. Following the chequerboard reagent 
titration, the optimal dilution of 1 /20000  obtained for sheep anti-homidium 
sera was similar to that obtained for homidium-HRP conjugate. Similar to 
Assay 1, the number of serum samples analysed in duplicate was 34. Analysis 
of 34 samples at an antibody dilution of 1/20000 showed that one ml of each 
of undiluted sheep anti-homidium sera and the homidium-HRP conjugate 
would be adequate for the analysis of approximately 50,000 samples.
Calibration curves
The calibration curve obtained using Assay 2 was markedly similar to 
that obtained using Assay 1 (Fig. 3.3). The four-parameter logistic method was 
used for data reduction and similarly showed a good response to the QC 
standards.
Parallelism
Parallelism was demonstrated following determination of homidium 
concentrations in the Day 2 serum sample diluted in pooled negative control 
sera. There was however, lack of parallelism in the Day 2 serum diluted in 
commercially available NBS.
Intra- and inter-sample variation
The results for the intra- and inter-assay variance are shown in Table 
3.2. Variance due to the pre-dilutions and the solid phase were quite low
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resulting in overall low CVs for the assay. The consistency in reproducibility 
of the low intra- and inter-sample CVs was good (Tables 3.1 and 3.2).
Assay detection limit
The least detectable dose determined from the zero dose samples gave a 
value for the Mean B/B0 - 3SD read off the calibration curve as 0.1 ng m l1.
Cross-reactivity
Cross-reactivity of the anti-homidium reagents with diminazene was 
negligible. The value obtained was 0.001%. Cross-reactivity with 
isometamidium was however significant giving a value of 126%.
Determination o f serum homidium concentrations treated cattle
The plot showing mean ± SD serum drug concentration versus time plot 
of samples analysed by Assay 2 is given in Fig. 3.5. One hour following 
treatment the mean serum concentration was 72.5±2.22 ng m l1 (65.95 - 78.4). 
This declined to 9.77±1.78 ng m l1 (range 7.7 - 12.05) in 24 hours, 0.22+0.02 
ng m l1 (range 0.14 - 0.28) in 60 days and 0.15±0.07 ng m l1 (range 0.10 - 
0.27) in 90 days (limit of detection: 0.1 ng ml 0. No peak concentrations were 
observed since the first sample collection was one hour following treatment.
Comparison of Assays 1 and 2
Reagent titration
High antibody titres were obtained following the immunisation protocol 
used. Following antibody purification and biotinylation, the antibody titre was 
still high resulting in the use of an optimal dilution of purified, biotinylated 
IgG of 1/7000 in Assay 1. However, the optimal dilution of the unpurified 
sheep anti-homidium sera used in Assay 2 was 1/20000.
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Fig. 3.5
A ssay 2: M ean (+SD, n = 5) serum hom idium  concentrations in norm al 
cattle treated with hom idium  at a dose rate o f 1 mg kg"l b.w.
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In both Assays, the dilutions for homidium conjugates were also high and 
allowed the use of small volumes of reagents for large numbers of samples.
Calibration curve
There was marked similarity in the calibration curves obtained 
following analysis of spiked homidium standard solutions. Fig. 3.3 shows a 
typical calibration curve (mean B/B0 ± SD, n = 15) obtained from data 
collected following replicate determinations using either of the assays.
Intra- and inter-sample variation
Low intra-assay (intra-sample) CVs were obtained for the QC standards using 
either of the assays showing high within run precision (Table 3.2). Whilst 
QC1 and QC2 gave markedly similar inter-assay CVs using Assay 1, the same 
QCs gave different values using Assay 2. The concentration of QC2 fell 
within the most sensitive part of the dose-response curve, the concentration of 
QC1 fell within the less sensitive part of the curve in which small changes in 
response resulted in large changes in the calculated concentration.
Parallelism
Whilst parallelism was demonstrated in pooled Day 2 serum sample 
obtained from homidium-treated cattle diluted in either negative control sera 
or the commercially available NBS using Assay 1, there was lack of 
parallelism when the serum sample was diluted in the commercially available 
NBS using Assay 2. The optical densities appeared to decrease with increase 
in the amount of NBS added resulting in higher homidium concentrations than 
the expected. Parallelism was however, demonstrated when the Day 2 serum 
sample was diluted in the negative control sera and analysed using Assay 2.
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Cross-reactivity
Using both assays, significant cross-reactivity with anti-homidium 
reagents was demonstrated with isometamidium. However, cross-reactivity 
was negligible with diminazene.
Assay detection limit
The limit of detection obtained for both assays was 0.1 ng m l1 showing 
that both assays were highly sensitive.
Serum homidium concentrations
In comparing the two assays, no peak serum concentrations were 
determined since the first sampling interval was one hour following treatment. 
Whilst a wide variation in serum homidium concentrations between individual 
animals was observed using Assay 1 (Fig. 3.4), the drug disappearance curve 
obtained using Assay 2 was much smoother with most data points closer to 
line obtained by the log curve-fit of the mean (±SD) serum drug 
concentration-versus-time semi-log plot (Fig. 3.5).
However, the differences between the serum homidium concentrations 
obtained using the two assays at any given time following treatment were 
insignificant (p>0.05).
DISCUSSION
The development and validation of two sensitive enzyme competitive 
assays for the determination of homidium in the sera of treated cattle are 
reported in the present Chapter. Assay 1 was an indirect homidium 
competition ELISA in which the microtitre plates were coated with homidium- 
ovalbumin and the detection of homidium carried out via the biotin - 
streptavidin-horseradish peroxidase system (using biotinylated anti-homidium 
IgG). The homidium in the homidium-ovalbumin conjugate coated on the plate
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competed with the homidium in the test sera for the biotinylated anti- 
homidium IgG (Fig. 3.1).
Assay 2 was a direct competition assay in which the microtitre plates 
were coated with sheep anti-homidium serum. The homidium in the 
homidium-HRP conjugate competed with the homidium in the test sera for the 
sheep anti-homidium serum coated on the plate. Both assays showed high 
sensitivity and good reliability. Both assays had a limit of detection of 0.1 ng 
m l1 serum.
In view of the limitations of the previous methods for the detection of 
homidium in the blood of treated animals, the development of these ELISAs is 
significant. The previous methods suffered from several drawbacks. These 
included the relative insensitivity of biological assay (Goodwin and Tierney, 
1977), the poor specificity of both the biological and radiometric techniques 
and the poor sensitivity and high volumes of sera required for the HPLC 
technique. The ELISAs described offer significant advantages over these 
previous methods.
The high antibody titres obtained by the immunisation procedure 
described allowed the use of very high dilutions of the anti-homidium reagents 
in the assays. This meant that very low volumes of reagents were needed. For 
instance, in Assay 1 the biotinylated anti-homidium IgG was used at an 
optimal dilution of 1/7000 suggesting that one ml of the antibody and 
approximately two ml of the homidium-ovalbumin conjugate would be 
adequate to analyse approximately 20,000 samples at 34 samples per plate (in 
duplicate). With Assay 2, one ml of each of the unpurified sheep anti- 
homidium serum and homidium-HRP conjugate at an optimal dilution of 
1/20000 would be adequate to analyse approximately 50,000 samples. 
Demonstration of parallelism showed that samples containing high 
concentrations of homidium could be diluted in the pre-treatment sera without 
affecting the outcome of the final result and that commercially available NBS
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was found to unsuitable for use in Assay 2 due possibly, to the presence of 
cross-reacting substances.
The assessment of assay precision and establishment of assay working 
concentration range was carried out through the precision profiles (obtained 
by analysing in duplicate the spiked homidium standards and plotting the CV 
against known concentrations). It was important that the random and 
systematic errors were reduced to the minimum. The determination of the 
intra- and inter-assay variations helped in assessing these errors. Inclusion of 
homidium-spiked sera and QCs assisted in monitoring changes in assay 
conditions and the results of the test samples adjusted accordingly based on 
the B/B0 values. Minor day to day variations in OD did not affect 
concentration determinations significantly, since calibration standards, 
subjected to the same variations in OD were included on every ELISA plate. 
The inclusion of QCs allowed this to be verified on an on-going basis.
With these assays, low levels of homidium were still detectable in 
serum 12 weeks after drug administration. These methods are easy to perform, 
require no sample extraction and approximately 120  samples could be 
analysed in a day once the systems are established. For every assay only 25 pi 
of serum was required compared to 10 ml needed for HPLC . However, Assay 
1 showed a wider variability in the serum homidium concentrations between 
individual animals plus lack of consistency in the reproducibility of the 
results. This could have been due to the inherent nature of the two assays. 
Whilst the micro-titre plates were coated on a daily basis in Assay 1, plates 
were coated in batch in Assay 2 suggesting that one could coat enough plates 
to cover samples from one whole experiment. Also, the overnight incubation 
at +4°C of the plates following the addition of the homidium-horseradish 
peroxidase and the test sera could have contributed to the reproducibility of 
the results. On the basis of these findings, Assay 2 was adopted for use in the 
subsequent investigations on homidium pharmacokinetics.
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Reaction to anti-homidium reagents by isometamidium but not 
diminazene was expected since homidium shares structural similarities with 
isometamidium but not diminazene.
Determination of homidium levels in Friesian cattle showed that the 
serum drug levels rapidly declined within 24 hours following drug 
administration. Thereafter, the drop was slow to below 1 ng m l1 within 10 
days and to concentrations between 0.15 and 0.3 ng m l1 within 8 weeks.
From the afore-going, it is evident that the ELISA methods developed 
are highly sensitive to be used to determine low concentrations of homidium 
in sera of treated cattle for long periods of time following treatment. The 
assays have afforded the use of very low volumes of reagents to analyse large 
numbers of samples. The volume of sera required per test in duplicate was 
only 25 pi with neither sample extraction (cf HPLC) nor physical separation 
of bound drug (cf radioimmunoassays). Approximately 120 test sera could be 
analysed daily. The assays are easy to perform and require no expensive 
equipment. All the above criteria make the ELISA methods ideal for analysing 
large volumes of field samples.
Assay 2 was selected and later used in studies both in the laboratory 
and in the field. The results of these studies are reported in the subsequent 
Chapters (Chapters 4, 5, 6 and 7).
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CHAPTER FOUR
PHARMACOKINETICS OF HOMIDIUM BROMIDE IN 
FRIESIAN AND BORAN CATTLE USING AN ENZYME- 
LINKED IMMUNOSORBENT ASSAY (ELISA)
INTRODUCTION
There has only been one previously reported study of the 
pharmacokinetics of homidium and that was by Gilbert and Newton (1982). 
Their study was conducted in uninfected and T. congolense-infected rabbits 
and cattle using 14C homidium. However, a detailed pharmacokinetic 
evaluation of the drug was not given in the study by Gilbert and Newton 
(1982), although the results did show a rapid elimination of the drug in both 
rabbits and cattle following drug administration. Details of these studies by 
Gilbert and Newton are discussed in Chapter 8 .
The radiometric method used in the earlier study had a number of 
potential disadvantages. One is that the method determines total radioactivity 
and this may not represent intact homidium. Morover, radiometric studies 
require expensive radiolabelled drugs and their use is limited to laboratory 
studies in relatively small numbers of animals. The development of a reliable 
and sensitive ELISA for the detection of homidium has several advantages 
over the radiometric method. These include high sensitivity, low volumes of 
sample and reagents required per test, suitability for analysis of large numbers 
of samples, the ease with which the assays are performed and the relatively 
low cost of equipment and reagents.
The second enzyme-linked immunosorbent assay (Assay 2) described 
in Chapter 3 was used in present study to determine the pharmacokinetic 
parameters o f homidium in Friesian and Boran cattle. The study using Friesian 
(.Bos taurus) cattle was carried out in the Veterinary School of the University 
o f Glasgow whilst the study using Boran (Bos indicus) cattle was carried out 
in Kenya. The study using Boran cattle was considered to be desirable since 
this is one of the breeds that is indigenous to trypanosomiasis endemic areas 
and is widely kept on many ranches in Kenya for production of beef.
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STUDY OBJECTIVES
This Chapter is divided into two Sections, one based on the studies in 
Friesian cattle and the other on the studies in Boran cattle.
Section One
(a) To determine homidium pharmacokinetics in Friesian cattle following 
intravenous (i.v.) drug administration.
(b) To determine homidium pharmacokinetics in Friesian cattle following 
intramuscular (i.m.) drug administration.
(c) To compare pharmacokinetic parameters obtained following i.m treatment 
of Friesian cattle with those obtained following i.v. injection of homidium.
Section Two
(a) To determine homidium pharmacokinetics in Boran cattle following i.m
drug administration.
(b) To compare the pharmacokinetic data obtained following treatment of 
Boran cattle with those obtained following i.m. treatment of the Friesian 
cattle reported in Section One of the present Chapter.
(c) To collect baseline data to be used in the subsequent investigations on the
performance of homidium both as a chemotherapeutic and a 
chemoprophylactic drug.
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SECTION ONE
Homidium pharmacokinetics in Friesian cattle following 
intravenous drug administration
Materials and Methods
Experimental cattle
Five six-month old Friesian cattle, bred in Scotland and with no history 
of exposure to trypanosomiasis or trypanocidal drugs were used. They 
weighed between 185 and 210 kg. Their management before and during the 
experiment was as described in Chapter 2.
Drug treatment
Homidium bromide (Ethidium®, Laprovet, France; Batch No. 52072/N 
[NP30L]) was used. A 2.5% (w/v) solution prepared in sterile water 
immediately prior to use was injected by the intravenous route into the jugular 
on the side of the neck opposite to the cannulated jugular vein.
Sample collection
(a) Pre-treatment sera
Two days before homidium treatment, all five cattle were prepared with 
intra-jugular cannulae. Following cannulation, 50 ml pre-treatment blood 
samples were collected aseptically from the jugular vein via the cannula using 
a syringe and dispensed into plain vacutainers. Pre-treatment sera was 
prepared, pooled and stored as described in Chapter 2. The pooled pre­
treatment sera were used as negative control and in the preparation of 
homidium-spiked and quality control standards.
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(b) Serum samples fo r drug analysis
Ten ml of blood were collected via the jugular cannulae immediately 
prior to homidium treatment, and at 5, 15, 30, 45 minutes, 1, 2, 4, 6 , 8 and 12 
hours following treatment, and then twice a day for the next 3 days. After 
three days, the cannulae were removed and further blood samples were 
collected by venipuncture into vacutainers twice daily for days 4, 5, 6 and 7, 
once daily during the second week, three times a week during the third week, 
and twice a week during the fourth week. Thereafter the sample collection was 
once a week to the end of the observation period of 40 days. Serum was 
separated and samples stored at -20°C until required. These serum samples 
were used in the determination of homidium concentration.
Determination o f serum homidium concentrations
Serum homidium concentrations were measured using the second 
homidium ELISA method (Assay 2) described in Chapter 3.
Data evaluation
Procedures followed for the evaluation of data from the drug assays 
were as described in Chapter 2. Statistical evaluation included determination 
of standard deviation and coefficient of variation of sample replicates and 
inter- and intra-sample variation.
Pharmacokinetic evaluation
Compartmental and non-compartmental pharmacokinetic analyses were 
carried out on data from all the five i.v.-treated animals. The serum 
concentration-versus-time data following i.v. drug administration were fitted 
with two-compartmental and three-compartmental models using a weighted 
non-linear least squares regression using PCNONLIN computer package. 
Akaike's Information Criterion (AIC) described by Yamaoka et al. (1978) was
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used to compare the adequacy of the two-compartmental and three- 
compartmental models.
Previous studies have shown that serum homidium concentrations decline 
rapidly following i.m. treatment (Gilbert and Newton, 1982), No i.v. data was 
available. These results suggest that serum homidium concentrations following 
i.v. treatment would similarly be low due to the rapid decline. Therefore, 
during compartmental analysis of i.v. data, weighting was used in order to 
improve on the numerical stability of the data especially when dealing with 
very low concentrations.
The formulae used for the various pharmacokinetic parameters were as 
described in Chapter 2.
The results from the i.v. injection were later compared with the results 
obtained in similar cattle given homidium by i.m. injection (Section Two of 
the present Chapter).
Results
All the five cattle remained healthy throughout the experimental period, 
except one which developed complications during the third week after 
treatment. These complications included stiffness of the neck which made it 
difficult for the animal to turn its head. This animal was removed from the 
experiment and humanely destroyed during the fourth week following drug 
administration. A post-mortem report on the calf showed that it had contracted 
meningitis.
Serum drug concentrations
Semi-log plots of the serum drug concentration versus time representing 
animal Nos. 1 to 5 are given in Figs. 4.1(a) to 4.1(e) respectively. Five minutes 
following i.v. treatment, the mean drug concentration in serum was 2 2 0 .1± 
40.7 ng m l1. The decline in drug concentrations was exponential and rapid.
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Within one hour, the mean concentration was 31.9±2.1 ng m l1.
Concentrations after 24 hours and 15 days of drug administration were 3.9± 
0.4 ng m l1 and 0.16±0.03 ng m l1 respectively. No drug was detectable 17 
days following treatment in four of the five cattle {Figs. 4.1(a) to 4.1 (d); limit 
of detection: 0.1 ng m l1}. The drug was undetectable in the remaining animal 
within 22 days {Fig. 4.1(e)}. The mean (+SD, n = 5) serum homidium 
concentration versus time plot is shown in Fig. 4.2.
Compartmental pharmacokinetic analysis
The pharmacokinetic parameters obtained using the compartmental 
model are shown in Table 4.1. Using the compartmental model, the data from 
the cattle given the i.v. injection were best described by tri-exponential 
equations with half lives of 0.064+0.037 hours (range 0.048 - 0.144) for tVfctx, 
7.17+1.87 hours (range 5.54 - 10.70) for tl/2$ and 106.3+6.6 hours (range 
99.50 - 119.0) for d/27. The mean homidium serum concentration extrapolated 
to time 0 (CpO) was 576.8+292.9 ng ml-1 (range 130.9 - 1013.0). The mean 
AUCo_last and AUMC o.last values were 577.3+ 75.5 ng.h m l1 (range 477.1 - 
672.2) and 36675+7332 ng.h2 m l1 (range 29316 - 50042), respectively. The 
calculated MRT from these values was 63.39+7.51 hours (range 51.12 - 
74.45). The rest of the pharmacokinetic parameters are shown in Table 4.1. 
The volume of the central compartment (Vc) was 2.81+2.45 1 k g 1 (range 0.99 
- 7.63) and that of the steady state (Vd) as 111.6+18.01 k g 1 (range 80.2 - 
129.6).
The results obtained for the rate constants k12, k21, k 13 and k31 showed 
an approximately ten-fold difference between rate constants k12 and k21 and an 
approximately 50-fold difference between rate constants k 13 and k31. This 
demonstrated non-attainment of equilibrium of free drug concentrations 
between the plasma and the tissues and steady state was not achieved between 
the drug distribution and elimination phases. There was a strong tendency for
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Fig. 4.1(a) to 4.1(e)
Serum homidium concentration in five individual Friesian cattle 
following i.v. treatment with homidium bromide at 1 mg k g 1 b.w.
134
co
nc
en
tra
tio
n 
(n
g/
m
l) 
co
nc
en
tra
tio
n 
(n
g/
m
l)
Fig. 4.1(a)
Animal No. 1
2 0 0
1 0 0
200
100
10
>  *
0.00 0.20 0.40 0.B0 0.80 1.00
0.1
0.01
252 0151 05
Days post-treatment
Fig. 4.1(b) 
Animal No. 2
2 0 0
1 0 0
200 (
100
1.000.800.800.400.200.00
0 .1
0.01
2520151 0
Days post-treatment
Fig. 4.1(c)
Animal No. 3
400
400
1 0 0
100
0.80 1.000.600.400.200.00
0 .1
0.01
2 0 251 0 155
Days post-treatment
Fig. 4.1(d) 
Animal No. 4
2 0 0
1 0 0 200 ( >
0.40 0.600.00 0.20 0.80 1.00
0.1
0.01
0 5 1 0 15 20 25
Days post-treatment
co
nc
en
tra
tio
n 
(n
g/
m
l)
Fig. 4.1(e)
Animal No. 5
300
1 0 0
3001 >
100
o.eo 1.00o.so0.20 0.400.00
0.1
0.01
0 5 1 0 25
Days post-treatment
Fig. 4.2
The mean (+SD; n = 5) serum homidium concentrations in Friesian 
cattle following i.v. treatment with homidium bromide at 
1 mg kg" b.w.
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Table 4.1
Pharmacokinetic parameters of homidium in normal Friesian cattle after 
intravenous injection of homidium bromide at a dose rate of 1 mg kg-1 
b.w.: Compartmental analysis
Parameter Animal Nos. Mean ± SD
1 2 3 4 5
A (ng ml'1) 101.5 398.1 980.4 682.8 561.9 545.0±292.8
B (ng ml*1) 28.14 33.43 31.03 29.88 29.64 30.42±1.76
C (ng ml'1) 1.25 1.19 1.61 1.32 1.56 1.38±0.17
a 4.563 13.25 14.20 17.54 9.92 11.8914.39
P 0.065 0.125 0.108 0.113 0.085 0.09910.022
7 0.0071 0.0070 0.0070 0.0072 0.0060 O.OO^ OIO.OOOS
tVia (h) 0.144 0.048 0.048 0.048 0.072 0.06410.037
0/2p (h) 10.70 5.54 6.43 6.12 8.14 7.1711.87
tViy (h) 99.5 104.6 103.8 105.4 119.0 106.316.6
Vc (1/kg) 7.63 2.31 0.99 1.40 1.69 2.8112.45
Cp(0) (ng ml-1) 130.9 432.8 1013.0 714.0 593.1 576.81292.9
AUC (ng.h ml-1) 637.0 477.1 597.2 503.1 672.2 577.3175.5
AUMC(ng.h2 ml-1) 32560 29316 38666 32792 50042 3667517332
Vss (1 kg*1) 80.2 128.8 108.4 129.6 110.7 111.6118.0
Cl (mlh-^g-1) 26.16 34.93 27.91 33.13 24.79 29.3913.96
MRT (h) 51.12 61.44 64.75 65.18 74.45 63.3917.51
k |2 (h_1) 3.287 10.82 11.09 14.57 8.047 9.5613.76
k,, (h-1) 1.073 1.172 0.557 0.871 0.599 0.85410.246
k^Oi-1) 0.060 0.470 0.961 0.791 0.477 0.55210.309
k31 (h-1) 0.009 0.010 0.011 0.011 0.009 0 .01010.001
k10 (h-1) 0.206 0.907 1.696 1.419 0.882 1.02210.512
tVMc10(h-i) 3.370 0.768 0.408 0.480 0.720 0.83411.11
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the movement of the drug into the tissues. Despite the non-achievement of a 
steady state in the drug distribution, the calculated values for the Vd in all 
animals were extremely large.
Non-compartmental pharmacokinetic analysis
The pharmacokinetic parameters obtained using the non-compartmental 
model are given in Table 4.2. The value for the terminal phase half-life using 
this model was 58.58+1.52 hours (range 56.69 - 61.07). The mean A U C ^  and 
AUMCq.^ observed values were 585.6±67.9 ng.h mb1 (range 498.6 - 657.1) 
and 36757+4724 ng.h2 mb1 (range 30064 - 44314), respectively. Using these 
values, the M RT^observed was calculated as 62.98+5.91 hours (range 53.21
-70.18).
Homidium pharmacokinetics in Friesian cattle following 
intramuscular drug administration and comparison with data 
obtained from cattle treated by intravenous injection
M aterials and Methods
Experimental cattle
Five Friesian cattle aged 6 months and weighing between 160 and 175 
kg were used. Their management before and during the experiment was as 
described in Chapter 2 (Materials and Methods). These animals were bred in 
Scotland and had no history of exposure to trypanosomiasis or trypanocidal 
drugs.
t
i
! Drug treatment
Homidium bromide (Ethidium®, Cameo, U.K) was used at a dose rate 
o f 1 mg kg-1 b.w. A 2.5% (w/v) solution was prepared in sterile water
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immediately prior to use and administered by deep i.m. injection as a single 
bolus into the muscles of the neck.
Experimental design
Following treatment, serum homidium concentrations were determined 
for a period of 90 days. A comparison was carried out of the pharmacokinetic 
parameters calculated from the serum homidium concentration- versus-time 
data obtained following i.m. treatment and the i.v. treatment already reported 
in the present Section.
Sample collection
(a) Pre-treatment sera
Two days before homidium treatment, 50 ml blood samples were 
collected aseptically from each animal via the jugular vein into plain 
vacutainers. The procedures for the preparation of sera were as described in 
Chapter 2 (Materials and Methods). A large pool was prepared from these 
serum samples, aliquoted and stored at -20°C until required. Each of the 
aliquots prepared was enough to last one week at +4°C once thawed. The rest 
of the sera were stored as individual samples. The pooled serum samples were 
used as negative controls and in the preparation of homidium-spiked and 
quality control standards.
(b) Serum samples fo r drug assays
Ten ml blood samples were collected as described above immediately 
prior to treatment and at the following times after treatment: one and 8 hours, 
twice daily for the first week, daily for the second week, thrice during the third 
week, twice during the fourth week and once a week from the fifth week to the 
end of the observation period of 90 days. Procedures followed in the
preparation and storage of sera for drug analysis were as described in 
Chapter 2.
D ata evaluation
Procedures followed for the evaluation of data from the drug assays 
were as described in Chapter 2. Statistical evaluation included determination 
o f the standard deviation and coefficient of variation o f sample replicates, and 
the inter- and intra-sample variation.
The student's t-test was used to test for significance at both 95 and 99% 
confidence limits in comparing means of various pharmacokinetic parameters 
obtained between the different groups of cattle treated with homidium.
Pharm acokinetic evaluation
Non-compartmental pharmacokinetic analysis was carried out on serum 
homidium concentration-versus-time data following i.m. drug administration 
following procedures described in Chapter 2. The parameters determined 
using included the AUC, the AUMC, MRT, F and MAT.
The F and the MAT were calculated using i.v. data reported above.
Results
Plasma homidium concentrations
The drug concentrations in serum showed an exponential decline. 
Semi-log plots o f the serum homidium concentration-versus-time data for the 
five individual cattle are shown in Figs. 4.3(a) to 4.3(e). The plot showing the 
mean ± SD serum drug concentration-versus-time is given in Fig. 4.4. The first 
sample collection was one hour following treatment when a mean serum drug 
concentration of 72.5±2.2 ng m l1 was attained. This declined to 9.8±1.8 ng mb 
1 at 24 hours, 0.22±0.02 ng mb1 at 60 days and 0.15±0.07 ng mb1 at 90 days 
(limit o f detection: 0.1 ng mb1). The values for Cmax and tmax were not
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Fig. 4.3(a) to 4.3(e)
Serum homidium concentration in five individual Friesian cattle 
following i.m. treatment with homidium bromide at 1 mg kg-1 b.w.
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The mean (+SD; n = 5) serum homidium concentration in Friesian 
cattle following i.m. treatment with homidium bromide at 
1 mg kg"l b.w.
142
co
nc
en
tra
tio
n 
(n
g/
m
l)
Fig. 4.4
300
100
1 0 0
0.00 0.20 0.40 0.60 0.80 1.00
0.01
806040
Days post-treatment
determined since the first sample was collected one hour following treatment 
at which time the drug was already in the distribution phase.
Non-compartmentalpharmacokinetic analysis
The pharmacokinetic parameters are given in Table 4.3. The 
extrapolated observed mean AUC and AUMC values were 1935+397 ng.h ml*1 
(range 1245 - 2345) and 890244+466474 ng.h2 mb1 (range 351600 - 1545188). 
The value for the M R T ^  observed was 439.7+185.1 hours 
(range 261.3 - 724.3).
A comparison of homidium pharmacokinetics in Friesian cattle 
following intravenous and intramuscular drug administration
Homidium serum concentration
A comparison of the mean (±SD) serum concentration versus time plot 
between i.v.-treated and i.m.-treated cattle is given in Fig. 4.5. A mean serum 
homidium concentration of 31.9±2.1 ng m l1 obtained one hour following i.v. 
treatment was markedly lower than 72.5±2.2 ng ml*1 obtained one hour 
following i.m. treatment. Similar differences in drug concentrations were 
observed 24 hours following treatment; whilst a mean drug concentration of 
3.9±0.4 ng mb1 was obtained following i.v. treatment, the value was 9.8+1.8 
ng mb1 in the i.m.-treated cattle.
No drug was detectable after 17 days in four of the five cattle treated by 
the i.v. route whilst low levels remained in the circulation of five cattle for 
over 10 weeks following i.m. treatment.
Pharmacokinetic parameters
As shown in Table 4.4, a comparison in the non-compartmental 
pharmacokinetic parameters obtained from the i.v-treated cattle data and the
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Fig. 4.5
A comparison of the mean ± SD (n = 5) serum homidium 
concentration between i.v.-treated and i.m.-treated Friesian cattle 
following treatment with homidium bromide at 1 mg kg-1 b.w.
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i.m.-treated cattle data showed that the values from the i.v.-treated cattle were 
all highly significantly lower than those obtained in cattle treated by the 
intramuscular injection (p < 0.05; Table 4.4). Using the i.v. data, the 
bioavailability of the intramuscular dose was calculated as 31.9±8.1% and the 
MAT as 376.7+185.1 hours.
SECTION TWO 
Homidium pharmacokinetics in Boran cattle following 
intramuscular drug administration and comparison with data 
obtained from Friesian cattle
Materials and Methods
Drug administration, blood sample collection, data handling and 
pharmacokinetic evaluation were as described in Section One of the present 
Chapter.
Experimental cattle
Five Galana Boran (Bos indicus) cattle used in this study were bred at 
the Kenya Trypanosomiasis Research Institute (KETRI), Kikuyu, Kenya, and 
had no previous exposure to tsetse and/or trypanocidal drugs. The cattle were 
aged between 16 and 20 months, and weighed between 180 and 200 kg. Their 
management before and during the experiments were as described in 
Chapter 2.
Experimental design
All five Boran cattle were treated with homidium bromide by deep i.m. 
injection at a dose rate of 1 mg kg-1 b.w. into the neck muscles. Serum samples 
were then collected for a period of 90 days following i.m. treatment. The sera
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Table 4.4
A comparison of the mean ± SD (n = 5) of the pharmacokinetic parameters 
of homidium in normal Friesian cattle following either intravenous or 
intramuscular injection of homidium bromide at a dose rate of 1 mg kg-1 
b.w.: Non-compartmental analysis
Parameter intravenous intramuscular Significance
P 0.0122±0.0003 0 .0 0 2±0 .001 ***
tV&P (h) 58.58±1.52 488.2±163.6 **
AUC0 -last (nS-h ml-1) 582.5±69.4 18111361 **
A U C ^  observed (ng.h ml-1) 585.6±67.9 19351397 **
AUCq.^ predicted (ng.h ml'1) 583.7±69.5 18821388 **
AUMCo-iast (ng-h2 “ I'1) 34877±5480 5333081200646 **
AUMCq.^ observed (ng.h2 ml-1) 36757±4754 8902441466474 *
AUMCq.^ predicted (ng.h2 ml-1) 35589±5575 7396521374143 *
MRT0.last (h) 59.87±5.63 285.5177.3 **
MRTq.^ observed (h) 62.98±5.91 439.71185.1 *
MRTq.^ predicted (h) 60.98±5.81 374.91154.9 *
* * * p <  0.001
** p < 0 .01
* p < 0.05
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were thereafter analysed using the second of the two homidium assays (Assay 
2) described in Chapter 3. Non-compartmental pharmacokinetic analysis was 
carried out on the serum homidium concentration-versus-time data. The 
pharmacokinetic parameters obtained were compared to those obtained in 
similarly treated Friesian cattle reported in Section One of the present Chapter.
Results
Serum homidium concentrations
Following treatment of the Boran cattle, there was a rapid decline in the 
serum homidium concentrations within the first 24 hours. Plots of the serum 
homidium concentration-versus-time data for the five individual cattle are 
given in Figs. 4.6(a) to 4.6(e). The mean serum homidium concentration after 
one hour following drug administration was 112.1140.3 ng mb1. This declined 
to 13.013.3 ng mb1 in 24 hours. Sixty and 90 days following treatment, these 
values were 0.1810.05 ng m l1 and 0.1710.09 ng mb1, respectively. The mean 
(1 SD, n = 5) serum homidium concentration versus time plot following 
treatment of Boran cattle is shown in Fig. 4.7.
Non-compartmental pharmacokinetic analysis
The pharmacokinetic parameters obtained from non-compartmental 
analysis of the i.m. data are shown in Table 4.5. The AUC and the AUMC 
values were 20561341 ng.h mb1 (range 1585 - 2401) and 177351137189 ng.h2 
mb1 (133392 - 219725), respectively. The mean value for MRT calculated 
from extrapolated observed AUC and AUMC values was 92.3121.1 hours 
(range 61.9 - 123.2).
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Fig. 4.6(a) to 4.6(e)
Serum homidium concentration in five individual Boran cattle 
following i.m. treatment with homidium bromide at 1 mg kg-1 b.w.
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Fig. 4.7
The mean (±SD; n = 5) serum homidium concentrations in Boran 
cattle following i.m. treatment with homidium bromide at 
1 mg kg-1 b.w.
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A comparison of serum homidium concentrations and 
pharmacokinetics between Friesian and Boran cattle following 
intramuscular treatment
Serum homidium concentrations
Fig. 4.8 shows a comparison of the mean ± SD (n = 5) serum homidium 
concentration-versus-time profiles between the Boran and Friesian cattle 
following i.m. treatment. The results show that the drug profiles were similar 
between the two breeds of cattle. However, the mean drug concentration of 
112.1±40.3 ng mF1 obtained one hour following treatment of Boran cattle was 
markedly higher than the value of 72.5±2.2 ng mb1 obtained in the Friesian 
cattle. A wider variability in concentration one hour following treatment was 
observed between individual Boran cattle (66.0 - 169.6 ng mb1) than between 
individual Friesian cattle (65.9 - 78.4 ng mb1).
Pharmacokinetic parameters
Table 4.6 gives a comparison of the pharmacokinetic parameters for the 
Boran and Friesian cattle. The AUC values obtained were not significantly 
different from those obtained in Friesian. The first sampling time following 
treatment of the Boran cattle was 30 minutes whilst that of the Friesian was 
one hour. Therefore, the Cmax and tmax were not determined since the drug was 
already in the distribution phase at both times. The mean residence time of 
92.3±21.1 hours (range 61.9 - 123.2) obtained in Boran cattle was significantly 
lower than that obtained in the Friesian of 439.7±185.1 hours (p < 0 .0 1 ).
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Fig. 4.8
A comparison of the mean ± SD (n = 5) serum homidium 
concentration between Friesian and Boran cattle following i.m. 
treatment with homidium bromide at 1 mg kg-1 b.w.
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Table 4.6
Comparison of pharmacokinetic parameters of homidium between Friesian 
and Boran cattle following intramuscular injection of homidium bromide 
at a dose rate of 1 mg kg*1 b.w.: Assay 2, Non-compartmental analysis
Parameter Friesian Boran Significance
tmax (h) nd nd
Cmax (ng ml-1) nd nd
P 0 .0 0 2±0 .001 0.004±0.001
***
tfcp (h) 488.2±163.6 177.8±23.4 ***
AUC0-last (ng-h ml*1) 1811±361.2 2051±341.4
AUCo_oo observed (ng.h ml-1) 1935±397.3 2056±341.4
AUCq^ , predicted (ng.h ml*1) 1882±388 205453±342
AUMC0.last (ng.h2 ml*1) 533308±200646 177351±37189
AUMCq^ observed (ng.h2 m l1) 890244±466474 177351±37189 *
AUMCq^, predicted (ng.h2 ml'1) 739652±374143 180714±37651 *
MRT0.last (h) 285.5±77.3 87.5±16.8 **
MRTq^  observed (h) 439.7±185.1 92.3±21.1 *
MRTq.^ predicted (h) 374.9±154.9 89.1±17.5 *
*** p < 0.001
** p < 0.01
* p < 0.05
nd = not determined
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DISCUSSION
This Chapter describes investigations into the pharmacokinetics of 
homidium bromide in Friesian cattle following i.v. and i.m. treatment, and in 
Boran cattle following i.m. treatment. The studies were made possible 
following successful development and validation of the highly sensitive 
ELISA methods reported in Chapter 3, one of which was used. The results 
showed rapid elimination of the drug from circulation within approximately 
three weeks following i.v. treatment whilst the drug could be monitored 
successfully for periods over 10 weeks following i.m. treatment.
The results obtained in Friesian cattle following i.v. treatment showed a 
rapid exponential decline in the serum homidium concentrations (Fig. 4.2). 
Following i.v. treatment, the mean drug concentrations had declined from over 
200 ng ml*1 at five minutes to approximately 30 ng mb1 at one hour. Within 24 
hours the value was about 4 ng mb1. No drug was detectable within 17 days of 
treatment in four of five cattle following i.v. treatment. However, following 
i.m. treatment of the Friesian cattle, the mean homidium levels after one hour 
and 24 hours were approximately 70 ng mb1 and 10 ng mb1 respectively 
showing the decline was more rapid in the i.v. treated cattle than in the i.m. 
treated cattle. Levels of about 0.2 ng mb1 were detected within 90 days in the 
cattle treated by i.m. injection. These results suggest rapid elimination of the 
drug from the body following i.v. treatment and that the low levels in 
circulation approximately three weeks following i.m treatment could be 
attributed to the injection site drug depot.
In the pharmacokinetic evaluation, the results obtained by fitting an 
open compartmental model showed that the i.v. data was best described by tri­
exponential equations. The half-lives obtained were 0.064±0.037 hours for tYi 
a , 7.17±1.87 hours for TAp and 106.3±6.6 hours for tViy. These results showed 
rapid distribution of the drug within minutes of treatment. The low AUC and
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MRT values reflect the rapid disappearance of the drug from serum following 
i.v. treatment.
The differences observed in values for the rate constants between k12 
and k21 and also between k13 and k3l showed that no equilibrium was 
established between the free drug concentrations in the blood and tissues and 
therefore, no steady state. Despite the non-attainment of a steady state in the 
drug distribution/elimination, the calculated volume of distribution in all the 
five animals was extremely large. The volume of the central compartment of 
2.81±2.45 1 kg-1 and that of apparent volume of distribution of 111.6+ 18.0 1 
kg-1 were extremely large and far exceeded the normal plasma volume for 
cattle o f approximately 35.9 ml kg-1 and the normal total blood volume of 
approximately 51.2 ml kg-1 (Ruckebusch et al, 1991). These large calculated 
volumes of distribution suggest extensive extravascular distribution of the 
drug. This observation also suggests that the serum drug concentration-versus- 
time data could have fitted models with more than three compartments. 
Determination of the rate constants k12, k21, k13 and k3] could possibly give an 
insight into the interactions between homidium and the host following 
treatment. Determination of these constants revealed that homidium movement 
into tissues was unsaturated at the recommended dose of 1 mg kg-1.
Use of a non-compartmental model to fit the data from Friesian cattle 
treated by i.v. injection was necessary so that the extrapolated AUC and MRT 
values could be calculated. The results showed no marked differences in the 
AUC and the MRT values between the two pharmacokinetic models, 
compartmental and non-compartmental. In the determination of MAT in the 
i.m treated Friesian cattle, the mean MRT value from the non-compartmental 
model fitting of the i.v. data was therefore, used.
Following the establishment of pharmacokinetic parameters of 
homidium in Friesian after both i.v. or i.m drug administration, a study was 
carried out in Boran cattle, a breed indigenous to the tsetse infested areas o f
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sub-Saharan Africa following i.m. treatment. After i.m. treatment of Boran 
cattle, the mean serum homidium concentration obtained one hour following 
treatment was approximately 115 ng m l1. This level fell to about 15 ng mb1 
and 0.2 ng mb1 after 24 hours and 90 days respectively, following drug 
administration. In the Friesian cattle these values were approximately 70 ng 
mb1, 10 ng mb1 and 0.2 ng mb1 after one hour, 24 hours and 90 days, 
respectively following i.m. treatment. Although the mean serum homidium 
concentrations obtained in Boran and Friesian cattle were not significantly 
different after 24 hours following treatment, those in the Boran showed a 
wider variability between individual animals than those in the Friesian. The 
mean (±SD) concentration versus time plots were however, not markedly 
different (Fig. 4.8).
AUC values for Friesian and Boran cattle were not significantly 
different. Flowever, there were significant differences in the estimated AUMC 
values (p < 0.05) which were probably due to the differences in the initial 
sampling periods. Usually, the AUC is estimated from the drug concentration 
versus time plot but the AUMC is estimated from the plot of the product of 
drug concentration and time versus time. The estimated values for the two 
parameters would therefore be inherently different. The first sampling time 
following i.m. treatment was 30 minutes in Boran and one hour in Friesian 
cattle. Since, the estimation of the AUMC is based on the plot of the product 
of concentration and time versus time, the differences in the initial sampling 
times between the two breeds of cattle could have been responsible for the 
large differences observed in the AUMC values. This suggests that the time 
intervals at which samples are collected will clearly influence the estimation of 
the secondary pharmacokinetic parameters. A protocol that included as many 
data points as possible around the serum drug concentration peak would give 
more accurate estimates of the secondary pharmacokinetic parameters. The 
sampling protocol used in the present study had only three data points up to 24
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hours following treatment. The estimated parameters were therefore high due 
to the uncertainties in the estimation of the AUMC following i.m. injection.
Previous studies on homidium pharmacokinetics were conducted using 
a radiometric technique (Gilbert and Newton, 1982). Details of these studies 
and comparisons with the results of the ELISA method are discussed in 
Chapter 8 . In the present study high values for Vd and the large differences 
observed between the rate constants k12 and k2] and between k 13 and k31 
suggested extensive extravascular distribution of the drug and the 
demonstrated unsaturable pharmacokinetics. Similar observations were made 
in results reported in Chapter 8 using radioisotopes. Besides the use of 
radiolabelled drug, no other earlier techniques were able to detect and monitor 
the drug for sufficiently long periods of time to make estimates of 
pharmacokinetic parameters.
The results of the present study have demonstrated non-attainment o f 
equilibrium between the free serum homidium concentrations in the blood and 
tissues following treatment at the recommended therapeutic dose suggesting 
that the transport of the drug into host cells could be unsaturated at 
pharmacological concentrations.
It has been demonstrated that tissue levels of homidium remain high 
for long periods following either i.v. or i.m. drug administration (Gilbert and 
Newton, 1982) which suggests covalent binding of the drug to tissue proteins 
may occur. Contribution of these residues to the circulating drug 
concentrations appears negligible as has been shown by the results o f the 
present study in which it was demonstrated that levels fell below the detection 
limit within 17 and 22 days in animals treated by the i.v. route. In the i.m. 
treated cattle however, levels in circulation remained detectable for over 10 
weeks, suggesting that the injection site depot was the only primary source of 
possibly the intact drug from two weeks following treatment onwards.
Although the nature of binding of homidium to tissue proteins is not
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well understood, Newton (1976) showed that the drug intercalates with DNA 
and has a high selectivity for mitochondrial DNA; a property that has enabled 
it to be used extensively as a biochemical probe. Other studies have shown 
that the binding of homidium to DNA in vivo may involve more than simple 
intercalation. Mahler and Bastos (1974), studying the uptake of 3H-homidium 
by Saccharomyces cerevisiae found that homidium associated with 
mitochondrial DNA accounted for approximately 2.3% of total homidium 
bound by DNA. There was some evidence that it might be a (metabolic) 
derivative of homidium formed within the mitochondrion which becomes 
covalently bound to mitochondrial DNA.
Our present knowledge of homidium metabolism is limited. Gilbert and 
Newton (1982) investigated the possibility o f metabolites in sera from 14C 
homidium-treated rabbits and cattle (some infected with T. congolense) using 
thin layer chromatography (TLC) and gel chromatography. No evidence of 
metabolites was obtained using TLC, a relatively insensitive semi-quantitative 
technique, but two non-homidium radiolabelled components were detected in 
the urine and bile. These accounted for 46% (with one bearing 38%) of the 
total radioactivity eluted.
Results of the present studies and those reported previously (Gilbert 
and Newton , 1982) suggest rapid elimination of much of the injected dose of 
homidium. The present study using the more sensitive ELISA technique, has 
however, demonstrated measurable concentrations o f homidium for longer 
periods than was possible using the earlier, less sensitive technique.
Homidium could be detected with ELISA for as long as 17 days following 
intravenous treatment o f cattle. Following intramuscular treatment, the drug 
was measurable for up to 10 weeks, a duration in keeping with the 8 to 17 
week period of prophylaxis reported for homidium use in the field (Dolan et 
al., 1990). This suggests that the ELISA could prove to be a useful tool in 
investigating the relationship between the circulating drug concentrations and
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protection against trypanosome challenge in chemoprophylactic situations, and 
might on long term basis assist in the planning of appropriate prophylactic and 
therapeutic regimens for field use. The relationships between homidium 
concentrations and chemotherapy and chemoprophylaxis of T. congolense 
infections in Boran cattle are investigated further in the two following 
Chapters (Chapters 5 and 6 ).
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CHAPTER FIVE
INVESTIGATION INTO THE EFFECTS OF 
TRYPANOSOMA CONGOLENSE INFECTIONS ON THE 
PHARMACOKINETICS OF HOMIDIUM IN BORAN
CATTLE
INTRODUCTION
Control of trypanosomiasis in endemic areas has depended largely on 
the use of chemotherapeutic or chemoprophylactic agents. One such agent is 
homidium which was classified mainly as a chemotherapeutic agent but has 
been reported to offer some protection against infection in the field (Mwambu, 
1971; Dolan et al., 1990). After its introduction, several studies were carried 
out to determine the minimum curative and maximum tolerated doses (Wilson 
and Fairclough, 1953; Wilde and Robson, 1953; Unsworth, 1954a, b). These 
studies are covered in detail in Chapter 1, Section Two.
The normal use of homidium has been in the treatment of infections 
due to both T. congolense and T. vivctx in cattle, sheep and goats at the 
recommended dose rate of 1 mg k g 1 bodyweight (b.w.) and several million 
doses are administered to African livestock each year. However, so far there 
has been no detailed pharmacokinetic evaluation of the drug in either non­
infected or trypanosome-infected cattle following treatment. The only previous 
study by Gilbert and Newton (1982) using 14C homidium bromide, lacked 
details on pharmacokinetics.
The results of the study by Gilbert and Newton (1982) carried out in 
non-infected and trypanosome-infected rabbits and calves showed that there 
were no differences in homidium concentrations in blood and tissue fluids in 
both non-infected and T. congolense-infected cattle. Blood and tissue fluid 
drug levels reached maximum levels of 120 -170 ng m l1 one hour following 
i.m. treatment of calves at 1 mg k g 1 b.w. The levels fell rapidly within 24 
hours and then slowly to 15 ng m l1 in 8 days. Separation of trypanosomes 
from other blood components in samples collected from an ear vein at 1, 6  and 
12 hours after treatment of calves at 1 mg k g 1 demonstrated that 
approximately 80% of total radioactivity detected in the blood was bound to 
trypanosomes.
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Following i.m. treatment of non-infected rabbits at 1 mg kg-1, Gilbert 
and Newton (1982) showed that serum homidium concentrations reached 
maximum levels of 180 ng ml*1 in blood and 50 ng mb1 in tissue fluid one hour 
following i.m. treatment. These levels fell to less than 10 ng mb1 within 96 
hours. Increase in the dose rate from 1 to 10 mg kg-1 b.w. increased the blood 
and tissue drug levels by only 2 - 3  fold. Intramuscular treatment o f rabbits at 
1 mg kg-1 or 10 mg kg-1 8 days after T. congolense infection (lxlO6 
trypanosomes) caused parasitaemia to become sub-patent within 48 hours. No 
cure was effected despite the fact that these trypanosomes were drug-sensitive. 
Infections initiated in mice from stabilates or by sub-inoculation from infected 
rabbit blood after homidium treatment were always cured by homidium at 1 
mg kg-1 b.w. after the infection had become patent.
They also demonstrated that infection of previously non-infected and 
re-infection of infected rabbits 5 days after treatment with 1 mg kg-1 revealed 
an apparent prophylactic effect in the case of the infected animal. The pre­
patent period lasted 8 days compared to 3 days observed in either non-infected 
rabbits or homidium-treated non-infected rabbits. Despite these observations 
in both non-infected and infected rabbits, the drug concentrations in the blood 
and tissue fluid were found to be similar.
Determination of anti-trypanosome antibody in the sera from T. 
congolense and T. 6rwce/-treated rabbits revealed that the levels of antibody 
were unaffected by the homidium treatment. The trypanocidal activity in the 
serum samples, measured by the method of Goodwin and Tierney (1977) was 
compared with the levels of radioactivity in the same sera. Their results 
showed higher levels o f trypanocidal activity following i.m. treatment of 
infected rabbits with homidium than in the non-infected rabbits. Following 
treatment of infected rabbits, Gilbert and Newton (1982) observed a smaller 
initial fall in activity during the first 3 days after treatment after which serum 
trypanocidal activity was sustained for a further 30 days.
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Removal of IgG from serum taken 5 hours after homidium treatment of 
infected rabbits resulted in the reduction of the trypanocidal activity to 46% 
that of serum from which IgG had not been removed, taken at the same time. 
Removal of IgG from serum taken 10 and 19 days after homidium treatment 
caused a complete loss of in vitro trypanocidal activity. In both cases, all 
trypanocidal activity was present in the IgG containing fraction. Removal of 
the IgG from sera of homidium-treated non-infected rabbits did not affect the 
in vitro trypanocidal activity of these samples.
Despite the observations involving homidium as a chemotherapeutic 
drug, little information was previously available on the effects that 
trypanosome infections might have on the pharmacokinetics of the drug and 
subsequent prophylactic activity. The availability of the highly sensitive 
ELISA method (Chapter 3, Assay 2) for the detection and monitoring of 
homidium levels in cattle has made the present study possible.
STUDY OBJECTIVES
The objectives of this study were:
(a) To determine the pharmacokinetics of homidium in cattle, using ELISA,
infected with one of two trypanosome populations of T. congolense', one 
drug-sensitive and the other drug-resistant.
(b) To compare the pharmacokinetics of homidium in cattle infected with T. 
congolense and in non-infected cattle (reported in Chapters 4 and 6).
MATERIALS AND METHODS 
Experimental cattle
A total of 10 castrated male Boran calves obtained from 01 Maisor 
Farm, Laikipia District, Central Province, Kenya, were used. This area is free 
from endemic trypanosomiasis. The calves were six months old and weighed
163
between from 120 and 140 kg. The procedures followed in the management of 
the animals, before and during the experimental period, were as described in 
Chapter 2.
Pre-infection sera
Collection and storage of large pools of pre-infection sera were carried 
out as described for 'pre-treatment sera' in Chapter 2.
Trypanosomes
The trypanosome populations used and preparation of the infecting inoculum 
were as described in Chapter 2 (Materials and Methods).
Experimental design
On the day of infection the 10 animals were divided into two groups. 
One group of five calves was inoculated with lx l 0  ^ homidium-sensitive 
trypanosomes (71 congolense IL 1180) whereas the other group of five calves 
was inoculated with 1x10^ homidium-resistant trypanosomes (7. congolense 
IL 3330). The inoculum was given by intravenous injection to all animals. All 
calves were treated with homidium bromide 7 days after trypanosomes were 
first demonstrated in the peripheral blood of all animals in each group.
Assessment of parasitaemia and PCV
Following infection, animals in both groups were monitored for 
parasitaemia and PCV. Ear vein blood samples were taken daily from the first 
day of infection in heparinised capillary tubes and the presence of 
trypanosomes and PCV determined as previously described in Chapter 2.
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Drug treatment
Homidium bromide (Ethidium®, Cameo, UK; Lot No. B4B3) was used to 
treat the animals following infection. A 2.5% (w/v) solution of the drug was 
prepared in sterile water immediately prior to treatment The dose given was 1 
mg kg-1 body weight (b.w.). The drug was given as a single bolus by deep 
intramuscular (i.m.) injection into the muscles of the neck.
Sample collection
Sampling for parasitaemia and PCV continued following treatment. In 
addition, blood samples were collected for drug assays at the following 
intervals after treatment: 5, 10,15, 30 minutes, 1, 2, 4, 6 , 8 and 12 hours, 
twice a day during the first week, daily during the second week, thrice during 
the third week, twice during the fourth week, and thereafter weekly to the end 
of the observation period of 90 days. Total serum protein and serum albumin 
levels were determined in all the samples.
Determination of total serum protein
Total serum protein was determined by using the Coomassie® Plus 
Protein Assay Reagent. The procedure followed is described in Chapter 2.
Determination of serum albumin
For the determination of serum albumin, a quantitative, colorimetric 
procedure (Procedure No. 631, Sigma Diagnostics) was used, as described 
elsewhere (Chapter 2).
Determination of homidium concentrations
Serum homidium concentrations were analysed using Assay 2 of the 
homidium-ELISA methods. This method is described in Chapter 3.
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Handling of homidium ELISA data
The procedures followed in handling of ELISA are as described in 
Chapter 2.
Pharmacokinetic statistical evaluation
The procedures followed in the pharmacokinetic and statistical 
evaluation of the experimental data are as described in Chapter 4.
RESULTS
Boran cattle infected with a drug-susceptible population of 
T.congolense (IL 1180) and later treated with homidium bromide at 
1 mg kg-1 b.w. by the intramuscular route 
Parasitaemia
Fig. 5.1 shows the parasitaemia in cattle following trypanosome 
inoculation and the time of homidium treatment. Trypanosomes were first 
detected in the peripheral blood of four out of the five cattle in this group 
seven days following infection; the remaining animal was first detected 
parasitaemic on the eighth day. Individual animals exhibited different levels of 
parasitaemia, some animals being more heavily parasitised than others at the 
time of treatment, on day seven following demonstration of parasites in the 
peripheral blood of all the five animals (day 15 after trypanosome inoculation) 
(Table 5.1). On treatment with homidium at 1 mg kg-1 b.w., trypanosomes 
were cleared from the blood within 24 hours o f drug administration in 4 out of 
the 5 cattle of the homidium-sensitive group, the remaining animal cleared 
within 48 hours (Table 5.1). This latter animal had the highest parasite density 
before treatment. All the animals remained negative to the end of the 
observation period, which was 90 days.
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Fig. 5.1
A comparison of parasitaemia in Boran cattle treated (>l) with 
homidium at 1 mg kg-1 b.w. following infection with either a drug 
sensitive (T. congolense IL 1180) or a drug-resistant trypanosome 
population (T. congolense IL 3330)
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Table 5.1
No. of trypanosomes per field, estimated by the thick blood smear method 
(Mag. x 400), at the time of homidium treatment of cattle infected with either 
a drug-sensitive or a drug-resistant trypanosome population
Animal No. No. of trypanosomes 
per field
Homidium conc. 
at 5 min. following 
treatment (ng ml-1)
Time taken to clear parasites 
following treatment
41()t 16 34.1 24 hours
41 It 12 57.9 24 hours
412t 20 74.1 48 hours
413t 8 40.9 24 hours
414t 8 174.7 24 hours
Mean ± SD 12.8±4.7 76.4±51.1
415tt 10 78.7 not cleared (resistant)
416tt 20 104.3 not cleared (resistant)
417tt 8 121.2 not cleared (resistant)
418t+ 14 173.1 not cleared (resistant)
419tt 3 113.4 not cleared (resistant)
Mean ± SD 11.0+5.7 118.1±31.0
t=  cattle infected with the drug-sensitive trypanosome population 
tt = cattle infected with the drug-resistant trypanosome population
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Serum drug concentrations
Figs. 5.2(a) to 5.2(e) show the serum homidium concentration-versus- 
time plots o f individual animals. The mean drug concentration 5 minutes 
following treatment was 76.4±51.1 ng m F (range 34.1 - 174.7 ng ml-1; Table 
5.1). The mean ± SD peak serum concentration (Cmax) was 180.4±34.7 ng ml*1 
(range 112.0 - 204.3), and the mean time at which this peak occurred (tmax) 
was 0.226±0.029 hours (range 0.168 - 0.240). Only animal No. 413 had a tmax 
value of 0.17 hours. The value of 0.24 hours was obtained in all the remaining 
four animals o f this group. By day 36 post-treatment, the concentration of 
homidium in serum ranged from 0.15 - 0.30 ng m F.
Pharmacokinetics
An exponential decline in the serum concentration was observed and 
the non-compartmental pharmacokinetic model was used to describe the 
experimental data. Pharmacokinetic parameters are given in Table 5.2. The 
AUCq.^ and the AUMCq.00 observed values were 1667±233 ng.h m F (range
1453 - 2117) and 480580±239402 ng.h2 m F (range 177106 - 806586), 
respectively. Using these values, the MRTq.^ observed was calculated as 296.7
±158.9 hours (range 121.9 - 504.6). The results showed wide variations in the 
MRT values between individual infected animals (Table 5.2).
Haematological indices
From the onset of parasitaemia, there was a rapid drop in PCV from a 
mean pre-infection value of 38.4±4.4% to 24.8±1.6% within 7 days of 
demonstration of parasites in the peripheral blood (Fig. 5.3). The PCV values 
returned to the pre-infection levels within one week of drug administration in 
all animals. The animals in this group fed well and generally gained weight 
throughout the experiment.
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Figs. 5.2(a) to 5.2(e)
Serum homidium concentration in five individual Boran cattle 
treated with homidium at 1 mg kg-1 b.w. following infection with a 
homidium-sensitive Trypanosoma congolense population (IL 1180)
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Mean ± SD (n = 5) packed cell volume (%) in Boran cattle treated 
( i )  with homidium at 1 mg kg-1 b.w. 15 days following inoculation 
with a homidium-sensitive trypanosome population (71 congolense 
IL 1180)
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Total serum proteins levels
The mean total serum protein of the five cattle obtained from pre­
treatment sera was 46.05±2.25 mg mb1. Within 15 days of inoculation with 
the drug-sensitive T. congolense i.e., at the time of treatment, this value was 
39.5±0.4 mg m l1, which was significantly different from the pre-infection 
value (p < 0.05). On treatment of the cattle the levels increased to the pre­
treatment values within one week (Fig. 5.4) and continued to rise to an average 
value o f approximately 50 mg mb1 within 14 days o f treatment, which was 
maintained to the end of the experimental period of 90 days.
Serum albumin levels
The mean pre-infection serum albumin value of the five cattle was 
26.0±2.5 mg mb1. Fifteen days following trypanosome inoculation at the time 
o f drug treatment, this value was 22.2±2.4 mg mb1 (Fig 5.5). This valu^ was 
not significantly different from that obtained before trypanosome inoculation. 
Pre-infection serum albumin levels were generally maintained to the end of the 
observation period of 90 days after treatment (Fig. 5.5).
Total serum globulin levels
Fig. 5.6 shows the total serum immunoglobulin levels in the five cattle 
infected with the homidium-sensitive trypanosome population. Total serum 
globulin levels were calculated from the difference between the total serum 
protein levels and the serum albumin levels. The results showed an initial drop 
in globulin levels during the first 14 days post-infection from pre-infection 
values o f 20.4±1.5 mg mb1 to approximately 16+1.9 mg mb1. Approximately 
13 days following treatment, concentrations of 24.05±2.0 mg mb1 were 
attained, peaking at approximately 30 days post-infection (approximately 15 
days after treatment) (Fig. 5.6). After the peak, values of 24.9±1.8 mg mb1
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Fig. 5.4
Mean ± SD (n = 5) total serum protein levels in Boran cattle treated 
( i )  with homidium at 1 mg kg-1 b.w. 15 days following inoculation 
with a homidium-sensitive trypanosome population (T\ congolense 
IL 1180)
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Fig. 5.5
Mean ± SD (n = 5) serum albumin levels in Boran cattle treated ( i )  
with homidium at 1 mg k g 1 b.w. 15 days following inoculation with 
a homidium-sensitive trypanosome population (7". congolense IL 
1180)
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Fig. 5.6
Mean ± SD (n = 5) total serum globulin levels in Boran cattle treated 
(>l) with homidium at 1 mg kg-1 b.w. 15 days following inoculation 
with a homidium-sensitive trypanosome population (71 congolense 
IL 1180)
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were attained approximately 25 days following treatment. These levels were 
generally maintained to the end of the observation period of 90 days.
Boran cattle infected with a drug-resistant population of 
T. congolense (IL 3330) and later treated with homidium 
bromide at 1 mg kg-1 b.w. by the intramuscular route 
Parasitaemia
Fig. 5.1 shows the parasitaemia in cattle following trypanosome 
inoculation and the time of homidium treatment. Trypanosomes were first 
demonstrated in the peripheral blood of all the five animals in this group seven 
days following infection. On the day of treatment, which was 7 days after all 
animals were first detected parasitaemic (14 days post-inoculation), individual 
animals exhibited different levels of parasitaemia (Table 5.1). After treatment, 
trypanosomes did not completely disappear from the blood. However, there 
was a decline in the parasitaemia in all animals. This drop in parasitaemia 
lasted approximately 10 days (Fig. 5.1), after which trypanosomes reappeared 
in the circulation and rose to a series of peaks.
Serum drug concentrations
The homidium concentration versus time plots for animal Nos. 415 to 
419 are given in Figs. 5.7(a) to 5.7(e), respectively. Five minutes following 
treatment of the group of cattle infected with homidium-resistant trypanosome 
population, the circulating drug level in serum was 118.1 ±31.0 ng m l1 (range 
78.7 - 173.1 ng ml*1) (Table 5.1). The mean peak serum drug concentration 
(Qnax) was 179.6±29.3 ng m l1 (range 131.8 - 220.2) and the time at which the 
maximum concentration occurred ( t ^ )  was 10-15 minutes. As already 
mentioned, trypanosomes did not clear from the circulation following 
treatment. Ten days following treatment, no drug was detectable in serum of 
any of the five animals in this group. The results showed that in the presence
177
Figs. 5.7(a) to 5.7(e)
Serum homidium concentration in five individual Boran cattle 
treated with homidium at 1 mg kg-1 b.w. following infection with a 
homidium-resistant Trypanosoma congolense population (IL 3330)
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of a homidium-resistant trypanosome population, the rate of disappearance of 
the drug from serum was accelerated.
Pharmacokinetics
Decline in serum homidium concentration was exponential and the non- 
compartmental pharmacokinetic model was used to describe the experimental 
data. The results are given in Table 5.3. From the AUCq.^ and AUMCq.^
observed values of 1329±157 ng.h mb1 (range 1110- 1561) and 4351317554 
ng.h2 m l1, the MRTq.^ observed value was calculated as 32.8+4.5 hours
(range 25.5 - 37.5). Large variations in the MRT values between individual 
infected animals were observed.
Haematological indices
The drop in PCV in the animals infected with the homidium-resistant 
trypanosomes was gradual following trypanosome inoculation from a mean 
pre-infection value of 38.4+2.5% to 31.0+3.1%. There was a slight elevation 
in PCV to approximately 35% following treatment, after which the drop was 
rapid, reaching levels of 19.0+1.2% at 70 days as the peaks of parasitaemia 
continued (Fig. 5.8). Over this period, there was loss of appetite, accompanied 
by deterioration in body condition and loss in body weight. The lowest 
recorded PCV value was 17%. Because the animals were in poor condition, 
they were removed from the experiment 77 days after treatment, when each 
animal was treated with three doses of diminazene aceturate; the first dose was 
14 mg kg-1 b.w. followed by 7 mg kg-1 b.w. on the second day and 7 mg kg-1 
b.w. on the third day. No parasites were found in the blood of any of the 
animals when examined for trypanosomes after this treatment. Up to a period 
of 60 days following diminazene treatment, no trypanosomes were detected in 
their peripheral blood. Three of the animals were still too weak even after the 
diminazene treatment and were humanely killed three days
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Fig. 5.8
Mean ± SD (n = 5) packed cell volume (%) in Boran cattle treated 
(>l) with homidium at 1 mg kg-1 b.w. 14 days following inoculation 
with a homidium-resistant trypanosome population (T. congolense 
IL 3330)
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following diminazene treatment. However, two of the animals survived and 
gained weight.
Pathology
On post-mortem of the three cattle from the group which was infected 
with the drug-resistant trypanosome population, it was found that the animals 
had enlarged lymph nodes and splenomegaly. In addition, there was evidence 
of muscle wasting, depletion of the body fat and accumulation of oedematous 
fluid in the pericardium. The surfaces of the liver, kidneys and lungs showed 
focal areas of haemorrhage.
Total serum protein levels
The mean (±SD) pre-infection total serum protein level was 47.12±1.34 
mg mb1. Fourteen days following infection, at the time of treatment, the mean 
total serum protein concentration was 42.05±4.63 mg m l1. The pre-infection 
value was slightly higher but not significantly different from the value at 15 
days at 95% confidence limit. Following homidium treatment, concentrations 
rose to pre-infection values within one week, despite the fact that the animals 
were not cured. Thereafter, there was a gradual drop to 39.68=1=2.18 mg mF1 on 
day 36 day following treatment (Fig 5.9).
Serum albumin levels
Pre-infection serum albumin levels were 25.7±1.4 ng mF1. A mean 
± SD value of 24.5±2.5 mg mF1, obtained 14 days after trypanosome 
inoculation (Fig. 5.10) was lower but not significantly different from the pre­
infection levels. Within 36 days of trypanosome inoculation, the serum 
albumin levels had dropped to only 21.5±0.37 mg mF1. This was found to be 
significantly lower from the pre-infection value (p < 0.05)
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Fig. 5.9
Mean ± SD (n = 5) total serum protein levels in Boran cattle treated 
(4^ ) with homidium at 1 mg kg-1 b.w. 14 days following inoculation 
with a homidium-resistant trypanosome population (T. congolense 
IL 3330)
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Fig. 5.10
Mean ± SD (n = 5) serum albumin levels in Boran cattle treated (>1<) 
with homidium at 1 mg kg~] b.w. 14 days following inoculation with 
a homidium-resistant trypanosome population (T. congolense IL 
3330)
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Total serum globulin levels
Fourteen days following infection, there was a drop in the total serum 
globulin concentrations from a pre-infection value of 22.58±0.98 mg mb1 to 
approximately 20.6±0.5 mg m l1 (Fig. 5.11). Concentrations did not appear to 
change significantly over a two week period following treatment, after which 
two peaks were observed at 40 and 65 days post-infection which appeared to 
coincide with parasitaemia peaks. A mean value of 21.5±0.4 mg mF1 was 
recorded 36 days following homidium treatment.
Comparison of homidium serum concentration and 
pharmacokinetics between trypanosome-infected and non- infected 
cattle reported in Chapters 4 and 6 
Serum homidium concentrations
Fig. 5.12 and 5.13 show a comparison of the mean ± SD serum 
homidium concentrations between non-infected cattle and cattle infected with 
either a sensitive or a resistant population of T. congolense. The values for 
non-infected cattle were obtained from the experiments described in Chapter 
4. The earliest sampling time for the non-infected cattle reported in Chapter 4 
was 30 minutes. Data on serum homidium concentrations in these animals 
before 30 minutes post-treatment are therefore lacking. However, the serum 
homidium concentrations five minutes after the treatment of ten non-infected 
cattle are available from the experiment reported in Chapter 6 and are used in 
the comparison in Table 5.4.
Five minutes following homidium treatment, the mean drug 
concentration in cattle infected with a drug-sensitive trypanosome population 
(76.4±51.1 ng mb1) was significantly lower than that obtained in non-infected 
Boran cattle, (235.6±118.3 ng mb1; n= 10; Chapter 6 ) (p < 0.05). Similarly, the 
mean peak serum drug concentration of 180.4±34.7 ng mb1 obtained in cattle
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Fig. 5.11
Mean ± SD (n = 5) total serum globulin levels in Boran cattle treated 
(>l) with homidium at 1 mg kg-1 b.w. 14 days following inoculation 
with a homidium-resistant trypanosome population (T\ congolense 
IL 3330)
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Fig. 5.12
Mean ± SD (n = 5) serum homidium concentrations in non-infected 
cattle and cattle infected with a homidium-sensitive trypanosome 
population (T. congolense IL 1180).
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Fig. 5.13
Mean ± SD (n = 5) serum homidium concentrations in non-infected 
cattle and cattle infected with a homidium-resistant trypanosome 
population {T. congolense IL 3330).
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Table 5.4
Serum homidium concentrations five minutes following treatment of non- 
infected and cattle infected with either a sensitive or a resistant population of 
T. congolense 
(a) Non-infected cattle
Animal No. concentration (ng m l-1) Animal No. Concentration 
(ng m l-1)
426 169.9 435 454.2
429 332.7 437 95.6
430 226.3 438 356.8
433 146.7 442 87.6
434 490.2 444 250.4
Mean ± S D  (n = 10) 261.1±135.7
(b) Sensitive trypanosome population
Animal No. concentration (ng ml)
410 34.06
411 57.92
412 74.13
413 40.91
414 174.74
Mean ±  SD 76.35±51.12* *
(c) Homidium-resistant trypanosome population
Animal No. concentration (ng ml)
415 78.66
416 104.3
417 121.2
418 173.1
419 113.4
Mean ±  SD 118.11±31.0*
Comparison with the mean value of uninfected cattle using the student’s t-test
* * p < 0.01
* p < 0.05
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infected with the sensitive trypanosome population was significantly lower 
than 276.2±83.4 ng m F reported in non-infected cattle (p < 0.05). Following 
treatment of cattle infected with a drug-resistant trypanosome population, the 
mean serum drug concentration obtained at five minutes, 118.1±31.0 ng ml-1, 
was significantly lower than that obtained in non-infected cattle (p < 0.05). 
Similarly, the peak concentration of 179.6±29.3 ng m F was found to be 
significantly lower than that observed in non-infected cattle (p < 0.05) but not 
significantly different from the value obtained in the cattle infected with the 
drug-sensitive trypanosome population.
For the remaining comparison of non-infected and infected cattle, the 
values obtained in non-infected cattle reported in Chapter 4 rather than 
Chapter 6 were used because data up to 90 days post-treatment were available 
for the experiment described in Chapter 4. The serum homidium 
concentration-versus-time plot obtained following treatment of cattle infected 
with a drug-sensitive trypanosome population showed an accelerated rate of 
drug elimination within the first 10 days of treatment which reverted to normal 
following the disappearance of trypanosomes from the circulation (Fig. 5.12) 
and an elevation in PCV. However, the accelerated rate o f drug elimination 
observed in cattle treated following infection with a drug-resistant 
trypanosome population continued until the drug was no longer detectable in 
the circulation (approximately 10 days following treatment) (Fig. 5.13).
Pharmacokinetics
A comparison of the pharmacokinetic parameters between non-infected 
cattle and cattle infected with either the sensitive or resistant populations o f T. 
congolense is given in Table 5.5. The mean AUC value obtained following 
treatment of cattle infected with the sensitive trypanosome population was 
higher but not significantly different from the value in non-infected cattle. The
190
Table 5.5
Homidium pharmacokinetic parameters in non-infected Boran cattle and cattle 
infected with either a sensitive (IL 1180) or a resistant (IL 3330) population of 
T. congolense following treatment with homidium bromide at 1 mg kg-1 b.w.
Parameter Non-infected 
Boran cattle
Boran cattle 
Infected with 
IL 1180 
sensitive
Boran cattle 
Infected with 
IL 3330 
resistant
hnax (h) nd 0.2256+0.0288 0.1968+0.0353
Cmax (ng ml 1) nd 180.4+34.8 179.6+29.3
P 0.0040±0.0005 0.0018+0.0006 0.0097+0.0022
tV2f> (h) 177.8±23.4 423.7+145.6** 75.46+16.89**
AUCo-last (ng-h ml'*) 2051+341 1616+261 1320+157*
AUCq-oo observed (ng.h mb1) 2056±341 1667+233 1329+156*
AUCq-oo predicted (ng.h mb1) 205453±342 1648+247 1325+157
AUMC0_Iast (ng.h2 mb1) 177351±37189 340428+96872 38028+5881
AUMCq.^ observed (ng.h2 mb1) 177351±37189 480580+239401 43513+7554
AUMCq.^ predicted (ng.h2 mb1) 180714±37651 430070+172827 41018+7087
MRT0_last (h) 87.5±16.8 216.2±72.0* 28.82+2.78*
MRTq.^ observed (h) 92.3+21.1 296.7±158.8* 32.78+4.46*
MRTq.^ predicted (h) 89.1±17.5 269.5±120.2 30.97+3.78
nd = not determined.
Group comparisons of means between non-infected and infected cattle:
** p < 0.01
* p < 0.05
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MRT value of 296.6+158.9 hours obtained in cattle infected with the drug- 
sensitive trypanosome population was, however, significantly higher than the 
value obtained in non-infected cattle of 92.27+21.14 hours (p < 0.05), and the 
value of 32.78+4.46 hours obtained in cattle infected with the drug-resistant 
trypanosome population (p < 0 .0 1 ).
The AUC and MRT values obtained in cattle treated following 
infection with the drug-resistant trypanosome population were found to be 
significantly lower than the values obtained in non-infected cattle and in cattle 
infected with the sensitive trypanosome population (p < 0.01) (Table 5.3).
DISCUSSION
The present study has demonstrated that T. congolense infections can 
have pronounced effects on serum homidium's concentration profile and 
pharmacokinetics following treatment of infected cattle with homidium 
bromide at the recommended therapeutic dose rate (1 mg kg-1). Evidence was 
obtained showing that drug elimination rate was accelerated in the presence of 
an infection. The mean residence time of the drug in cattle treated following 
infection with a drug-sensitive trypanosome population was significantly 
higher than that observed in non-infected cattle in cattle infected with a drug- 
resistant trypanosome population.
Following i.m treatment, trypanosomes were cleared within 24 hours 
from the peripheral blood of four out of five cattle infected with a homidium- 
susceptible trypanosome population. The remaining animal, which had the 
highest parasitaemia density became aparasitaemic within 48 hours. No 
trypanosomes were detected in the peripheral blood of any of these animals to 
the end of the observation period (90 days), suggesting complete cure. The 
parasitology results showed that with the homidium-sensitive parasites there 
was only a slight variability in the time taken for the trypanosomes to clear 
from blood following homidium treatment.
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Five minutes following homidium treatment of cattle infected with the 
drug-sensitive trypanosome population, the mean ± SD serum drug 
concentration was 76.4±51.1 ng m l1 (range 34.1 - 174.7) (Table 5.4). The 
drug profile results showed an acceleration in rate of decline in serum 
concentrations in the infected cattle within the first 10  days following 
treatment after the peak which was observed at 10 minutes. The rate reverted 
back to normal following the elimination of parasites from circulation (Fig. 
5.12) and at a time when an elevation in PCV levels was observed (Fig. 5.3). 
The accelerated rate of the elimination of the drug from the circulation during 
the first 10  days could have been due to the changes in the host following 
infection, such as fever, PCV and parasitaemia. Other important changes could 
be changes in the protein levels and tissue damage caused by the infection, 
which are also mentioned in this discussion at a later stage.
A mean residence time of 296.6±158.9 hours (range 121.9 - 504.6) 
obtained in cattle infected with the drug-sensitive trypanosome population 
following treatment was quite long. The results suggest a longer mean 
residence time for the drug in cattle following treatment of cattle infected with 
the drug-sensitive trypanosome population than was observed in non-infected 
cattle suggesting that such cattle would be protected for a much longer period 
in case of repeated exposure to trypanosome infections than the non-infected 
cattle. This would in turn reduce the number of treatments required per animal 
per year, thereby reducing the cost of keeping the animals in a tsetse- infested 
area. This finding is supported by the observation made by Whiteside (1962) 
in which he demonstrated a reduction in the number of treatments from five to 
one in a year following repeated exposure to trypanosome infections and 
successful cure with diminazene. He attributed this to the combined effect of 
the immune response and drugs.
Studies by Gilbert and Newton (1982) showed that i.m. treatment of T. 
congolense infected and T. brucei-infected rabbits with 14C homidium bromide
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at 1 and 10 mg kg-1 b.w. did not result in cure. Only an increase in the pre­
patent period from 3 days (homidium-treated non-infected rabbits) to 8 days 
(homidium-treated infected rabbits) was observed. The trypanosome 
populations used were not drug-resistant. Their observations showed 
similarities in homidium concentrations between infected and non-infected 
rabbits. The differences between these results and those obtained in the present 
study could be as a result of a species difference in drug absorption, 
distribution and elimination.
One interesting observation made by Gilbert and Newton (1982) was 
that despite the fact that the rabbits were not cured following treatment at the 
two dose rates, sub-inoculation of the blood from these rabbits into mice 
resulted in cure at a dose rate of 1 mg kg-1 b.w. Removal o f IgG from serum 
taken five hours after homidium treatment of infected rabbits resulted in the 
reduction of the trypanocidal activity to 46% that of serum from infected 
homidium-treated rabbits taken at the same time. All trypanocidal activity in 
samples collected at 10 and 19 days following treatment of infected rabbits 
was associated with IgG and this was demonstrated by the complete loss of 
trypanocidal activity in serum in vitro when IgG was removed. These results 
of Gilbert and Newton (1982) support the above observations made by 
Whiteside (1962) on the contribution of the host's immune response to 
chemotherapy.
The high values for MRT obtained following treatment of cattle 
infected with a drug-sensitive trypanosome population could possibly be as a 
result of the presence of anti-trypanosome antibodies. This is also supported 
by the elevated total serum globulin levels observed.
Following i.m treatment of the cattle infected with the homidium- 
resistant trypanosomes, the parasites did not clear from the circulation 
although there was a drop in the trypanosome density for about 10 days (Fig. 
5.1), after which the peaks of parasiteamia continued over the observation
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period of 70 days. The homidium-resistant trypanosomes were therefore 
confirmed to be highly resistant to the recommended therapeutic dose of 
homidium of 1 mg kg-1 b.w. Five minutes following treatment, the mean 
serum drug concentration in these animals was 118.1±31.0 ng mb1 (range 78.7
- 173.1) (Table 5.4). The value for Cmax was 179.6±29.3 ng ml*1 (range 131.8
- 220.2) and this occurred between 10 minutes (animal Nos. 416, 417 and 418) 
and 15 minutes (animals 415 and 419) following treatment (Table 5.3). 
However, no drug could be detected 10 days post-treatment in these cattle, 
showing that the homidium-resistant trypanosome infection markedly altered 
the drug's concentration profile (Fig. 5.13).
The mean residence time of 32.8+4.5 hours (range 25.5 - 37.5) was 
obtained in the animals infected with the drug-resistant trypanosome 
population. All the animals in this group showed low MRT values. Low values 
for MRT obtained in these cattle suggest that either the drug was not held for 
long periods at the injection site due to physiological changes in the host, or 
that it was released as metabolites by the trypanosomes, undetected by the 
ELISA method used.
Comparisons of the mean ± SD serum drug concentrations between the 
two infected groups of cattle and non-infected cattle showed that five minutes 
following homidium treatment, there were significant differences in drug 
concentrations. For instance, the mean drug concentration at this time in the 
cattle infected with the drug-sensitive trypanosome population was 
significantly lower than that in non-infected cattle (p < 0.01; Table 5.4).
During the same period (five minutes following treatment), the mean drug 
concentration in the cattle infected with the drug-resistant trypanosome 
population was also significantly lower than that in the non-infected cattle (p <
0.05). However, the Cmax values between the two groups of infected cattle 
were not significantly different. This suggests a significant uptake of the drug 
by trypanosomes and is supported by the observation by Gilbert and Newton
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(1982) using 14C homidium in which approximately 80% of the drug was 
bound to trypanosomes separated from ear vein blood collected at 1 , 6  and 12 
hours post-treatment. Although blood samples obtained at 30 minutes 
following treatment were not examined, it appears that appreciable uptake of 
the drug takes place within minutes of treatment when the parasitaemia is high 
(Fig. 5.1).
It is of interest that homidium uptake by trypanosomatids Crithidia 
fasculata  and C. seymouri has been demonstrated to be biphasic and that the 
characteristics of the two phases are consistent with the hypothesis that there 
is an initial specific external binding followed by a very slow process of 
transport into the cells (Coolbear and Midgely, 1986). It was also 
demonstrated in the same study that homidium uptake by the trypanosomatids 
could not be saturated over a large concentration range. The study of 
Sutherland et al. (1992) on isometamidium uptake by T. congolense 
demonstrated an energy dependent transport of the drug into trypanosomes.
The acceleration in the rate of decline in the serum drug levels observed 
in both groups of infected cattle during the first 10 days following treatment 
reverted back to normal only in the cattle infected with the drug-sensitive 
trypanosome population but not in the cattle infected with the drug-resistant 
trypanosome population (Figs. 5.12 and 5.13). Although the rate of drug 
elimination reverted to normal in the group of cattle infected with the drug- 
sensitive trypanosome population, the drug concentrations remained generally 
low compared to those observed in non-infected cattle (Fig. 5.12). This 
acceleration in the rate of drug elimination could have been as a result of 
several factors which include drug uptake by trypanosomes, changes in the 
host physiology or a combination of these factors. Whilst no drug was 
detectable in the peripheral blood of all animals infected with the drug- 
resistant trypanosome population within approximately 10  days of treatment, 
drug levels of between 0.1 and 0.3 ng m l1 were still detectable 8 to 13 weeks
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post-treatment in non-infected cattle and in cattle infected with the homidium- 
sensitive trypanosomes. The observation of elevated rate of drug elimination 
in trypanosome-infected catde is similar to that of Eisler et al. (1994) who 
observed this phenomenon in cattle with isometamidium.
The pharmacokinetics of homidium in cattle infected with the drug- 
sensitive trypanosome population indicated that the MRT values were 
significantly higher than the values obtained in non-infected cattle (p < 0 .0 1 ; 
Table 4.5). A mean residence time of 296.6±158.9 hours obtained in cattle 
infected with the drug-sensitive trypanosome population was significantly 
higher than 92.27±21.14 obtained in non-infected cattle. The same value 
obtained in cattle infected with the drug-resistant trypanosome population 
32.78+4.46 hours, was even lower, showing that a persistent trypanosome 
infection could lead to drug failure by increasing the rate of disappearance 
following treatment.
Differences in homidium's pharmacokinetics were therefore observed 
between (i) the non-infected cattle and cattle infected with either homidium- 
sensitive or homidium resistant trypanosome populations and (ii) the two 
groups of infected animals. The results demonstrated that the mean residence 
time of the drug cattle in infected with drug-sensitive trypanosomes was 
longer than in non-infected animals and in animals in which the trypanosomes 
persisted following treatment.
The changes in pharmacokinetics of homidium in trypanosome-infected 
cattle may be linked to changes in host metabolism. Groothuis et al. (1978) 
studied the effect of experimental Echerichia coli endotoxaemia on ampicillin 
: amoxycillin blood levels after oral and parental administration of either 
ampicillin or amoxycillin to each of the calves (8  calves per group) at standard 
dose rates equivalent to 1 g amoxycillin and 1 g amplicillin. They 
demonstrated that there was a significant delay in absorption of the drugs 
following infection and treatment and that the drug concentrations were
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markedly lower in the febrile than in the non-febrile controls. In further work, 
it was shown that effects on drug absorption reverted back to normal following 
the disappearance of fever.
In similar work, van Miert et al. (1976) carried out experiments to 
evaluate the effect of endotoxin-induced fever on the biotransformation and 
blood levels of sulphafurazole in adult goats, and observed that the blood drug 
levels were higher in four out of six goats during the febrile episode. During 
fever, the half-life of the non-metabolised sulphafurazole was shortened by 
12% and was attributed to increased blood flow in the kidneys and liver. The 
pattern of urinary metabolites was also altered during the period of fever. Van 
Miert et al. (1976) also illustrated how changes in haemodynamics in the 
absence of fever could affect drug kinetics possibly due to reduced blood flow 
in the liver and kidneys. They suggested a modification of the dosage regimen 
of a drug or of the route of administration in such situations. However, 
sufficient data would be needed to permit such modifications.
Studies on blood sulphonamide levels in feedlot cattle with respiratory 
disease (Young 1973) has demonstrated that depressed rumen motility leads to 
lowered sulpha absorption rates and sub-optimal plasma sulphonamide 
concentrations of the drug administered orally.
In the field of animal trypanosomiasis, infections have been associated 
with peaks of fever, which usually coincide with the appearance of 
trypanosomes in the blood, and peaks of parasitaemia.
The occurrence of fever in various diseases, including trypanosomiasis, 
poses potential problems in drug treatment if fever per se alters the absorption, 
distribution, biotransformation and/or excretion of drugs. For homidium, it is 
difficult to predict how the drug's metabolism may be affected by febrile 
periods. The significant changes in drug concentrations observed five minutes 
following treatment would suggest that the initial rapid disappearance of the 
drug could possibly be due to trypanosomes metabolising the drug. However,
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elevated temperatures and an associated increase in metabolic rate 
(Katunguka-Rwakishaya et al., 1993) could also play a part.
Since most drugs are bound to serum albumin, it is also possible that in 
the presence of decreased amounts of serum albumin during trypanosome 
infection, as shown in the present study, the movement of the drug to target 
cells could be affected.
Besides episodes of fever and enhancement in the rate of host 
metabolism and the low serum albumin levels associated with trypanosome 
infections, other host changes include changes in the PCV and damage to 
tissue. PCV has been used in trypanosomiasis to determine the severity of the 
disease. Katunguka-Rwakishaya et al. (1993) showed that the observed 
anaemia was due to accelerated extravascular destruction of red blood cells 
and heamodilution. Van Miert et al. (1976), in their work using amoxycillin in 
goats observed that haemodynamic changes may influence drug kinetics. 
Therefore, the haemodilution associated with trypanosome infections could 
have contributed to the changes in the drug pharmacokinetics observed in the 
present study possibly also due to reduced blood flow in the liver and kidneys.
The results of the present study showed the drop in PCV during the 
first seven days of infection was more gradual in the group infected with the 
homidium-resistant than the group infected with the drug-sensitive 
trypanosomes suggesting that the drug-sensitive trypanosome population was 
possibly more virulent than the drug-resistant trypanosome population. The 
results showed that PCV levels were approximately 24% in the cattle infected 
with the homidium-sensitive trypanosomes compared to approximately 34% in 
cattle infected with the homidium-resistant trypanosomes on the day of 
treatment (14 to 15 days following infection). Pre-infection levels were 
i 38.4±4.6%. Whilst PCV levels attained 14 days following trypanosome
i
I infection with the drug-sensitive trypanosome population were elevated within
| one week following homidium treatment (Fig. 5.3), levels in the group
infected with the drug-resistant trypanosome population continued to decline, 
although the treatment helped maintain levels nearly constant for 
approximately 10 days, between day 14 and day 24 of infection.
In work on serum changes in T. congolense-infectzd cattle, Wellde et 
al. (1974) observed that total serum protein concentrations fell sharply during 
the first 5 weeks of infection, then increased gradually to normal levels. Serum 
albumin levels followed a similar pattern for the first 5 weeks, then remained 
at relatively low levels. Although gamma globulin levels also declined during 
the first 5 weeks their levels were gradually elevated, surpassing the pre­
infection values.
In another study, Nielsen et al. (1978) investigated changes in serum 
immunoglobulins and complement components in infected animals. The 
results obtained after infecting calves with 5.5x10^ parasites of Trypanosoma 
congolense, showed that some animals were more parasitised than others; 
parasitaemia levels ranged from heavy to medium to low. There was no 
change in the IgGj and IgG2  levels. IgM increased early in infection and the 
amount of increase appeared related to the parasite burden. The amounts of 
IgA and IgE were both very much decreased and this appeared to be related to 
the numbers of parasites in the blood. They were able to demonstrate a 
correlation between immunoglobulin levels and parasiteamia by treating each 
animal as a single entity rather than use of average values.
The results reported in this Chapter which included variations in 
parasite density following infection (14 -15  days post-infection) between 
individual animals, a drop in PCV following the establishment of infection and 
decreased levels of serum albumin are in agreement with the findings of 
Wellde et al. (1974) and Nielsen et al. (1978). However, the present study 
showed a general decrease in serum globulin levels in both groups of infected 
cattle following infection. The increase in the globulin levels in the cattle 
treated following infection with the homidium-sensitive population of
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trypanosomes was quite evident. In contrast, the total globulin levels in the 
cattle infected with the drug-resistant trypanosome population were generally 
maintained at pre-infection values except for two peaks at approximately 40 
and 65 days following infection which appeared to coincide with the 
parasitaemia peaks (Figs. 5.1 and 5.11).
Most tissues and organs are damaged during the course of trypanosome 
infection although some are more severely affected than others. One organ 
which undergoes severe damage is the heart. Initially, lesions occur beneath 
the epicardium and the endocardium. However, in advanced cases, the entire 
myocardium may be involved (Murray and Morrison, 1980) leading to 
degeneration of the myocardial fibres. The pericardium eventually fills with 
fluid probably due to increased vascular permeability which allows leakage 
from the blood of the protein-rich fluid. Results of this study showed that the 
animals which were humanely killed approximately 8 weeks following 
infection with drug-resistant trypanosome population (after drug failure) had 
an accumulation of fluid in the pericardium. Tissue damage which included 
the heart, the liver and the spleen as observed in the present study would 
therefore possibly lead to vigorous changes in micro-circulation, likely to have 
affected circulation of the drug following treatment.
Although the physiological changes occurring in the animals appeared 
to be much faster in the animals infected with the drug-sensitive trypanosome 
population as demonstrated by the rapid drop in PCV compared to the animals 
infected with the drug-sensitive trypanosome population, these changes were 
easily reversed following treatment.
Results of the present study indicate that even with homidium-sensitive 
trypanosomes, the parasites take at least 24 hours to clear from the circulation 
following treatment with homidium bromide at 1.0  mg k g 1 b.w. and even 
longer in more heavily parasitised animals. Unsworth (1954b) demonstrated 
that trypanosomes took as long as 84 hours to clear from the circulation
following treatment with homidium bromide at 0.1 mg k g 1 b.w. With dose 
rates of 0.3 and 0.9 mg k g 1 b.w., trypanosomes took 48 and 32 hours 
respectively to clear from the circulation.
In conclusion, the aforementioned observations made on the 
pharmacokinetics of homidium in infected cattle were made possible through 
the availability of the highly sensitive ELISA method. The changes observed 
in the serum drug concentration-versus-time profiles were similar to those 
made in cattle using isometamidium (Eisler et al., 1994). These could be due 
to the fact that the two compounds share structural similarities. The present 
results have, however, given an insight into one important factor that could 
contribute to drug failure following treatment, thereby reducing the efficacy of 
the drug; that is, drug resistance.
Holmes and Torr (1988) suggested several possible explanations for 
drug failure which included: underdosing, preparation, administration, fraud, 
not treated, cryptic foci, reinfection and drug resistance
In the field, these explanations may not only occur singly but in 
combination and/or sequentially. Administration of trypanocidal drugs in the 
field is often carried out by the farmer who may not have adequate knowledge 
on how to prepare and administer the drugs which are easily acquired from the 
drug retailers. Inaccessibility to diagnostic facilities could lead to treatment of 
animals based on clinical signs which may not be due to trypanosomiasis. 
Lack of weighing scales and economic hardships faced my the majority of 
small scale farmers would suggest that animals could be underdosed. 
Therefore, the ease at which trypanocidal drugs are acquired, lack of 
knowledge on drug preparation and administration combined with lack of 
facilities and economic hardships could contribute to the development of drug 
resistance in the field.
The results of the present study showed that presence of drug-resistant 
trypanosomes would lead to drug failure. Therefore, ways have to be found of
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minimising the development of drug resistance in the field. This could be 
through stricter control in the application of the drugs which would involve 
qualified personnel and not left solely in the control of the farmer.
Treatment regimens such as that suggested by some workers 
(Whiteside, 1962; Mwambu, 1971) involving alternating homidium and 
diminazene every two years once drug-resistance has been identified could 
assist in the control of the spread of drug resistance. Identification of drug 
resistant trypanosomes with some degree of certainty would be the first 
important step in tackling the problem of resistance. Several methods have 
been tried which include studies in animals and use of tissue culture methods. 
The alternative approach suggested by Holmes and Torr (1988) was the 
development of laboratory tests to quantify drug concentrations in treated 
cattle. Presence of trypanosomes in cattle with drug levels which are known to 
be normally trypanocidal could be a valuable index of drug resistance. The 
highly sensitive ELISA method used in the present study and the work 
reported in Chapter 4 has demonstrated the value of this assay in studies 
towards this goal.
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CHAPTER SIX
INVESTIGATION INTO HOMIDIUM AS A 
CHEMOPROPHYLACTIC AGENT
INTRODUCTION
In addition to therapeutic activity, homidium has also been reported to 
offer protection against trypanosomiasis ranging from a few weeks to several 
months. Leach et al. (1955) reported limited prophylactic activity of homidium 
at a dose rate of 1 mg k g 1 b.w. since it protected cattle against T. congolense 
infection for 4 weeks and T. vivax for 6 weeks. In contrast, Whiteside (1962), 
Mwambu (1971) and Dolan et al. (1990) have reported prophylactic activity of 
several months.
Mwambu (1971), in his studies observed the fact that sporadic 
treatment of suspected, or positiv ely identified animals often excluded healthy 
carriers and designed a block treatment regimen using homidium bromide for 
cattle trypanosomiasis in an endemic area in Bukedi District, Uganda. The 
results showed that the incidence of infections was reduced and maintained at 
a low level for at least three months following homidium treatment compared 
to the control herd (in which diminazene aceturate was used to treat only 
positively diagnosed cases at 7.0 mg k g 1 b.w.). The results also showed that 
block treatment of herds of cattle with homidium maintained good condition 
longer than when individual cases were sporadically treated with diminazene 
aceturate. By reducing the number of treatments required in a year through 
block treatment, the control of the disease was more economical and efficient 
than when only positively diagnosed cases were treated with diminazene 
aceturate.
Dolan et al. (1990) carried out a study to investigate homidium 
prophylaxis in two breeds of cattle, the trypanotolerant Orma Boran and the 
improved Kenya Boran (Galana Boran) exposed to natural tsetse challenge on 
the Galana Ranch, Coastal Region Kenya. Each breed was divided into two 
groups; one treated with homidium bromide at 1 mg kg-1 b.w. and the other not 
treated but kept as control herd. Treatment of the homidium herd of each 
breed depended on the trypanosome infection rate in the control herds;
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homidium treatment was given when 20% of the control herd were detected 
positive in a 29 day period. Subsequent homidium treatments were given if 
three breakthrough infections were detected in the homidium-treated herd. The 
study lasted 12 months in which all the animals were herded together. During 
the 12-month period, all animals detected positive in either the control or the 
homidium-treated herd of each breed were treated with diminazene aceturate 
at 7.0 mg k g 1 b.w.
No animals died due to the effects of trypanosomiasis in any of the 
groups during the 12 months. The number of infections in the Orma Boran 
remained low throughout the year, therefore, no homidium treatment was 
given. A total of 16 infections were recorded in the Orma control herd 
compared to 58 in the Galana control herd within 12 months. Only the Galana 
Boran received homidium treatment. The first treatment was given three 
months after the trial began, at the time when trypanosomes were detected in 
20% of the control herd. No infections were recorded in these homidium- 
treated animals for 19 weeks following drug administration. The second 
homidium treatment was given to the Galana Boran 5 months after the first 
treatment. From the time of this second treatment to the 18th week when one 
animal was detected parasitaemic, no trypanosomes were detected in any of 
the animals in this herd; during the same 18-week period, 34 infections were 
recorded in the control group. Thirty infections out of the 58 detected during 
the 12-month study period were due to T. congolense and the remainder due to 
T. vivax.
In all the above experiments, drug levels were not determined due to 
lack of a sensitive and accurate method for the analysis of homidium. 
Therefore, it was not possible to relate the observed prophylactic periods to 
the circulating drug concentrations.
205
STUDY OBJECTIVES
1. To treat cattle with homidium, as would occur in the field when 
prophylactic cover is given to non-infected animals, and monitor the drug 
concentrations using ELISA.
2. To use the above data to determine whether homidium pharmacokinetics 
in individual animals before exposure to trypanosome challenge influence 
the length of the observed prophylaxis following trypanosome infection of 
the treated animals.
3. To challenge the animals at intervals of 30 days after homidium 
administration with either a drug-resistant or a drug-sensitive population 
of Trypanosoma congolense while continuing to monitor the serum drug 
concentrations until trypanosome infections were detected.
3. To attempt to correlate serum drug concentrations with the duration of 
prophylaxis following trypanosome challenge of treated cattle in an effort 
to determine the minimum protective serum homidium concentrations for 
the different trypanosome populations used for challenge.
MATERIALS AND METHODS 
Experimental cattle
A total of 15 steers aged 9 months and weighing between 150 and 165 
kg body weight were used. The steers were purchased from the Kapiti Farm, 
Machakos District, Eastern Province of Kenya; an area free from endemic 
trypanosomiasis. The management of the animals before and during the 
experiments were as described in Chapter 2.
206
Trypanosome populations
Two stabilates of T. congolense were used for the challenge infections (IL 
1180 and IL 3330). The former was known to be relatively drug sensitive 
(CD50 in mice = 0.018 mg kg-1 b.w. with isometamidium chloride and 2.3 mg 
k g 1 b.w. with diminazene aceturate [Peregrine et al., 1991]) and the latter 
homidium resistant (CD50 in mice > 20 mg kg-1 b.w. for homidium chloride,
20 mg k g 1 b.w. for isometamidium chloride and > 30 mg kg-1 b.w. for 
diminazene aceturate [Codjia et al., 1993]). In cattle, T. congolense IL 1180 is 
sensitive to 0.001 mg kg-1 b.w. for isometamidium chloride (Sones et al.,
1988) and IL 3330 is resistant to 7.0 mg kg-1 b.w. diminazene aceturate and 
0.5 mg kg-1 b.w. isometamidium chloride (Codjia et al., 1993). Both T. 
congolense IL 1180 and T. congolense IL 3330 had also been tested in vitro 
using metacyclic forms. These trypanosomes were incubated at 35°C for 48 
hours with concentrations ranging from 0.5 ng - 50 pg m R  of either homidium 
bromide or homidium chloride. The trypanosomes were thereafter transferred 
to cultures containing bovine endothelial cell monolayers to assess their 
viability over the following five days. Sensitivity was expressed as the 
minimum effective drug concentration which killed 100% of trypanosomes in 
a given population within five days. The results were compared to controls 
incubated without drug. T. congolense IL 1180 was shown to be sensitive to 
100 ng mb1 of either homidium bromide or chloride with a minimum level of 
sensitivity of 50 ng m l1, whilst the IL 3330 population was resistant to 1000 
ng mb1 of either homidium salts (Gray and Peregrine, 1993).
Preparation of trypanosome inoculum and infection of cattle
Groups of five sub-lethally irradiated male Swiss white mice were 
inoculated with the either T. congolense IL 1180 or T. congolense IL 3330 
stabilates. Trypanosome inoculations for the infection of cattle were prepared 
in mice as described in Chapter 2. The cattle Nos. 426, 429, 430, 433 and 434
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were inoculated with IL 1180 whilst Nos. 435, 437, 438, 442 and 444 were 
inoculated with EL 3330. The number of trypanosomes given was 1 x 105 by 
subcutaneous (s.c.) injection. The s.c. route was chosen since it was the 
closest possible to the inoculation of an animal with trypanosomes during a 
tsetse bite.
Drug treatment
The drug compound used was homidium bromide (Ethidium®, 
Laprovet, France; Batch No. 52072/N [NP30L]). A 2.5% (w/v) solution was 
prepared in sterile water immediately prior to use. Administration of the drug 
was by a deep intramuscular injection at 1 mg k g 1 into the neck muscles.
Experimental design
Cattle were divided into three groups of five animals; those challenged 
with the homidium-sensitive population (Group HS), those challenged with 
the homidium-resistant population (Group HR), and the challenge controls 
(Group CC). The HS and HR groups were first treated with homidium 
bromide, then challenged at intervals of 30 days with either a homidium- 
sensitive (Group HS) or a homidium-resistant trypanosome (Group HR) 
population. The remaining five animals (Group CC), which did not receive 
homidium treatment were used as untreated controls. The challenge of 
homidium-treated cattle was repeated every 30 days until infections were 
detected. At each 30 day challenge of either Group HS or HR, one control 
from group was challenged in order to test the viability of the trypanosomes 
used.
Homidium concentrations were determined in all the treated animals for 
as long as it was detectable after trypanosome breakthrough infections had 
been detected. Following the development of trypanosome infections in the 
drug-treated catde they were removed from the experiment and treated with
208
diminazene aceturate at 7.0 mg k g 1 b.w. for the homidium-sensitive 
trypanosome population and at 14 mg k g 1 b.w. for the homidium-resistant 
population when they attained a PCV of 15%. A dose rate of 7.0 mg kg-1 was 
chosen for the drug-sensitive trypanosome population since this is the dose 
rate usually employed in the field to treat breakthrough infections in cattle 
under a prophylactic regime. For the drug-resistant trypanosome population, a 
dose rate of 14 mg k g 1 b.w. was chosen since the population has been 
reported to be resistant to a dose rate of 7.0 mg k g 1 b.w. in cattle (Codjia et 
al., 1993).
Detection of anti-trypanosome antibodies
The main objective of the present study was to investigate the 
relationship between serum homidium concentrations and the observed period 
of prophylaxis following trypanosome challenge of homidium-treated cattle. It 
was also important to find out whether anti-trypanosome antibodies developed 
during the challenge periods and whether these contributed to the observed 
period of prophylaxis. The serum samples examined for anti-trypanosome 
antibodies were collected immediately before each trypanosome challenge at 
30, 60 and 90 days post-treatment in Groups HS and HR and at 0 and 30 days 
post-infection in Group CC. The method used is described in Chapter 2.
Collection of samples
Pre-treatment sera
Two days before homidium treatment, fifty millilitres of blood samples 
were collected aseptically into plain vacutainer tubes by venipuncture from 
each animal. The procedures followed for the subsequent preparation and 
storage of sera were as described in Chapter 2. These serum samples were 
used as negative control sera in the preparation of spiked homidium standards 
and the quality control standards.
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Pre-infection sera
On each day of the trypanosome challenge, ten millilitres of blood were 
collected from each animal immediately before trypanosome challenge, sera 
were prepared and stored as described in Chapter 2 for pre-treatment sera. This 
sera was used to determine individual animal serum homidium concentration 
at the time of trypanosome inoculation and also the presence of anti- 
trypanosome antibodies. The sera collected at 30 days when the first challenge 
was given were used to determine the pre-infection values for total serum 
proteins, serum albumin and the total serum globulins.
Blood samples for packed cell volume (PCV) and parasitological examination
Blood samples from cattle for PCV and parasitological examination 
were collected in heparinised capillary tubes before and after trypanosome 
inoculation following the sampling protocol described in Chapter 2. The 
blood-filled capillary tubes were centrifuged in a haematocrit centrifuge at 
12000  g for 10 minutes after which they were read with a micro-haematocrit 
reader. After determination of the PCV, the buffy coat was examined for 
trypanosomes using the phase contrast/buffy coat method of Murray et al. 
(1977).
Determination of serum homidium levels
Ten ml blood samples were collected immediately prior to treatment 
and at the following intervals after treatment; 5, 15, 30, 45 minutes, 1, 2, 4, 8 , 
12 hours, twice daily during the first week, daily during the second week, 
thrice during the third week, twice during the fourth week and thereafter once 
a week to the end of the observation period (determined by the detection of 
trypanosomes in all animals). Sera were prepared and stored as described in 
Chapter 2. Homidium concentrations were determined using Assay 2 of the
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enzyme-linked immunosorbent assays (ELISA) for homidium described in 
Chapter 3.
Data handling
The procedures for data handling were as described in Section 2.8.
Pre-challenge pharmacokinetic evaluation
Pharmacokinetic evaluation of the serum concentration-versus-time 
data was carried out using data collected up to 30 days after homidium 
treatment (i.e., before the first trypanosome challenge). The procedures used 
were as described in Chapter 2.
RESULTS
Cattle treated with homidium bromide and challenged at monthly 
intervals with a homidium-sensitive trypanosome population
Pre-challenge pharmacokinetics of homidium
The pre-challenge pharmacokinetic parameters obtained from a non- 
compartmental analysis of the serum drug concentration data are shown in 
Table 6.1. The mean AUC0^  observed value was 1681±177 ng.h mb1 (range 
1540 - 1960). The M R T ^  observed was 82.2±16.7 hours (range 64.7 - 110.0). 
The results showed wide variation in the observed MRT values between 
individual animals. MAT values could not be determined since data of serum 
drug concentration following i.v. injection of non-infected Boran cattle was 
not available.
Serum homidium concentrations
The individual animal serum homidium concentration-versus-time plots 
are given in Figs. 6.1(a) to 6.1(e). The mean serum homidium concentration-
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Figs. 6.1(a) to 6.1(e)
Serum homidium concentrations in individual Boran cattle after 
treatment with homidium bromide at 1 mg k g 1 and challenged at 30 
day intervals (T)with a drug-sensitive population of T. congolense 
(IL 1180)
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versus-time plot is shown in Fig. 6.2. The results showed a rapid decline in the 
concentrations during the first 24 hours of drug administration followed by an 
extremely slow terminal phase. Five minutes following treatment, the mean 
serum drug concentration was 218.9± 71.8 ng m F The mean peak serum 
homidium concentration (Cmax) was 269.6±45.4 ng m F attained between 5 and 
15 minutes after drug administration. Twenty four hours later, the mean 
circulating drug concentration was 7.1±1.4 ng ml-1. Thereafter, the decline 
was extremely slow, reaching levels of 0.22+0.05 and 0.18±0.06 ng m F at 30 
and 60 days, respectively. Ninety days following treatment, three of the 
animals had concentrations between 0.13 and 0.2 ng m F in circulation 
whereas two others had concentrations below the assay detection limit (0.1 ng 
mb1). The decline in the serum concentrations was similar to that observed in 
non-infected Boran cattle reported in Chapter 4 following i.m. injection.
Trypanosome infections
Group CC
Following the 30-day trypanosome challenge of homidium-treated 
cattle, the challenge control animal at each challenge developed an infection 8 
days following trypanosome inoculation.
Group HS
Following the trypanosome challenge at 30 days after homidium 
treatment with a drug-sensitive stabilate of T. congolense, no trypanosomes 
were detected in any of the treated animals whilst trypanosomes were 
demonstrated in the peripheral blood of the challenged untreated control 
animal. The five homidium-treated Group HS cattle were therefore considered 
protected. These Group HS cattle were later challenged at 60, 90 and 120 days 
following treatment. Table 6.2 shows the individual as well as the group mean 
serum concentrations at the time of trypanosome challenge and the number of
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Fig. 6.2
Mean ± SD serum homidium concentrations in Boran cattle (n = 5) 
following challenge at 30 day intervals with a drug-sensitive 
population of T. congolense (IL 1180) after treatment with 
homidium at 1 mg k g 1 b.w.
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animals protected in Group HS cattle. Trypanosomes were first detected in 
peripheral blood of one animal (No. 429) 30 days after the third challenge on 
day 90; the same day the fourth challenge was due to be given. No 
trypanosomes were detected in the remaining four cattle at day 90 and they 
were therefore, considered protected. Trypanosomes were first detected in the 
peripheral blood of these four animals in Group HS 14, 17, 23 and 24 days 
after challenge at 120 days following drug administration. These four animals 
were therefore, not protected at 120 days following homidium treatment. Pre­
patent periods determined from the time of trypanosome inoculation to the 
time when the trypanosomes were first detected in the blood of all five Group 
HS cattle ranged from 14 to 30 days. Table 6.3 shows a comparison in pre­
patent periods between Group CC and Group HS animals. The periods 
between treatment and the first detection of trypanosomes in the peripheral 
blood of the five animals ranged from 120 to 144 days (Table 6.3).
For animal No. 429 which became infected following trypanosome 
challenge on day 90 post-treatment, the serum drug concentration at this time 
was already below the detection limit (0.1 ng mb1 [Table 6.2]). This same 
animal had the lowest MRT value in the group. Animal No. 434 in which 
trypanosomes were first detected on day 144 following homidium treatment 
did not become infected following trypanosome challenges at 60 and 90 days 
post-treatment when homidium serum concentrations were below the limit of 
detection at both times (Table 6.2). The individual pre-challenge 
pharmacokinetics of the two animals (Nos. 429 and 434) which showed the 
shortest and the longest periods between treatment and demonstration of 
trypanosomes in the blood are given in Table 6.1. The two animals had 
similar Cmax and AUC values but animal 429 showed markedly lower values 
for tmax, and MRT.
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Table 6.3
A comparison in the pre-patent periods following trypanosome inoculation at 
90 and 120 days post-treatment (p.t.) between Groups HS and CC
Group HS
Animal No. Limit of protection 
(days)
Pre-patent period 
Group HS (days)
426 120 14
429 90 30
430 120 23
433 120 17
434 120 24
Group CC 
Animal No.
Date when challenge 
was given
Pre-patent period 
(days)
436 90 8
431 120 8
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Pathogenesis
All the untreated challenge control animals developed clinical signs that 
were similar to those reported in Chapter 5 following trypanosome infection. 
These signs included loss of appetite, a drop in PCV levels and loss in weight. 
In contrast, all the homidium-treated cattle remained healthy until after 
breakthrough trypanosome infections were detected; no significant changes 
were obseived in the PCV from the pre-infection values of approximately 40% 
until trypanosome breakthrough infections were established. After 
establishment o f infection, the changes observed were similar to those reported 
in Chapter 5. Following treatment of infected Group HS cattle with 
diminazene when they had attained a PCV of approximately 15%, 
trypanosomes were cleared from the peripheral blood within 48 hours. 
Thereafter, all the above clinical signs were reversed with animals feeding 
well and an elevation of the PCV to pre-infection values within one week. The 
animals then remained aparasitaemic during a follow-up period of two months.
The pre-infection mean total serum protein of Group HS animals was 
44.9±4.0 mg m l1 serum. The values obtained after 60 and 90 days were 
46.1 ±3.0 and 42.8±2.6 mg mb1, respectively. There were no significant 
differences between these values and those obtained before infection (Fig.
6.3). Similarly, no significant differences were observed between pre­
treatment serum albumin and total globulin levels and the levels obtained over 
the same period of 90 days (Figs. 6.4 and 6.5).
Anti-trypanosome antibodies
No anti-trypanosome antibodies were detected by IF AT in the samples 
collected at 30, 60, 90 days following treatment of Group HS (collected 
immediately prior to trypanosome challenge). However, antibodies were 
detected in the serum samples collected from the untreated challenge controls 
at 30 and 60 days following trypanosome inoculation.
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Fig. 6.3
Mean ± SD total serum protein levels in Boran cattle (n = 5) 
following challenge at 30 day intervals with a drug-sensitive 
population of T. congolense (IL 1180) after treatment with 
homidium at 1 mg k g 1 b.w.
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Fig. 6.4
Mean ± SD serum albumin levels in Boran cattle (n = 5) following 
challenge at 30 day intervals with a drug-sensitive population of 71 
congolense (IL1180) after treatment with homidium at 
1 mg k g 1 b.w.
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Fig. 6.5
Mean ± SD total serum globulin levels in Boran cattle (n = 5) 
following challenge at 30 day intervals with a drug-sensitive 
population of T. congolense (IL1180) after treatment with 
homidium at 1 mg k g 1 b.w.
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Cattle treated with homidium bromide and challenged at monthly 
intervals with a homidium-resistant trypanosome population 
Pre-challenge pharmacokinetics of homidium
The pre-challenge pharmacokinetics obtained from a non- 
compartmental analysis are shown in Table 6.4. The mean A U C ^  observed 
value was 1556±173 ng.h mb1. The M R T ^  observed values was 72.3+13.4 
hours. These pre-challenge pharmacokinetic parameters were found to be 
similar to the pre-challenge pharmacokinetic parameters obtained in Group HS 
cattle and in Boran cattle reported in Chapter 4 following i.m. treatment.
Serum homidium concentrations
Serum homidium concentration-versus-time plots for the individual 
animals in Group HR are given in Figs. 6 .6 (a) to 6 .6 (e). The mean peak serum 
concentration was 282.8+108.5 ng mb1 attained between 5 and 15 minutes 
following treatment. The serum homidium concentration-versus-time profile 
obtained during the first 30 days following treatment of Group HR cattle was 
similar to that observed in Group HS cattle during the same period. At the time 
of the first trypanosome challenge at 30 days post-treatment, the mean 
homidium concentration in serum was 0.20+0.05 ng mb1 (range 0.15 - 0.30). 
Fig. 6.7 shows the mean (+SD) serum homidium concentration-versus-time 
profile following challenge of homidium-treated Group HR cattle
Following the first trypanosome challenge at 30 days after homidium 
treatment o f the Group HR cattle, the challenge control was detected 
parasitaemic 8 days later. Trypanosomes were detected in four of five Group 
HR cattle after 9 days and in the remaining one animal 10 days following 
trypanosome inoculation. Thus, the pre-patent periods were only one or two 
days longer than the Group CC animal. The results showed that the serum 
homidium concentrations at the time of trypanosome inoculation were not 
protective against establishment of infection.
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Figs. 6.6(a) to 6.6(e)
Serum homidium concentrations in individual Boran cattle after 
treatment with homidium bromide at 1 mg k g 1 and challenged at 30 
day intervals ( t )  with a drug-resistant population of T. congolense 
(IL 3330)
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Fig. 6.7
Mean ± SD serum homidium concentrations in Boran cattle (n = 5) 
following challenge at 30 day intervals with a drug-resistant 
population of T. congolense (IL 3330) after treatment with 
homidium at 1 mg k g 1 b.w.
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No drug was detected in the circulation of all Group HR cattle 13 days 
following the first trypanosome challenge given at 30 days (approximately 43 
days following treatment; 6 days after trypanosomes were first detected in the 
peripheral blood). An acceleration in the drug disappearance rate in serum was 
observed during the 13 days (Fig. 6.7). The decline in serum homidium 
concentrations following establishment of infection was more rapid than that 
observed in cattle which did not become infected until the third or fourth 
trypanosome challenges. This accelerated rate of decline in drug concentration 
was, however, similar to that obtained in cattle infected with the resistant 
trypanosome population, reported in Chapter 5. Fig. 6.8  shows a comparison 
o f the mean ± SD serum homidium concentrations for cattle in Groups HS and 
HR following trypanosome challenge after homidium treatment.
Pathology and pathogenesis
As in the cattle challenged with the homidium-sensitive trypanosomes, 
there were no significant changes in the packed cell volume from the time of 
homidium treatment until the time of the first trypanosome challenge which 
was carried out 30 days later. But after the establishment of parasitaemia, there 
was a drop in the PCV from 35% to 20% within two weeks of challenge.
Out of the six animals challenged with the homidium-resistant 
trypanosome population (one control and five homidium treated), one died on 
day 85 following homidium treatment when the PCV was 16%, three were 
treated with diminazene at a dose rate of 14 mg kg-1 b.w. on day 86  following 
homidium treatment (56 days following trypanosome challenge) on the day 
they attained a PCV of 15%. The remaining two animals died on days 88 and 
92 respectively, one day after both attained a PCV of 15% and before 
diminazene could be given.
In the diminazene-treated animals, trypanosomes were cleared from 
peripheral blood of all the three animals within 24 hours. Thereafter, two
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Fig. 6.8
Mean ± SD serum homidium concentrations in Boran cattle (n = 5) 
following challenge at 30 day intervals ( t )  with either a drug- 
sensitive (IL 1180) or a drug-resistant (IL 3330) population of T. 
congolense after treatment with homidium bromide at 
1 mg kg-1 b.w.
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remained negative during a two-month follow-up period whereas one relapsed 
39 days after diminazene treatment.
The three animals which died from trypanosomiasis in Group HR were 
still in reasonable physical body condition although they had lost up to 2 1 % of 
body weight. On post-mortem, petechial haemorrhages of the kidneys, 
oesophagus, abomasum, small intestine, colon and the vascular system were 
observed. Lymph nodes were enlarged and haemorrhagic. The larynx, trachea, 
bronchi and lungs appeared frothy. The pericardium and peritoneal cavity 
were filled with straw-coloured fluid and the heart appeared flabby. 
Enlargement of the liver and the spleen were also observed.
Determination of the total protein levels in Group HR cattle showed 
that from a mean pre-infection value of 44.9±4.0 mg mb1, the values were 
37.0±5.9 and 39.7±8.2 mg mb1 after 60 and 90 days, respectively. These 
values were not significantly different from pre-infection values (Fig. 6.9). 
Sixty and 90 days post-treatment, the serum albumin levels were 21.3±0.3 and 
19.3±0.5 mg mb1, respectively, a significant drop from the mean infection 
value of27.8±0.3 mg mb1 (Fig. 6.10). There was however, a slight elevation in 
the total immunoglobulin levels from the pre-infection value of 17.1±1.5 mg 
mb1 to 20.4±1.8 mg mb1 within 90 days of treatment (Fig. 6.11).
DISCUSSION
Having demonstrated in the previous studies reported in this thesis 
(Chapters 4 and 5) that serum homidium concentrations o f between 0.1 and 
0.3 ng mb1 are detectable in circulation of non-infected cattle for periods of 
over 10 weeks, it was decided that studies be carried out to determine whether 
these low drug concentrations are protective against trypanosome infections. 
The results o f the present study in which cattle were challenged with either a 
drug-sensitive or a drug-resistant trypanosome population following homidium 
prophylactic treatment showed that the low serum homidium concentrations
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Fig. 6.9
Mean ± SD total serum protein levels in Boran cattle (n = 5) 
following challenge at 30 day intervals with a drug-resistant 
population of T. congolense (IL 3330) after treatment with 
homidium at 1 mg k g 1 b.w.
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Fig. 6.10
Mean ± SD serum albumin levels in Boran cattle (n = 5) following 
challenge at 30 day intervals with a drug-resistant population of T. 
congolense (IL3330) after treatment with homidium at 1 mg kg-1 
b.w.
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Fig. 6.11
Mean ± SD total serum globulin levels in Boran cattle (n = 5) 
following challenge at 30 day intervals with a drug-resistant 
population of T. congolense (IL3330) after treatment with 
homidium at 1 mg k g 1 b.w.
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were protective against challenge with a drug-sensitive trypanosome 
population for periods of over 90 days in four of five cattle in the group. 
Presence of anti-trypanosome antibodies was not demonstrated. However, 
prophylaxis against challenge by a drug-resistant trypanosome population was 
not achieved at 30 days post-treatment.
Following i.m. treatment of Group HS cattle with homidium, the drug 
decline was exponential with an initial rapid fall during the first 24 hours, 
followed by a slow phase of elimination of the drug. Pre-challenge 
pharmacokinetics were similar to those reported in Chapter 4 o f this thesis for 
non-infected Boran cattle. However, the results showed wide variations in 
MRT values between individual animals suggesting that the difference in the 
mean residence time of the drug in a group of animals given similar treatment 
could vary as much as two-fold.
At each trypanosome challenge of Group HS cattle carried out at 30 
day intervals after treatment, each of the challenged untreated controls were 
detected parasitaemic on day 8 following trypanosome inoculation showing 
that the trypanosomes were infective.
Following the 90 day trypanosome challenge of Group HS cattle, 
trypanosomes were first detected in animal No. 429, 120 days after homidium 
treatment and on the day it was due for the fourth challenge. The pre-patent 
period was 30 days. The remaining four animals in this group became 
parasitaemic following the fourth challenge carried out on day 120 after 
homidium treatment. The exact periods from homidium treatment to first 
detection of trypanosomes in the four animals were 134, 137, 143 and 144 
days with pre-patent periods o f 14, 17, 23 and 24 days. These periods were 
similar to those reported in the field using homidium bromide at dose rates of 
1.0 mg kg-1 b.w. (Unsworth, 1954b; Mwambu, 1971; Dolan et al, 1990).
The results of the present study showed that homidium's pre-challenge 
pharmacokinetics appeared to contribute to the length of the observed period
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between treatment and demonstration of parasites in the circulation in the 
Group HS cattle. Animal No. 429 in which trypanosomes were first detected 
on day 120 following treatment had an extrapolated MRT value of 
approximately 65 hours which was the lowest recorded in the group (Table
6.1). This low MRT value would suggest that the drug did not reside in the 
body for long periods of time and hence reduced period of protection 
compared to the other four animals in the group.
At the first trypanosome challenge of Group HS cattle carried out at 30 
days following homidium treatment, the group mean serum drug concentration 
in the animals was 0.22+0.05 ng m l1 which was effective against 
establishment of trypanosomes following challenge. Similarly, a mean 
concentration of 0.18±0.06 ng m l1 at the second challenge carried out at 60 
days following treatment, was significant to protect cattle against challenge by 
a drug-sensitive population of T. congolense. However, at this time, one 
animal (No. 434) had a drug concentration below the limit of detection of the 
assay but did not develop a trypanosome infection. At 90 days post-treatment, 
two animals (Nos. 429 and 434) showed drug concentrations below the limit 
of detection (0.1 ng ml-1), but when challenged one animal (No. 429) 
developed a trypanosome infection whereas the other (No. 434) did not. 
Interestingly, animal No. 434, in which homidium was undetectable at 60 days 
remained negative even after the third challenge at 90 days post treatment. 
These two animals showed marked variations in t ^  and MRT values. Whilst 
the peak serum homidium concentration in animal No. 429 appeared at 0.07 
hours, that of animal No. 434 occurred at 0.24 hours. The MRT values were 
approximately 65 and 72 hours in animal Nos. 429 and 434, respectively 
(Table 1) demonstrating differences in the mean average time drug molecules 
resided in the body. Although the drug was undetectable in the serum of 
animal No. 434 at 60 and at 90 days post-treatment, the drug levels appeared 
to be protective.
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From the present study, it has been established that the periods between 
homidium treatment and first detection of parasites in peripheral blood ranged 
between 120 and 144 days with pre-patent periods ranging from 14 to 30 days. 
However, at the time parasite infections were detected in Group HS catde, 
serum homidium concentrations in all five animals were undetectable and it 
was not possible to determine the minimum effective serum drug 
concentration. Animal No. 429 was fully protected from infection by the 
serum homidium concentration at day 60 challenge but not at day 90 
challenge, at which time the homidium concentration was below 0.1  ng m l1.
Akol and Murray (1982) demonstrated that appearance of 
trypanosomes in the peripheral blood and lymph nodes occur simultaneously. 
The high drug levels in the superficial lymph nodes as demonstrated in studies 
reported in Chapter 9 using 14C homidium could play some role in protecting 
the animals from infection especially in cases where circulating drug levels 
could not be demonstrated as in the present study.
No anti-trypanosome antibodies were detected in any of the serum 
samples collected from Group HS cattle immediately before challenge at 30,
60 and 90 days, suggesting that the prophylactic period observed was solely 
attributed to the presence of the drug and not the presence of anti-trypanosome 
antibodies. A similar observation was made by Whitelaw et al. (1986) in 
studies on isometamidium prophylaxis against T. congolense challenge in 
Boran cattle in which drug residues were demonstrated to effectively limit 
trypanosome multiplication; immune responses were not detectable in any of 
the animals under chemoprophylaxis. Peregrine et al. (1988) demonstrated that 
antibodies to metacyclic trypanosomes that were used to challenge the cattle 
did not appear in any of the animals under isometamidium prophylactic cover 
except in the animals challenged with 5x10s metacyclics. In the present study, 
low antigen levels not capable of producing a measurable antibody response 
could possibly have been due to the low inoculum used (1x 10s trypanosomes)
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and the presence of the drug which did not allow establishment and 
multiplication of trypanosomes.
Pre-challenge pharmacokinetics obtained in Group HR cattle were 
similar to those reported in the Group HS cattle (Table 6.1 and 6.5). 
Subsequent to the 30-day trypanosome challenge of Group HR catde (given 
homidium and challenged with the resistant trypanosome population), no 
protection was observed as all animals became parasitaemic. The parasitaemia 
pre-patent periods were one or two days longer than that observed in the 
untreated challenge control animal which was detected parasitaemic 8 days 
following trypanosome inoculation. It therefore appears that homidium 
concentrations of between 0.15 and 0.3 ng m l1 at the time of trypanosome 
inoculation could not inhibit trypanosomes from establishing and producing 
disease symptoms. These findings were not unexpected since this particular 
stabilate of trypanosomes has been demonstrated to be resistant to homidium 
bromide at the recommended therapeutic dose rate of 1 mg kg-1 b.w. as 
discussed in Chapter 5.
The results of the present study have demonstrated that the 
development of parasitaemia following challenge of homidium-treated animals 
with homidium-resistant trypanosomes markedly alters homidium's 
pharmacokinetics in cattle by enhancing elimination of the drug following 
establishment of the infection. Gilbert and Newton (1982) in their studies on 
homidium pharmacokinetics demonstrated that approximately 80% of the drug 
in the circulation at 1, 8 and 12 hours following treatment of calves with 14C 
homidium was bound to trypanosomes suggesting substantial drug uptake of 
homidium by trypanosomes immediately following treatment. This could 
partly explain the increased rate of drug disappearance from circulation in the 
presence of trypanosomes.
As discussed in Chapter 5 of this thesis, trypanosome infections in 
cattle and sheep have been associated with fever, accelerated rate of
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metabolism, fall in packed cell volume, haemodilution and decrease in serum 
albumin, among others (Katunguka-Rwakishaya et al., 1993). These changes 
may also have contributed to the accelerated rate of drug elimination in cattle 
with patent infections (Chapter 5).
Although several factors could be attributed to the variation in length of 
prophylactic period observed in the field, such as fly density (intensity of 
challenge), infection rates in flies and host susceptibility, the results obtained 
in this study have shown that serum homidium concentrations in individual 
animals and individual animal pre-challenge pharmacokinetics as well as the 
drug sensitivity of challenging trypanosome infections play an important role.
As already discussed in Chapter 5, in natural trypanosome populations 
there is considerable variation in drug sensitivity between individual 
trypanosome populations (Unsworth, 1954a; Peregrine, 1991). In the presence 
of drug-sensitive trypanosome population, the results of the present study 
suggest that animals would remain protected for long periods of time 
especially in the presence of low tsetse challenge. Protection of the animals 
was associated with the circulating homidium concentrations ranging between
0.1 and 0.3 ng m l1. Four out of the five Group HS cattle became parasitaemic 
when homidium concentrations had fallen below the assay limit of detection 
(0.1 ng m l1). However, these drug levels do not protect homidium-treated 
cattle against challenge by drug-resistant trypanosome populations.
Following the establishment of drug resistant trypanosome populations, 
the rate of drug disappearance was enhanced in a similar manner to the 
observations made in Chapter 5. This emphasises the urgent need for 
development of methods that can be used in identifying drug resistant 
trypanosomes, factors that contribute to development of drug resistance and 
ways of minimising its occurrence and spread in the field. Results of a field 
study investigating the use of homidium as a chemoprophylactic are reported 
in Chapter 7.
237
CHAPTER SEVEN
INVESTIGATION INTO THE EFFICACY OF 
HOMIDIUM BROMIDE IN THE CONTROL OF 
BOVINE TRYPANOSOMIASIS AT GALANA RANCH, 
COAST PROVINCE, KENYA
INTRODUCTION
Studies on homidium prophylaxis reported in Chapter Six demonstrated 
that homidium bromide administered at a dose rate of 1 mg kg*1 b.w. can offer 
protection to cattle against trypanosome challenge with homidium-sensitive 
trypanosomes for periods ranging from 120 to 144 days. After establishing this 
long period of protection in controlled studies in the laboratory, it was decided 
that a field study should be carried out to determine the efficacy of this drug 
under field conditions. Dolan et al. (1990) reported that homidium conferred 
periods of prophylaxis of over 18 weeks following treatment of cattle with 
homidium bromide at a dose rate of 1 mg k g 1 in work carried out on Galana 
ranch, Coastal Region, Kenya during 1989. However, later work also at 
Galana (Dolan et al., 1992) carried out in 1990 suggested resistance to 
phenathridine derivatives (isometamidium and homidium) and this work did 
not include monitoring of homidium concentrations. As a result, it was not 
possible to relate the periods of protection observed to the circulating drug 
levels. The development of homidium-detection ELIS As has now permitted 
such a study to be undertaken at Galana Ranch to investigate this relationship 
between the duration of protection and circulating drug levels in homidium- 
treated cattle.
STUDY OBJECTIVES
1. To determine the incidence of trypanosomiasis in the Dakabuku area of 
Galana Ranch, Coast Province, Kenya, and the effectiveness of homidium 
in controlling infections.
2. To measure and determine individual variations in serum homidium 
concentrations in cattle under prophylactic cover in the field.
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3. To investigate the relationship between homidium concentrations and the 
length of prophylactic cover in cattle exposed to natural tsetse challenge.
4. To look for evidence of drug resistance
MATERIALS AND METHODS 
Study area
The experiments were carried out at the Dakabuku area of Galana 
Ranch, Coastal Region, Kenya; an area of endemic trypanosomiasis. Tsetse 
challenge in this area has previously been reduced by the use of a 'pour-on' 
insecticide for two years before the present study.
Experimental animals
A herd of 160 Boran catde were selected for use in this study from a 
group of 350 animals which had been ear-tagged, branded, weighed and kept 
in an area of low tsetse challenge for nearly two months. A few days prior to 
treatment, the cattle were moved to Dakabuku but kept close to the dip tank, 
where the tsetse challenge was low, until after treatment.
Experimental design
The cattle were divided into two groups. Eighty were treated with 
homidium bromide on the day before being moved to an area of high natural 
tsetse challenge, whilst the remaining group of 80, which did not receive 
homidium, served as controls and grazed along with the homidium-treated 
animals. The experiment was planned to coincide with the beginning of the 
| rainy season when trypanosome challenge was expected to be high. The
| experiment was therefore carried out over the months of December/March
1994/95 which included one rainy season (mid-December/mid-January). Any 
cattle in either the control herd or the homidium-treated herd found to be
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infected with trypanosomes were treated with diminazene aceturate at 7 .0  mg 
kg-1 b.w.
Collection of pre-treatment blood samples
On the day before treatment, venous blood was collected into plain 
vacutainer tubes from all 160 cattle. These samples were allowed to clot, 
centrifuged to separate the sera, which was then frozen immediately and 
transported to the Kenya Trypanosomiasis Research Institute (KETRI) 
Laboratories for use as negative control sera in drug analysis.
Prophylactic drug treatment
A 2.5% (w/v) solution of homidium bromide (Ethidium®, Laprovet, 
France, Batch No. B18V2), prepared as already described in Chapter 2 
(General Materials and Methods) was given by deep intramuscular injection 
into the middle one third of the neck at a dose rate of 1 mg k g 1 b.w. This 
prophylactic treatment was administered only once, at the start of the 
experiment.
Collection of blood samples for drug analysis
Ten millilitre blood samples were collected weekly from animals in the 
homidium-treated group, following trypanocidal treatment and every four 
weeks in the control group, and sera prepared as described above for pre­
treatment sera. These samples were frozen and transported to KETRI 
laboratories for drug analysis.
Exposure of cattle to natural tsetse challenge
From the day following prophylactic treatment, all the 160 cattle (80 
homidium-treated and 80 controls) were driven daily into the tsetse infested 
bush around the Dakabuku dip tank.
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Parasitological examination
All animals were monitored for trypanosomes on the day before 
prophylactic treatment and at weekly intervals to the end of the observation 
period which lasted 14 weeks. Procedures followed in the detection of 
trypanosomes were as described in Chapter 2.
The incidence of trypanosome infections was determined weekly. In the 
control herd, the calculation was based on the number of animals exposed, 
excluding those that had been treated with diminazene the previous week. This 
was based on the assumption that the animals were still protected by the 
diminazene following treatment (diminazene offers protection against 
infection for a period of two weeks following treatment). And, if infected on 
day 14 the infection will not be detected by the third week. In the homidium- 
treated herd, all animals previously detected positive were excluded from the 
calculation of incidence of infection.
All the animals were weighed every month during the study period of 14 
weeks.
RESULTS 
Control herd
Incidence o f  infection
Fig. 7.1 shows the weekly incidence of trypanosome infections in the 
control herd which did not receive homidium treatment. During the 14 weeks 
in which the animals were examined, trypanosomes were detected in all the 
animals in the control herd. Most of the infections were recorded in the third 
and fourth weeks, which coincided with the period when the heavy rains were 
recorded. Any infections detected during this period were treated with 
diminazene aceturate. Within six weeks of treatment, 75 infections were
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Fig. 7.1
Weekly incidence of trypanosome infections in the control herd and
the homidium-treated herd following exposure to natural tsetse
challenge
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detected in the 80 animals. Within ten weeks a total of 101 infections were 
detected and all the animals in the group had been detected infected at least 
once. Out of the 101 infections detected, 55 were due to T. vivax and the 
remaining due to T. congolense. One of the T. vivax infections was of the 
'haemorrhagic type'; this animal died in spite of the diminazene treatment.
Packed cell volume
Fig. 7.2 shows the mean (±SD; n = 79) PCV values obtained over a 
period of 14 weeks. Individual animal values are shown in Appendix C. All 
animals which were detected positive with trypanosome infections were 
treated on the same day of trypanosome detection. The weekly PCV values 
calculated were based on the total number of animals in the group irrespective 
of whether they were infected or not. During the first week of the study 
period, a mean (±SD) PCV value of 27.6±2.3% was recorded. A slight 
increase in the mean PCV value was observed over the second and third weeks 
(Fig. 7.2). However, a significant drop was recorded during the fourth week 
(p < 0.01). Similarly, the mean PCV values recorded during the 8th and 12th 
weeks were also significantly lower than those obtained during the first week 
of the study (p < 0.001). PCV values as low as 14% were observed in some 
animals. Some animals showed consistently low PCV values over several 
weeks despite diminazene treatment. It was also observed that not all low PCV 
values were associated with detectable trypanosome infection and the 
contribution of concurrent infections to the low PC Vs was suspected. 
Approximately half of the PC Vs of 20% and below were associated with 
detectable trypanosome infections. The animal which died, possibly from the 
suspected haemorrhagic T. vivax had a PCV drop from 24 to 12 % within one 
week and died two days after trypanosomes were first detected in peripheral
i
I blood.
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Fig. 7.2
Mean (+SD; n = 79) weekly packed cell volume (%) in the control
herd and the homidium-treated herd following exposure to natural
tsetse challenge
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Body weight gain
Fig. 7.3 gives the four-weekly values for live weight (kg) in the 
untreated control herd. At the beginning of the experiment, the mean (± SD ; 
n = 80) body weight o f the untreated control animals was 179+15 kg. During 
the first four weeks, the mean live weight gain per animal was 12.6+6.9 kg. 
During this same period, weight loss was recorded in two animals whilst four 
animals maintained their original weights. The highest weight gain was 25 kg 
in five animals and 19 animals (including the five with weight gain of 25 kg) 
showed a weight gain of 20  kg and above.
During the second four-week period, the animals gained on average 
10.4 kg per animal. However, two animals showed a loss in weight; these were 
not the same animals which lost weight during the first four weeks. Five 
animals maintained the weight they had attained during the first four-week 
period. At the end of the second four-week period, this latter animal did not 
show any gain in weight from pre-treatment values and showed persistently 
low PCV values throughout the 14 weeks of observation. During this same 
period, weight gain of 20  kg and above per animal was observed in eight 
animals including one animal which showed a weight gain of 25 kg.
During the third four-week period following treatment (between weeks 
eight and twelve), the animals gained on average 4.6 kg. Nine animals showed 
a loss in weight whilst 14 maintained the weight gained during the second 
four-week period. The highest weight gain during this period was 15 kg per 
animal in three animals.
Overall, the mean (+SD; n = 79) body weight in the control animals at 
the end of the twelfth week was 207+19 kg compared with 179+15 kg 
recorded at the start o f the experiment. The results showed that low weight 
gains were associated with low PC Vs. However, low PC Vs were not always 
associated with trypanosome infections.
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Fig. 7.3
Mean (±SD; n = 79) four-weekly live weight (kg) in the control herd
and the homidium-treated herd following exposure to natural tsetse
challenge
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Incidence o f  infection
The weekly trypanosome incidence is shown in Fig. 7.1. The earliest 
trypanosome infections were detected three weeks following homidium 
treatment, when five animals were detected positive. Infections were also 
detected after five weeks (one animal), six weeks (one animal), eight weeks 
(three animals) and nine weeks (two animals). A total of 12 infections were 
therefore detected in the 14-week period. All infections, except one, were due 
to T. vivax. The only T. congolense infection detected was during the sixth 
week after drug administration.
The number of cattle protected in the homidium-treated group is shown 
in Table 7.1. A total of 75 out of the 80 animals were fully protected during 
the four weeks following treatment and which included the period of high 
trypanosome challenge which occurred during the third week. The results 
showed that the weekly percentage of animals remaining uninfected out o f the 
total exposed (excluding the previous breakthrough infections) ranged 
between 93.8 - 100%.
Packed cell volume
Fig. 7.2 shows the mean (±SD) PCV (%) observed during the 14 weeks 
of observation following treatment. There was an increase in the mean PCV 
value of 27.5±2.2% to 29.1±2.8% within the first four weeks of treatment. By 
the fifth week, a mean value of 27.3±2.4% was observed; thereafter the PCV 
remained close to this value until the twelfth week after which an increase was 
recorded (Fig. 7.2).
Almost all the low PCV < 20% were associated with trypanosome 
infections. The PC Vs of all but one of the twelve animals in which infections 
were detected were elevated after treatment with diminazene aceturate (Table
7.2). However, four of the 12 animals in which trypanosome infections were
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Table 7.1
Number of cattle in which new trypanosome infections were detected at 
Galana Ranch each week in animals given homidium bromide at 1 mg k g 1 
b.w. and in animals not given homidium.
Time post-treatment
(weeks) +ve
controls
infected/exposed +ve
homidium herd
infected/exposed
1 3 3/80 (3.75%) 0 0/80 (0%)
2 7 7/77 (9.09%) 0 0/80 (0%)
3 23 23/73 (31.51%) 5 5/80 (6.25%)
4 23 23/57 (40.35%) 0 0/75 (0%)
5 10 10/57 (17.54%) 1 1/75 (1.33%)
6 9 9/70 (12.85%) 1 1/74(1.35%)
7 5 5/71 (7.04%) 0 0/73 (0%)
8 14 14/75 (18.67%) 3 3/73 (4.11%)
9 4 4/66 (6.06%) 2 2/70 (2.86%)
10 3 3/76 (3.95%) 0 0/68 (0%)
11 0 0/77 (0%) 0 0/68 (0%)
12 0 0/79 (0%) 0 0/68 (0%)
13 0 0/79 (0%) 0 0/68 (0%)
14 0 0/79 (%) 0 0/68 (0%)
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detected (Table 2, Animal Nos. 182, 186, 187 and 249) maintained low PCV 
values even after diminazene treatment. One of these three animals had 
persistently low PCVs of 23% or below (Animal No. 249) before trypanosome 
infections were detected in the peripheral blood. Table 7.2 shows individual 
PCV values in homidium-treated cattle in which infections were detected.
Weight gain
Fig. 7.3 shows the mean (±SD) body weight (kg) o f homidium-treated 
cattle measured at four-weekly intervals over the 12 weeks following 
homidium treatment. The mean (±SD;) live weight (kg) of the homidium- 
treated cattle at the beginning of the experiment was 180±13 kg. During the 
first four-week period, the average live weight gain was 18.18 kg per animal. 
One animal showed a loss in weight. A trypanosome breakthrough infection 
was detected in this animal during the fourth week. The highest weight gains 
recorded were 30 kg in two animals. The number of animals with a weight 
gain of 20 kg and above was 48.
During the second four-week period, the animals gained on average 
13.61 kg. Two animals showed a loss in live weight. Breakthrough 
trypanosome infections were detected in both these animals; one in the sixth, 
the other in the ninth week following treatment. Two animals maintained 
weights measured after the first four weeks. These two animals developed 
breakthrough trypanosome infections during the fifth and eighth weeks 
following treatment. The highest weight gains observed were 20 kg, in 16 
animals.
Between the eighth and the 12th weeks, the cattle gained on average 
5.51 kg. Three animals showed a weight loss and 11 maintained the weight 
attained at the end of the second four week period following treatment. The 
highest weight gains recorded were 15 kg, in two animals.
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Overall, the mean (±SD; n = 79) live weight of the homidium-treated 
cattle at the end of week 12 was 217±17 kg, an increase of 37 kg over the 
mean pre-treatment value.
Comparisons between homidium-treated and untreated control groups
Incidence o f  infection
Fig. 7.1 shows the weekly incidence of infection in the homidium-treated and 
the control and herds. Similarly, Table 7.1 shows the number o f trypanosome 
infections detected in the homidium-treated and in the control herds over a 
period of 14 weeks. During the first six weeks, when 75 infections were 
recorded in the control herd, only seven infections were recorded in the 
homidium-treated animals. A total of 12 infections were detected in the 
homidium-treated animals in the 14-week period compared to 101 detected in 
the control herd. Whilst no new trypanosome infections were recorded after 10 
weeks until the end of the observation period of 14 weeks in the homidium- 
treated group, only one infection was detected in the untreated control herd.
In the control herd the infections recorded were due equally to both T. 
congolense and T. vivax, but in the homidium-treated herd only one of the 12 
breakthrough infections was due to T. congolense (46) and all the remainder 
were due to T vivax (55). In each group of cattle, one T. vivax infection 
resulted in a haemorrhagic syndrome condition.
Packed cell volume
Fig. 7.2 shows the mean (±SD) weekly PCV (%) of the homidium- 
treated and the untreated control groups following exposure to natural tsetse 
challenge. From the fourth week of the study period, the PCVs of the 
homidium-treated cattle were significantly higher than those of the untreated 
controls (p < 0.001). In the cattle under homidium prophylactic cover, PCV 
values of 2 0 % and below were nearly always associated with trypanosome
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infections. These low PCV values increased in all except four animals 
following treatment with diminazene aceturate. However, in the untreated 
control herd, animals with PCV of 20% and below were not always 
trypanosome infected. In the two cases of haemorrhagic T. vivax, the PCV 
drop was marked irrespective of whether the animal was under prophylactic 
treatment or not. These animals died within a day or two after detection of 
trypanosomes in circulation despite therapeutic intervention with diminazene 
aceturate.
Weight gain
Fig. 7.3 shows a comparison of the mean (±SD) four-weekly live 
weight between the untreated controls and the homidium-treated cattle. There 
were no significant differences in the mean (±SD; n = 80) live weight between 
the controls and the homidium-treated cattle at the start of the experiment. 
Thereafter, homidium-treated cattle showed a significant increase in live 
weight over the 12-week period (Table 7.3). The animals in the control herd 
required 101 diminazene doses over a 14-week period whilst the homidium 
herd received only one homidium treatment and 12 doses of diminazene over 
the same period. Although both groups showed an increase in live weight 
which was associated with the rainy period, the increase recorded in the 
homidium-treated group was significantly higher than that of the controls over 
the same period.
Serum homidium concentrations
Determination of serum homidium concentrations in individual animal 
pre-treatment sera showed that six out of 80 animals showed homidium 
concentrations above 0.1  ng m l1 (assay detection limit) whilst the remaining 
animals were below this value. Fig. 7.4 shows the mean ± SD (n = 79) serum 
homidium concentration-versus-time plot.
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Table 7.3
A comparison of the mean (±SD) four-weekly live weights (kg) between the 
untreated controls and homidium-treated cattle following exposure to natural 
tsetse challenge
Time post- Untreated controls Homidium-treated Significance
treatment (weeks)_________________________________________________
0 179±15 180±13
4** 192±18 198±14 *
g*** 202±19 212±15 **
207±19 217±17 **
** p = 0 .01
* * * p <  0.001
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Fig. 7.4
Mean ± SD (n = 79) serum homidium concentrations in cattle 
treated with homidium bromide at 1 mg kg"l b.w. and exposed to 
natural trypanosomiasis challenge
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Weeks post-treatment
Ten days following homidium treatment, the mean serum homidium 
concentration was 0.52±0.02 ng m l1. At 10 days following treatment, only one 
animal had a concentration below the limit of detection. This particular animal 
did not become infected at all during the observation period of 14 weeks.
Three weeks following homidium treatment when the highest number of 
breakthrough infections was recorded, the mean serum homidium 
concentration was 0.36±0.02 ng m l1 (Table 7.4). The animals in which 
trypanosomes were detected had serum homidium levels of 0.12, 0.14, 0.27,
0.35, 0.40 and 0.57 ng m l1 at the time of parasite detection. One animal which 
was found to be infected at week 5 after homidium treatment had a serum drug 
concentration of 0.12 ng m l1. By week 6 following treatment, the group mean 
(n = 80) serum drug level was 0.25±0.02 ng m l1 but 15 animals had drug 
levels below the assay detection limit. Ten weeks after homidium treatment 
two more animals became infected; these were among the 15 in which the 
drug could no longer be detected by week 6 .
DISCUSSION
The results of the present study carried out on Galana Ranch, Coastal 
Region, Kenya, demonstrated that homidium treatment conferred significant 
prophylactic cover against trypanosome infections in an area of high tsetse 
challenge. During a 14-week period, 101 trypanosome infections were 
detected in 80 cattle which did not receive homidium whilst in a similar 
number of cattle which received homidium at 1 mg k g 1 b.w. only 12 
trypanosome infections were detected over the same period. Homidium 
prophylaxis was also associated with higher weight gains and haematocrit 
values.
The present study also demonstrated that serum homidium 
concentrations could be monitored successfully in blood samples of individual 
ranch cattle for at least six weeks following treatment using ELISA.
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Table 7.4
Time at which breakthrough trypanosome infections were detected and the 
serum concentrations of individual cattle following prophylactic treatment 
with homidium bromide at a dose rate of 1 mg k g 1 b.w. and exposed to natural 
tsetse challenge at Galana Ranch
Animal No. Time post-treatment 
(weeks)*
Homidium concentration 
(ng mb1)
176 3 0.14**
2 2 0 3 0.57
234 3 0.40
241 3 0.27
259 3 0.35
179 5 0 .12***
* Time (weeks) after treatment when trypanosomes were detected in individual cattle
** The mean (±SD) serum homidium concentration in the treated cattle at three 
weeks post-treatment was 0.36±0.02 ng mb1
*** The mean (±SD) serum homidium concentration in the treated cattle at five 
weeks post-treatment was 0.25±0.02 ng mb1
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The weekly incidence of trypanosome infections in the homidium- 
treated and the untreated control cattle showed that infections were lower in 
the homidium-treated herd over the study period of 14 weeks. By six weeks 
following homidium prophylactic treatment, a total of seven infections were 
detected in the homidium-treated cattle compared to 75 detected in the control 
herd. This showed that although the challenge was high, 73 out of 80 
homidium-treated animals did not develop trypanosome infections during that 
period.
Similar numbers o f infections due to both T. vivax (55) and T. 
congolense (46) were recorded in the control group. However, only one animal 
in the homidium-treated group developed a T. congolense infection and the 
remaining 11 infections were with T. vivax. This finding suggests that the 
sensitivity of the T. congolense populations to homidium was higher than that 
of the T. vivax populations. Similar observations were made by Dolan et al. 
(1992) who showed that most of the infections detected in the homidium- 
treated herd on Galana Ranch were T. vivax where the prevalence of both T. 
vivax and T. congolense were similar.
The mean weekly PCV values obtained in the homidium-treated cattle 
were significantly higher (p < 0 .0 0 1 ) than those obtained in the control herd 
from week four onwards. The low PCV values observed in individual 
homidium-treated animals were nearly always associated with trypanosome 
infections. In contrast, the low PCV values of 20% and below in the control 
herd were not always associated with detectable trypanosome infections. The 
persistently low PCV values in cattle in the control herd in the absence of 
detectable trypanosome infection could have been as a result of undiagnosed 
trypanosome or concurrent infections. In the two cases of haemorrhagic T. 
vivax (one in each group of cattle) a dramatic drop in PCV was observed and 
this was not prevented by diminazene treatment.
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Both groups of animals showed an increase in body weight over the 12- 
week experimental period. The highest live weight gain was recorded during 
the fourth week in both groups; this was during the rainy season and at the 
time when the incidence of infection was highest. The lowest live weight gain 
was recorded between the 8th and the 12th weeks in both groups; this was at 
the end of the rainy season at a time when the incidence of infection was very 
low. The increase in body weight recorded in the homidium-treated herd was 
significantly higher than that recorded in the controls (p < 0.01; Table 7.3). 
This was despite diminazene treatments given to all positive cases.
Homidium concentrations in serum could be monitored in individual 
animals for at least six weeks following treatment. However, it was not easy to 
determine the minimum protective concentration from the present study. The 
results appear to suggest that even in the presence of extremely low 
concentrations in serum (below 0.1 ng mb1) protection was achieved in some 
cattle. The observation that six weeks following treatment fifteen of the treated 
animals had serum homidium concentrations below the detection limit and yet 
did not become infected throughout the rest of the 14-week observation period 
is consistent with the above suggestion that serum drug levels below 0.1 ng 
m l1 may still be protective. A similar observation was made in Chapter 6 in 
which one animal had drug levels below 0.1 ng m l1 at 60 days following 
treatment but did not become infected when challenged at either day 60 or day 
90 following drug administration.
In the present study however, infections developed in some animals 
which had drug concentrations between 0.12 and 0.57 ng mb1 serum on the 
day they were detected positive. The trypanosome populations of T. vivax 
causing these breakthrough infections were therefore apparently less sensitive 
to homidium than the T congolense population.
Some factors identified from the present study which may contribute to 
the length of the prophylactic period were (a) rainy period associated with
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high incidence of infection possibly due to increase in tsetse challenge 
(information on tsetse populations was however, not included) (b) the nature 
of the trypanosome populations and their sensitivity to homidium; infections 
recorded in the control herd were equally due to both T. vivax and T. 
congolense but breakthrough infections in the homidium-treated herd were 
mostly T. vivax showing variations in the drug sensitivity (c) individual animal 
pharmacokinetics.
The use of homidium as a chemoprophylactic has had its problems, one 
of which has been the development of drug resistance, observed as early as 
1966 (Jones-Davies and Folkers, 1966). In Kenya, failure of 
chemoprophylaxis has been reported with both homidium bromide and 
isometamidium chloride (Dolan et al., 1992; Munstermann et al., 1992;
Maloo, 1993; Stevenson et al., 1995). In a similar study to that described by 
Dolan et al. (1990), Dolan et al. (1992) reported failure of prophylaxis on the 
Galana Ranch, Kenya, associated with both homidium and isometamidium 
administered at 1 mg k g 1 b.w. The study lasted 12 months, during which the 
trypanosome challenge was found to be exceptionally high; a total of 178 
infections were detected in 90 animals in the control herd, 81% of which were 
T. vivax and the remainder T. congolense. Eight prophylactic treatments were 
given to each of the homidium and isometamidium herds over a period of 6-7 
months.
The period of protection obtained in the present study ranged from 
three weeks to over 14 weeks in the same region on the Kenyan Coast where 
the studies reported by Dolan et al. (1990,1992) were carried out. Findings 
from the present study that the animals which had breakthrough infections had 
different serum homidium concentrations would suggest the presence of 
trypanosome populations which varied in their sensitivity to homidium on the 
Galana Ranch. Failure of chemoprophylaxis in some animals could have been 
to be due to infection with drug-resistant trypanosomes.
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The observation made by Dolan et al. (1992) on the Galana ranch that 
breakthrough trypanosome infections were mainly due to T. vivax was similar 
to the findings in the present study and occurred despite the similar incidence 
of T. vivax and T. congolense in the control herd. This would support the 
suggestion that the level of sensitivity to homidium in T. congolense 
populations at Galana is higher than that in T. vivax and higher levels of the 
drug may be needed to protect animals in this area against T. vivax.
The study of Stevenson et al. (1995) at Nguruman, Kenya, covering the 
period February 1990 to February 1991 which included a period of high 
incidence of infections (March to July) showed 215 infections (59% T. vivax, 
27% T. congolense, 4% T. brucei and 10% mixed species) in the control herd 
of 30 animals. During the year, 25% of the animals in the control herd either 
died or were removed from the experiment because they were too weak 
suggesting failure of diminazene to provide effective control at 7 mg k g 1 b.w.
However, in the homidium-treated herd in the Nguruman studies, 
eleven homidium treatments (1 mg k g 1 b.w.) were required for a similar 
number of animals over the same period. Thirty eight new infections were 
detected in the homidium-treated herd over the year of which 60% were T. 
congolense. There was evidence of drug resistance in the T. congolense 
populations at Nguruman. These results were in contrast to the findings at the 
Galana Ranch both in the study by Dolan et al. (1992) and in the present 
study.
In the Dakabuku area of Galana Ranch, it could be concluded that 
homidium is an effective chemoprophylactic drug, a three to four monthly 
cover being appropriate during a period of low trypanosome challenge since 
significantly higher PC Vs and weight gains were recorded compared to the 
controls. The low incidence of infections observed in the homidium-treated 
herd compared to the untreated controls suggested that most trypanosome
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populations were drug-sensitive. However, detection of 12 infections in the 
homidium-treated cattle showing serum homidium concentrations that would 
have been effective in the presence homidium-sensitive trypanosomes suggests 
the presence of drug resistance. This drug resistance was however, not 
widespread.
The results of the present study showed that the ELISA method can be 
used effectively to determine serum homidium concentrations in individual 
ranch cattle. Although the homidium concentrations were determined for a 
period of only six weeks in the present study, the drug profile obtained was 
similar to that reported in Chapter 6 following challenge of homidium-treated 
cattle with a drug-sensitive trypanosome population. The results also showed 
that some of the animals were still protected even when the drug levels were 
below the limit of detection. Breakthrough trypanosome infections occurred in 
animals which still had detectable levels of homidium at concentrations which 
would be protective against drug-sensitive trypanosome populations (Chapter 
6 ) and suggests the presence of drug resistance. Anti-trypanosomal antibodies 
were not determined in the present study. However, in the study reported in 
Chapter 6  it was demonstrated that immunological responses were not 
responsible for the observed variations in the prophylactic period. Further 
studies are therefore needed to investigate the contribution, if any, of anti- 
trypanosome antibodies to the observed period of prophylaxis in the field. 
Similarly, further studies are also needed to investigate the development and 
spread of drug resistance and the relationships between serum drug 
concentrations, drug resistance and immunity to trypanosome infections in 
field situations. The homidium ELISA makes these studies possible.
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CHAPTER EIGHT
PHARMACOKINETICS AND TISSUE RESIDUES OF 
i4C HOMIDIUM IN NON-INFECTED AND 
TRYPANOSOMA CONGOLENSE-INFECTED BORAN
CATTLE
INTRODUCTION
Since its introduction into the field in 1952, homidium, a 
phenanthridinium compound has been widely used in the treatment of 
infections due to Trypanosoma vivax and Trypanosoma congolense in cattle, 
sheep and goats (Watkins and Woolfe, 1952). Mass treatment which followed 
its introduction (Wilson, 1960) was associated with the development of 
resistance in some countries.
Despite its continued widespread use and increasing reports of drug 
resistance, there is deficiency in the knowledge of the pharmacokinetic 
behaviour of the drug. The first report on homidium pharmacokinetics was by 
Gilbert and Newton (1982) who carried out studies using 14C homidium in 
rabbits and calves given the drug by intramuscular injection. Details of the 
pharmacokinetic behaviour of homidium were, however, not given. Elsewhere, 
it was found that 50-55% of the drug given intraperitoneally at a dose rate of 
15 mg k g 1 to mice was recovered in bile 16-18 hours later, most of it being 
monoacetyl-amino conjugates (MacGregor and Clarkson, 1971).
The present study examines in more detail the absorption, distribution and 
elimination characteristics of homidium in non-infected cattle treated either 
intramuscularly (ijn.) or intravenously (i.v.) with 14C homidium chloride at a 
dose rate of 1 mg k g 1. Results obtained using both the radiometric and ELISA 
methods in two of the animals have been included.
STUDY OBJECTIVES
1. To treat non-infected catde with 14C homidium by either intravenous 
(i.v.) or intramuscular (i.m.) injection and to determine the levels of 
radioactive drug in plasma and in tissues.
2. To treat T. congolense infected cattle with 14C homidium by 
intramuscular (i.m.) injection and determine the levels of radioactive
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drug in plasma/serum and in tissues at the end of the study period
3. To determine 14C homidium pharmacokinetics and tissues distribution.
4. To compare pharmacokinetics between i.v.-treated and i.m.-treated 
cattle, inorder to determine absorption characteristics.
5. To compare serum homidium concentrations and pharmacokinetics 
between non-infected and infected cattle following i.m. treatment
6 . To compare serum homidium concentrations and pharmacokinetic 
parameters with those obtained using the enzyme-linked 
immunosorbent assay (ELISA) in non-infected cattle reported in 
Chapters 4 following i.v. treatment.
7. To compare serum homidium concentrations and pharmacokinetic 
parameters obtained through the use of 14C-homidium with those 
obtained using ELISA in non-infected and infected cattle reported in 
Chapters 4 and 5 following i.m. treatment.
MATERIALS AND METHODS 
Experimental cattle
Eight healthy male Boran castrates weighing between 150 and 200 kg were 
obtained from a trypanosome free area and housed in a fly proof bam for three 
weeks to acclimatise to laboratory conditions before the start o f experiments. 
Their management before and during the experiments was as described in 
Chapter 2. After the three weeks of acclimatisation, the animals were placed 
individually in metabolic cages.
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Infection of cattle
A drug-sensitive population of Trypanosoma congolense IL 1180 
(Sones et al., 1988; Peregrine et al., 1991) was used. An inoculum of lxlO6 
trypanosomes prepared as described in Chapter 2 from a heavily infected 
mouse was given by intravenous injection into the jugular vein.
Haematological examination
The procedures followed for the determination of packed cell volume 
(PCV) were as described in Chapter 2.
Parasitological examination
Ear-vein blood was examined for the presence of trypanosomes 
following infection of the animals using the procedures described in 
Chapter 2.
Radiolabelled homidium, dosage and administration
The drug compound used for treatment was 6 -14C homidium chloride 
ethanolate of specific activity 69.13 jLtCi m g 1. A 2%w/v solution was freshly 
prepared in sterile water immediately prior to use. The drug was administered 
as a single bolus at 1 mg k g 1 body weight by either the intravenous (i.v.) or 
intramuscular (i.m.) route deep into the neck muscles. Infected cattle were 
treated when they attained a PCV value of between 20 and 25%. The radio 
labelled drug was supplied by May and Baker, Dagenham, U.K through the 
International Atomic Energy Agency.
Experimental design
The cattle were divided into three groups. One group of three 
uninfected cattle were treated with 14C homidium by i.v. injection and another 
group of three by i.m. injection. The remaining two animals were treated by
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intramuscular injection after trypanosome infection. The infected cattle were 
treated on the day after attaining a PCV value of 25%. Following drug 
administration, levels of radioactivity were measured in plasma, serum, urine, 
faeces and tissues obtained at the end of the experimental period which ranged 
between 14 and 36 days.
Sample collection
Pre-treatment plasma/serum samples
Immediately prior to treatment, 10 ml samples of blood were collected 
by venipuncture into EDTA-coated vacutainers (Becton, Dickinson, Coventry, 
UK) from all the animals. Plasma was separated by centrifuging the blood at 
1200 g for 30 minutes and stored at -20°C until required. In animals in which 
serum and blood samples were required besides the plasma, 15 ml blood 
samples were collected instead of 10 ml; 5 ml of the blood was stored in 
EDTA-coated vacutainer tubes, 5 ml was used in the preparation of serum 
using the procedures described in Chapter 3 and the remaining 5 ml were used 
to prepare plasma.
Plasma/serum samples for radioactive drug analysis
Ten millilitre blood samples were collected as described above from all 
the three animals following i.v. treatment. The blood samples were collected 
at the following intervals: 5, 10, 15, 30, and 45 minutes, 1, 2, 4, 6 , 8 , 12 and 24 
hours, thereafter daily for 14 days and three times a week to the end of the 
experimental period which varied between 14 and 36 days. Similarly, blood 
samples were collected from cattle following i.m. drug administration but 
omitting the 5 and 10 minute sample collections. Plasma/serum was prepared 
and stored at -20°C until required.
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Serum samples for ELISA
Ten millilitre blood samples were collected as described above from 
animal No. 368 following i.v-treatment and animal No. 369 following i.m. 
treatment at the following intervals: 5, 10, 15, 30, and 45 minutes, 1, 2, 4, 6 ,
8 , 12 and 24 hours, thereafter daily for 14 days and three times a week to the 
end of the experimental period of 30 days. Serum was prepared as described in 
Chapter 2, aliquoted and stored at -20°C until required.
Faecal and urine samples for drug analysis
Twenty-four hour urine samples were collected in a receiver via a funnel 
fixed to the preputium of the animal. The volume was measured, samples 
aliquoted. One set of aliqouted samples was stored at -20°C until required 
whilst the radioactivity was measured within 24 hours of collection in the 
remaining aliquots. Similarly, 24-hour faecal samples were collected onto a 
rubber mat placed on the floor of the metabolic cage. Samples were 
thoroughly mixed through a sieve of 10 mm wire mesh and aliquoted, some of 
which was stored at -20°C whilst radioactivity was determined in the 
remainder within 24 hours of sample collection.
Tissue samples fo r drug analysis
Tissue samples were collected after the animals were killed at the end of the 
observation periods which were 14 and 21 days for the animals treated by the
i.v. route and 14 and 28 days for the animals treated by the i.m. route. The 
tissue samples for immediate analysis were homogenised using an Ultra 
Turrax Homogeniser and aliquoted. The remaining un-homogenised samples 
were aliquoted (200 g aliquots) and stored at -20°C
Sample preparation and determination of radioactivity
Radioactivity was measured in a beta-counter (Tri-carb® 4000 Series
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Liquid Scintillation Systems, Model 4530, Packard Instruments Co., Inc., 
U.S.A.). To one millilitre plasma/serum or urine was added 10 ml scintillation 
cocktail (Insta-Gel®, Packard Instruments Co., Inc., Meriden, U.S.A.) and 
radioactivity determined. Highly coloured samples were decolourised using 
hydrogen peroxide as described below. Blood samples were solubilised using 
the procedure described below for faecal samples. To 200 mg accurately 
weighed mixed faeces or tissue were added 1 ml Soluene®-350 (Packard 
Instruments Co., Inc., Meriden, U.S.A.), 0.5 ml isopropanol and the resulting 
mixture was incubated at 56°C overnight or until solubilisation was achieved. 
This was followed by the addition of 0.5 ml hydrogen peroxide for 
decolorisation. After the addition of the peroxide, samples were incubated for 
a further 20  minutes with the scintillation vial cap removed to expel all 
residual peroxide. Due to the high alkalinity of the Soluene®, one millilitre of 
2M hydrochloric acid was then added to the mixture to neutralise the sample 
followed by 10 ml of the scintillation cocktail. Alternately, 200 mg sample of 
the mixed faeces were weighed into combustion boats, dried at 56°C for 2 
hours and then combusted in a biological oxidiser (Biological Material 
Oxidiser OX-400, R.J. Instrument Corporation). Labelled carbon dioxide was 
collected in 15 ml 14Carbon cocktail (OX-161, R.J. Harvey Instrument 
Corporation) and activity determined. Blank determinations were carried out 
using plasma/serum obtained prior to homidium treatment. Quench corrections 
were by the external standard source in-built in the counter. The radioactivity 
measured was expressed as disintegrations per minute (dpm).
ELISA method
Homidium ELISA method (Assay 2) described in Chapter 3 was used to 
determine homidium concentrations in the serum samples of two animals 
collected following either i.v. (animal No. 368) or i.m. (animal No. 369) 
injection.
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Data analysis
During radioactivity determination, samples with low radioactivity were 
counted for at least 30 minutes until low coefficients of variation (CVs) as 
computed by the counter between the counts were attained. The cut-off point 
for acceptable CVs was 5%. The limit of detection was taken as four times the 
background count. Homidium concentration was calculated using the 
expression:
dpm sample/dpm std x dilution factor 
obtained by repeatedly analysing diluted 14C homidium (labelled:unlabelled) 
containing 1 ng undiluted 14C homidium (= 170 dpm)
All concentrations have been expressed in nanograms per ml or per 
gram sample (Mean ± SD) calculated from the radioactivity measured. This 
did not take into account the metabolic state of the drug
Handling of the ELISA data was as described in Chapters 3 and 4.
Statistical evaluation
Comparisons of pharmacokinetic parameters between the various 
treatment groups and the various methods was carried out using the student's t- 
test at both 95 and 99% confidence limits.
Pharmacokinetic evaluation
Compartmental pharmacokinetic analysis was carried out on 
experimental data from the i.v.-treated cattle. The plasma/serum concentration 
versus time data following i.v. drug administration were fitted by 
monoexponential, biexponential and triexponential disposition functions by 
using a curve stripping procedure followed by a weighted non-linear least 
squares regression. Akaike's Information Criterion (AIC) described by 
Yamaoka et al. (1978) was used to compare the adequacy of monoexponential
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versus multiexponential models. Both the i.v. and the i.m. experimental data 
were similarly analysed using a non-compartmental model from which the 
total area extrapolated to infinity was estimated. The area under the curve 
(AUC) and the area under the moment curve (AUMC) were determined using 
the trapezoidal rule from the concentration versus time plots. The formulae for 
the various pharmacokinetic parameters were as described by Gibaldi and 
Perrier (1982). These have been more fully covered in Chapter 4.
RESULTS
Non-infected Boran cattle treated with 14C homidium by the
intravenous route 
Serum homidium concentrations
Plots of the plasma/serum homidium concentration versus time are shown in 
Figs. 8.1(a) to 8.1(c). The results show a rapid exponential decline in the 
plasma drug concentrations within the first 24 hours followed by slow 
elimination phase. A mean (± SD) plasma homidium concentration versus time 
plot is shown in Fig 8.2. Five minutes following treatment, the mean plasma 
concentration was 499.6±97.9 ng m l1. Concentrations of 226.4±22.3, 
100.3±8.0 and 23.5±1.4 ng m l1, were obtained within 15 minutes, one hour 
and one day, respectively. The drug profiles obtained in animal No. 368 on 
homidium concentrations in plasma, serum and blood are shown in Fig. 8.3. 
Concentrations of approximately 5 ng m l1 were detectable three weeks 
following treatment.
Compartmental, pharmacokinetic analysis
The plasma/serum concentration versus time profile best fitted a three- 
compartment open model. The pharmacokinetic parameters are shown in 
Table 8.1. Half-lives of 0.06±0.01,4.14±0.49 and 177.1±5.3 hours for the 
distribution, post-distribution and elimination phases, respectively were
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Fig. 8.1(a) to 8.1(c)
Serum homidium concentrations in individual Boran cattle 
following intravenous treatment with 14C homidium at a dose rate 
of 1 mg kg-1 b.w.
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Fig. 8.2
Mean ± SD (n = 3) serum homidium concentrations in non-infected 
Boran cattle following intravenous treatment with 14C homidium at 
a dose rate of 1 mg kg-1 b.w.
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Fig. 8.3
Homidium concentrations in serum, plasma and blood following 
intravenous treatment of animal No. 368 with 14C homidium at a 
dose rate of 1 mg kg-1 b.w.
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Table 8.1
Pharmacokinetic parameters of homidium in non-infected Boran cattle after 
intravenous drug administration of 14C homidium chloride at 1 mg kg-1 body 
weight. Compartmental analysis
Parameter Animal 
No. 214
Animal 
No. 215
Animal 
No. 368
Mean ± SD
A (ng mW) 1496 832 1545 1291±325
B (ng mh1) 98.5 91.8 160.5 116.9±30.9
C (ng ml-1) 20.09 18.11 22.63 20.28±1.85
a 13.86 12.64 11.05 12.52+1.15
p 0.15 0.17 0.19 0.17±0.02
y 0.004 0.004 0.004 0.004+0
t'/ia (h) 0.05 0.05 0.06 0.06+0.01
tViP(h) 4.76 4.10 3.57 4.14+0.49
t'/2y(h) 171.5 184.1 175.7 177.1+5.3
Cp(0) (ng ml-1) 1617 942 1728 1426+348
Vc (1 kg'*) 0.62 1.06 0.58 0.75+0.22
AUCo-iast (pg.h ml-1) 5.75 5.42 6.70 5.96+0.54
AUMC0.last pg.h ml-1) 1232.1 1281.1 1458.5 1323.9+97.2
Vd „ ( 1  kg-1) 37.3 43.6 32.5 37.8+4.6
Clb (ml h-> kg-1 173.9 184.5 147.9 168.8+15.4
k ,2 (h'1) 11.32 10.03 8.44 9.93+1.18
k2i (h-1) 1.13 1.60 1.33 1.35+0.19
kj, (h-1) 0.026 0.029 0.025 0.026+0.002
k | 3 (h-1) 1.26 0.98 1.21 1.15+0.12
M RT(h) 214.4 236.4 217.6 222.8+9.7
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obtained. The plasma/serum concentration at time 0 (CpO) was 1426±348 ng 
m l1 and the volume of the central compartment (Vc) 0.75±0.221 k g 1. The 
calculated rate constants k12 and k21 were 9.93±1.18 and 1.35±0.19 per hour, 
respectively. The k13 and the k31 values were 1.15±0.12 and 0.026±0.002 per 
hour, respectively. The mean value for the volume of distribution was 
37.8±4.61 k g 1. The value obtained for the observed area under the curve AUC 
after i.v. treatment was 5.96±0.54 (ig.h m l1. The value for the mean residence 
time was 222.8±9.7 hours.
Non-compartmental pharmacokinetic analysis following Lv. 
treatment
Table 8.2 gives the pharmacokinetic parameters of the non-compartmental 
model fitting of the i.v data. The mean value obtained for AUCq.^ observed
was 5.39±0.71 pg.h m l1 and the A U M C ^ was 859.66±145.13 jig.h2 m l1. 
Using these values, the mean residence time was calculated as 158.9±6.7 
hours. The AUC values obtained using both compartmental and non- 
compartmental pharmacokinetic models were similar but marked variations 
were observed in the MRT values.
Non-infected cattle treated with 14C homidium by the 
intramuscular route 
Serum homidium concentrations
The serum homidium concentration versus time plots are given in Figs. 8.4(a) 
to 8.4(c). The maximum plasma drug concentration (C,,^) obtained in non­
infected cattle after i.m. treatment was 159.7±77.9 ng m l1 plasma and the time 
at which it occurred (t,^ )  was 15 to 30 minutes. These plasma concentrations 
declined to 103.0±3.0 ng m H  and 10.8±1.4 within one and 24 hours, 
respectively. Four weeks later, the plasma concentrations of between 2 and 3 
ng m l1 were attained. The mean (± SD) plasma homidium concentration
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Table 8.2
Pharmacokinetic parameters of homidium in non-infected Boran cattle after 
intravenous administration of 14C homidium chloride at 1 mg kg-1 b.w. Non- 
compartmental analysis
Parameter Animal
No.660
Animal 
No. 663
Animal 
No.369
Mean ± SD
p 0.009 0.008 0.007 0.008±0.001
t'/2p(h) 77.55 82.28 93.25 84.36±6.57
AUC0.iast (ng.h ml-') 4458 4104 5333 4632±516
AUC0.oo obs (pg.h mb1) 5.08 4.71 6.37 5.39±0.71
AUCq.00 pre (pg.h ml*1) 4.81 4.49 5.87 5.06+0.59
AUMC0_last(pg.h2 ml-1) 487.08 471.84 577.26 512.06±46.52
AUMCq.oo obs(pg.h2 mb1) 766.17 748.18 1064.64 859.66±145.13
AUMCq.oo Pre(pg.h2 mb1) 644.62 646.37 830.80 707.27±87.36
MRT0_iast(h) 109.3 115.0 108.3 110.8±3.0
MRTq.oo observed (h) 150.8 158.8 167.2 158.9±6.7
MRTq.oo predicted (h) 134.0 144.0 141.5 139.8±4.3
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Fig. 8.4(a) to 8.4(c)
Serum homidium concentrations in individual Boran cattle 
following intramuscular treatment with 14C homidium at a dose 
rate of 1 mg kg-1 b.w.
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versus time plot is given in Fig. 8.5. The plasma, serum and blood homidium 
concentrations versus time plots of animal No. 369 are shown in Fig. 8 .6 .
Non-compartmental pharmacokinetic analysis
The mean A U C ^  (observed) value for i.m.-treated cattle was 3.37±0.87 
p.g.h mb1 Using the AUC0^  values obtained, mean value for bioavailability of 
the i.m. dose of homidium was 56.7±14.7%. The mean residence time was 
200.10±62.48 hours giving a mean absorption time of 41.8±62.5 hours. The 
rest o f the pharmacokinetic parameters are shown in Table 8.3.
A comparison in pharmacokinetic parameters between
intravenous and intramuscular 14C homidium-treatment 
Compartmental and non-compartmental analysis after intravenous 
treatment
Following i.v. treatment, the observed total (extrapolated) AUC and 
MRT values using the non-compartmental pharmacokinetic analysis were 
5.39=1=0.71 pg.h mb1 and 158.9=1=6.7 hours respectively. Using the 
compartmental open model, these values obtained were 5.96±0.54 pg.h mb1 
and 222.8±9.7 hours. The variations in the AUC values were, therefore 
insignificant. Significant variations were however, observed in the MRT 
values (p < 0.05).
Non-compartmental analysis: after intravenous and intramuscular 
treatment
A comparison of the non-compartmental pharmacokinetic parameters 
between the i.v.-treated cattle and the i.m.-treated cattle is shown in Table 8.4. 
The results for AUC (extrapolated) and MRT following i.m. treatment were 
3.37=1=0.87 pg.h mb1 and 200.10=1=62.48 hours respectively. The mean 
extrapolated AUC obtained following i.m. treatment was significantly lower
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Fig. 8.5
Mean ± SD (n = 3) serum homidium concentrations in non-infected 
Boran cattle following intramuscular treatment with 14C homidium 
at a dose rate of 1 mg kg-1 b.w.
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Fig. 8.6
Homidium concentrations in serum, plasma and blood following 
intramuscular treatment of animal No. 369 with 14C homidium at a 
dose rate of 1 mg kg-1 b.w.
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Table 8.3
Pharmacokinetic parameters of homidium in non-infected Boran cattle after 
intramuscular administration of 14C homidium chloride at 1 mg kg-1 b.w. Non- 
compartmental analysis
Parameter Animal 
No. 660
Animal 
No. 663
Animal
No.369
Mean ± SD
tmax (h) 0.25 0.5 0.25 0.3310.12
Cmax (n§ ml"1) 88.2 122.8 268.0 159.7+77.9
P 0.003 0.007 0.007 0.00610.002
t!/2p(h) 233.9 94.0 97.7 141.9165.1
AUCo.iast (M-g-h ml-1) 1.90 2.34 3.87 2.7010.84
AUCq.qo obs (jLig.h m l1) 2.81 2.70 4.6 3.3710.87
AUCq.oq pred (pg.h m l1) 2.73 2.58 4.28 3.191.077
AUMC0.last(pg.h2 m l1) 200.89 232.02 403.88 278.93189.26
AUMCq.00 obs (fig.h2 m l1) 809.74 402.80 756.75 656.431180.64
AUMCq.oo pred(pg.h2 m l1) 759.12 344.75 600.06 567.981170.68
MRT0.last (h) 105.65 99.21 104.51 103.1212.81
MRTq.oo observed (h) 288.62 149.14 164.35 200.10162.48
MRTq.oo predicted (h) 278.03 133.74 140.33 184.03166.52
MAT (h)(approx.) 129.71 -9.77 5.44 41.8162.5
% F 47.1 45.3 77.3 56.7114.7
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Table 8.4
A comparison of mean (±SD)pharmacokinetic parameters in normal cattle 
between the intravenous and the intramuscular routes following administration 
of l4C homidium at 1 mg k g 1 b.w. Non-compartmental analysis
Parameter Intravenous (n=3) intramuscular
(n=3)
Significance
(3 0.008±0.001 0.006±0.002
t‘/2p(h) 84.36±6.57 141.85±65.07
AUCo-iast (pg.h m l1) 4.63±0.52 2.70+0.84
AUC0_oo obs (pg.h m l1) 5.39±0.71 3.37±0.87 *
AUC0.oo pre (pg.h m l1) 5.06±0.59 3.19±0.77
AUMC0.iast (pg.h2 m l1) 512.06±46.52 278.93±89.26
AUMCo_oo obs(pg.h2 m l1) 859.66±145.13 656.43±180.64
AUMCq.00 pre(pg.h2 m l1) 707.27±87.36 567.98±170.68
MRTo_last (h) 110.82±2.96 103.12±2.81
MRTq.00 observed (h) 158.91±6.70 200.10±62.48
MRT0.oo predicted (h) 139.84±4.25 184.03166.52
* p > 0.05
Differences in the means between the rest of the parameters were insignificant 
at both 95 and 99% using the student's t test
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than the values obtained following i.v. treatment (p < 0.05). Although the 
MRT values obtained in cattle following i.m. treatment appeared higher, they 
were not significantly different from those obtained following i.v. treatment.
T. congolense-infected cattle treated with 14C homidium by 
the intramuscular route
Trypanosomes were detected in peripheral blood six days following infection 
and the animals were treated seven days later. From the time the parasites 
were demonstrated in blood to the time of treatment, a rapid drop was 
observed in the PCV from pre-infection values of approximately 40% to 25%. 
This was within a period of two weeks of following infection. On treatment, 
trypanosomes cleared from circulation within 48 hours and there was an 
elevation in the PCV to pre-infection values within a period of approximately 
one week.
Serum homidium concentrations
The serum homidium concentration versus time plots for animal Nos. 254 and 
256 are given in Fig. 8.7(a) and 8.7(b). The decline in drug concentrations was 
exponential and similar to the observations made in non-infected cattle. 
However, there was an initial accelerated elimination of the drug from plasma 
during the first week of treatment after which the rate of decline reverted to 
normal (Fig. 8 .8). This was more pronounced in animal No. 256 [Fig. 8.7(b)]. 
A mean (n = 2) peak serum drug level of 90.83 ng mb1 was attained 15 
minutes following treatment. Mean plasma drug concentrations of 64.9, 8.9 
and 3 ng m l1 were obtained within one hour, 24 hours and 28 days 
respectively.
Non-compartmental pharmacokinetics
The pharmacokinetic parameters obtained using a non-compartmental
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Figs. 8.7(a) and 8.7(b)
Serum homidium concentrations in T. congolense-infected Boran 
cattle following intramuscular treatment with 14C homidium at a 
dose rate of 1 mg kg-1 b.w.
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Fig. 8.8
Mean (n = 2) serum homidium concentrations in T. congolense- 
infected Boran cattle following intramuscular treatment with 14C 
homidium at a dose rate of 1 mg kg-1 b.w.
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pharmacokinetic model are given in Table 8.5. The mean (n = 2) value 
obtained for AUC was 3.11 pg.h mb1. The mean value for MRT was 352.33 
hours. Variations in the AUC values between individual animals were very 
small. Large variations were however, observed between individual animals in 
the MRT values.
A comparison of plasma homidium concentrations and 
pharmacokinetics between non-infected and T. congolense- 
infected cattle following i.m treatment with 14C homidium
Following i.m. treatment of non-infected cattle with 14C homidium, the 
mean (± SD, n = 3) peak serum concentration (Cmax) was 159.7±77.9 ng mb1. 
The plasma concentrations declined exponentially to 103.0±3.0 and 10.8±1.4 
ng m l1 within one and 24 hours respectively. Following i.m. treatment of T. 
congolense-mfQcted cattle, the mean (n = 2) Cmax was 90.83 ng mb1 and 
occurred 15 minutes following drug administration. Serum concentrations of 
64.9 and 8.9 ng mb1 were obtained within one and 24 hours respectively. 
Although the concentrations appeared higher in non-infected cattle, the 
variations between the two animals were not markedly different. Because of 
the small number of animals used, meaningful statistical analysis could not be 
carried out.
A comparison of the pharmacokinetic parameters between non-infected 
and infected cattle in given in Table 8 .6 . Following 14C homidium treatment of 
non-infected cattle the mean value obtained for the AUC was 3.37±0.87 pg.h 
mb1. The values for the other pharmacokinetic parameters were 200.10+62.48 
hours for the MRT, 41.79±62.5 hours for the MAT and 56.7+14.7% for F. 
Values obtained following similar treatment of infected cattle were 3.11 pg.h 
mb1 for the extrapolated AUC and 352.33 hours for MRT. No values for MAT 
and F were determined due to lack of i.v. data in infected cattle. Marked 
variations were observed between non-infected and infected animals in the
285
Table 8.5
Pharmacokinetic parameters of homidium in Trypanosoma congolense- 
infected Boran cattle after intramuscular administration of 14C homidium 
chloride at 1 mg k g 1 b.w. Non-compartmental analysis
Parameter Animal 
No. 7
Animal 
No. 8
Mean
c max(ngml-') 0.50 0.25 0.375
lmax 0 0 67.78 113.88 90.83
P 0 .0 0 2 0.005 0.004
tViPCh) 333.8 129.6 231.7
AUC0.ia.st (ng.h m l1) 1.57 2.15 1.86
AUCq.^  obs (ng.h m l1) 3.15 3.08 3.11
AUCq.^  pred (ng.h m l1) 2.67 2.61 2.64
AUMCo-iast (ng.h2 m l1) 170.10 255.73 212.91
AUMC0.oo obs (ng.h2 m l1) 1465.27 738.51 1101.89
AUMC0.oo prod (ng.h2 m l1) 1072.70 494.17 783.44
MRT0.iast (h) 108.33 118.84 113.58
MRT0.oo observed (h) 464.51 240.15 352.33
MRTq.oo predicted (h) 401.12 189.49 295.30
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Table 8.6
Mean (±SD) pharmacokinetic parameters in non-infected and T. congolense- 
infected cattle following i.m. administration of 14C homidium at 1 mg k g 1 b.w. 
Non-compartmental analysis.
Parameter Normal (n=3) Infected (n=2)
Mean ± SD Mean
Cmax (ng nil'1) 0.33±0.12 0.375
hnax (h) 159.7±77.9 90.83
P 0.006±0.002 0.004
tV4P(h) 141.85±65.07 231.66
AUCo.iast (Pg-h ml-1) 2.70±0.84 1.86
AUCq.oo °bs (Pg-h ml*1) 3.37±0.87 3.11
AUCq.00 pred (pg.h mb1) 3.19+0.77 2.64
AUMC0_iast (pg-h2 ml-1) 278.93±89.26 212.91
AUMCo.00 obs (|ig.h2 mb1) 656.43±180.64 1101.89
AUMCq.00 pred (fig.h2 mb1) 567.98±170.68 783.44
MRT0_jast (h) 103.12±2.81 113.58
MRT0.oo observed (h) 200.10±62.48 352.33
MRT0_oo predicted (h) 184.03±66.52 295.30
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MRT values whilst the variations in the AUC values were not marked. As 
observed above, no meaningful statistical evaluation was possible due to the 
small number of animals used.
A comparison between the radiometric and ELISA methods 
Serum homidium concentrations
Intravenous treatment
Using the radiometric method, the mean (±SD) serum homidium 
concentrations attained within 5, 15 minutes, one and 24 hours were 499.6± 
97.9, 226.4+22.3, 100.3±8.0 and 23.5±1.4 ng mb1 respectively. Using the 
ELISA method (Chapter 4), these values were 220.1+81.3, 62.1+14.4, 31.9+ 
4.3 and 3.9+0.9 ng mb1 respectively. Concentrations of approximately 5 ng 
m b1 were detected in circulation within three weeks of treatment using the 
radiometric method whilst concentrations were undetectable within 17 days of 
treatment using the ELISA method.
Following 14C homidium treatment of animal No. 368, it was shown 
that the concentrations between plasma and serum were markedly similar (Fig. 
8.3). Using the ELISA method to analyse serum samples from this 14C 
homidium-treated animal, it was demonstrated that the serum drug levels fell 
below the limit of detection of the method (0.1 ng mb1) within approximately 
20 days following i.v. treatment (Fig. 8.9). These findings support the 
observations reported in Chapter 4 in which drug levels were undetectable 
within 17 days of i.v. treatment with unlabelled homidium. However, 
variations in serum drug concentrations were observed as early as five minutes 
following i.v. treatment between the radiometric and the ELISA methods (Fig. 
8.9). Using the radiometric method high homidium levels were demonstrated 
in circulation for over three weeks following i.v treatment whilst using the 
ELISA method drug concentrations were undetectable within approximately 
three weeks.
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Fig. 8.9
Serum homidium concentrations obtained using both the ELISA 
and the radiometric methods following intravenous treatment of 
animal No. 368 with 14C homidium at a dose rate of 1 mg kg-1 b.w.
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(a) Non-infected cattle
Following i.m 14C homidium treatment, plasma drug concentrations 
remained generally lower than following i.v. treatment. Using the radiometric 
method, the mean (n = 3) peak serum homidium concentration was 159.7±77.9 
ng m l1. One and 24 hours following treatment, drug concentrations of 103+3.0 
and 10.8±1.4 ng ml' 1 were attained. Using ELISA (Chapter 4), concentrations 
were 193.24+81.63 ng m f1 for Cmax. Concentrations of 112.05±40.27 and 
12.96±3.29 ng m f1 attained after one and 24 hours respectively. Variations in 
homidium concentrations were insignificant up to 24 hours post-treatment. 
Thereafter, marked differences in concentrations were observed. Fig. 8.10 
shows a comparison in homidium serum concentrations in animal No. 369 
between radiometric and ELISA following i.m. treatment with 14C homidium. 
The concentration versus time profiles were quite similar but with an 
approximately 10-fold difference in concentration between them.
(b) T. congolense-infected cattle
Using the radiometric method, the mean (n = 2) peak serum homidium 
concentration was 90.83 ng m l1. Concentrations after one and 24 hours were 
64.6 and 8.9 ng m l1. Drug concentrations of approximately 3 ng mF1 were still 
detectable within 28 days of treatment. Using ELISA (Chapter 5), the mean (n 
= 5) peak serum homidium concentration was 180.4±34.7 ng m l'1. One and 24 
hours following treatment, these values were 84.85±8.15 and 8.04±2.03 ng 
m l1. Low concentrations of between 0.2 and 0.3 ng ml' 1 were detected 28 days 
following treatment. Using the radiometric method it was observed that the 
peak concentrations were lower that those obtained using the ELISA method. 
The initial acceleration in the rate of drug elimination within the first week of 
treatment after which the rate of decline reverted back to normal was observed 
using both the radiometric and the ELISA methods.
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Fig. 8.10
Serum homidium concentrations obtained using both the ELISA 
and the radiometric methods following intramuscular treatment of 
animal No. 369 with 14C homidium at a dose rate of 
1 mg kg-1 b.w.
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Similar to the observations made above, the small numbers o f animals 
used could not permit a meaningful statistical evaluation of the data. However, 
marked variations were observed in plasma/serum concentrations between the 
radiometric and ELISA methods reaching as high as 10-fold in 28 days 
following i.m. treatment of infected cattle.
Pharmacokinetic parameters
Intravenous treatment
(a) Compartmental analysis
Table 8.7 gives a comparison of the mean pharmacokinetic parameters 
using the compartmental, open model in non-infected cattle using the 
radiometric (n = 3) and the ELISA (n = 5, Chapter 4)) methods. Similarities 
were observed in some of the pharmacokinetic parameters which included the 
large volumes of distribution and the wide variations in the rate constants k12, 
k2] and k13, k31. The mean value for the volume of distribution, although high 
using both techniques, was three-fold higher using ELISA than using the 
radiometric method. Some parameters such as the AUC and the MRT were 
markedly higher using the radiometric method. The approximately 10-fold 
difference in the serum drug concentrations have been reflected in the 
calculated AUC values (Table 8.7).
(b) Non-compartmental analysis
Table 8.8 shows a comparison of mean (±SD ) pharmacokinetic 
parameters in non-infected cattle using the radiometric (n = 3) and the ELISA 
(n = 5, Chapter 4) following i.v. treatment. The observed extrapolated AUC 
values were 5.39±0.71 and 0.59±0.07 ng.h mb1 using the radiometric and the 
ELISA methods, respectively. The MRT values calculated from the 
extrapolated AUC values were 158.9±6.7 hours using the radiometric method 
and 62.98±5.91 hours using the ELISA method. All the parameters obtained
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Table 8.7
Mean (±SD) pharmacokinetic parameters in non-infected cattle obtained using 
both the radiometric and the ELISA methods following i.v administration of 
homidium at 1 mg kg*1. Compartmental analysis
Parameter Mean ± SD (n=3) 
Radiometric
Mean 1 SD (n=5) 
ELISA
Significance
A (ng ml*1) 1291±325 5451293
B (ng ml*1) 116.95±30.93 30.4211.76
C (ng ml*1) 20.28±1.85 1.3810.17
a 12.52±1.15 11.8914.39
(3 0.17±0.02 0 .1 0 1 0 .0 2 *
y 0.00410.00 0.006510.0003 **
tVtix (h) 0.05610.005 0.06410.037
tV6P (h) 4.1410.49 7.1711.87 *
d/27 (h) 177.115.3 106.316.6 **
Cp(0) (ng m l1) 14261348 576.81292.9 *
Vc (1 kg-1) 0.7510.22 2.8112.45
A U C 0-last (l g^*h m 1 1 ) 5.9610.54 0.5810.08
**
AUMC0.iast M-g-h ml-1) 1323.91197.24 36.6817.33 **
Vd^eadkg-1) 37.7914.56 111.6118.0 **
Clb (ml h 1 kg-1 168.8115.4 29.3913.96 **
k n  (h 1) 9.9311.18 9.5613.76
k2i (h*1) 1.3510.19 0.8510.25 *
ki3 (h-1) 1.1510.12 0.5510.31 *
kai (h-1) 0.02610.002 0.010010.0006 **
MRT (h) 222.819.7 63.3917.51 **
** p < 0.01
* p < 0.05
293
Table 8.8
Mean (±SD) pharmacokinetic parameters of homidium in non-infected Boran 
cattle obtained using both the radiometric and the ELISA methods following 
intravenous administration of homidium at 1 mg kg-1 b.w. Non-compartmental 
analysis
Parameter Radiometric (n=3) ELISA (n=5) Significance
p 0.008±0.002 0.01210.003
t'/2p (h) 84.36±6.57 58.5811.52 *
AUCo.iast (|ig.h ml-1) 4.63±0.52 0.581.0.07
AUCo_oo obs (jig.h ml*1) 5.39+0.71 0.5810.07 *
AUCo.eo pre (fig.h ml*1) 5.06±0.59 0.5810.07
AUMC0_last (|ig.h2 m l1) 512.06146.52 34.8815.48
AUMCq^o obs(fig.h2 m l1) 859.661145.13 36.7614.75 *
AUMCo_oc pre (|ig.h2 ml-1) 707.27187.36 35.5915.58
MRTo-iast (h) 110.8212.96 59.8715.63
MRTo_oc observed (h) 158.9116.70 62.9815.91 *
MRTo^ predicted (h) 139.8414.25 60.9815.81
* p < 0.01
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using the radiometric method were markedly higher than those obtained using 
ELISA. The 10-fold difference observed in the AUC between the two methods 
was similar to the results obtained using the compartmental analysis.
Intramuscular treatment
(a) Non-infected cattle
Table 8.9 shows a comparison of mean (±SD) pharmacokinetic parameters in 
non-infected cattle between the radiometric method (n = 3) and the ELISA (n 
= 5, Chapter 4) following i.m. treatment. Using the radiometric method, the 
values obtained for AUC and MRT were 3.37±0.087 pg.h mb1 and 200.10± 
62.49 hours respectively. The values for the same parameters using ELISA 
were 2.06±0.34 ^ig.h mb1 and 92.27±21.14 hours, respectively. The 
pharmacokinetic parameters obtained using the radiometric method, though 
higher, the variations were only slightly significant (p > 0.05).
(b) T. congolense-infected cattle
Table 8.10 shows the comparison in the pharmacokinetic parameters in 
T. congolense-mfQCtQd. cattle between the radiometric and the ELISA (Chapter 
5) methods. Using the radiometric method (n = 2) the values obtained for the 
AUC and MRT were 3.11 fig.h mb1 and 352.33 hours, respectively. The 
values obtained using ELISA (n = 5, Chapter 5) were 1.68±0.23 pg.h mb1 for 
the extrapolated AUC and 296.67±158.84 hours for MRT calculated from the 
extrapolated AUC values. No marked differences in the MRT values were 
observed between the two methods despite the variations in the AUC values.
Excretion and tissue residues following i.v. treatment
The amount of drug excreted in urine and faeces during the two weeks 
following treatment was approximately 76% of the total dose administered 
(Table 8.11). Tissue drug levels obtained fourteen days following treatment
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Table 8.9
Mean (±SD) pharmacokinetic parameters of homidium in non-infected Boran 
cattle obtained using the radiometric ELISA methods after intramuscular 
administration of homidium at 1 mg kg*1 b.w. Non-compartmental analysis
Parameter Radiometric
(n=3)
Mean ±SD
ELISA (n=5) 
Mean +SD
Significance
Cmax (ng ml-') 0.33±0.12 nd
tmax (h) 159.66±77.9 nd
P 0.006±0.002 0.0040+0.0005
t ‘/2p(h) 141.85+65.07 177.84+23.42
AUC0.|ast (ng.h ml-1) 2.70±0.84 2.05+0.34
AUCq.oo obs (pg.h m f1) 3.37±0.87 2.06+0.34 *
AUCq.00 pred (pg.h mb1) 3.19±0.77 2.05+0.34
AUMC0.Iast (p-g.h2 ml-1) 278.93+89.26 177.35+37.19
AUMCq.00 obs (pg.h2 ml-1) 656.43+180.64 177.35+37.19 * *
AUMCq.00 pred (|ug.h2 mb1) 567.98+170.68 180.71+37.65
MRT0_last (h) 103.12+2.81 87.47+16.8
MRTq.oo observed (h) 200.10+62.48 92.27+21.14 *
MRTo.^ predicted (h) 184.03+66.52 89.07+17.47
MAT (h) (approx.) 41.79+62.50 28.88+21.14 *
% F 56.7+14.7 32.0+5.7 *
nd = not determined, first interval of sample collection following treatment 
was 30 minutes
* p > 0.05
** <0.05
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are shown in Table 8.12. Tissue drug levels accounted for approximately 20% 
of the total dose given. High drug levels were observed in the major excretory 
organs persisting for longer periods in the liver which had values of 2195 and 
2454 ng g-1 after 14 and 21 days respectively after treatment.
Excretion and tissue residues following i.m. treatment
Tables 8.11 and 8.12 show the excretion and tissue drug levels 
following either i.v. or i.m. drug administration using the radiometric method. 
Approximately 90% of the total dose given was excreted through urine and 
faeces within two weeks of drug administration. Twenty eight days following 
treatment, tissue residues accounted for approximately 13% of the total dose 
administered. Similar to the observations made following i.m treatment, the 
drug levels remained high in the major excretory organs.
DISCUSSION
The use of the radiometric method permitted homidium plasma/serum 
concentrations to be measured for up to 28 days post-treatment in both i.v and
i.m.-treated cattle and pharmacokinetic parameters to be determined. 
Persistence of drug levels in tissues following treatment was demonstrated.
A comparison of data on plasma/serum homidium concentrations and 
pharmacokinetics in non-infected and T. congolense-infected cattle obtained in 
the present study using radiolabelled drug and those reported in Chapters 4 
and 5 using ELISA showed some very interesting observations which are 
discussed.
Following i.v. 14C homidium treatment and using the radiometric 
method to determine the homidium concentrations, a rapid decline in 
plasma/serum drug levels was observed. Drug levels declined exponentially 
from a mean (±SD) of 499.6±97.9 ng ml' 1 obtained five minutes following 
treatment to 23.53±1.36 ng ml' 1 in 24 hours. The drug concentrations generally
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Table 8.11
Homidium excretion (cumulative percentage) in urine and faeces two weeks 
after administration 14C homidium chloride at 1 mg k g 1 body weight to non- 
infected and trypanosome-infected Boran cattle
Treatment type Drug in urine 
% (MeaniS.D)
Drug in faeces 
% MeanlS.D)
Drug excreted 
% (total)
Non-infected, i.v.-treated (n=3) 2 2 .6±2.8 53.412.7 76.0
Non-infected, i.m.-treated (n=3) 17.8±0.6 72.014.1 89.8
Infected, i.m.-treated (n=2 ) 13.3 75.9 89.2
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Table 8.12
Homidium tissue residues (ng g 1) after *i.v. and i.m. administration of 14C 
homidium chloride at 1 mg kg*1 body weight to Boran cattle
Time post-treatment (days)
intravenous intramuscular
normal infected
Tissue Type 14
n=l
21
n=l
14
n=l
28
n=2
14
n=l
28
n=l
Liver 2195 2454 1411 1199 nd 1333
Kidneys 1354 904.2 648.8 448 485.7 161.1
Heart 48.5 51.1 32.2 16.4 42.9 19.5
Spleen 134.3 100.8 64.3 46.3 53.8 nd
Limb skeletal muscle 504.3 352.3 309.7 156.8 137.1 94.5
Lung 296.0 146.2 66.3 37.3 78.6 61.4
Skin 22.1 18.1 22.6 22.3 26.9 22.4
Small intestine wall 74.7 39.4 25.3 27.4 29.9 38.5
Large intestine wall 48.8 25.2 16.5 16.6 48.8 34.5
Abomasum 59.1 33.4 30.5 28.1 48 90.2
Omasum 31.5 18.4 24 9.4 18.7 54.4
Rumen 17.1 30.7 nd 8.3 29.8 nd
Reticulum 6.9 26.1 19.4 14.2 22.4 7.1
Tongue 273.3 233.0 342.9 160.2 199.4 57
Hump 188.9 220.6 nd 219.4 180.9 125.9
Superficial lymph nodes 549.0 nd 139.6 55.6 nd nd
Pancreas 408.6 120.7 175.6 47.5 169.8 28.7
Bile 109.8 82.2 35.6 35.4 58.6 nd
Injection Site nd nd nd nd 41449 nd
Brain 16.3 12.6 nd 12.2 10 10
Urinary Bladder 26.5 24.1 26.2 21.7 28.5 10.7
Gall Bladder 19.7 14.8 26.4 21.8 13.7 21.8
nd = not determined
* tissue samples from only two of the animals analysed
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remained higher in the animals treated by i.v. than those treated by i.m. 
injection. It was demonstrated that there were no marked differences in 
homidium concentrations between plasma and serum. However, the slightly 
lower values obtained in the blood could have been due to quenching o f counts 
during determination of radioactivity or due to the insignificant binding to the 
red blood cells.
Compartmental pharmacokinetic evaluation of the i.v. data obtained 
using radiometric method showed high values for the volume of the central 
compartment and the apparent volume of distribution. The mean volume of 
distribution (Vdarea; 37.8±4.6 1 kg-1) was higher than normal plasma volume 
of approximately 35.9 ml kg-1 and normal total blood volume of approximately 
51.2 ml k g 1 (Ruckebusch et al., 1991) and indicate that the drug was 
distributed extensively extravascularly following treatment. Large volumes of 
distribution inevitably indicate that the fraction of the drug in plasma is very 
small. This suggests that once in the tissues, the rate of movement of the drug 
back into the circulation was extremely slow. This is consistent with the 
observation that residues remained high for long periods of time. Further 
evidence in support of this is in the large differences in the rate constants k12 
and k21 and also between k13 and k31.
This persistence of the drug in the tissues suggests possibly covalent 
binding of the drug to tissue components, e.g. proteins. This situation suggests 
non-attainment of equilibrium and steady state between the plasma/serum drug 
concentrations and the tissues. The low drug concentrations in circulation 
following i.m. treatment were attributed mainly to the injection site depot 
following the observation that in the i.v. treated cattle, the drug was 
undetectable within 17 days of treatment using ELISA.
In the present study, the AUC values obtained using both 
compartmental and non-compartmental pharmacokinetic models following i.v 
treatment were similar but there was a marked variation in the MRT values.
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Whereas the three-compartmental open model gave a mean value of 222.8±9.7 
hours (range 214.36 - 236.36), the non-compartmental model gave mean 
values of 158.91±6.7 hours (range 150.77 - 167.18) based on the total AUC 
and AUMC values (extrapolated to infinity).
Following i.m. drug administration, disappearance of the drug from 
plasmaserum was rapid and, indeed, it was observed that following the i.m. 
dose, the drug concentrations fell from 159.7±77.9 ng mb1 15 minutes 
following treatment to 10.76±1.39 ng mb1 within 24 hours and to levels 
between 2 and 3 ng mb1 within 4 weeks; after the initial rapid fall in the 
plasma/serum concentrations, low concentrations remained in circulation for 
long periods of time. The mean residence time of value of 200.1±62.5 hours 
shows that the mean time drug molecules reside in the body is long. The 
bioavailability of the i.m dose was 56.6% showing that almost half of the i.m. 
dose given did not reach the systemic circulation.
Following i.m. treatment of infected cattle, the drug levels declined 
exponentially with an accelerated rate of elimination within the first week of 
treatment after which the rate of decline reverted back to normal following 
disappearance of trypanosomes from circulation. Similar to the non-infected 
cattle, low levels of the drug remained in circulation for long periods of time 
following treatment. The mean residence time of 352.52 hours was quite long.
In comparing the homidium concentrations and pharmacokinetics 
between the non-infected and infected cattle, it was shown that peak 
concentrations were markedly higher in non-infected cattle. The acceleration 
in the rate of decline of the drug during the first one week following i.m. 
treatment of infected cattle was not observed in uninfected cattle. Thereafter, 
variations in the concentrations between the non-infected and infected cattle 
were not markedly different. The low peak concentrations observed in the T. 
congolense-mfQQ\Q& cattle could possibly have been as a result of either drug 
uptake by trypanosomes or the enhancement of elimination of the drug due to
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changes in the host metabolism as a result of the infection as observed in 
Chapter 5. The mean extrapolated AUC value obtained was 3.11 jig.h mb1 in 
infected cattle.
In comparing the radiometric and the ELISA methods, the 
plasma/serum drug concentrations obtained using radiometric method 
following i.v. treatment were found to be markedly higher than those obtained 
using ELISA (Chapter 4) from as early as five minutes following treatment. 
Whilst drug levels of approximately 5 ng were detected in circulation by the 
third week following i.v. treatment using the radiometric method, the drug 
levels were below the detection limit within three weeks of treatment using the 
ELISA method. This has been demonstrated in the results o f the present study 
in animal No. 368 and in the study reported in Chapter 4.
The variations in the drug concentrations reflect the differences in the 
analytical methods used to determine homidium. The radiometric method 
detected the total radioactive species in solution all of which may not be 
attributed to intact drug. The disappearance of the drug from circulation within 
three weeks following i.v. treatment using the ELISA method and the 
detection of drug concentrations of approximately 5 ng mb1 in similarly 
treated cattle using the radiometric method would suggest the presence of 
metabolites from as early as five minutes following treatment. These 
metabolites could possibly have been undetected by the ELISA method used.
Following i.m.-treatment, the concentrations obtained using ELISA in 
Boran cattle were 214.29±61.02, 80.83±5.23 and 7.07±1.21 ng mb1 after 15 
minutes, one hour and one day respectively (n= 5, pre-challenge 
pharmacokinetics, Chapter 6 ). From the above results, it appears that marked 
differences in the concentrations occurred after 24 hours o f treatment unlike in 
the i.v.-treated cattle in which differences were observed as early as five 
minutes following treatment.
Following i.m. treatment of infected cattle, marked variations were
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observed in the mean peak serum homidium concentrations. Although the peak 
concentrations were markedly higher using ELISA, the concentrations 
obtained 24 hours following treatment were similar between the two methods. 
Marked differences were however, observed after 24 hours of treatment, 
similar to the above findings in non-infected cattle. The observation of 
accelerated rate of elimination of the drug during the first one week of 
treatment after which it reverted back to normal on the disappearance of 
trypanosomes from the circulation was similar using either the radiometric or 
the ELISA method.
In comparing the pharmacokinetic parameters in non-infected cattle 
following i.v treatment between the methods, a ten-fold difference in the AUC 
values was obtained (Tables 8.7 and 8 .8 ). Compartmental pharmacokinetic 
analysis of the i.v. data obtained using ELISA showed a mean residence time 
of 63.39±7.51 hours which was significantly lower than the value of 222.8± 
9.7 hours obtained in the present study using the radiometric method, 
suggesting that drug molecules detected by the radiometric method reside for 
longer periods in the animals following treatment and that all the released drug 
from the tissue depots three weeks following i.v. treatment could possibly be 
homidium metabolites.
Following i.m treatment of non-infected cattle, the extrapolated AUC 
values obtained using the radiometric method were higher than those obtained 
using the ELISA method. Similar observations were made in the MRT values. 
However, these variations were only slightly significant (p > 0.05, Table 8.9). 
Interestingly, the ten-fold differences observed in the serum drug 
concentrations after 24 hours of treatment have not been reflected in any of 
the pharmacokinetic parameters such as the extrapolated AUC values (Table 
8.7) in which only slightly significant differences were reported. This 
interesting observation suggests that the interaction of the drug with the host 
under normal conditions would be similar as demonstrated by similar serum
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concentrations during the first 24 hours using both the radiometric and ELISA 
methods to study the pharmacokinetics.
Pharmacokinetic parameters obtained in infected cattle were markedly 
different between the two methods. Whilst the AUC value in infected cattle of 
3.11 p.g.h ml*1, was similar to 3.37±0.87 pg.h mb1 obtained in non-infected 
cattle using the radiometric method, a value of 1.67 ng.h mb1 was obtained in 
infected cattle using ELISA. Table 8.10 shows a comparison of 
pharmacokinetic parameters in non-infected and infected cattle between the 
radiometric and the ELISA (Chapters 4 and 5) methods following i.m. 
treatment. The approximately ten-fold difference in the serum drug 
concentrations between the radiometric and the ELISA methods have, 
similarly not been reflected in the extrapolated AUC values following 
treatment o f infected cattle in which only a two-fold difference in the AUC 
values between the methods was observed. (Table 8.10). The results however, 
suggest an appreciable amount of drug metabolism by the trypanosomes. The 
results demonstrated that 50% of the drug molecules reaching the systemic 
circulation could possibly be metabolites, undetected by the ELISA method 
used. These metabolites were detected by the radiometric method which 
determined total radioactivity rather than the intact drug. The detection of 
homidium levels for longer periods in non-infected and T. congolense-infected 
cattle following i.m treatment suggests that all the drug detected using ELISA 
could be attributed to the injection site depot.
The detection limit of the radiometric method used in the present study 
was one ng which was equivalent to 169 dpm (corrected for background). This 
activity was four times the background count. Because of the uncertainties in 
the determination of such low counts, all samples with low radioactivity were 
counted for a longer period until the counter computed CVs obtained were 
below 5%. The results o f the present study showed that the highest CVs 
recorded were 2.5%. Similarly, with the ELISA, the homidium concentrations
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were extremely low after 24 hours of treatment. To be able to distinguish these 
low drug levels from the background, the limit of detection of the assay was 
measured by assaying several replicates of the zero standard and calculating 
the mean and the standard deviation. The mean minus three standard 
deviations (mean - 3SD) read in dose on the standard curve was taken as the 
limit of detection of the assay. Due to the extremely low concentrations 
involved, the mean - 3SD was used inorder to increase the confidence limits to 
the detection of the low serum concentrations for over long periods following 
treatment.
It has been established in work reported in Chapters 6  that low 
homidium concentrations can protect cattle from trypanosome infection for 
periods ranging from 120 to 144 days following treatment in the presence of a 
homidium-susceptible trypanosome populations. Whilst levels of 
approximately 2  ng ml 1 were detected in circulation up to four weeks 
following i.m. treatment with 14C homidium, concentrations detected using 
ELISA ranged between 0.15 and 0.4 ng m l1. Also, whilst no drug was 
detectable within approximately three weeks of treatment in the i.v.-treated 
cattle, serum homidium levels were approximately ten-fold higher after 24 
hours of i.m drug administration. These findings suggest the presence of 
homidium metabolites in serum detectable by the radiometric but undetectable 
by the ELISA procedure which may have been specific for homidium.
In light of the observations made in the present study, investigations 
need to be carried out to determine the identity of homidium metabolites and 
whether they possess any trypanocidal activity since it appears that out of the 
total homidium levels in circulation, only 10% could be intact homidium. 
Despite the differences observed between the two techniques in the AUC and 
MRT values following intramuscular drug administration to uninfected cattle, 
the calculated MAT and F values were markedly similar except for one animal 
in the 14C homidium group.
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So far there are no reports on the detection of homidium metabolites in 
serum of treated animals possibly due to the unavailability of sensitive and 
accurate analytical procedures for homidium. The availability o f the homidium 
ELISA reported in Chapter 3 and used in the studies reported in the present 
Chapter and in Chapters 4 and 5 should make investigations into homidium 
metabolites possible.
The major route of excretion was in the faeces via bile. Fourteen days 
after intravenous injection, the fractions of the dose excreted through urine and 
faeces were 22.6±2.8% and 53.4±2.7% respectively. Higher drug levels were 
observed in urine of cattle after i.v. treatment than after i.m. treatment 
suggesting that the kidneys play an important role in the elimination of the 
initial high levels o f homidium following iv. treatment. Drug levels in tissues 
accounted for approximately 2 0 % of the i.v. dose given with high levels in the 
liver, kidneys, lungs and tongue. Due to the high levels in the tongue it appears 
as though there could have been some salivary excretion of the drug in 
addition to the other routes mentioned although this drug would ultimately end 
up in the faeces. Drug levels were however not determined in the salivary 
glands. Decline in drug levels in the kidneys was significant compared to the 
liver between 14 and 21 or 28 days following treatment, showing persistence 
in the liver over longer periods after either i.v. or i.m. treatment.
Coolbear and Midgley (1986) in their work on the uptake of homidium 
by two trypanosomatid flagellates Crithidia fasculata and Leptomonas 
seymouri found that homidium transport could not be saturated over a large 
concentration range. Results of the present study showed that there was non­
attainment of equilibrium between free homidium concentrations in host 
tissues and plasma in cattle following drug administration at the recommended 
therapeutic dose (1 mg kg4) also suggesting covalent binding of the drug 
molecules to tissue proteins. Homidium was found to be eliminated relatively 
slowly and if the drug movement was by simple diffusion, there would be an
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equilibrium established between free homidium concentrations in tissues and 
plasma with similar rates of movement into and out of tissues. The observation 
o f non-attainment of equilibrium would suggest that transport into host cells 
was unsaturated and would possibly be similar to the observations made by 
Coolbear and Midgley (1976) in the trypanosomatid flagellates.
Homidium has been shown to intercalate with DNA and this property 
has made the compound be used widely as a biochemical probe (Newton, 
1976). Studies on the nature and extent of binding of the drug was not 
covered by the present study but previous work has shown that binding of 
ethidium in vivo may involve more than simple intercalation with DNA 
(Mahler and Bastos, 1974). Results of their study on the uptake of 3H-ethidium 
by Saccharomyces cerevisiae, showed that ethidium was associated with 
mitochondrial DNA and accounted for about 2.3% of the total ethidium bound 
to DNA with evidence that it might be a metabolic derivative of homidium 
formed within the mitochondrion which then becomes covalently bound to 
mitochondrial DNA. Mattem (1976) and MacGregor and Johnson (1977) 
similarly demonstrated that ethidium bromide interacts with nucleic acids not 
only by a reversible intercalation reaction but also through an irreversible, 
enzyme mediated binding.
The present study has demonstrated that the drug concentrations persist 
in tissues for long periods of time. It is this persistence of the bound homidium 
concentrations in the cells that could possibly explain the widespread nature of 
homidium resistance in trypanosomes and why this can increase several fold 
within a very short period of constant exposure even in the presence of 
extremely low concentrations in circulation. It is possible (due to the 
persistence of the drug in the liver) that toxic levels could build up when high 
doses of homidium are administered as demonstrated by Unsworth (1954a).
Since the lymphoid system is actively involved in the early events 
following trypanosome infection, the levels of the drug in the lymph nodes
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could be of some practical significance and in susceptible animals would 
contribute to determining whether an infection becomes established. Luckins 
and Gray (1979) demonstrated that trypanosomes first appear in the lymph 
nodes before they are detected in the general circulation and Akol and Murray 
(1982) observed that the development of a chancre and enlargement of the 
lymph nodes after a tsetse fly bite occur simultaneously. This could play a 
significant role in the prophylactic treatment. Low MRT values have been 
associated with reduced prophylactic period (Chapter 6 ).
Using a chemical assay developed by Bratton and Marshall in 1939, 
MacGregor and Clarkson (1971) reported rapid excretion of a 15 mg k g 1 dose 
of homidium bromide given intraperitoneally to mice and that 50-55% of the 
dose was found to be excreted in the bile 16-18 hours after drug 
administration. Between 20-25% of the drug recovered was unchanged 
whereas 75-80% was in the form of monoacetyl amino derivatives. 
Kandaswamy and Henderson (1963) in their studies in mice reported that 51% 
of the dose given was excreted unchanged within 24 hours while Gilbert and 
Newton (1982), working with cattle found 2 acid labile compounds in urine 
represented 46% of the total activity eluted and neither were mono- or diacetyl 
amino conjugates. Results from this laboratory (unpublished) have confirmed 
the presence of monoacetyl derivatives in rat faeces within the first 24 hours 
of drug administration during which time none were found in cattle indicating 
the difficulties associated with extrapolating results from one animal species to 
another brought about by differences in their rates of metabolism.
Owing to the fact that homidium remains in tissues for long periods of 
time, it is highly important that bioavailability studies be carried out to 
determine the tissue levels that would be safe in animal products destined for 
human consumption. The effect of low level intake over prolonged period 
should be examined for purposes of determining the minimum acceptable 
levels.
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In conclusion, the use of the radiometric method showed detectable 
pasma/serum concentrations up to four weeks following either i.v. or i.m.- 
treatment of non-infected cattle. Drug concentrations in both plasma and 
serum from the same animal were markedly similar. No binding of homidium 
to red blood cells was demonstrated since concentrations were markedly lower 
than those obtained in plasma or serum of the same animal. Extensive 
extravascular distribution of the drug following i.v. treatment was 
demonstrated. Bioavailability of the i.m. dose was 50% showing that half of 
the dose given did not reach the systemic circulation. Drug levels were shown 
to remain in tissues for long periods of time.
Following treatment of infected cattle, an increased rate of drug 
uptake/elimination by trypanosomes was demonstrated within the first 3 days 
o f treatment. This rate reverted back to normal within one to two days 
following disappearance of trypanosomes from circulation. However, the 
mean residence time was higher than that observed in non-infected cattle.
The use of both ELISA and radiometric methods made possible a 
number o f tentative conclusions to be made from the present study, on the 
assumption that the ELISA method detected mainly intact homidium and the 
radiometric measured total radioactive species in solution which may have 
included metabolites. These tentative conclusions are: (a) that extensive 
homidium metabolism occurs in cattle following either i.v. or i.m. treatment; 
this was observed from as early as five minutes following i.v. treatment (b) 
that failure to detect homidium in serum of i.v.-treated cattle within 
approximately three weeks using ELISA suggests that the low concentrations 
observed for over 10 following i.m. treatment (Chapter 4) could be almost 
wholly be attributed to the injection site drug depot (c) that the approximately 
ten-fold difference in the plasma/serum homidium concentrations observed 
using both ELISA and the radiometric methods following i.m. treatment of 
cattle suggests higher levels of metabolites than intact homidium (d) that
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although high drug levels were demonstrated in the tissues for as long as 4 
weeks following either i.v. or i.m. treatment the extensive metabolism of the 
drug could suggests a reduction in the toxic effects of homidium following 
treatment at the normal doses.
The above findings suggest that further investigations are required to 
determine the nature of these metabolites and their contribution, if any, to the 
development of drug resistance and the observed period of prophylaxis since 
their levels appear to be ten-fold higher than those observed using ELISA.
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CHAPTER NINE
COMPARATIVE PHARMACOKINETICS OF 
HOMIDIUM AND ISOMETAMIDIUM
INTRODUCTION
Both homidium and isometamidium have been used extensively in the 
control of animal trypanosomiasis. Homidium is mainly used as a 
chemotherapeutic drug, although reports have appeared showing that it can 
offer protection of several months. Isometamidium is used both as a 
chemotherapeutic and a chemoprophylactic drug. Several studies have been 
reported showing that isometamidium can confer protection for up to six 
months (Chapter 1, Section Two). Homidium and isometamidium belong to 
the phenathridinium group of compounds. In fact, isometamidium contains a 
homidium moiety in its structural formula (Appendix B). Thus, both drugs 
share structural similarities.
The shared structural similarities would suggest similarities, to some 
extent, in their mode of action. In the field, both drugs are usually 
administered at a dose rate of 1 mg k g 1 b.w. Also, trypanosomes which are 
resistant to homidium have been shown to be cross-resistant to isometamidium 
due to the structural similarities. These have discussed in detail in Chapter 1, 
Section Two.
However, the major differences in the two drugs as far as field use is 
concerned, is in the period of prophylaxis observed following exposure of 
cattle to natural tsetse challenge after i.m. treatment of cattle. (Dolan et al., 
1992; Stevenson et al., 1995). The period of protection afforded by 
isometamidium was approximately two-fold higher than that afforded by 
homidium and yet in terms of productivity, homidium appeared to perform 
better (Dolan et al., 1992) and was cost-effective compared to isometamidium 
despite more treatments given (Stevenson et al., 1995). It was on the basis of 
these findings that formed the basis of the present comparative study of the 
pharmacokinetics of both drugs.
312
STUDY OBJECTIVES
1. To measure the levels of radioactive drug in the plasma of non-infected
cattle treated with 6 -14C isometamidium by intravenous (i.v.) injection 
and to determine the pharmacokinetic parameters.
2. To measure the levels of radioactive drug in the plasma of non-infected
cattle treated with 6 -14C isometamidium by intramuscular (i.m.) 
injection and to determine the pharmacokinetic parameters.
3. To measure the levels of radioactive drug in the plasma of T.
congolense- infected cattle treated with 6 -,4C isometamidium by 
intramuscular (i.m.) injection and to determine the pharmacokinetic 
parameters.
4. To compare plasma drug concentrations and pharmacokinetic
parameters between non-infected and infected cattle following 
treatment with 6 -14C isometamidium.
5. To compare plasma drug concentrations and pharmacokinetic
parameters obtained following i.v. treatment of non-infected cattle with 
6 -14C isometamidium with those obtained after similar treatment with 
6 -14C homidium reported in Chapter 8 .
6 . To compare plasma drug concentrations and pharmacokinetic
parameters obtained following i.m. treatment of non-infected cattle 
with 6 -,4C isometamidium with those obtained after similar treatment 
with 6 -14C homidium reported in Chapter 8 .
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7. To compare plasma drug concentrations and pharmacokinetic
parameters obtained following i.m. treatment of T. congolense-infected 
cattle with 6 -14C isometamidium with those obtained after similar 
treatment with 6 -,4C homidium reported in Chapter 8 .
MATERIALS AND METHODS 
Animals
Seven healthy male Boran castrates weighing between 120 and 145 kg, 
were purchased from a trypanosome-ffee area of Central Province, Kenya, and 
housed in a fly-proof bam for three weeks to acclimatise to laboratory 
conditions before the start of experiments. At the start of each experiment the 
animals were placed in individual metabolic cages. Their management before 
and during the experiments was as described in Chapter 2.
Infection of cattle
A drug-sensitive trypanosome population (T. congolense IL 1180) was 
used. The inoculum given and the procedures followed for the infection of 
cattle were as described in Chapter 8 .
Radiolabelled isometamidium, dosage and administration
The drug used for treatment was 6 -14C isometamidium chloride of 
specific activity 44.53 pCi mg-1. The radiolabelled drug was kindly supplied 
by May and Baker, Dagenham, U.K., through the International Atomic Energy 
Agency. A 2% w/v solution was freshly prepared in sterile water immediately 
prior to use. The drug was administered as a single bolus at 1 mg kg-1 body 
weight by either i.v. or i.m. route.
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Experim ental design
The cattle were divided into three groups. The first group of three non- 
infected animals was treated with 6 -14C isometamidium by i.v. injection; the 
second group of two non-infected animals were treated by i.m. injection; and 
the third group of two animals were treated by i.m. injection approximately 
three weeks following trypanosome infection. Following drug administration, 
levels o f radioactivity were measured in duplicate in plasma from all treated 
cattle.
Sample collection
Pre-treatment plasma samples
Immediately prior to treatment, 10 ml blood samples were collected 
from all the seven animals by venipuncture into EDTA-coated vacutainers 
(Becton, Dickinson, Coventry, UK). Plasma was separated by centrifuging the 
blood at 1200 g for 30 minutes and stored at -20°C until required.
Plasma samples for radioactive drug analysis
Ten millilitre blood samples were collected by venipuncture into 
EDTA-coated vacutainers from all the animals immediately prior to treatment 
and at the following intervals following treatment: 5, 10, 15, 30 and 45 
minutes, 1, 2, 4, 6 , 8 , 12 and 24 hours, thereafter daily for 30 days, and three 
times a week to the end of the experimental period which varied between 21 
and 60 days for the i.v.-treated cattle and between 60 and 120 days for i.m.- 
treated cattle. Blood samples were collected from cattle following i.m. drug 
administration but omitting the 5 and 10 minute sample collections. Plasma 
was separated as already described and stored at -20°C until required.
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Sample preparation and determination o f  radioactivity
Procedures followed in sample preparation and radioactivity 
determination were as described in Chapter 8 .
Data analysis
Determination of radioactivity and computation of coefficients of 
variation (CVs) by the counter in-built mechanism were as described in 
Chapter 8 . During radioactivity determination, samples with low radioactivity 
were counted for at least 30 minutes until low (CVs) between the counts were 
attained. The cut-off point for acceptable CVs was 5%. The limit o f detection 
was taken as four times the background count which was equivalent to 1 ng 
radiolabelled drug, determined as described in Chapter 8 .
All concentrations were expressed in nanograms per ml or per gram 
sample (Mean±SD), calculated from the radioactivity measured. This did not 
take into account the metabolic state of the drug.
Statistical evaluation
The mean and standard deviations (SD) were calculated for the 
replicate determinations of the radioactive drug using Lotus 1-2-3 Software 
(Release 4). Comparison of pharmacokinetic parameters between the various 
treatment groups was carried out using the student's t-test at both 95 and 99% 
confidence limits.
Pharmacokinetic evaluation
The pharmacokinetic evaluation was carried out following the 
procedures described in Chapter 8 for 6 -14C homidium.
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RESULTS
Non-infected cattle treated with 6-14C isometamidium by i.v.
injection
Plasma 6-14C isometamidium concentrations
The mean (±SD) plasma drug concentration-versus-time plot obtained 
following treatment of non-infected cattle with 6 -14C isometamidium is given 
in Fig. 9.1. Five minutes following i.v. treatment, the mean (±SD) plasma 
6 -14C isometamidium concentration was 4458±834 ng ml*1. This concentration 
declined exponentially to 33.9±1.9 ng ml*1 at 24 hours, 10.1±0.2 ng ml*1 at 7 
days and 5.4±0.9 ng ml*1 at 21 days. The exponential decline was especially 
rapid during the first 24 hours following treatment.
Pharmacokinetics
The pharmacokinetic parameters obtained following i.v. treatment of 
cattle with 6 -14C isometamidium at a dose rate of 1 mg kg*1 are shown in Table 
9.1. The data were best described by a three-compartmental model with half- 
lives of 0.13=1=0.02, 1.22=1=0.19 and 173.2=1=94.8 hours for t/4a, tYifi and FAy, 
respectively. The value for CpO was 5979±2000 ng ml*1 and those for Vc and 
Vss were 0.18±0.02 and 13.8±7.4 1 kg*1, respectively. The value for the AUC 
was 9923±922 ng.h ml*1, giving an MRT of 82.3±11.1 hours. The values 
obtained for k 12 and k2] were 1.15=1=0.12 and 0.026=1=0.002 per hour, 
respectively, and those for k13 and k31 were 2.24±0.24 and 1.86±0.66 per hour, 
respectively. The similarities in the rate constants k 13 and k31 demonstrated that 
an equilibrium was attained between the free drug in plasma and in tissues.
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Fig. 9.1
Mean (±SD*; n = 3) plasma isometamidium concentrations in non- 
infected Boran cattle treated with 6-14C isometamidium by i.v. 
injection at a dose rate of 1 mg k g 1 b.w.
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Table 9.1
Pharmacokinetic parameters of 6 -14C homidium and 6 -14C isometamidium in 
non-infected cattle following i.v. treatment at 1 mg kg-1 (mean ± SD)
Parameter Homidium Isometamidium Significance
Mean ±SD Mean 1 SD
(n = 3) (n = 3)
tVia (h) 0.056±0.005 0.1310.02 *
d/2p(h) 4.14±0.49 1.2210.02 *
d/zyOi) 177.1±5.3 173.2194.8
Cp(0) (ng ml-1) 1426±347 597912000 *
Vc (1kg-1) 0.75±0.22 0.1810.02 **
AUC (ng.h ml-1) 5957±544 99231922 **
AUMC (ng.h ml-1) 1323905±97239 450040141800 **
Vdssdkg*1) 37.8±4.6 13.817.4 *
k12 (h-1) 9.93±1.18 1.1510.12 **
k^ (h*1) 1.35±0.19 0.01710.007 **
k-i3 (h-1) 1.1510.12 2.2410.24 **
k31 (h*1) 0.02610.002 1.8610.66 *
MRT(h) 222.819.7 82.3111.1 **
* p < 0.05
** p < 0 .01
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Non-infected cattle treated with 6-14C isometamidium by i.m.
injection
Plasma 6 -14C isometamidium concentrations
The mean (+SD) plasma drug concentration-versus-time plot following 
treatment o f non-infected cattle with 6 -14C isometamidium is given in Fig.
9.2. Fifteen minutes following treatment the mean (±SD) plasma 6 -14C 
isometamidium concentration was 133.2±26.2 ng ml-1. This declined 
exponentially to 21.6±5.0 ng mF1 at 24 hours, and 15.1±1.7 ng m F at 7 days. 
At approximately 14 days following treatment, there appeared to be a slight 
increase in plasma drug concentrations which were thereafter maintained at a 
constant level (approximately 12 ng m F [Fig. 9.2]).
Pharmacokinetic parameters
The pharmacokinetic parameters obtained following i.m. treatment of 
non-infected cattle with 6 -14C isometamidium are given in Table 9.2. The 
Cmax and values were 160.5±1.2 ng m F and 0.38±0.13 hours, 
respectively. The mean value for MRT was of 289.6±23.5 hours. The AUC 
value was 5841 ±995 ng.h mF1. In conjunction with the AUC from the i.v. 
study a value for bioavailabilty of 58.9±10.0% and an MAT value of 
289.6±23.5 hours were obtained. The remaining pharmacokinetic parameters 
are given in Table 9.2.
T. congolense-iniected cattle treated with 6-14C
isometamidium by i.m. injection 
Plasma 6 -14C isometamidium concentrations
The plasma drug concentration-versus-time plot following treatment of 
infected cattle with 6 -14C isometamidium is given in Fig. 9.2. Fifteen minutes 
following treatment the mean (±SD) plasma isometamidium concentration was 
56.8±30.5 ng mF1. This declined exponentially to 8.3±0.3 ng mF1 at 24 hours.
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Fig. 9.2
Mean (±SD; n = 2) plasma isometamidium concentrations in non- 
infected and T. congolense-iniected Boran cattle treated with 6-14C 
isometamidium by i.m. injection at a dose rate of 1 mg k g 1 b.w.
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Table 9.2
Pharmacokinetic parameters of non-infected and T. congolense-infected cattle 
following intramuscular treatment with 6-14C isometamidium at 1 mg k g 1 b.w.
Param eter Non-infected
n = 2
Infected*
n = 2
tinax (h*) 0.38±0.13 0.25±0
Cmax (ng m l1) 160.5+1.2 56.8±30.5
AUC0-iast (ng-h n11*1) 5841±995 3751±9.2
AUCq^ o observed (ng.h ml*1) 17638±2600 100822±332668
AUMC0.last (ng.h2 ml-1) 921313±126834 666199+20249
AUMCq-oo observed (ng.h2 ml"1) 5168105±1167690 35611689111959594
MRTq.00 observed (h) 289.6±23.5 352.412.3
* T. congolense TL 1180
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An acceleration in the rate of drug elimination in plasma was observed during 
the first three days following i.m. treatment, during which time the 
concentrations fell below 10 ng mb1. Thereafter, the drug concentrations were 
elevated in both treated cattle to approximately 10 ng mb1 within one to two 
days following the disappearance of trypanosomes from the circulation. These 
plasma concentrations were maintained up to approximately 25 days following 
treatment (Fig. 9.2).
Pharmacokinetic parameters
The pharmacokinetic parameters obtained following treatment of 
infected cattle are given in Table 9.2. The values for the Cmax and the t , ^  
were 56.8+30.5 ng mb1 and 0.25+0 hours, respectively. The AUC value was 
3751+9.2 ng.h mb1, resulting in the calculated MRT value of 352.4+2.3 hours.
Comparison between non-infected and T. congolense-infected 
cattle following treatment with 6-14C isometamidium by the 
i.m injection 
Plasma isometamidium concentrations
A comparison of the plasma 6 -14C isometamidium concentration- 
versus-time profiles between non-infected and infected cattle is given in Fig.
9.2. Fifteen minutes following treatment o f non-infected cattle, the mean (± 
SD) plasma isometamidium concentration was 133.2±26.2 ng mb1. This 
declined exponentially to 21.6±5.0 ng mb1 at 24 hours, 15.1+1.7 ng mb1 at 7 
days, after which the drug concentrations appeared to be maintained at a 
constant level which was approximately 10 ng mb1. Following treatment of 
infected cattle however, the mean plasma isometamidium concentration 
obtained after 15 minutes was 56.8±30.5 ng mb1. This declined exponentially 
to 8.3+0.3 ng mb1 at 24 hours. A mean concentration of 9.6+1.0 ng mb1 was 
attained at 7 days. An acceleration in the drug elimination rate observed
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during the first three days following i.m. treatment of T. congolense-infected 
cattle was not observed in non-infected cattle given similar treatment. 
However, the drug concentrations appeared to be maintained at a constant 
level in non-infected cattle after 10 days and in infected cattle after 
approximately three days following i.m. treatment, although the concentrations 
of the radioactive drug were markedly lower in infected than non-infected 
cattle (Fig. 9.2).
Pharmacokinetic parameters
Following i.m. treatment of non-infected cattle, the Cmax and 
values of 160.5±1.2 ng mF1 and 0.38±0.13 hours respectively, were obtained. 
These values were 56.8±30.5 ng mb1 and 0.25±0 hours respectively following 
treatment o f infected cattle. The mean value for MRT of 289.6±23.5 hours, for 
non-infected cattle was lower than 352.4±2.3 hours obtained in infected cattle. 
However, the AUC value of 5841 ±995 ng.h mb1 for non-infected cattle was 
higher than the value of 3751±9.2 ng.h mF1 obtained in infected cattle. Clearly 
the presence of trypanosomes at the time of treatment had an effect on the 
pharmacokinetics of isometamidium in cattle.
Comparison of plasma drug concentrations and 
pharmacokinetic parameters in non-infected cattle between 
6-14C homidium and 6-14C isometamidium following 
intravenous treatment 
Plasma drug concentrations
The mean (±SD) plasma drug concentration-versus-time plot following 
i.v. treatment of non-infected cattle with either 6 -14C isometamidium or 6 -14C 
homidium is shown in Fig. 9.3. Both drugs showed an initial rapid exponential 
decline in the plasma drug concentrations. Five minutes following i.v. 
treatment with 6 -14C homidium, the mean plasma concentration was
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Fig. 9.3
Mean (±SD; n = 3) plasma drug concentrations in non-infected 
Boran cattle after intravenous injection of 6-14C isometamidium 
and 6-14C homidium at a dose rate of 1 mg k g 1 b.w.
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499.6±97.9 ng ml-1. Concentrations of 23.5±1.4 and 4.3±0.4 ng mb1 were 
obtained at 24 hours and 7 days, respectively. Five minutes following i.v. 
treatment of cattle with 6 -14C isometamidium at the same dose, the mean (± 
SD) plasma drug concentration was 4458±834 ng m f1. This concentration 
declined exponentially to 33.9±1.9 ng mb1 at 24 hours and to 10.1±0.18 ng 
m l1 at 7 days. The initial drug concentrations following treatment o f cattle 
with 6 -14C isometamidium (4458±834 ng mb1) were significantly higher (p <
0.05) than in cattle treated with 6 -14C homidium (500±100 ng mb1).
Pharmacokinetic parameters
Table 9.1 shows the mean (±SD) pharmacokinetic parameters and the 
significance of the difference between them in non-infected cattle following
1.v. treatment with either 6 -14C homidium or 6 -14C isometamidium at 1 mg 
kg-1 b.w. Most of the pharmacokinetic parameters were significantly different 
(Table 9.1; p < 0.01) between 6 -14C homidium-treated and 6 -14C 
isometamidium-treated cattle. The exception was the tV4y in which no 
significant difference was observed between the two drug compounds. 
Because of the rapid elimination of 6 -14C isometamidium the mean residence 
time was short (82.3±11.1 hours) compared to 222.8+9.7 hours obtained in 6 - 
I4C homidium-treated cattle. Whilst the three-compartmental model fitting o f 
the data from 6 -14C isometamidium-treated cattle showed an establishment o f 
equilibrium between drug concentrations in plasma and tissues during drug 
distribution, the data from the 6 -14C homidium-treated cattle showed non­
attainment of equilibrium (Chapter 8). However, the high values for the 
volume of distribution showed extensive extravascular distribution of both 
drugs following treatment.
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Comparison of pharmacokinetic parameters in non-infected 
cattle between 6-14C homidium and 6-14C isometamidium 
following i.m treatment
Plasma drug concentrations
The mean (±SD) plasma drug concentration-versus-time plots obtained 
following i.m. treatment of cattle with either 6 -14C isometamidium or 6 -14C 
homidium is given in Fig. 9.4. The maximum plasma drug concentration 
(Cmax) obtained in non-infected cattle after i.m. treatment with 6 -14C homidium 
was 159.7±77.9 ng m f1 plasma, and the time at which it occurred (W )  was 
0.33+0.12 hours. These plasma concentrations declined exponentially to 
103+3.01 and 10.8+1.4 ng mF1 at one and 24 hours, respectively. Fourteen 
days later, a plasma 6 -14C homidium concentration of approximately 4 ng mF1 
was attained. Following treatment of cattle with 6 -14C isometamidium, the 
mean (±SD) peak plasma 6 -14C isometamidium concentration (Cmax) was 
160.5+1.2 ng m l1 and occurred at 0.38+0.13 hours. This declined 
exponentially to 21.6+5.0 ng mF1 at 24 hours, 15.1+1.7 ng mF1 at 7 days and 
12.7+1.2 ng mF1 at 14 days. From approximately 10 days following treatment, 
isometamidium concentrations appeared to be maintained at a constant level 
(Fig. 9.4). It appeared as if the drug was 'infused' into the circulation from the 
drug depots which included the injection site. This was not observed in 
homidium-treated cattle given similar treatment.
Pharmacokinetics
Following i.m treatment of non-infected cattle with 6 -14C homidium, an 
exponential decline in plasma drug concentrations was observed (Fig. 9.4). 
However, following i.m. treatment of non-infected cattle with 6 -14C 
isometamidium the decline in plasma drug concentrations was exponential up 
to approximately 10 days after treatment. In fact, the drug concentration- 
versus-time profile following i.m. treatment with 6 -14C isometamidium
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Fig. 9.4
Mean (±SD; n = 2) plasma drug concentrations in non-infected 
Boran cattle after intramuscular injection of 6-14C isometamidium 
and 6-14C homidium at a dose rate of 1 mg kg1 b.w.
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resembled one of a 'steady state infusion' of the drug due to maintenance of 
constant drug levels in circulation.
Due to the small numbers of animals involved, a meaningful statistical 
evaluation was not possible. However, a comparison of pharmacokinetic 
parameters in the Boran cattle between 6 -14C homidium and 6 -14C 
isometamidium following i.m treatment is shown in Table 9.3. The mean Cmax 
and tj^ax values of 159.7±77.9 ng mb1 and 0.33±0.12 hours, respectively 
obtained using 6 -14C homidium were similar to 160.5±1.2 ng mb1 and
0.38±0.13 hours, respectively obtained in cattle following treatment with 6 -14C 
isometamidium. Similarly, the mean (±SD) value for MRT of 200.1±62.5 
hours obtained in cattle treated with 6 -14C homidium was markedly similar to 
the MRT value of 289.6±23.5 hours obtained in the 6 -14C isometamidium- 
treated cattle. The calculated F values were also similar (Table 9.3).
However, the MAT value of 207.3±33.3 hours obtained in the 6 -14C 
isometamidium-treated cattle was markedly higher than the value of 
41.79±62.5 hours obtained in cattle treated with 6 -14C homidium.
Comparison of pharmacokinetic parameters in cattle infected 
with a drug-sensitive population of T. congolense-infected 
cattle between 6-14C homidium and 6-14C isometamidium 
following i.m treatment 
Plasma drug concentrations
A comparison, over time, of the mean plasma drug concentration- 
versus-time data following treatment of infected cattle with either 6 -14C 
homidium or 6 -14C isometamidium is shown in Fig. 9.5. Following i.m. 
treatment with 6 -14C homidium, the peak plasma concentration was 90.6±23.3 
ng mb1, which occurred 15 minutes following drug administration. Plasma 
drug concentrations of 56.3±6 and 8.9±2.1 ng mb1 were obtained at one and 24 
hours, respectively following treatment. Following treatment with 6 -14C
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Table 9.3
Pharmacokinetic parameters of 6 -14C homidium and 6 -14C isometamidium in 
non-infected Boran cattle following intramuscular treatment at 1 mg k g 1 b.w.
Parameter 6-14C homidium
Mean ± SD (n = 3)
6-14C isometamidium
Mean ± SD (n = 2)
tjoax (h) 0.33±0.12 0.38±0.13
(•'max (n§ tnl 159.7±77.9 160.5±1.2
A U C 0-last ( n g -h  m l ' 1) 2701±841 5841±995
AUC0.oo obs(ng.h ml-1) 3370±873 17638±2600
AUMC0.last (ng.h2 m l'1) 278927±89262 921313±126834
AUMC0_oo obs (ng.h2 ml-1) 656432±180642 5168105±1167690
MRTq.00 observed (h) 200.1±62.5 289.6±23.5
MAT (h) 41.79±62.5 207.3±33.3
%F 56.6±14.7 58.9±10.0
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Fig. 9.5
Mean (±SD; n = 2) plasma drug concentrations in T. congolense- 
infected Boran cattle after intramuscular injection of 6-14C 
isometamidium and 6-14C homidium at a dose rate of 
1 mg kg-1 b.w.
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isometamidium, concentrations were 56.8±30.5 and 8.3±0.3 ng ml-1 at 15 
minutes and 24 hours, respectively. Similarities between the two drug 
compounds were demonstrated in the reduced drug concentrations obtained 
following i.m. treatment of infected cattle when compared to the equivalent 
values in non-infected cattle.
An acceleration in the drug elimination rate compared to the normal 
rate (obtained following treatment of non-infected cattle) was observed during 
the first three days following i.m. treatment of infected cattle with either 6 -14C 
isometamidium or 6 -14C homidium. This acceleration in the elimination rate 
reverted to normal within one to two days following the disappearance of 
trypanosomes from the circulation. The acceleration in the drug elimination 
rate immediately following i.m. treatment of infected cattle was not observed 
in non-infected cattle following treatment with either of the drug compounds. 
However, the observed plateau in the drug concentration which can be likened 
to the 'steady state infusion' of the drug possibly from the injection site was 
observed in non-infected cattle treated with 6 -14C isometamidium and also in 
infected cattle treated with either 6 -14C isometamidium or 6 - I4C homidium by
i.m. injection.
Pharmacokinetics
A comparison of the pharmacokinetic parameters between 6 -14C 
homidium and 6 -14C isometamidium following i.m treatment of T. congolense- 
infected cattle is given in Table 9.4. The Cmax values were low in both groups 
of cattle compared to those obtained in non-infected cattle. The AUC and the 
AUMC values obtained in the 6 -14C homidium-treated cattle were markedly 
lower compared to those obtained in the 6 -l4C isometamidium-treated cattle. 
The MRT value of 352.3±112 hours obtained in infected cattle treated with 6 - 
I4C homidium was similar to 352.4±2.3 hours obtained in infected cattle 
treated with 6 -14C isometamidium.
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Table 9.4
Pharmacokinetic parameters of 6 -14C homidium and 6 -14C isometamidium in 
T. congolense-infected Boran cattle following intramuscular treatment at 1 mg 
kg-1 b.w.
Param eter 6 -14C homidium
mean ± SD (n = 2)
6 -14C isometamidium
Mean ± SD (n = 2)
tmax (h) 0.38±0.13 0.25±0.0
Cmax (ng ml-1) 90.8±23.1 56.8±30.5
AUC0-last (ng-h m l'1) 1861±291 3751±9
AUC0.oo obs(ng.h m k1) 3114±40 100822±332668
AUMC0.last (ng.h2 ml-1) 212914±42819 666199±20249
AUMCq.^ obs (ng.h2 ml-1) 1101889±363383 35611689±11959594
MRTobserved (h) 352.3±112.0 352.4±2.3
DISCUSSION
In the present Chapter, plasma drug concentrations and 
pharmacokinetic parameters have been determined following i.v. treatment of 
non-infected Boran cattle with 6 -14C isometamidium and also following i.m. 
treatment o f non-infected and T. congolense-infected Boran cattle with the 
same drug. The results obtained were compared with similar groups of cattle 
treated with 6 -14C homidium reported in Chapter 8 . The major comparisons 
centred on the (a) the distribution and elimination characteristics of the two 
similarly radiolabelled compounds in non-infected cattle following i.v. 
treatment (b) the absorption, bioavailability and elimination characteristics 
following i.m. treatment and (c) the effects of T. congelense infection on the 
pharmacokinetics of the two drug compounds.
Several comparisons were made of the serum drug concentrations and 
pharmacokinetics using the data obtained above: (a) between non-infected and 
T. congolense-m&ctQd. cattle following i.m. treatment with 6 -,4C 
isometamidium (b) between 6 -14C isometamidium and 6 -14C homidium 
(Chapter 8) following i.v. treatment of non-infected cattle, and (c) between 6 - 
14C isometamidium and 6 -14C homidium (Chapter 8) following i.m. treatment 
of either non-infected or trypanosome-infected cattle. During these 
comparisons, several similarities and differences in serum drug concentrations 
and pharmacokinetics were observed between the various groups. These 
included: (a) extensive distribution of both isometamidium and homidium 
following i.v. treatment of non-infected cattle (b) the plateau in plasma drug 
profiles following i.m. treatment of non-infected and infected cattle with 
isometamidium but not with homidium which showed an exponential decline 
(c) an acceleration in the elimination rate of both drugs in the presence of 
trypanosomes and (d) differences in the rates of release of both drugs from the 
injection site following i.m. treatment.
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During the first 24 hours following i.v. treatment of cattle with 6 -14C 
isometamidium the drug concentrations in plasma declined rapidly (Fig. 9.1). 
The plasma drug concentration obtained at five minutes following treatment 
was over 100-fold higher than that observed at 24 hours. The low MRT values 
obtained following i.v. treatment suggested rapid elimination of the drug 
possibly saturating the elimination processes. The Vss value of approximately 
14 1 h-1 kg*1 was found to be larger than the normal plasma volume for cattle of 
approximately 35.9 ml k g 1 (Ruckebusch et al., 1991) suggesting extensive 
extravascular distribution of the drug and possible binding of the drug to tissue 
components including proteins. Similarities in the values obtained for rate 
constants k 13 and k31 suggested establishment of an equilibrium between free 
drug in plasma and free drug in tissues.
However, following i.m. treatment of non-infected with 
isometamidium, a plateau effect was achieved from approximately 10  days of 
treatment, with maintenance of constant drug levels in what appeared like a 
’steady-state infusion’ of the drug possibly from the injection-site depot. The 
present results are in contrast with those reported by Kinabo and Bogan 
(1988b) in which the drug was detected by HPLC for up to two hours only, 
following i.m. treatment of cattle with isometamidium chloride at 0.5 mg k g 1 
b.w. They did not detect any drug between three and 30 hours whist the 
present study showed approximately 10  ng m l1 in circulation for over two 
weeks following treatment. These differences could have been due to the 
nature of the two techniques and their sensitivities. Whilst HPLC measured 
intact isometamidium whose concentrations may have been too low to detect, 
the radiometric method measured total radioactive drug.
Eisler et al. (1994) using a highly sensitive ELISA method were able to 
detect isometamidium for over 100  days following i.m. treatment of cattle. 
They also showed an exponential decline in the serum drug concentrations. 
The plateau effect in drug profiles was not observed. The serum peak drug
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concentrations of between 40 and 50 ng m l1 obtained using ELISA were 
however, higher than those reported by Kinabo and Bogan (1988b) of 20 ng 
m l1. Both serum peak drug concentrations were, however, lower than 
approximately 160 ng m l1 reported in the present study.
Kinabo and Bogan (1988b) observed lesions at the injection site within 
one week of treatment which was characterised by structureless fibres. Their 
observations suggested congestive necrosis with acute inflammation. Six 
weeks following treatment, complete loss of muscle fibres was observed. This 
drug injection site depot supposedly slowly releases the drug into the 
circulation over long periods of time.
Following i.m. treatment of T. congolense-infected cattle with 6 -14C 
isometamidium, there was an acceleration in the elimination rate of the drug in 
plasma (when compared to the non-infected cattle) reaching levels of 
approximately 7 ng m l1 during the first three days of treatment from a peak 
concentration of approximately 60 ng m l1. Sutherland et al. (1992) in their 
studies on transport of isometamidium by both drug-sensitive and drug- 
resistant T. congolense observed significant drug uptake by drug-sensitive 
parasites. This could possibly also explain the acceleration in the elimination 
rate of the drug following i.m. treatment of cattle with isometamidium. The 
maintenance of constant drug levels from approximately three days following 
treatment (Fig. 9.2) could possibly be due to the drug depot at the injection 
site, similar to that observed in non-infected cattle.
The plasma drug concentration-versus-time profiles for 6 -14C 
isometamidium and 6 -14C homidium in non-infected cattle following i.v. 
treatment at the same dose rate (1 mg k g 1) (Fig. 9.3) showed them to be 
similar. Both drugs showed an exponential decline in plasma concentrations. 
They also showed extensive extravascular distribution and possible binding to 
tissue components. However, the significantly higher initial plasma drug 
concentrations and tV&a (p < 0.05) following i.v. treatment of cattle with 6 -14C
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isometamidium and a lower value for Vdarea (Table 9.1) would suggest that 
isometamidium was distributed much slower than homidium. Also, homidium 
could possibly have more regions accessible to it and higher binding to organ 
tissue components than isometamidium. This possibly higher accessibility and 
binding to tissue components could explain the high MRT values of 
approximately 220  hours obtained following i.v. treatment o f cattle with 
homidium compared to the value of approximately 80 hours obtained 
following similar treatment of cattle with isometamidium. Possible saturation 
o f elimination processes following i.v. treatment of cattle with 6 -14C 
isometamidium but not with 6 -14C homidium was suggested.
Following i.m. treatment of non-infected cattle with both 
isometamidium and homidium, similar peak plasma concentrations were 
observed. However, the differences observed in the drug profiles could have 
been as a result of the approximately five-fold higher value for MAT obtained 
following treatment of cattle with isometamidium.
The low MAT values obtained following i.m treatment o f non-infected 
cattle with 6 -14C homidium demonstrated that the release of the drug from the 
injection site depot was faster than that obtained following i.m. treatment with 
6 -14C isometamidium. Interestingly, the values for MRT of approximately 200 
hours and 290 hours and bioavailability of 57% and 59% following i.m. 
treatment with 6 -14C homidium and 6 -14C isometamidium, respectively, were 
similar.
Following i.m. treatment of T. congolense-infected cattle, plasma drug 
concentrations using both 6 -14C isometamidium and 6 -14C homidium showed 
that the concentrations were markedly reduced compared to non-infected cattle 
given similar treatment. This demonstrated initial rapid uptake/elimination of 
both drugs in a similar manner by the trypanosomes (Fig. 9.5 inset). Uptake of 
isometamidium by trypanosomes has been demonstrated by Sutherland et al. 
(1992). The demonstration by Newton and Gilbert (1982) that 80% of
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homidium in circulation at 1, 8 and 12 hours was found bound to 
trypanosomes and the similarities in some pharmacokinetic parameters 
following i.m. treatment with both drugs observed in the present study would 
suggest that isometamidium interacts with trypanosomes in a similar manner 
to homidium.
One interesting observation was a 'wave-like' pattern in the plasma drug 
profiles following treatment of trypanosome-infected cattle with 6 -14C 
homidium (Fig. 9.5). This was not observed following similar treatment of 
non-infected cattle (Fig. 9.4) with the same drug compound in which a smooth 
exponential decline was observed. These 'wave-like' patterns tended to be less 
pronounced with time post-treatment. This observation could possibly suggest 
that the drug was released from some sites in a variable manner. Anti- 
trypanosome antibodies or trypanosome antigens were not determined in the 
present study. It would have been interesting to find out if there was a possible 
relationship between these parameters and the observed pattern during, 
possibly, the release of the drug by the disintegrating trypanosomes over time.
Pharmacokinetic parameters for 6 -14C isometamidium and 6 -14C 
homidium following i.m. treatment of T. congolense-miQCtQd cattle showed 
marked differences in the AUC and AUMC values (Table 9.4). However, the 
calculated mean MRT values of 352.3±112 hours and 352.4±2.3 hours, 
respectively, were strikingly similar, suggesting that the length of time the 
drug resided in the body following treatment of cattle with either drug 
compound was similar.
Although both homidium and isometamidium react with tissue at the 
injection-site following i.m treatment with similar rates of disappearance of 
the drug in plasma and similar values for bioavailability, their major difference 
appears to be in the rate of release of the drug from the injection site depot 
(differences in the MAT values). This could be related to the nature of tissue 
reaction at the injection site. Stevenson et al. (1995) in their comparison of
338
isometamidium and homidium as prophylactic drugs observed that swellings 
appeared at the site o f injection in some of the cattle treated with 
isometamidium by week 51 of the one year trial and no swellings in the 
homidium-treated herd. This was despite the fact that the cattle treated with 
homidium received more treatments than those treated with isometamidium. 
These results by Stevenson et al. (1995) support the above observation that 
homidium release from the injection site depot was faster than that observed in 
the isometamidium-treated cattle.
The present study established the following findings after treatment o f 
cattle with 6 -14C isometamidium: (a) that an exponential decline was observed 
following i.v. treatment of cattle with 6 -14C isometamidium (b) that an 
equilibrium was attained in the drug distribution (c) that a steady state was 
established and maintained by the equilibrium (d) that an extensive 
extravascular distribution and possible binding of the drug was demonstrated 
(e) that a possible first reaction could have reverted to zero order due to the 
saturation of elimination processes (e) that there was lack of an obvious 
exponential decline in the plasma drug levels following i.m. treatment o f both 
infected and non-infected cattle and (g) that significant drug 
uptake/elimination by trypanosomes was observed.
The similarities between homidium and isometamidium appeared to be 
in (a) the exponential decline of the drugs in plasma following i.v. treatment 
(b) extensive distribution and possible binding of the drug (c) mean residence 
time and bioavailability of the drug following i.m. treatment o f non-infected 
cattle and (d) increased rate of drug elimination during the first three days of 
treatment in infected cattle and similar MRT values. The above similarities in 
pharmacokinetics could be due to the fact that both homidium and 
isometamidium share structural similarities.
Major differences appeared to be in (a) demonstration of an exponential 
decline in drug concentrations over time, following i.m. treatment o f non­
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infected cattle with homidium and lack of a similar decline following 
treatment of cattle with isometamidium and (b) the mean absorption time 
values following i.m. treatment were approximately five-fold lower in 
homidium treated cattle. Although both drugs form depots at the injection site 
following i.m. treatment, the release of the drug from the depot was faster in 
the homidium treated cattle than in the isometamidium treated cattle.
The similarities observed in most of the pharmacokinetic parameters 
following i.m. treatment of both non-infected and T. congolense-infected cattle 
with both 6 -14C homidium and 6 -14C isometamidium suggests that their 
mechanisms of action could possibly be similar.
From the above observations, isometamidium appears to form a depot 
releasing small quantities of intact isometamidium into the circulation, 
including, possibly 'homidium-like' metabolites. Field evaluation of 
isometamidium as a prophylactic has been reported using the established 
enzyme-linked immunosorbent assay (Eisler et al., 1994). However, in light of 
the above observations, isometamidium prophylaxis in the field needs to be re­
evaluated taking into account possible contribution of active metabolites 
which could include homidium which is a well established active trypanocide.
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GENERAL DISCUSSION AND CONCLUSIONS
This thesis addressed a number of objectives. These included:
- the development and validation of a sensitive ELISA method for use
in measuring homidium concentrations in the serum of treated cattle.
- the use of the above method to collect baseline data on homidium 
concentrations and pharmacokinetics in non-infected cattle for use in 
subsequent experiments.
- investigations into the effects of T. congolense infections on 
homidium pharmacokinetics following treatment of infected cattle.
- investigations into the prophylactic activity of homidium.
- investigations into the suitability of the ELISA method in determining 
serum homidium concentrations in samples collected from cattle 
following treatment and exposure to natural tsetse challenge.
- comparisons of serum drug concentrations and pharmacokinetics 
following treatment of cattle using both ELISA and the radiometric
methods.
- comparisons of pharmacokinetics following treatment of non-infected 
and infected cattle with both 14C labelled homidium and 14C labelled
isometamidium
These objectives were achieved and the results reported in this thesis 
demonstrated that:
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Two ELISA methods were developed which were highly sensitive 
(limit o f detection 0.1 ng mb1). One assay was selected for the subsequent 
studies. The assay was robust, highly sensitive, easy to perform, suitable for 
use to analyse large numbers of samples and relatively cheap.
The studies carried out in non-infected Friesian cattle showed that the 
decline in homidium concentrations over time was exponential and rapid 
during the first 24 hours following both i.v. and i.m. treatment o f cattle. 
Following i.v. treatment of non-infected cattle, no drug was detectable in 
serum within approximately three weeks of drug administration. However, low 
serum concentrations of between 0.10 - 0.30 ng mb1 were detectable in the 
circulation for over 10 weeks after the initial rapid fall in levels within the first 
24 hours following treatment of cattle by i.m. injection.
Extending the studies from Scotland to Kenya allowed studies to be 
carried out using a cattle breed that is reared extensively in the 
trypanosomiasis endemic areas of Kenya. Also, it allowed an evaluation to be 
carried out on the suitability of establishing ELISA drug testing facilities in a 
country with endemic trypanosomiasis.
The results obtained using Boran cattle showed that the serum drug 
concentration-versus-time profiles between the Boran and Friesian were 
markedly similar. Low serum drug concentrations were detectable in serum for 
over 10 weeks following i.m. treatment of Boran cattle. Pharmacokinetic 
parameters of homidium were also similar between the two breeds. The major 
difference observed was the wide variability in serum concentrations between 
individual Boran cattle when compared to the Friesian.
It was recognised that the time intervals at which samples were 
collected following treatment highly influenced the estimation of the 
secondary pharmacokinetic parameters. As many data points as possible 
around the serum peak drug concentration gave better estimates o f the 
secondary pharmacokinetic parameters especially in the determination of the
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area under the curve (AUC) and the area under the moments curve (AUMC) 
which in turn influenced the values for the mean residence time, mean 
absorption time and bioavailability estimations.
Usually, the use of homidium in the field is to treat trypanosome- 
infected animals. In investigations on the effects of T. congolense infections 
on the pharmacokinetics of homidium, it was observed that the rate of drug 
elimination was accelerated in the presence of both drug-sensitive and drug- 
resistant trypanosome populations. This accelerated rate of drug elimination 
reverted to normal rate (observed in non-infected cattle) within one to two 
days following the disappearance of trypanosomes from the circulation in the 
case of drug-sensitive trypanosome population. Low serum homidium 
concentrations were detectable in circulation up to 90 days following 
treatment in such situations.
However, in the animals which were infected with a drug-resistant 
population, the increase in the rate of drug elimination continued until the drug 
was no longer detectable, within 10 days after treatment. These observations 
demonstrated that homidium pharmacokinetics were altered in the presence of 
a trypanosome infection and especially if the infection was due to a drug- 
resistant trypanosome population.
The significant decrease in serum homidium concentrations compared 
to those observed in non-infected cattle observed at five minutes following 
treatment of infected cattle could be as a result of significant drug 
uptake/elimination by the trypanosomes. Gilbert and Newton (1982) 
demonstrated that 80% of the drug in circulation at 1, 8 and 12 hours 
following i.m. treatment of T. congolense-infQCtQd calves with homidium was 
bound to trypanosomes suggesting significant drug uptake. Drug-sensitive 
trypanosomes would eventually be eliminated by the drug.
Besides the possibilities of drug uptake/elimination by trypanosomes, 
the accelerated drug elimination rate in the presence of trypanosomes could
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have been as a result of any of the many pathophysiological effects associated 
with trypanosome infections which include fever, increased metabolic rate, 
anaemia, lowered serum albumin levels and tissue damage.
It is difficult to predict at this stage which of the above factors could be 
responsible for the changes and this requires further investigation. In 
trypanosome infections, fever has been associated with parasitaemia. Fever 
has been shown to affect the absorption, distribution and elimination of other 
drug compounds.
One of the current uses of homidium is as a chemoprophylactic agent 
against animal trypanosomiasis. Investigations into homidium 
chemoprophylaxis showed that the low homidium concentrations (0.10 to 0.30 
ng m l1) observed in non-infected cattle were protective against infections with 
a drug-sensitive trypanosome population.
Following monthly trypanosome challenge (by sub-cutaneous injection) 
of treated cattle, trypanosomes were first detected in four out of five animals 
challenged with a drug-sensitive trypanosome population after the challenge at 
120 days. Protection of the animals was demonstrated to be due to the 
presence of the homidium. Anti-trypanosome antibodies were not detected in 
the serum collected on each day of challenge and therefore played no role in 
the protection of cattle against infection. Failure of chemoprophylaxis was, 
however, demonstrated in the presence of the drug-resistant trypanosome 
population and the persistent parasitaemia had a very profound effect on 
serum drug concentrations. For the reasons described above, this could be due 
to drug uptake/elimination by trypanosomes and/or changes in host physiology 
including fever, increased rate of metabolism and decreased serum albumin 
levels.
An experiment conducted at Galana Ranch in Kenya showed that over 
95% of the cattle exposed to natural tsetse challenge following homidium 
treatment were protected for a period of 14 weeks. Low serum homidium
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concentrations were detectable for up to six weeks and were similar to those 
obtained in the controlled laboratory studies on homidium prophylaxis.
It was also demonstrated that the ELISA method could effectively be 
used to determine serum homidium concentrations in individual cattle samples 
from the field involving large numbers of animals on the Galana Ranch,
Kenya.
The presence of drug resistant trypanosomes has been demonstrated in 
the work reported in this thesis as an important contributor to drug failure. 
Several explanations for drug failure have been given by Holmes and Torr 
(1988) which include drug resistance. The ease with which drugs are acquired 
from the drug retailers, lack of knowledge of drug preparation and 
administration combined with lack of weighing and diagnostic facilities and 
economic hardships experienced by the majority of the small scale farmers 
probably contribute to the development of drug resistance in the field.
Use of both ELISA and the radiometric methods for drug detection 
showed that the drug was undetectable after approximately three weeks 
following i.v. treatment of non-infected cattle using ELISA whilst 
approximately 4 ng m l1 was detectable up to 28 days using the radiometric 
method. The serum drug concentrations were approximately ten-fold higher 
using the radiometric method than with the ELISA. One possible explanation 
for this difference is that the ELISA may detect only intact drug whilst the 
radiometric method may detect both intact and radioactive metabolites. There 
is also need to investigate possible metabolites of homidium using a variety of 
techniques. It would also be interesting to find out whether these metabolites 
are trypanocidal and their possible contribution to the development of drug 
resistance.
Comparisons between radiolabelled homidium and isometamidium 
showed several similarities in their pharmacokinetics in cattle. These included 
similarities in the mean residence time and bioavalability of the drug following
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i.m. treatment. Their major difference was in the mean absorption time, the 
values being higher in isometamidium-treated cattle. These observations 
showed that the release of isometamidium from the drug depots (which 
include the injection site) was slower than that observed in homidium-treated 
cattle. This could explain the longer prophylactic periods observed in cattle 
treated with isometamidium compared to that observed in cattle treated with 
homidium.
In order to obtain the maximum benefits from the small number of 
trypanocides which are currently available, greater knowledge of the factors 
influencing their efficacy in field situations is required. This includes the 
problem of drug resistance. To be able to monitor the spread of drug resistance 
in the field, Holmes and Torr (1988) suggested the development of laboratory 
tests to quantify drug concentrations in treated cattle; the presence of 
trypanosomes in cattle with drug levels known to be trypanocidal being a 
valuable index of drug resistance. The highly sensitive ELISA method used in 
the studies reported in this thesis could be valuable in further investigations of 
drug resistance in the field.
In conclusion, several areas have been identified which would merit 
further investigations in an effort to combat animal trypanosomiasis through 
the more effective use of drugs. These include:
(a) Use of ELISA and other parasitological techniques to study the
epidemiology of drug resistance in the field.
The detection of trypanosomes in animals with serum drug levels that 
have been shown to be effective against drug-sensitive trypanosomes indicates 
presence of drug resistance. Constant monitoring of serum homidium 
concentrations in treated animals including periods of high tsetse challenge 
(with a corresponding increase in drug use) in the field, could possibly 
indicate the level and spread of drug resistance.
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(b) Studies on homidium uptake/elimination by trypanosomes.
Gilbert and Newton (1982) used radiolabelled homidium to study drug 
uptake in cattle. Their findings showed that 80% of the drug in circulation was 
bound to trypanosomes. Interestingly, they did not observe any differences in 
pharmacokinetics between non-infected and T. congolense cattle. Their work 
however, lacked a detailed pharmacokinetic evaluation. Findings of the 
present study suggested significant drug uptake by trypanosomes. These 
interesting observations merit further investigations.
(c) Studies on other factors besides drug uptake/elimination which
contribute to increased elimination rate of the drug following treatment 
of infected cattle.
The possible factors identified in the present study were fever, 
increased rate of metabolism, decreased serum albumin levels and anaemia. 
Investigations need to be carried out in which each of the above factors would 
be determined as well as the serum drug concentrations following treatment of 
trypanosome-infected cattle. The information would assist in determining if a 
relationship exists between any of the above factors and the accelerated rate of 
drug elimination.
(d) Studies on the extent of in vivo homidium biotransformation including
the possible identification of metabolites and their role, if any, in the 
chemotherapy, chemoprophylaxis and in the development of drug 
resistance.
Biotransformation of homidium has not been reported in cattle. The 
findings in the present study that there was a ten-fold difference in serum drug 
levels using both the radiometric and the ELISA methods suggests presence of 
metabolites. These meabolites need to be identified, isolated and purified 
before their role in chemotherapy could be investigated.
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1.0 CHEMISTRY OF CURRENT ANIMAL TRYPANOCIDAL DRUGS
(S) ^1.1 Diminazene aceturate (Berenil , Veriben )
It is an aromatic diamine
1.1.1 Chemical names: p,p'-diaminodiazoaminobenzene diaceturate
l,3-Bis(4-amidinophenyl) triazene
1.1.2 Molecular formula: C22H29N9O6.4H2O
1.1.3 Molecular mass: 587.6 as the salt
1.1.4 Structural formula: See Appendix B.
1.1.5 Description: A yellow, odourless powder. Melting point 217°C with
decomposition.
1.1.6 Solubility: About 70% at 20°C in water. Slightly soluble in alcohol.
Sparingly soluble in ether and chloroform. Though stable when 
dry, an aqueous solution in contact with air is stable for only two 
or three days.
1.2 Homidium bromide (Ethidium )/Homidium chloride (Novidium )
It is a phenanthridinium compound.
1.2.1 Chemical name: 2,7-diamino-9-phenyl-10-ethylphenanthridinium
bromide/chloride anhydrate.
1.2.2 Molecular formula: C2H2oBrN3
C2H 2oC1N3
1.2.3 Molecular mass: 394 as salt
412.3 as a monohydrate
1.2.4 Structural formula: See Appendix B.
1.2.5 Description: A dark purple, almost odourless, crystalline or
amorphous powder with a persistent bitter taste and
highly fluorescent under UV light. Melting Point 245°C with
decomposition.
1.2.6 Solubility: 3.5% in water at 20°C and 10% at 100°C. A 5-6% solution in 
water is stable for several days at 20°C. Solubility is only 0.13% 
in chloroform.
1.3 Isometamidium chloride: (Samorin ’ Trypamidium )
Is a phenanthridinium compound
1.3.1 Chemical name: 7-(n-amidinophenyldiazoamino-)-7-amino-10-ethyl-9-
phenylphenanthridinium chloride hydrochloride
1.3.2 Molecular formula: C22H25CIN7HCI
1.3.3 Molecular mass: 531.5
1.3.4 Structural formula: See Section Appendix B.
1.3.5 Description: Marketed as Samorin and Trypamidium w it is composed
of 5 different isomers and the powder appears dark red in 
colour.
1.3.6 Solubility: Fairly soluble in water.
1.4 Melarsenoxide cyteamine (Mel Cy®)
1.4.1 Molecular mass: 501.3
1.4.2 Structural formula: See Section Appendix B.
1.4.3 Description: White crystalline powder. Contains 14.9% Arsenic.
1.4.4 Solubility: Highly soluble in water
1.5 Suramin (Antrypol®; Naganol®)
1.5.1 Chemical name: 8,8'-[carbonylbis[imino-3,l-
phenv lenecarbonylimino(4-methyl-3,1 -pheny lene)carbonyl- 
imino]]bis-l,3,5-naphthalenetrisulfonic acid hexasodium salt.
1.5.2 Molecular formula: C51H34N6Na6023S6
1.5.3 Molecular mass: 1429.21
1.5.4 Structural formula: See Appendix B.
1.5.5 Description: White or slightly pink or cream coloured powder. Slightly
bitter taste. Hygroscopic.
1.5.6 Solubility: Freely soluble in water and in physiological salt solution.
Sparingly soluble in ethanol. Insoluble in benzene, ether, 
petroleum ether and chloroform. Aqueous solutions are neutral 
to litmus.
1.6 Quinapyramine (Antrycide®)
1.6.1 Chemical name: 4-amino-6-[(2-amino-l,6-dimethylpyrimidinium-4-
yl)amino] quinolinium salts.
1.6.2 Molecular formula: Dimethoate C 19^ 8^ 0 3 8 2 .
1.6.3 Structural formula: See Appendix B.
1.6.4 Description: Creamy white crystals from aqueous methanol. MPt 265-
266.
1.6.5 Solubility: Freely soluble in water.
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H20- Sb/
O-CH-O 
_  O-CH
\ O-CH-COO
Kh
Fig. 1.1(a) Potassium antimony tartrate (tartar emetic)
NaOoS . X
Na03S
SC^Na
O
Fig. 1.1(b) Suramin
s
z
h3c
Fig. 1.1(c) Trypaflavine
Fig. 1.1(d) Phenidium (X,Y = NH2) Z = H
Dimidium (X, Z = NH2) Y = H
H,C N
NH'
Fig. 1.1(e) Surfen C
N +
nh 2
Fig. 1.1(f) Quinapyramine
N H '
c , h 5
Fig. 1.1(g) Homidium bromide
H COOH
Fig. 1.1(h) Diminazene aceturate
Fig. l.l( i)  Pyrithidium bromide
Fig. l.l( j )  Isometamidium chloride
S-CH2-CH2-NH2
S-CH2-CH2-NH2
Fig. l.l(k ) Melarsenoxide cysteamine
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